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S U M M A R Y
Soluble antibacterial substance(s) in lung lavage fluid (LLF) from healthy normal rats killed 
phase I Bordetella pertussis in vitro. Phase IV B. pertussis was insusceptible. LLF that 
was active towards phase I organisms was obtained from rats of the Sprague Dawley, 
Lewis, Brown Norway, and Hooded Lister strains. Two strains of B. pertussis were 
mainly used: B. pertussis 18-323 for viable count experiments and B. pertussis lux for 
tests with the luminometer. The former experiments were more time consuming but more 
reliable; luminometry, although rapid, was complicated by substances that affected the 
luciferase reaction. Electron microscopy showed that LLF caused severe damage to the B. 
pertussis cells, with loss of internal contents
Of the several mammalian species tested, the rat yielded LLF of the highest 
bactericidal activity (BA) towards B. pertussis. The other species LLF were: human, 
mouse, horse, dog, chicken, rabbit, sheep and calf. Typically rat LLF could be diluted 24 
times and still exhibit BA.
For assessment of the BA of LLF, both positive and negative control fluids were 
used. Normal rat serum, which killed the bacteria rapidly, was used for the former, and 
phosphate buffered saline (PBS), cyclodextrin liquid (CL) medium and casamino acids 
(CAA) for the latter. The half-life of B. pertussis at 37°C in PBS was 149 min and in CAA 
155 min. CL medium allowed growth.
To obtain LLF, four different methods of euthanasia were explored; the highest BA 
was in LLF obtained by anaesthetising the rats with halothane/ 02, then heart puncture for 
blood, and finally cervical dislocation. The least active LLF was obtained after CO2 
euthanasia.
LLF from normal rats was separated by ultracentrifugation at 55,000 g into 
supemate and surfactant (pellet) fractions. About 95 % of the BA towards B. pertussis 18- 
323 and lux was located in the surfactant fraction. No BA towards 18-323 was found in 
commercially-produced, protein-free artificial surfactant used for alleviating respiratory 
distress syndrome in premature infants .
Physical, chemical and biochemical treatments of LLF and its fractions suggested 
that the substance(s) responsible for the BA towards B. pertussis 18-323 and lux are
i v
probably long-chain fatty acids, protein and phospholipids. There appeared to be no 
involvement of antibody, complement and lysozyme in the BA of LLF towards B. 
pertussis. However, the lysozyme in LLF was able to kill and lyse Micrococcus luteus.
LLF from rats convalescent after infection with phase I B. pertussis tended to have 
BA lower than that from normal animals. This suggested that one of the toxins of B. 
pertussis might inhibit the synthesis or release of the substance(s) responsible for BA from 
the secreting cells in the lungs.
B. parapertussis was sensitive to the BA of both surfactant and supemate of LLF 
from normal rats, while B. bronchiseptica was resistant. Other LLF-resistant species were 
Staphylococcus aureus, Streptococcus pyogenes and Escherichia coli.
B. pertussis 18-323 was strongly sensitive to the BA of long-chain fatty acids, of 
which the most active was arachidonic (C20:4). The BA of LLF from normal rats could be 
replicated by a mixture of fatty acids from C14 to C20 at a concentration similar to that 
found in the LLF itself.
The reduced BA in LLF from convalescent rats might be due to the action of 
pertussis toxin on type II pneumocytes which are principally involved in production and 
recycling of surfactant. Further studies on the possible effect of PT on this system might 
provide valuable insights into pathogenic mechanisms in pertussis.
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1I N T R O D U C T I O N
BO RD ETELLA PE RTU SSIS
Whooping Cough (Pertussis)
Historical introduction
Whooping cough may historically be of relatively recent origin. The disease 
subsequently given the name pertussis by Sydenham in 1676 was first mentioned in 1540 
by Moulton (Lapin 1943). Linnemann (1979), states that the disease was first described in 
1578 by Guillaume de Baillou, otherwise known as Ballonious. The quoted description is 
as follows (Linnemann 1979): "At the close of summer almost the same diseases prevailed 
as before ....Principally that common cough ....Serious are the symptoms of this: The lung 
is so irritated by every attempt to expel that which is causing the trouble, it neither admits 
the air nor again easy expels it. The patient is seen to swell up and as if strangled holds his 
breath tightly in the middle of his throat ....For they are without the troublesome coughing 
for the space of four or five hours at a time, then this paroxysm of coughing returns, now 
so severe that blood is expelled with force through the nose and through the mouth. Most 
frequently an upset stomach follows .... For we have seen so many coughing in such a 
manner, in whom after a vain attempt semi-putrid matter in an incredible quantity was 
ejected"
Linnemann (1979) also suggests that pertussis was introduced into Europe in the 
Middle Ages by travellers from other parts of the world. The disease was certainly well 
recognised by the m id-18^ century; it was reported from diverse regions, such as 
Switzerland (1755), Germany (1769), Brunswick (1770) and Milan (1815). For more 
detailed historical descriptions see Lapin (1943) and Olson (1975).
Since earlier descriptions of illnesses cannot always be identified in modern terms, 
some reviewers have suggested that whooping cough (pertussis) appeared as a new 
infection of man during the last few centuries (Olson, 1975). Other historians have 
suggested that the disease was only new to Europe in the middle ages, having been 
imported from other parts of the world (Von Rosenstein, 1960, cited by Linnemann, 1979);
3still others have suggested that although it was a common disease, pertussis was not treated 
by physicians, and thus not mentioned in the medical literature of the times (Creighton, 
1894 cited by Linnemann, 1979).
The apparent reason for the disagreement among scholars is that historical 
descriptions of illnesses characterised predominantly by coughing are not sufficiently 
detailed to allow either the inclusion or exclusion of pertussis. Even Baillou's account does 
not contain a description of the inspiratory whoop which is the hallmark of the disease; 
Sticker has concluded that "the historical trail of whooping cough is associated with mental 
delusions " and one must accept that the exact origins of pertussis cannot be determined 
(Sticker, 1902, cited by Linnemann, 1979).
Whooping cough has been known in many countries by many names, including 
Chin cough or Kink cough in English, Coqueluche in French, Kinkhoest in Dutch, 
Keuchusten in Germany, Kighoste in Danish, or Kikhosta in Swedish (Radbill, 1943 cited 
by Linnemann, 1979). Also, pertussis is known in Arabic as alsual-aldiki. In English 
"hooping cough " was generally used until the end of the 19^ century but in the 2 0 ^ , 
pertussis has gradually replaced "whooping cough " in the medical literature.
Clinical disease
Bordetella pertussis, the causative organism of whooping cough (pertussis) infects 
only humans, and does not cause disease in animals (Tuomanen et a l 1983). It is a world­
wide pathogen, and all ages of Man are at risk (Fine, 1988). Its dominance, especially in 
developed countries during the last several decades, has been in sharp decline largely as a 
result of intensive vaccination programmes (Wardlaw, 1990).
Pertussis is a highly communicable disease, especially in home exposures (Medical 
Research Council, 1956); it has an attack rate of > 90 % among unimmunized individuals 
(Lambert 1965). Also, it was estimated by Fine and Clarkson (1984) and Muller et al. 
(1986) that the vast majority of the world's unvaccinated children contract the infection by 
the age of 5 years. Nevertheless, the disease is life-threating only in very young infants 
especially those under 6 months of age (Gordon and Hood, 1951). The latter authors
4emphasised that the variable severity of pertussis is influenced by the age and immune 
status of the patient. It is well established that B. pertussis is transmitted by aerosol 
droplets from active cases.
According to Lapin (1943), after contracting the infectious agent, the incubation 
time can vary from 6 to 20 days. In the catarrhal stage, the disease manifests itself in the 
new host as a cold or mild cough, slight conjunctivitis and coryza with little fever (Walker, 
1988). After 1-2 weeks the characteristic paroxysmal cough appears. Bouts of coughing, of 
which there may be an average of about 10 per 24 h (Walker et a l 1981) are frequently 
followed by the inspiratory "whoop" and equally frequently by vomiting; apnoea and 
cyanotic attacks after a paroxysm are the commonest precipitating reason for hospital 
admission.
Brain damage through cerebral anoxia or subdural haemorrhage may occur if the 
paroxysms are sufficiently severe (Cherry, 1984). Whooping cough may last for several 
months and is not modified by specific therapy (Miller and Fletcher, 1976), although 
steroids have been advocated for severe cases (Zoumboulakis et a l 1973 ).
Prevention and treatment
For prevention, patients should be isolated from other healthy susceptible children 
and public places during the 3 weeks after the onset of the paroxysmal stage.
Soon after Bordet and Gengou (1906) isolated B. pertussis from the sputum of 
children with whooping cough, there were attempts by 1914 in the USA to develop a 
vaccine against the disease (Gordon and Hood, 1951). Some protection in children who 
received an early vaccine just before a pertussis epidemic in the Faroe Islands was 
demonstrated by Madsen (1933). Whole-cell pertussis vaccines are suspensions of heat- 
killed or chemically-killed bacteria with or without adjuvant such as aluminium hydroxide. 
They may be combined with diphtheria and tetanus toxoids. The UK whole-cell vaccine 
consists of killed B. pertussis cells (< 2 x 1 0 ^ )  per single human dose, combined with 
diphtheria and tetanus toxoids (DPT) adsorbed to aluminium hydroxide and with thiomersal 
as a preservative (Department of Health, London, 1990). According to Noble et a l (1987),
5concern with vaccine safety in the middle of the 1970s, caused vaccine uptake to fall from 
80 % to 40 % in the UK. Pertussis vaccination is effective for 2-3 years (Medical Research 
Council, 1959). Sherris et al. (1986) reported that among all the world's new bom in 1985, 
45 % received 3 doses of pertussis vaccine. The degree of protection afforded by whole-cell 
vaccines against the disease is greater than the protection against infection (Fine and 
Clarkson, 1987). The adverse effects of whole-cell vaccine range from transient reactions 
such as high fever, uncontrolled crying and seizures (Cherry et al., 1988) to brain damage 
(Griffith, 1989).
Because of the adverse effects of the whole cell vaccines mentioned above, 
attempts have concentrated on producing less reactogenic and more effective vaccines. 
Acellular vaccines which are derived from cultures of B. pertussis and are cell-free 
preparations containing inactivated pertussis toxin, filamentous haemagglutinin and some of 
the agglutinogens are being evaluated. The first of the defined acellular pertussis vaccines 
were developed by Sato et al. (1984). For more details see Table 1.
In a field trial in Sweden (1986-1987), a monocomponent pertussis toxoid (PTd) 
and a two-component PTd + FHA (filamentous haemagglutinin) pertussis vaccine, showed 
a lower reactogenicity and efficacy than whole-cell vaccines (Ad hoc group, 1988). Despite 
this disappointing result, vaccines containing PTd with or without other antigens provided 
good protection against severe disease. Tricomponent acellular pertussis vaccination of 12 
month old infants induced T-cell responses specific for the vaccine components (Zepp et al. 
1996). WHO reported that pertussis caused the death of > 0.5 million among 60 million 
cases in unvaccinated communities (Muller et al., 1986). Marwick (1995) reported that 
multi-component vaccines, especially those containing pertactin, are highly efficacious and 
show few adverse effects.
In a study of effectiveness of antibacterial agents on Bordetella organisms localized 
on ciliated epithelium, the bordetellae were resistant to bacitracin (Rosen et al., 1954) and 
to penicillin and streptomycin (Ganaway et al., 1965). Also Bass et al. (1969) reported that 
the clinical illness may be aborted or attenuated if any of several antibiotics such as 
erythromycin, tetracycline, and chloramphenicol are given during the catarrhal stage.
6Table 1. Examples of defined acellular pertussis vaccines (Parton, 1994)
Vaccine Composition 
generation (Toxoiding process)
Stage of development
1st: PTd and FHA as main components,
co-purified from culture supemate
PTd + FHA (+AGGs + other) Routine use in Japan since 1981
(Formaldehyde) Licensed as booster in USA, 1991
PTd + FHA Swedish phase 3 trials, 1986
(Formaldehyde)
2nd; Individually-purified and chemically-
inactivated components
PTd Swedish phase 3 trials 1986
(Formaldehyde)
PTd + FHA + AGGs + pertactin Phase 3 trials
(Glutaraldehyde)
3rd: Containing recombinant proteins
from B. pertussis or other organisms
Recombinant PTd + FHA + pertactin Phase 3 trials
(Genetic)
The course of pertussis at the paroxysmal stage cannot be altered by introduction of 
anti-microbial agents (Welkins and Wehrle, 1979). Erythromycin, because of its safety 
profile in children, was preferred for treatment of early disease and for prophylaxis of 
exposed, susceptible individuals (Linnemann et al. 1975, Altemeir and Ayoub, 1977). The 
Center for Disease Control and Prevention reported that an erythromycin-resistant B. 
pertussis strain was isolated from a 2-month-old male infant living in Yuma County, 
Arizona (Lewis, 1995). The same source stated that susceptibility testing at the hospital 
laboratory suggested that the isolate was resistant to erythromycin but sensitive to 
trimethoprim- sulfamethoxazole.
Bordetella pertussis 
Introduction to the bordetellae
The Bordetella organisms are highly communicable, obligatory parasites of the 
respiratory tract of human, and other warm-blooded animals including birds. So far as is 
known, they have no reservoirs in the natural environment; nor do they have significant 
capacity for survival outside of their hosts. B. pertussis and until recently B. parapertussis 
were regarded as having a single host species, man. Recently, however, B. parapertussis 
was isolated from healthy and pneumonic lambs (Porter et al. 1994). B. bronchiseptica has 
been isolated from different host species- cat, dog, fox, pig, hedgehog, horse, koala bear, 
monkey, opossum, mouse, rabbit, raccoon, rat, skunk, turkey and occasionally man. B. 
avium has been isolated from turkey, duck, and goose (Kersters et al., 1984).
Recently, two new species have been added to the genus Bordetella on the basis of 
DNA hybridisation studies, DNA base ratio determinations and other genotypic and 
phenotypic characteristics (Parton, 1996). They are B. holmesii and B. hinzii. The former 
was isolated from blood cultures of patients, some of whom were immunocompromised 
(Weyant et al., 1995). B. hinzii was the name given to a B. avium-like group of organisms 
from the respiratory tract of turkeys and chickens (Vandamme et al., 1995). Also, two other 
strains of B. hinzii were isolated from Man, one from sputum and the other from blood of
8an AIDS patient.
It is generally thought that B. pertussis is a non-invasive organism and can only 
reside on the ciliated epithelium of the human respiratory tract; but recent evidence suggests 
that it may have an intracellular stage. This was deduced by recovering viable organisms 
from gentamicin-treated HeLa cell monolayers and by transmission electron microscopy 
(Ewanowich et al., 1989). The uptake and intracellular survival of B. pertussis in human 
macrophages was reported by Friedman et al. (1992). For more detailed information about 
the characteristic diseases caused by Bordetella species see Table 2.
Bordet and Gengou (1909) described how they isolated their first pure B. pertussis 
(the causative agent of whooping cough) culture from sputum in 1906. Paroxysmal 
coughing has been the hallmark of this acute bacterial infection of the respiratory tract but 
occasional instances of similar illness have been attributed to B. parapertussis and rarely to 
B. bronchiseptica.
B. parapertussis was first isolated by Bradford and Slavin (1937) and Eldering and 
Kendrick (1938) from cases of mild whooping cough. B. bronchiseptica was obtained by 
Ferry (1911) and M'Gowan (1911) from the respiratory tract of dogs with distemper and 
mistakenly identified as the cause of that disease.
The genus Bordetella was introduced by Moreno-Lopez (1952), the first three 
recognised species being: B. pertussis, B. parapertussis, and B. bronchiseptica which had 
previously been referred to as Haemophilus pertussis, Bacillus parapertussis and Brucella 
bronchiseptica (Pittman, 1957, 1974).
The suggestion of including the whole Bordetella genus in the family Brucellaceae 
together with Brucella and Alkaligenes was proposed by Johnson and Sneath (1973), and 
emphasised the differentiation between the (G + C) content of Haemophilus DNA (39-42 
mol %) (Hill, 1966) and that of Bordetella DNA (61.6 - 69.5 mol %). B . pertussis, B. 
parapertussis, and B. bronchiseptica were placed in the same genus because of their 
similarity in physiology and of a close genetic relationship; See Table 3; for a comparison 
between Bordetella and other similar genera.
9Table 2. Characteristics of the diseases caused by the "classic" Bordetella species (all 
transmitted by aerosol).
Characteristic
Bordetella
pertussis a parapertussis b bronchiseptica c avium d
Name
of
disease
Whooping cough 
(pertussis)
Atypical 
whooping cough
Kennel cough 
Atrophic rhinitis
Infectious coryza 
Rhinotracheitis 
Bordetellosis 
Turkey coryza
Reservoir Man Man Dogs, pigs, and 
various wild 
animals
Turkeys, chickens 
and other birds
Symptoms Catarrhal, 
paroxysmal and 
convalescent 
stages
As with 
B.p
Nasal atrophy and 
snout deformation, 
coughing, sneezing, 
ocular and nasal 
discharge, reduced 
weight gain .
Exudative 
conjunctivitis 
sneezing and 
serious disc­
harge, trac­
heal rales, 
reduced 
feeding.
Site of 
infection
Cilia of respiratory As with 
epithelium B.p
Nasal and respiratory 
epithelium cilia.
Respiratory 
epithelial cilia.
Carriers None None Dogs, cats, rats, 
and swine .
Not known.
Immunity Solid after infection As with 
Short-lived with B.p. 
immunization .
As with 
B.p.
Not known.
Duration Several months As with 
B.p
Up to 14 
weeks
About 12 weeks
Treatment No effective 
treatment
As with 
B.p
As with 
B.p
As with 
B.p
Vaccine Whole cell 
Acellular
None Whole cell 
Acellular
Whole cell
a, b, c and d = Information for each species were gathered from following sources: 
a: Connor (1986); Friedman (1988); Pittman and Wardlaw (1981) and Wardlaw and Parton
(1988).
b Eldering and Kendrick (1938); Linneman and Perry (1977); Connor (1986); Chen et al.
(1989).
c Thompson et al. (1976); Bemis et al. (1977a); McCandlish et al. (1978); Goodnow 
(1980); Rutter (1985) and Papasian et al. (1987).
d Hinz and Kunjara (1977); Kersters et al (1984) and Simmons et al. (1978, 1984).
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Morphology, physiology, and growth
The bordetellae are small gram-negative cocco-bacilli measuring 0.3 - 0.5 |im x 0.5 
- 2.0 pm arranged singly, in pairs or in small groups; upon primary isolation, cells are 
uniform in size, but in subcultures they become quite pleomorphic, filamentous and thick 
bacillary forms are common (Wardlaw, 1990). The surface component known as 
filamentous haemagglutinin (FHA) which was first detected by Keogh et al. (1947), when 
purified consists of filaments with fimbrial dimensions. They are different from the fimbriae 
that were seen in micrographs of whole cells and identified by Ashworth et al. (1982) as the 
agglutinogens.
The Bordetella organisms are strict aerobes with a respiratory metabolism, and not 
producing H2S, indole, or acetyl methyl carbinol. Unlike Haemophilus species, X- factor 
(haematin) or V-factor (nicotinamide adenine dinucleotide) are not used by bordetellae 
species as a nutritional requirements for growth. Lactoferrin and transferrin supported 
growth of B. pertussis, and bordetellin (hydroxamate siderophore) produced by the same 
organism plays a major role in Fe uptake (Agiato and Dyer, 1992).
Primary isolation of the whooping-cough bacillus was first achieved by Bordet and 
Gengou (1906) from sputum cultured in a glycerol-potato-extract agar medium, without 
peptone but containing 50 % defibrinated horse blood. Various solid and liquid media 
without blood have also been developed for bulk growth of cells, for the production of 
toxin-containing supemates, and for genetic studies. The amount of blood in Bordet- 
Gengou medium may be reduced to 15-20 % for easier detection of haemolysis around the 
colonies; to improve selectivity, penicillin is added to the BG-medium if required (Pittman 
and Wardlaw, 1981). Also, isolation of B. pertussis from patients has been achieved by 
suction (Herzog and Gaiffe, 1958, cited by Pittman and Wardlaw, 1981)), cough plate 
(Lautrop, 1960) and nasopharyngeal swab (Kendrick and Eldering, 1969).
Rapidity of growth on Bordet-Gengou medium is such that, with inocula destined to 
give single colonies of B. pertussis, the colonies are still invisible after 24 h at 35 - 37 °C, 
but start to appear by about 3 days. B. pertussis colonies on BG-agar are dome-shaped, 
pinpoint in size, around 0.5 mm in diameter, and by 5-6 days the diameter
11
Table 3. Differential characteristics of the genus Bordetella and other morphologically and 
physiologically similar genera (modified from Pittman , 1984).
Characteristics Bordetella Alcaligenes Brucella Haemophilus
Strictly parasitic . + - + -
Saprophytic - + - -
Localise on respiratory cilia + - - -
Strictly aerobic + + + -
Growth requirement:
Thiamine - - + -
Nicotinamide + - - -
X and V factor - - - +
Ferment carbohydrates - - - +
Nitrate reduction D D + +
Litmus milk alkaline + + - -
Oxidation of amino acids + + + -
Tetrazolium reduction + - b +
Growth on 320 mg/litre
Potassium tellurite - + -
Citrate utilised D + - -
PAGE resemblance0 - - -
Mol % G +C  of DNA 61-70 (Tm) 56-70 (Tm) 55-58 (Tm) 38-44 (Tm)
a Symbols : + = positive reduction ; (-) no reaction ; (D) variable 
b Blank space indicates no information 
c PAGE patterns are distinct for each genus
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increases to 2-3 mm, when they are smooth, convex, glistening almost transparent, and 
pearl-like in appearance.
The growth of bordetellae other than B. pertussis may take place on MacConkey’s 
agar; for the primary isolation of B. bronchiseptica either blood agar (Thompson et al., 
1976) or MacConkey’s agar with or without selective ingredients is used. The inhibitory 
agents which improve selectivity: nystatin, furasolidone and furaltadone were proposed by 
Farrington and Switzer (1977).
For the culture of B. avium, a blood agar containing Colombia agar base and 7% 
defibrinated ox-blood or veal-infusion agar was recommended by Kersters et al. (1984).
Growth of B. parapertussis is more rapid than B. pertussis, visible growth 
being achieved in 1-2 days to the same colony size as B. pertussis at about 3 days. Also a 
brown discolouration is produced by B. parapertussis and is more pronounced on peptone 
agar or tyrosine agar, as recommended by Lautrop (1960). B. bronchiseptica and B. 
avium are the most rapidly growing among Bordetella species, their visible colonies being 
detectable after 24 h on BG-medium. B. bronchiseptica on MacConkey’s agar gives 
reddish colonies surrounded by a small red zone with amber underlying medium.
The nutritional requirements of B. pertussis, B. parapertussis, and B. 
bronchiseptica were studied by Proom (1955): Eight amino acids were sufficient for 
growth, and nicotinamide was the only vitamin needed; starch was necessary for B. 
pertussis. Jebb and Tomlinson (1957), found that glutamic acid and a sulphur-containing 
amino acid - cysteine, cystine or methionine-together with nicotinic acid were sufficient for 
a number of strains of B. pertussis, and concluded that difficulties in growing the organism 
were due to its susceptibility to inhibitors in the medium. These inhibitors appeared to be 
unsaturated fatty acids (Pollock, 1947), colloidal sulphur or sulphides (Proom, 1955) and 
possibly organic peroxides (Rowatt, 1957). Of these inhibitors, fatty acids may be the most 
critical. Free fatty acids appear to be formed by B. pertussis (Pollock, 1947) suggesting 
that auto-inhibition may take place. Growth of B. pertussis was inhibited by long-chain 
fatty acid concentrations as low as 1 ppm (Field and Parker, 1979). The other Bordetella 
were not susceptible to the inhibitors of B. pertussis that are found in complex media.
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Liquid media were developed by Homibrook (1939, 1940) and Cohen and Wheeler 
(1946), primarily for vaccine production. They contained salts, amino acids, nicotinic acid 
and soluble starch. Neither of these media allows growth from small inocula, and when 
solidified with agar they do not permit single cells to give rise to separated colonies. Starch 
and albumin because of their affinity for lipids, were included in the original isolation 
medium of B. pertussis. As alternatives to starch (Ungar et al., 1950), albumin (Pollock, 
1947), charcoal (Pollock, 1947; Holt, 1962), and anion-exchange resins may be used 
(Kuwajima et al., 1957, Sutherland and Wilkinson. 1961). More recently, cyclodextrins 
(Imaizumi et al., 1983 a, b), polyvinyl acetate, polyvinyl alcohol (Greenspan, 1985) and 
methylcellulose (Nikolajewski et al., 1990) have been proposed, all of which appear to act 
by adsorbing a growth inhibitor.
Goldner et al. (1966), found that glutamic acid and proline were the only amino 
acids needed for the growth of B. pertussis. Stainer and Scholte (1970) developed a 
chemically defined liquid medium containing glutamic acid, proline, and cystine, together 
with ascorbic acid, niacin, glutathione, salts and Tris buffer. Although suitable for the bulk 
growth of cells for vaccine production, Stainer and Scholte medium did not permit growth 
from small inocula. Imaizumi et al. (1983a) overcame this latter difficulty by adding 
dimethyl-p-cyclodextrin (DMpCD), after which it was solidified with agarose to constitute 
the first defined medium for B. pertussis to allow reliably the growth of separated colonies 
from dilute inocula. A modified Stainer-Scholte medium was used by Sato et al. (1984) to 
induce B. pertussis to release substantial quantities of pertussis toxin (PT) and filamentous 
haemagglutinin (FHA) into culture supemates and thereby facilitate the manufacture of 
acellular vaccines containing these components.
Because of ammonia formation during growth of the bordetellae, the buffering of 
culture media is required to prevent excessive rise in pH.
Susceptibility to physical and chemical agents
Exposure of bordetellae to a temperature of 56 °C is lethal within 30 min and the 
heat-labile toxin is destroyed, after which a suspension potentially suitable, after
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standardization, for use as a vaccine may be obtained. Outside the host body, B. pertussis 
in dried droplets was found to survive up to 5 days on glass, 3 days on cloth, and a few 
hours on paper (Ocklitz and Milleck, 1967, cited by Wardlaw, 1990).
Biochemical activities and metabolism
None of the bordetellae ferments sugars but there are species-associated differences 
in other biochemical tests (Johnson and Sneath, 1973; Pittman and Wardlaw, 1981; 
Kersters et al., 1984). Some of their cultural and biochemical features are presented in Table
4.
There have been only a very few basic studies on metabolism. Dobrogosz et al. 
(1979) reported that B. pertussis, B. parapertussis, and B. bronchiseptica have the 
following enzymes that are important in oxygen metabolism: superoxide dismutase, 
catalase, and peroxidase. McPheat and Wardlaw (1980) showed that the uptake of 
radiolabelled nicotinic acid and nicotinamide by B. pertussis was temperature and energy 
dependent and required potassium ions; also certain analogues of nicotinic acid acted as 
specific inhibitors of its uptake by B. pertussis, but without inhibiting either the growth of 
the bacteria in nutrient medium or the ability of washed bacterial suspensions to oxidize 
glutamate.
Virulence factors and other cellular components
B. pertussis produces a group of toxins, aggressins and adhesins. These virulence 
factors and cellular components (Table 5) are regarded as important components in bacterial 
pathogenicity, as follows:
Heat-labile toxin (HLT): Also known as dermonecrotizing toxin, the first reported 
toxin of B. pertussis (Bordet and Gengou, 1909). The toxin is heat-labile, with toxic 
activity lost upon heating for 10 min at 56 °C (Manclark and Cowell, 1984). The toxin 
causes inflammation and necrotic skin lesions after subcutaneous injection at low doses in 
mice but is lethal at high doses (Cowell et al., 1979; Livey and Wardlaw, 1984; and Nakase
15
Table 4. Differentiation between Bordetella species: B. pertussis (B.p), B. parapertussis 
(B.pp), B.bronchiseptica (B.b), B. avium. (B.a),B. hinzii (B.hi) and B. holmesii (B.ho) 
(modified from Pittman, 1984 ; Parton, 1997).
Characteristics B.p B.pp B.b B.a B.hi B.ho
Growth: colonies 
visible in (days) 3 1-2 1 1 2 2-3
Peptone agar: 
Phase I + + + ? ?
Phase IV + + + + ? ?
growth - + + + + +
browning - + - - - +
Growth on 
MacConkey agar + + + + +
Motile, Peritrichous 
flagella + + + .
(3-like haemolysis + + V V ? -
Citrate utilization - V + V + -
Nitrate reduction - - + - - -
Oxidase + - + + + -
Urease - + + - V -
Litmus milk 
alkaline + + + + ? ?
Major cellular
fatty acids* Ci6:lw7c C l6 :0 Cl7:Ocyc C l6 :0 Cl 6:0 Cl6:0
C l6 :0 Cl7: O eye Cl6:lw7c Cl7:Ocyc Cl7:Ocyc Cl7:Oc)
G+C content of
DNA (mol%) 67.7-68.9a 68.1-69.0a 68.2-69.5b 61.6-62.6c 65-67 61.5-6'
+, positive; negative; v, some strains positive, others negative; ?, unknown.
*The number before the colon is the number of carbon atoms and the number after the colon 
is the number of double bonds; w, double bond position; c, cis isomer; eye, cyclopropane 
ring.
a = Johnson (cited by Johnson & Sneath, 1973); b = Type strain; c = Strain 591/ 77 of 
Hinz.
and Endoh, 1985).
Tracheal cytotoxin (TCT): A glycopeptide which was first discovered by Goldman et 
al. (1982). TCT can caused ciliostasis and specific damage to ciliated cells in hamster 
tracheal ring cultures and inhibition of DNA synthesis (Goldman and Baseman, 1980). TCT 
appears to be non-immunogenic (Goldman, 1988). The study by Heiss et al. (1993) 
implicated interleukin-1 a , produced by epithelial cells in response to TCT, as a potential 
intracellular mediator of the primary respiratory cytopathology of pertussis. Heiss et al. 
(1994) have implicated nitric oxide, synthesised in response to IL -la , as the actual 
cytotoxic factor
Adenylate cyclase toxin (ACT): The existence of B. pertussis ACT was first 
reported by Wolff and Cook (1973) in studies with whole cell vaccine. ACT is a bi­
functional protein with both AC and (weak) haemolytic activities (Coote, 1992). ACT is 
primarly cell-associated, but may also be extracytoplasmic, and is activated by calmodulin 
(Wolff et al., 1980). This activation enables the ACT to penetrate a variety of mammalian 
cells and to cause intoxication by catalysing the production of cyclic adenosine 3',5'- 
phosphate (cAMP) (Confer and Eaton, 1982). Bourne et al. (1974) showed that the 
inhibition of various phagocytic functions can be due to elevated cAMP.
Studies by Utsumi et al. (1978) showed that AC could be recovered from B. 
pertussis cells by urea extraction and that the cyclase activity was quite stable under these 
conditions. The extract inhibited human polymorphonuclear leukocyte (PMN) functions, 
including chemotaxis and oxygen consumption.
The production of superoxide by human PMN and alveolar macrophage was 
inhibited by dialysed AC urea extract (Confer and Eaton, 1982). Also, the AC urea extract 
caused an accumulation of cAMP to a high levels in PMN, lymphocytes, monocytes, 
Chinese hamster ovary (CHO) cells, mouse S49 lymphoma cells and isolated rat pituitary 
cells (Hewlett et al., 1985). The toxin itself is an AC enzyme that enters target cells where it 
catalyzes the conversion of intracellular ATP to cAMP. In phagocytic leukocytes, this
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massive accumulation of cAMP results in paralysis of killing function (Confer and Eaton, 
1982; Pearson et al., 1987). Hewlett and Gordon (1988) demonstrated effects of ACT on 
immune effector cells (Table 5) such as macrophages, monocytes and neutrophils, causing 
an inhibition of chemotaxis.
Gusio et al (1991) showed that active immunization with purified B. pertussis AC- 
HLY or AC (a fragment of the AC-HLY molecule carrying only the adenylate cyclase 
activity but no toxin activity in vitro) protected mice against B. pertussis intranasal 
infection. They reported also that the immunization with AC-HLY or AC significantly 
shortened the period of bacterial colonization of the mouse respiratory tract.
Pertussis toxin (PT): Among Bordetella species virulence factors, PT is produced only 
by B. pertussis. The name of PT was proposed by Pittman (1979), and the toxin was 
previously known as pertussigen (Munoz and Bergman, 1977), histamine-sensitizing factor 
(HSF), leukocytosis and lymphocytosis promoting factor (LPF) and islet-activating protein 
(IAP) (Yajima et al., 1978).
PT may play a major role in the pathogensis of whooping cough (Pittman, 1979; 
1984). PT is composed of 6 protein sub-units SI, S2, S3, S4 and S5 in a molar ratio in the 
native molecule of 1:1:1:2:1 (Tamura et al., 1982). Similar to other toxins that cross cell 
membranes, PT has an A-B structure. Whereas the A-subunit promoter consists of subunit 
S 1 which is enzyme active as an ADP-ribosyl transferase and NAD-glycohydrolase, the B 
(binding) portion consists of S2, S3, 2 of S4, and S5; and is responsible for binding PT to 
specific cell receptors and enabling the enzymatic A portion to reach its site of action in the 
cell (Katada and Ui, 1982). T cell mitogenic and haemagglutinating activities of PT are due 
to the B subunit binding to cell surface ( as reviewed by Parton, 1997).
Katada and Ui, 1982 showed that the A enzymatic portion catalyzes the ADP- 
ribosylation of a 41kDa membrane protein (GTP-binding protein, Ni of the membrane 
adenylate-cyclase system) in a variety of cell types. The ADP-ribosylation of Ni protein 
inhibits its regulatory involvement in the inhibitory control of mammalian cellular AC 
function, causing enhanced activity of the mammalian cellular AC (Gilman, 1984). This
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increased AC activity in turn causes an increase of cAMP, with consequent disturbance to 
normal cells. In addition to its toxic activities, PT acts as an adhesin (Tuomanen, 1988) 
(Table 5). The clinical observations of lymphocytosis, hypoglycemia and impaired rise in 
serum glucose in response to epinephrine, all effects of PT, were seen in patients with 
pertussis (Bader-El-Din et al., 1976). B. pertussis BP357 (PT deficient) was found to be 
severely impaired in the ability to cause lethal infection in the infant mouse model (Weiss et 
al. 1984; Weiss and Goodwin, 1989). Weiss and Hewlett (1986) mentioned a group of 
functions (Table 6) which were inhibited by PT, such as: oxidative burst of neutrophils, 
migration of monocytes, homing pattern in vivo of lymphocytes, degranulation of mast cell 
and target cells lysis by natural killer cells.
The conversion of PT into toxoids for their use in acellular vaccines was done by 
treatment with glutaraldehyde (Munoz et al., 1981a, b), formaldehyde (Sato et al., 1984) 
and carbodi-imide (Christodoulides et al., 1987). Due to this conversion, the immuno- 
genicity was retained while toxicity was lost, although it seems with the formaldehyde 
treatment that partial reversion may occur (Iwasa et al., 1985).
Mice were passively protected from a lethal aerosol challenge with B. pertussis by 
intraperitoneal injection of anti-PT rabbit hyperimmune sera (Sato et al., 1981). Also, mice 
immunized with detoxified PT (treated with glutaraldehyde) were protected against 
intracerebral challenge with B. pertussis (Cowell et al., 1982). Sato et al. (1984) stated that 
mice were protected against intracerebral and aerosol challenge with B. pertussis by either 
active immunization with PT-toxoid or passively with anti-PT sera. In a study of the 
properties of the B oligomer of PT, Nencioni et al. (1991) reported that it was able to induce 
protective immunity in mice but was less potent than molecules containing the S1 subunit 
also.
The relationship between anti-PT serum titres and long-term immunity to B. 
pertussis infections in children was demonstrated by Granstrom et al. (1985).
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Filamentous haemaglutinin (FHA): FHA, like PT has in vitro haemagglutinating 
activity. The molecule is highly hydrophobic, and filamentous, and appears in the electron 
microscope as a fine filament-like protein 2 nm in diameter and 40-100 nm in length. It can 
agglutinate various types of erythrocytes (Arai and Sato, 1976; Morse and Morse, 1976). 
The involvement of FHA in the initial attachment and adherence of B. pertussis to ciliated 
epithelial cells of the upper respiratory tract to start infection was suggested by Tuomanen 
et al. (1984); Tuomanen and Weiss, 1985). This suggestion was later confirmed by in vitro 
studies using human WiDr cells (Urisu et al., 1986).
In vitro, both FHA and PT were required for a strong adhesion of B. pertussis to 
the ciliary tufts of human respiratory-tract cells (Tuomanen, 1988). Menozzi et al. (1994) 
demonstrated that FHA contains at least three different binding sites, a feature unusual for 
bacteria adhesins but similar to features of eukarytic adhesins and extracellular matrix 
proteins. According to Parton (1997), because of its adhesive and mouse-protective 
activities, FHA was included as a prime component in acellular pertussis vaccines. 
Tommaso et al. (1991) suggested that subregions of FHA that do not contain sequences that 
are potentially cross-reactive with self proteins may be sufficient to induce an immune 
response against the whole protein.
Fimbriae (Agglutinogens , AGGs): In the early decisive serological work on the 
genus Bordetella, 14 AGGs were described by Eldering et al. (1957). Nowdays, only 
AGGs 1, 2 and 3 of B. pertussis are generally recognised and AGGs 2 and 3 form part of 
the fimbrial structures (Parton, 1997). The role of AGGs in pathogenicity is still unclear. 
Sato et al. (1979) reported that antibodies to AGGs numbers 1 and 2 inhibited attachment of 
B. pertussis to HeLa cells. It was reported that AGGs play no major role in the attachment 
of B. pertussis to the ciliated cells of the human respiratory tract (Tuomanen, 1988). 
However, monoclonal antibodies to type 2 or type 3 fimbriae blocked the adhesion of B. 
pertussis to Vero cells (Gorringe et al., 1985). Preston (1988) recommended that 
pertussis vaccine should contain AGGS 1, 2 and 3 to ensure immunization against the major 
serotypes. In a novel adherence model using tracheal rings removed from baboon monkey,
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Funnell and Robinson (1993) demonstrated a functional role (in initial stages of 
colonization) for the fimbriae of B. pertussis.
Endotoxin: The endotoxin of B. pertussis has similar biological activities to those of 
endotoxins from other gram-negative bacteria. B. pertussis endotoxin is generally refered 
to as a lipo-oligosaccharide consists of lipid A and an oligosaccharide core with 2-keto-3- 
deoxyoctulosonic acid, but it does not have the long-chain polysaccharide O antigen typical 
of lipopolysaccharide endotoxins (Brodeur et al. 1993). Endotoxin properties in general, 
include pyrogenicity and adjuvanticity, ability to induce antiviral activity, B cell mitogenicity 
and polyclonal B cell activation (Chaby and Caroff, 1988).
Pertactin (PRN): A  69 kDa outer-membrane adhesin protein was identified by Brennan et 
al. (1988). Leininger et al. (1990) reported that PRN and FHA both contain arginine- 
glycine-aspartic acid (RGD) sequences which may be involved in binding to integrin 
receptors of mammalian cells. These findings support the idea that PRN and FHA have a 
role in binding of B. pertussis to mammalian cells. As reviewed by Parton (1996), vaccines 
containing PRN provide protection of mice against aerosol challenge with B. pertussis and, 
when given with FHA, protect against intracerebral challenge.
Other virulence-associated outer-membrane proteins are 1) Bordetella resistance to 
killing (BrkA), mentioned by Fernandez and Weiss (1994) who found that a mutant 
deficient in BrkA was less virulent for mice, less adherent and less invasive to HeLa cells, 
and at least 10-fold more susceptible to killing by normal human serum than the parent cells. 
2) Tracheal colonization factor (TCF) which was described by Finn and Stevens (1995). 
They found that a B. pertussis mutant lacking TCF had reduced ability to colonize mouse 
tracheal cells, compared with the parent strain.
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Table 5. The virulence factors and cellular components of the classic Bordetella species: B. 
pertussis (B.p), B. parapertussis (B.pp), B. bronchiseptica (B.b) and B. avium (B.a). 
(Modified from Wardlaw, 1988; and Parton 1997)
Component B .p B.pp B .b B. a Probable role in pathogenicity
Toxins :
Heat-labile toxin + + + + Local inflammatory effect
Tracheal cytotoxin + + + + Ciliostasis, epithelial cell
Adenylate cyclase toxin/ + + + -/?
cytotoxicity 
Interference with immune
Haemolysin 
Pertussis toxin +
effector cells/? 
Adhesin/invasion, interference
Filamentous
haemagglutinin + + +
with immune effector cells 
Adhesin/invasion
Pertactin + + + - Adhesin/invasion
BrkA + ? + - Adhesin/invasion,
Tracheal colonization 
factor +
serum resistance 
Adhesin
Endotoxin* +LOS +LPS +LPS +? Pyrogenicity
Agglutinogens: 
1, 2, 3,4, 5, 6. +
Adhesin/invasion
7 + + + ?
8, 9, 10 - + + ?
11, 12 - - + ?
13 + - + ?
14 - + - ?
+ , positive; - ,  negative; ?, unknown .
* LOS, lipo-oligosaccharide; LPS, lipopolysaccharide
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Table 6. Inhibitory effects of adenylate cyclase toxin (ACT) and pertussis toxin (PT) on the 
functions of immune effector cells. From Weiss and Hewlett (1986).
Toxin Target cell Functions inhibited
ACT
PT
Neutrophil
Alveolar macrophages
Monocyte
Natural killer cells
Neutrophil
Monocyte
Lymphocyte
Mast cell
Natural killer cells
Chemotaxis, phagocytosis, superoxide generation 
bacterial killing
Oxidative burst, bacterial killing 
Oxidative burst, bacterial killing 
Target cell lysis 
Oxidative burst 
Migration
Homing pattern in vivo 
Degranulation 
Target cell lysis
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In vitro killing of B. pertussis by serum
Serum of humans and many animals possesses a rapid and efficient bactericidal and 
bacteriolytic activity against a wide variety of Gram-negative bacteria (Taylor, 1983). In 
fact, any procaryote that presents a lipid bilayer membrane to the external enviroment would 
appear to be potentially susceptible to complement killing (Taylor, 1983).
Increased phagocytosis of B. pertussis in the presence of antibody was reported by 
Kendrick et al. (1937). In vitro, specific antisera plus complement are highly bactericidal to 
B. pertussis (Dolby and Standfast, 1961). They suggested that in intracerebrally-infected 
mice the diffusion of circulating antibodies to the brain (due to blood-brain barrier 
permeability) may cause the rapid and progressive fall of bacterial viable count. Antisera to 
B. pertussis are bactericidal for some strains of the same bacteria in the presence of 
complement and lysozyme (Dolby, 1965). She also stated that phase I strains that were 
virulent for mice by the intracerebral and intranasal routes, are sensitive to the bactericidal 
effect of antiserum and most mouse avirulent strains are not sensitive. Ackers and Dolby 
(1972) reported that lipopolysaccharides (lipooligosaccharides) of B. pertussis elicit 
bactericidal antibody active in vitro in the presence of complement against serum-sensitive 
strains.
The protective ability of sera from vaccinated or infected children to protect mice 
against small, lethal brain infections was correlated with the complement-mediated bacterici­
dal antibody titres of the sera, but this was not related to the state of immunity in the 
children (Dolby and Stephens, 1973). Strains of B. pertussis varied in their ability to elicit 
(in mice) an antibody bactericidal for an antiserum-sensitive strain of B. pertussis, although 
antibody was usually detectable after only one injection (Dolby and Ackers, 1974).
Viable cell numbers (CFU/ml) of B. pertussis strains decreased by 99 % after 
exposure for 1 h to porcine hyperimmune serum (Byrd et al., 1991). Fernandez and Weiss 
(1994) showed that the serum component mediating the killing of susceptible B. pertussis 
organisms appears to be complement. Also, they demonstrated that both heat-inactivation 
and the pretreatment of serum with ethylenediaminetetraacetic acid, which removes divalent 
cations required for complement activation, resulted in the complete abrogation of serum
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killing. There appear to be no studies on the possible BA of respiratory tract secretions on 
B. pertussis.
Animal Models of Pertussis 
Introduction
"Animals not only are necessary for determining the etiology of specific infectious 
diseases and the pathogenicity of particular cultures of bacteria, but are also utilized as a 
means of isolation, to determine in more detail certain specific pathogenic mechanisms, to 
maintain species that grow best in vivo, to increase pathogenicity, and to produce 
antibodies" (Warren, 1957). The same investigator mentioned that the bacterial species and 
the property to be studied determine the choice of the experimental animals.
A great many efforts have been made to reproduce typical human pertussis in 
laboratory animals. Most of the studies have been with the mouse respiratory infection 
model, because of its several advantages and this has yielded much knowledge on 
pathogenesis and immunity in pertussis (Sato and Sato, 1988).
Mice
Only two sites of infection, with a measured volume of standardized bacterial 
suspension, have been used in the mouse: intranasally into the lung and intracerebrally into 
the brain (Standfast and Dolby, 1961). These investigators found that the terminal viable 
count in the lungs and brain was always around 10^ CFU, with death occurring on the 4th 
and 5th day after infection (lethal infections).
Intracerebral infection: The intracerebral infection of mice was first suggested by 
Norton as a result of a successful use of this route with Salmonella typhi (Norton and 
Dingle, 1935). Two different routes of intracerebral infection were used, one through the 
foramen magnum and the other through the parietal bone (Berenbaum et al., 1960). 
Multiplication of the bacteria took place in the ciliated layer over the ependyma. No 
organisms were detected in the lungs, spleen and liver of the cerebrally-infected mice, but
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some organisms were found in the blood stream.
Multiplication of B. pertussis in the brains of unvaccinated and vaccinated mice 
occurred at the same rate until day 3 of the infection. Thereafter, with vaccinated animals the 
infection peak occurred on day 4 with around 10^ organisms and then the number of 
bacteria declined until day 5 or 6 and the animals survived (Berenbaum et al., 1960).
Standfast and Dolby (1961) reported that as the cerebrally-infecting dose was 
lowered from 10^ to 10 viable organisms, the critical level at which death occured also 
decreased from 10&-5 to 10*7*8 organisms respectively. Also as the infecting dose 
decreased, the time taken for the critical level appeared to increase from 4 to 13 days 
respectively.
Sublethal infections is not possible in the brain, since regardless of the initial 
inoculum, colony count numbers consistently increased to 10& CFU, with eventual death. 
Dolby and Standfast (1961) reported the possibility of growth of a single B. pertussis cell 
in the brain to a critical lethal level.
Intranasal infection: Burnet and Timmins (1937) described the intranasal technique for 
the infection of mice with B. pertussis. They demonstrated that intranasal adminstration of 
B. pertussis cultures to anaesthetized mice results in characteristic pneumonic lesions, and 
in large doses is rapidly fatal. Also by histological sections, they observed an interstitial 
pneumonia and a typical intense proliferation of bacilli in the mucus lying on the ciliated 
surface of the bronchial epithelium. The same investigators stated that a significant degree 
of immunity can be demonstrated after intraperitoneal inoculation of living cultures or 
formolized vaccines.
Sublethal lung infections were induced in mice with 1(P CFU. The lung count 
increased steadily to 10^ until the 10th to 14th day after infection and then slowly declined 
over some weeks or months until the lungs became sterile.
Sato et al. (1980) introduced a system for the aerosol infection of mice with B. 
pertussis by placing the animals on a mesh screen in a glass chamber fitted with a 
nebulizer. The animals were exposed to aerosol droplets for 30 min by spraying 0.4 ml of
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bacterial suspension per min at a nebulizer pressure of 1.5 kg / cm^. This system gave a 
more accurate and reproducible inoculum. From a bacterial concentration of 2 x 10^ CFU / 
ml, an initial delivered inoculum of 2 x 10^ CFU / lung was obtained, which increased to a 
maximum of 10^ CFU / lung in 14 days, after which the viable count decreased. Again the 
lethal dose by this route was found to be 10^ CFU / lung.
Although B. pertussis is not a natural pathogen for mice, valuable basic information 
about the pathogenesis of human pertussis has been obtained from the studies of 
respiratory infection in this species. However, the infected mice do not cough and do not 
pass the disease to other mice. Nevertheless, the mice respiratory infection resembles that in 
humans in a number of respects:
(1) younger mice have a higher susceptibility to the infection, while adult mice generally do not 
show severe symptoms; infant or suckling mouse have characteristic symptoms and mortality 
from the disease. (2) The period of pulmonary infection is of similar duration to that in humans. 
(3) there are pathophysiological changes such as histamine-sensitization, hypoglycaemia, 
hyperinsulinaemia, and marked leukocytosis, that persist even after the bacteria have 
disappeared (Sato and Sato, 1988).
Transposon-insertion mutants deficient in the production of either pertussis toxin 
(PT) or adenylate cyclase toxin (ACT) are markedly reduced in their virulence for infant 
mice when given intranasally (Weiss and Goodwin, 1989).
Intratracheal infection: Bradford (1938) observed characteristic lung lesions and 
hyperleukocytosis after the intratracheal inoculation of mice with suspensions of recently 
isolated B. pertussis. Also he isolated pure cultures of the bacteria from the infected lungs 
of the mice.
Other species
Infection of chick embryos with B. pertussis was done by inoculating the amniotic 
fluids of the embryonated hen's eggs (Gallavan and Goodpasture, 1937). The infection was 
concentrated especially on the ciliated epithelial cells of trachea and oesophagus with less
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preference to the ciliated epithelial cells of the bronchi and bronchiole.
Prim ates’. Early work using primates as animal model of pertussis was carried out by 
Inaba (1912, cited from Lapin 1943), when he infected macacus monkeys with freshly 
isolated B. pertussis using a pharyngeal swab. Paroxysmal cough and vomiting were 
observed within 10 days. Also paroxysmal cough was found with macacus and cebus 
monkeys challenged with freshly isolated B. pertussis either by pharyngeal swab or by 
injecting into the larynx (Sauer and Hambrecht, 1929). Laboratory examinations revealed 
B. pertussis on the respiratory epithelium of the animal, with leukocytosis and 
lymphocytosis. Also, the animals which recovered were immune to subsequent injections 
of various strains of B. pertussis.
Young ring-tail monkeys developed a whooping cough after exposure to B . 
pertussis infection by spraying of aerosol (Inaba and Inamori, 1934). Also in 1934, the 
same investigators reported the transmission of the disease among monkeys, after the 
animals were infected by spraying a culture of B. pertussis into the nares and pharynx, and 
developed paroxysmal coughing and leukocytosis. Lin (1958) reported that Macacus 
cyclopsis monkeys could be infected with B. pertussis strains 18-323, 10-5362 and 23- 
757 by aerosol and subsequently exhibited a paroxysmal cough with lymphocytosis.
Experimental whooping cough was confirmed in Taiwan monkeys by Huang et al. 
(1962). Rhesus and cynomologus monkeys and marmosets were used for experimental 
pertussis by Stanbridge and Preston (1974). However, neither rhesus nor cynomologus 
monkeys showed any signs of illness after pemasal inoculation with 1 0 ^  organisms. The 
failure to infect these monkeys might have been due to previous infection with B. pertussis 
or other Bordetella species. In marmosets, there are several features of pertussis infection 
similar to those seen in children with whooping cough, such as catarrh and persistence of 
colonization of the nasopharynx with B. pertussis; however, marmosets failed to produce 
either the paroxysmal cough or vomiting.
Immunity following reinfection has been demonstrated in monkeys (Sauer and 
Hambrecht, 1929; Lin, 1958). A possible active immunization by vaccination in Taiwan
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monkey was also reported (Huang et al. 1962). They also reported that sera from 
convalescent and vaccinated Taiwan monkys were successfully used for passive 
immunization of the same species.
Rabbits'. The early work of using the rabbit as an animal model of pertussis was by 
Mallory and his colleagues (1913), when they intratracheally infected animals with B. 
pertussis. In addition to emaciation as a clinical observation, they also observed histological 
lesions characteristic of pertussis in the ciliated epithelium of the bronchi and bronchioles of 
the animal. The same investigators however, also stated that their clinical and laboratory 
observations could have been due to B. bronchiseptica.
With rabbits, lymphocytosis within 2-4 days of B. pertussis infection (intratrach­
eally) and interstitial mononuclear pneumonia were observed by Sprunt et al. (1938). A 
persistent colonization (9-10 months) of the rabbit nasopharynx and catarrh with no 
coughing or vomiting was reported by Preston et al. (1980).
In addition to their attempts to induce B. pertussis infection in rabbits, Mallory et 
al. (1913) also mentioned re-isolation of the same organisms from the respiratory tract of 
normal puppies 15-25 days after intratracheal infection, with characteristic lesions and 
spasmodic coughing.
Rats: Homibrook and Ashbum (1939) reported that the intranasal instillation of live phase 
I B. pertussis into ether-anaesthetised young rats produced a non-specific interstitial 
broncho-pneumonia, cough-like paroxysms, and recovery of the bacteria from lung 
homogenates.
Fifty years later, Woods et al. (1989) showed that with B. pertussis infection using 
the virulent phase I strain Tohama, the infected ether-anaesthetized adult male Sprague- 
Dawley rats gave the same clinical and physical changes that was seen in the infected 
human, including the paroxysmal cough. A reproducible infection, similar to the human 
disease was produced in the rat with colonization of the lungs, the organisms being 
recovered at 3 and 7 days after infection. The bacteria were not recovered at days 10 and 14
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in lung homogenates but apparently reappeared at 21 days from infection.
The same investigators stated that at day 3, a mild lymphocytic infiltrate was present 
in the bronchi, with progressive lymphoid hyperplasia peribronchially. By day 7, a necro­
tizing inflammation of the tracheobronchial mucous membranes, characterized by both 
mononuclear and polymorphonuclear cells, was noted. Clinical findings in infected rats 
included hypoglycaemia, circulating lymphocytosis and paroxysms in which air was 
forcibly expelled from the mouth or nose. No histological changes were noted in rats 
infected with B. pertussis phase III strain Tohama, which was also not recoverable from 
infected rat lungs after 3 days from inoculation.
The procedure of Wood et al (1989) was modified and continued by Wardlaw et al. 
(1993); Parton et al. (1994) and Hall et al. (1994). Paroxysmal cough, leukocytosis and 
significant retardation of weight gain were observed with adult Sprague-Dawley rats 
exposed to a non-lethal infection by phase I B. pertussis 18-323 encased in agarose beads 
and adminstrated intrabronchially. Their procedure differed from that of Woods et a l 
(1989) in several respects, specifically: a) B. pertussis strain 18-323 was used instead of 
Tohama b) low-melting point agarose was employed in place of Ionagar no 2; c) a 
temperature of 37 °C, instead of 50 °C was taken when suspending the bacteria in the 
agarose d) a bacterial dose of 10$ CFU per rat, rather than 5x10^ was given; e) 
Hypnorm/Hypnovel anaesthesia was used in place of ether, as anaesthetic for the operation 
(although ether was administered for 2 min post-infection for enhancement of coughing). In 
addition, coughing was quantitated with sound-activated tape recorders (Wardlaw et al.,
1993). Young rats (around 200 g) were more responsive to the infection than older animals 
(330 g).
The same strain of rats produced a paroxysmal cough when infected with either 
agarose-beads containing phase I B. pertussis strains 18-323, Tohama, L84 or transposon- 
insertion mutant BPM 1809, which lacks only the heat-labile toxin (HLT) (Parton et al.,
1994). Phase IV variant of B. pertussis strain L84, BP357, a transposon-insertion mutant 
which is deficient only in pertussis toxin (PT) and B. parapertussis were inactive in 
inducing the cough (Parton et al. 1994). They also reported that DPT (whole-cell) vaccine
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greatly reduced the incidence of coughing in rats challenged subsequently with phase I B. 
pertussis. Finally, by serological tests, there was confirmation of the PT-positive or 
-negative status of the strains in vivo by the detection of appropriate presence or absence of 
anti-PT IgG in convalescent sera by ELISA.
Both paroxysmal cough and leucocytosis were at peak levels after 8-10 days of 
infection (Hall et al., 1994). The same investigators reported a number of a following 
observations: 1) A 2-min exposure of the rats to ether inhalation after delivery of the beads 
enhanced the number of the subsequent coughing episodes; 2) Paroxysmal coughing was 
also enhanced when carrageenan was included in the beads; 3) Moderate amounts of 
coughing and leucocytosis were achieved in rats infected intranasally with B. pertussis 
suspension. Only low levels of coughing, or no coughing, was detected with untreated rats, 
or with rats given sterile beads; 4) No cough induction or leucocytosis were observed with 
rats infected intrabronchially either with heat-killed B. pertussis in beads or with live 
organisms in suspension without beads; 5) Finally, anti-IgG antibodies against both 
pertussis toxin (PT) and filamentous haemagglutinin (FHA) were detected in the 
convalescent serum of infected rats.
RESPIRATORY TRACT SECRETIONS (RTS)
In the following text a distinction will be made where possible between whole lung 
secretions and lung washings. The latter means the diluted lung secretions collected by 
means of washing (lavage) the lungs with buffers, and the former means undiluted 
secretions collected from the lungs by suction.
Collection 
Whole lung secretions and washings
In the conducting airways, the submucosal glands and surface epithelial (goblet) 
secretory cells are the major contributors to the mucus secretions (Reid, 1960). Attempts to 
collect RTS started back in 1882 when Rossbank used blotting paper to dry the exposed
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tracheal mucous membrane of cats and dogs during his research into mucus replenishment 
(cited by Boyd, 1954).
Henderson and Taylor (1910) collected RTS in calcium chloride tubes attached to a 
tracheal canula. The procedure of postural drainage and bronchoscopic suction was 
described by Jackson and Jackson (1934). In 1941, Perry and Boyd used a glass tube 
attached to a tracheal canula to collect the fluid. A special catheter with a cuffed tip was 
passed into an individual lower lobe of dog lungs. The cuff was inflated and three 100 ml 
aliquots of isotonic saline were gently instilled and withrawn through the catheter (Finley et 
al., 1968). The trachea of rats was cannulated with sterile polyethylene tubing in order to 
collect RTS (Juers et al., 1976). The trachea of rabbits was cannulated with a sterile plastic 
tube fitted to a three-way stopcock (LaForce et al., 1979). Mice trachea were exposed and 
cannulated with a blunt 20-gauge needle (Nugent and Fick, 1987).
In order to obtain tracheobronchial washings (TBW) or lung lavage fluids (LLF), 
different buffer fluids have been used to wash the lungs: isotonic saline for dog lungs 
(Pfleger and Thomas, 1971) while pig lungs were washed with 150 ml/kg 20 mM Tris 
(hydroxymethyl) aminomethane- 0.15 M sodium chloride, pH 7.4 (Pruitt et al., 1971). 
LaForce et al. (1979) lavaged rabbit lungs with 50 ml of sterile heparinized saline, whereas, 
a PBS of pH 7.4 was used to wash rat lungs (Coonrod and Yoneda, 1983). Mouse lungs 
were washed with 1ml of PBS pH 7.4 (Nugent and Fick, 1987). Finally, Brogden (1992) 
used PBS, pH 7.2, containing 100 |ig of gentamycin per ml to wash the lungs of ewes, a 
calf and rats.
Processing of the collected lung washings in most cases consisted of centrifugation 
and accumulation of the cell-free supemate, which was distributed in aliquots, then stored 
(if it was not used immediately) frozen at -20 or -70°C (Yeager, 1971; Low et al., 1978; 
Boat and Cheng, 1980).
Lung surfactant
Lung surfactant has been investigated extensively since its discovery by Pattle 
(1955). Finley et al. (1968) fractionated surfactant from dog lung washings fluids by
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centrifugation for 20 min at 27,000 g at 0°C. The resulting sediment consisted of 2 layers, 
the upper white layer (surfactant) and the lower brown layer (mainly blood cells). 
Surfactant from LLF of pigs was fractionated by passing crude LLF through cheesecloth, 
the frothy white floating material removed by suction and the lavaged material then 
centrifuged for 10 min at 1000 g. The dark red pellet was then discarded and the supernate 
was centrifuged for 20 min at 27,000 yielding an off-white, densely packed pellet 
(surfactant), which then was resuspended in buffer (Pruitt et al., 1971).
Isolation of surfactant from crude lung lavage (samples containing blood were 
rejected) of ox, rabbit, rat, and sheep was done by initial centrifugation for 20 min at 300 g 
to remove cells. This was followed by further centrifugation of the supernate for 60 min at 
1000 g and the pellet was resuspended in 21 % (w/v) NaCl. Further centrifugation for 25 
min at 1500 g resulted in a three-phase separation into an insoluble floating fraction 
(surfactant pellicle), a soluble fraction (soluble surfactant), and a small precipitate at the 
bottom of the tube. The surfactant pellicle was dialysed against water for 48h, freeze-dried 
and stored under N2 at - 15 °C (Harwood et al., 1975).
Another method of fractionating surfactant from rabbit crude LLF was by 
centrifugation for 7 min at 700 g. The deposit containing alveolar macrophages was 
discarded and the cell-free supernate was recentrifuged for 20 min at 25,000 g at 4 °C. The 
pellet (surfactant) was reconstituted to its original volume with Hank's balanced solution 
pH 7.2 (LaForce et al., 1979). Coonrod et al. (1984) isolated surfactant by initial 
centrifugation of crude LLF for 5 min at 160 g to remove leukocytes. The supernate was 
either concentrated 20-fold by positive-pressure filtration through a 10,000 mol. weight 
exclusion filter or by centrifugation for 20 min at 40,000 g. The pellet (surfactant) was then 
resuspended in PBS in one-twentieth the volume, and stored at - 70°C.
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Composition 
Whole lung secretions and washings
General composition: Human RTS contained approximately 95 % water and 5% solids 
(Matthews et al., 1963). The water was either free or bound at one of several levels of 
affinity to macromolecular components, or was trapped within interstices of a gel matrix, 
formed by polymerization and aggregation of the mucous glycoproteins and other 
macromolecular components. The 5 % solid content of human RTS included 2-3 % proteins 
and glycoproteins, 1% lipids, and 1% minerals (Mattews et al., 1963).
The water in the RTS contained inorganic salts, proteins and glycoproteins 
(Richardson and Phipps, 1981). The respiratory mucus is very complex and includes 95-98 
% of water, ions, sugars, amino acids and 1-3 % of proteins, glycoproteins and lipids 
(Robinson et al., 1989). Variations in the value of respiratory tract fluids component of 
different material by different investigators is probably due to the method followed for fluid 
collection and dilution.
Inorganic components: Chloride, sodium, phosphorus, calcium and potassium levels in 
RTS of various animals were reported by different investigators (Table 7). Boyd (1954) 
detected chloride in rabbit, cat, and dog LLF at concentrations of 5.2 ± 2.6 mg / ml, and 
potassium levels in cat RTS of 0.76 mg / ml. The inorganic analysis of human RTS was 
studied by Matthews et al. (1963) and Potter et al. (1967). The first investigated the overall 
chemical composition of pulmonary secretions, whereas Potter et al. (1967) studied the ionic 
environment of secretions from patients with cystic fibrosis and bronchiectasis. The 
concentrations of sodium and chloride were high in normal secretions compared with 
potassium and calcium which occurred at much lower concentrations. About 15 % of the 
monovalent ions and 30 % of calcium were not removed by dialysis, suggesting that there 
was considerable ion-binding to macromolecular components (Potter et al. 1967).
Proteins'. Protein concentration in human LLF depended on the method of collection, 
especially the extent of dilution. This probably explains the different values (Table 8) 
reported by the following investigators: Matthews et al. (1963) found 10.0 ± 3 mg / ml 
(mean ± SD) protein; while Low et a l . (1978) reported 0.068 ± 0.029 mg / ml, and Davis 
et al. (1982) got 0.114 ± 0.005 mg/ml. These differences in estimated protein levels in 
human RTS, by the last two workers compared with Matthews findings, was due to the 
dilution during sample collection.
Among animal RTS, 0.3 mg/ml of protein was found in the alveolar liquid from the 
foetal lamb (Adamson et al., 1969); in 1944, Boyd and his group reported protein levels 
(mg/ml) in rabbit, cat, and a cockerel RTS of 1.04 ± 0.21, 1.36 ± 0.37, and 2.6 ± 0.4 
mg/ml respectively. Wardlaw and Stevenson (1984) stated that tracheobronchial washings 
of mice had a protein concentration approximately equivalent to a 1/50 dilution of serum. 
Amino acid components of respiratory tract fluids from human and different animal species 
were reported by Potter et al. (1967) and Porter and Wardlaw (1994).
Lysozyme and lactoferrin, another protein which has anti-microbial effects, were 
reported in RTS (Masson and Heremans, 1973); anti-proteases (Boat and Cheng, 1980); 
proline-rich polypeptides were noted in bronchial secretion (Bailleul et al., 1977); and 
glycoproteins (Yeagor et al., 1971; Reasor et a l ., 1978). Total protein concentrations in 
various animal TBWs were reported by Porter and Wardlaw (1994) (Table 8).
RTS may contain immune system components. Yeagor (1971) reported that mucous 
membranes may have their own immune system, thus supporting the previous studies which 
detected immunoglobulins in human RTS: Keimowitz (1964) reported B2A-globulin and 
gamma-globulin, while Masson et al. (1965) identified IgA and IgG.
Reynolds and Thompson (1973) measured the albumin and immunoglobulin 
concentrations in rabbits vaccinated with Pseudomonas aeruginosa (Table 9). Reynolds and 
Newball (1974) reported that albumin and immunoglobulins are the major serum proteins 
present in human LLF, and Reasor et al (1978) detected immunoglobulin in cat fluid (Table
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Table 7. Inorganic composition (mg/ml unless stated) of human and animal (stated) 
respiratory tract fluids.
Reference Inorganic component
(mean ± SD)
Boyd (1954) Cl = 5.2 ± 2.6 (rabbit, cat and dog)
K = 0.76 (cat)
Matthews et al. (1963) Ca = 0.062 ± 0.02
P = 0.27 ±0.16
N a=  1.65 ±0.42
Cl = 1.62 ±0.6
K = 0.132 ±0.054
Potter et al. (1967) Na = 211.1 ±33.8 mM/L
K = 16.6 ±3.4  mM/L
Ca = 2.45 ±1.11 mM/L
Cl = 156.7 ± 24.6 mM/L
Table 8. Protein concentrations of human and animal (stated) respiratory tract fluids.
Reference Protein concentration (mg/ ml)
(mean + SEM unless otherwise stated)
Boyd et al. (1944)* 1.04 ±0.21 (rabbit)
1.36 ±0.37 (cat)
Matthews et al. (1963)* 10.0 ± 3 (mean ± SD)
Adamson etal. (1969)* 0.3 (foetal lamb)
Low etal. (1978)** 0.068 ± 0.029 (mean ± SD)
Davis et al. (1982)** 0.114 ±0.005 (mean ± SD)
Porter and Wardlaw (1994)** 2.17 ±0.10
0.09 ± 0.02 (chicken)
0.60 ± 0.02 (dog)
1.29 ±0.12 (horse)
1.01 ± 0.03 (mouse)
0.32 ± 0.02 (rabbit)
0.77 ± 0.07 (sheep)
* data of respiratory secretions
** data of tracheobronchial washings
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Table 9. Albumin and immunoglobulin concentrations3 in rabbit serum and bronchial 
secretions after vaccination with Pseudomonas aeruginosa. (Reynolds and Thompson, 
1973).
Protein
(no. of samples)
Bronchial secretions^ 
(range)
Serum
(range)
Bronchial: 
serum ratio
Albumin 1.67 ±0.25 40.8 ± 1.6 0.04
(60) (0.24-5.0) (28.0-65.0)
IgA 2.47 ± 0.20 0.50 ± 0.05 4.9
(64) (0.9-5.4) (0.2-1.7)
IgG 1.79 ± 0.12 13.88 ±0.66 0.13
(71) (0.6-4.31) (4.4-23.0)
IgM < 0.1c NDd
a. Concentrations in mg/ml + SEM; b. Concentrated 100-fold to final 1-ml volume, 
c. Detected in 4/73 (5%)samples; d. ND = not done.
Table 10. Immunoglobulins detected in human and animal (stated) respiratory tract fluids.
Reference Immunoglobulin content
(mean + SD)
Reynolds and Newball (1974) IgA = 0.91 ± 0.11 mg / ml
IgG = 0.17 ± 0.05 mg / ml 
IgE = 73.2 ±8.2  ng /ml  
Reasor etal (1978) IgG and IgM detected (dog) ^
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A lpha-1 -antitrypsin, alpha-1 -antichymotrypsin, alpha-1 -acidglycoprotein, 
fibrinogen, ceruloplasmin, haemopexin and several complement components are found in 
RTS (Boat and Cheng, 1980). Complement titres (Table 11) in serum and bronchial 
secretions of rabbits vaccinated with P. aeruginosa were detected by Reynolds and 
Thompson (1973). The same investigators reported that even though bronchial lavage fluids 
appeared free of blood contamination, Wright's-stained differential counts of the cell pellets 
showed 1 to 5 % red blood cells to be present. They suggested that because of the extreme 
sensitivity of the complement assay, the low titres detected in bronchial secretions might 
represent leakage from the pulmonary vasculature due to trauma in lavaging the lungs.
Carbohydrates: concentrations in human RTF were reported by many investigators 
(Table 12). Yeagor (1971) stated that carbohydrates made up 20-50 % of the nondialysable 
material in airway fluids.
Lipids: Lipid and phospholipid concentrations in humans and animals were also reported 
by various investigators (Table 13). Sahu and Lynn (1977) stated that human LLF contains a 
relatively large amount of lipid, about 40 % of the dried insoluble material.
Lung surfactant
Extracellular surfactant can be harvested from the air spaces by bronchoalveolar 
lavage and can be further purified by various centrifugation steps (King and Clement, 1972a; 
King, 1984).
Lipids: Dog surfactant contained about 80-90 % lipid by weight; more than 80 % of the 
lipid was phospholipid (King and Clements, 1985). Of this phospholipid, the components 
were phosphatidylcholine (60-70 %), phosphatidylglycerol (5-10 %), phosphatidyl- 
ethanolamine (5-10 %), and phosphatidylinositol and phosphatidylserine at 3-6 % of total 
phospholipids.
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Table 11. Complement titres detected in serum and bronchial secretions of rabbits 
vaccinated with Pseudomonas aeruginosa. (Reynolds and Thompson, 1973).
Component 
(no. of samples)
Serum
(range)
Bronchial secretions* 
(range)
Cl 51,000 ± 12,000 20 ±5.4
(7) (32,258-80,000) (0-40)
C4 187 ± 17.5 o**
(5) (152-208)
C6 526 ± 64 9.3 ± 5.8
(9) (200-700) (0-51)
* One hundred-fold concentration to 1 ml at 4 °C, immediately after lung lavage and 
separation of cells.
** Of note was the finding that C4 titres in bronchial secretions diminished approximately 
50 % with storage of the fluids for 48 h at - 40 °C. One millilitre of fresh serum diluted to 
100 ml in modified Hanks' salt solution (MHS) and rapidly concentrated to its original 
volume also lost about 50 % of the C4 activity when compared with unaltered serum.
Table 12 . Carbohydrate concentration in human respiratory tract fluids.
Reference Carbohydrate concentration
(mg/ml ± SD unless stated)
Matthews et al. (1963) * 9.51 ± 2.18
Potter et al. (1967)* 19.3 ± 9.4 m M / m l
Low et al. (1978)** 0.008 ± 0.004
Davis et al. (1982)** 0.011 ± 0.002 (mean + SEM)
* Respiratory tract secretions
** Tracheobronchial washings
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These values were similar to those in pig surfactant (Pruitt et al., 1971), and ox, 
rabbit, rat and sheep surfactant (Harwood et al., 1975). Shelley et al. (1984) detected 
phospholipids in human and different animal surfactants (Table 14 ). Coonrod et al. (1984) 
reported the total lipid and fatty acids (FA) content of rat, dog and guinea pig surfactant 
(Table 15). Klaus et al. (1961) suggested that dipalmitoylphosphatidylcholine was the 
principal surface-active constituent of lung surfactant.
Proteins'. Protein comprises approximately 10 % of surfactant by weight (King et al., 
1973). King (1974) was the first to analyse the protein component of surfactant from the 
lavaged lung of dogs by sodium dodecyl sulphate polyacrylamide gel electrophoresis. Two 
major surfactant-specific proteins appeared to be present: one with a molecular mass of ~ 35 
kDa and the second quite hydrophobic protein, with a molecular mass of ~ 11 kDa.
Also, several protein of serum origin such as albumin and immunoglobulin G (IgG) 
were detected. In other studies, non-specific-surfactant proteins such as secretory 
immunoglo-bulin A (IgA) (Paciga et al., 1980) and actin (Postle et al., 1985) were detected.
Formation: The formation of surfactant starts during the terminal stages of gestation of the 
foetus (Farrell and Avery, 1975). One study by Crapo et al. (1983), of the cells in the 
alveolar region of rat, dog, baboon and human, suggested that there is a striking similarity 
in alveolar cell characteristics among mammals, even those with substantial differences in 
size and in lung functional characteristics. The air-facing surface(s) of the wall are lined by 
a continuous layer, one cell thick, of epithelial cells (type I cells). In addition to the type I 
cells, the alveolar epithelium contains smaller numbers of thicker specialized cells (type II 
cells).
The type I and type II cells comprise - 1 0  and 12 %, respectively of the total lung 
cell population. However, -  95 % of the total alveolar surface is occupied by the type I cells 
and -  5 % only by the type II pneumocytes (Figure 1). The type II cells contain the 
characteristic surfactant storage organelles, the lamellar bodies (Figure 2). It was reported 
that the human lung has about 350 million air pocket (alveoli), with a total absorbing area of
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Table 13. Lipid and phospholipid concentrations in human and animal (stated) respiratory 
tract fluids.
Reference Lipid and phospholipid concentration* 
(mg/ml ± SD, unless otherwise stated)
Boyd (1954)* 0.22 (cat)
0.28 (rabbit)
0.85 (dog)
Matthews etal. (1963)* 8.4 ± 2.7
Potter etal. (1967)* 19.3 ± 9.4 mM/L
Low et al. (1978)** 0.0778 ± 0.00768 (non-polar lipid)
0.0441 ± 0.0415 (polar lipid)
0.00109 ± 0.00033 (phospholipid)
Davis et al. (1982)** 0.167 ± 0.0219 (lipid; mean +SEM)
0.00109 ± 0.00016 (phospholipid; mean + SEM)
* Respiratory tract secretions; ** Tracheobronchial washings
Table 14. Surfactant phospholipid distribution of human and animal species. Percent of total 
phospholipid (Mean ± SE, n = 6). Data from Shelley et al. (1984).
Phospholipids Human Cat Dog Rabbit Rat
Phosphatidylcholine 80.5 86.3a 81.3 83.6 87.0
(±1.4) (± 1.7) (±1.4) (±0.8) (±0.8)
Phosphatidylglycerol 9.1 2.1a 11.1 8.0 8.3
(±0.4) (±0.7) (±1.1) (±0.5) (±0.4)
Phosphatidylethanolamine 2.3 3.2 2.0 3.5 0.7
(±0.8) (±0.8) (±0.6) (±0.4) (±0.2)
All other phospholipids^ 8.1 8.4 5.6a 4.9a 4.0a
(±0.6) (±1.0) (±0.3) (±0.6) (±0.9)
a. Significantly different from human surfactant with p < 0.05.
b. Includes sphingomyelin, phosphatidylinositol (Pl)phosphatidylserine (PS) and lysobis- 
phosphatidic acid. These phospholipids were determined separately in some^samples, and no 
differences were observed among the species. The amounts of PI ranged from 1.5-2.8 % 
and PS from 0.2-0 %. while the amounts of the others were more variable.
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Table 15. Quantitation of fatty acids (FA) in lung lavage of rat, dog and guinea pig by gas 
liquid chromatography. Data from Coonrod et al. (1984).
FFA (% in mixture) Abbreviation Rat Dog Guinea pig
Laurie Cl 2:0 0.1 - -
Myristic Cl4:0 2.8 7.1 2.5
Palmitic Cl 6:0 59.7 33.9 38.3
Palmitoleic Cl 6:0 9.7 7.8 5.4
Stearic Cl8:0 4.2 11.4 13.8
Oleic C18:1 8.6 32.4 36.8
Linoleic Cl8:2 8.5 6.1 0.6
Linolenic Cl8:3 0.3 0 0
Homo-y-linolenic C20:3 0.1 - -
Arachidonic C20:4 3.6 1.2* 0
Eicosapentaenoic C20:5 0.3 - -
Docosatetraenoic C22:4 0.2 - -
Docosapentaenoic C22:5 0.3 - -
Docosahexaenoic C22:6 0.9 - -
Unidentified 0.9 0.1 5.4
% Saturated 66.7 52.4 54.5
% Unsaturated 32.4 47.5 40.1
FFA total (pg/animal) 334 665 71.5
Lipid total (jig/animal) 2,121 16,740 4,757
FFA (as % total lipid) 13.2 4.5 0.97
* Data of arachidonic and higher unsaturated FA.
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Figure 1. A) Cross section through an area of the respiratory zone of  the human lung. 
There  are 18 alveoli, only 4 of  which are labelled. Tw o frequently share a com m on 
wall. B) Schematic enlargem ent of a portion of an alveolar wall. I = a lveolar type I 
cell; II = alveolar type II cell. Data cited from Vander et al. (1990).
A-
C a p i l l a r i e s
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Figure 2. Transmission electron micrograph of lamellar body (plain arrow) contents 
and the lattice-like tubular myelin (dotted arrow) in the alveolar lining fluids of a rat 
lung in situ, two typical morphological structures of pulmonary surfactant. Data cited 
from a review of host defence capacities of pulmonary surfactant (Pison et al., 1994).
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about 90 square meters - about the surface area of half a tennis court (Moore, 1995).
The dynamic conversions of the various surfactant structures in the alveolar lining 
fluid were described by Goerk and Clements (1986) as follows: "Surfactant is secreted as 
lamellar body into the alveolar lining fluid but converted into various macromolecular 
structures including tubular myelin. How surfactant phospholipids from the variety of 
structures present in the alveolar fluid move and adsorb to the surface film is not known, 
but the actual surface film in the lung changes its lipid composition during the dynamic 
compression to low non-equilibrium tensions on expiration and expansion of the film on 
inspiration. On inspiration new material adsorbs to the interphase, on expiration some 
material from the interphase is squeezed out or collapses".
Physiological Activities
The importance of surfactant for lung mechanics has been known since Neergard in 
1929, attributed the differences in recoil forces between fluid- and air-filled lungs to the 
action of surface tension (cited by Pison et al. (1994). Also, the presence of a substance 
which provided very low surface tension in pulmonary oedema fluid and lung tissue was 
demonstrated by both Pattle (1955) and Clements (1957).
The surface tension of the lung extract at different surface areas in vitro was 
measured by Clements (1957). Brief mention of surfactant functions were listed by Pison et 
al. (1994) as follows: a) modification of surface tension in relation to surface area, b) 
promotion of lung expansion on inspiration, c) prevents lung collapse on expiration at low 
transpulmonary pressure associated with normal breathing, and d) balances pulmonary 
fluids preventing lung oedema formation, and e) stabilizes small airways.
Hause et al. (1970) studied pulmonary surfactant of 11 species (mouse, guinea pig, 
rat, rabbit, sea lion, chicken, dog, man, cow, turtle, and frog), ie. representatives of four 
vertebrate classes. They stated that the amount of surfactant, estimated by quantitative 
spreading as a surface film, correlated well with alveolar surface area and with amount of 
saturated, mainly dipalmitoylphosphatidylcholine in the lung parenchyma. The quantities of 
other phospholipids did not correlate well with alveolar surface area. King and Clements
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(1972b) considered that at least 1 mg dry weight of surfactant material should be present per 
g weight of lung tissue in order to enable it to cover all alveolar surfaces. This approximate 
value may vary according to the species studied and the structure of its lungs (Clements, 
1971). Govan et al. (1991) reported a number of conditions due to absence of surfactant in 
premature babies leading to a hyaline membrane disease (Figure 3).
Antibacterial Activities
The defence system of the lung is made up of structural and mechanical mechanisms 
that are accomplished by miscellaneous non-specific factors, and designated cellular and 
humoral components (Brain et al., 1977). Many of the antibacterial functions of antibodies 
are related to their interactions with the components of the complement system (Ishizaka et 
al., 1965; South et al., 1966). However, current evidence suggests that respiratory 
secretions do not contain enough of the components of complement to result in complement- 
mediated responses in the absence of inflammation (Butler et al., 1970; Rossen et al., 1965, 
,1966). Opsonization and other antibacterial functions of some classes of antibodies may be 
denied to IgA (Wilson, 1972). Williams and Gibbons (1972) have suggested that limitations 
of adherence of bacteria to epithelial surfaces by IgA may also prevent colonization. 
Wardlaw and Stevenson (1984) reported antibody against LPS of B. pertussis strain 18- 
323 in LLF of convalescent mice, while no antibody was detected in serum from the same 
animals. No antibody against HLT was detected in either serum or LLF from these animals.
It was reported that nasal secretion contains antibacterial substances such as 
lysozyme that contributes to lysis of some bacteria and lactoferrin that inhibits the growth of 
bacteria dependent on iron by chelating soluble iron salts (Rossen et al., 1965).
Biggar and Sturgess (1977) reported that rat alveolar macrophages contain 10-fold- 
greater intracellular concentrations of lysozyme and release more lysozyme after stimulation 
than rat blood neutrophils. They also concluded that the greater quantities of lysozyme, both 
intracellular and released into the extracellular environment by alveolar macrophages,
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Figure 3. Absence of surfactant in premature babies and the hyaline membrane disease. 
This figure was cited from Pathology Illustrated text book edited by Govan et al. (1991).
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suggest that this factor may be a mechanism by which alveolar macrophages contribute to 
pulmonary defences.
Inactivation of staphylococci by alveolar macrophages with preliminary observations 
on the importance of alveolar lining material have been reported (LaForce et al. 1973). 
Enhancement of bactericidal capacity of alveolar macrophages by human alveolar lining 
material was reported by Jures et al. (1976). They have also confirmed that rat alveolar 
macrophages do not kill Staphylococcus aureus in vitro unless the bacteria have been 
incubated with rat alveolar lining material before phagocytosis.
LaForce and Boose (1981) described a peptide in normal cell-free rabbit lung lavage 
fluid (LLF) that faciliates deoxycholate kill of Esherichia coli. In another study, Fernandez 
and Weiss (1996) reported a susceptibility of B. pertussis strain BP 338 to a number of 
antimicrobial peptides.
Coonrod and Yoneda (1983) detected and characterized an anti-pneumococcal factor 
(s) in alveolar lining material of rats. They concluded that the lipid fraction of rat alveolar 
lining material affects alveolar macrophage membranes and receptor function. O'Neill et al. 
(1984) stated that human lung lavage surfactant enhances staphylococcal phagocytosis by 
alveolar macrophages. Other workers were able to show that the lipid fraction of rat alveolar 
lining material was responsible for the enhancement in killing of S. aureus by rat 
pulmonary alveolar macrophages (O'Neill et al., 1984). Coonrod et al. (1984) have 
attributed the direct bactericidal effects seen in their studies with pneumococci to the high 
content of free fatty acids in rat alveolar lining material.
Jonsson and coworkers (1986) detected no direct bactericidal effect of healthy 
nonsmokers human alveolar lining material, nor was there an enhancement of phagocytosis 
or killing of S. aureus, S. pneumoniae and H. influenzae (ie. common bacterial pathogens 
of the lung) by pulmonary alveolar macrophages. They also reported in lipid analysis of 
alveolar lining material that 98 % of the lipid fraction was phospholipid and no free fatty 
acids were detected. Pulmonary surfactant of sheep induced killing of Pasteurella  
haemolytica, E. coli and Klebsiella pneumoniae by normal serum (Brogden, 1992).
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In whooping cough (pertussis), the bacteria remain localized on the ciliated 
epithelium in the respiratory tract and it is reasonable to suppose that local host defence 
mechanisms are responsible for bacterial clearance at the onset of the convalescent stage of 
the disease. Little is known about such mechanisms in the human disease, and the emphasis 
has been on studying antibodies in convalescent sera, rather than in respiratory tract 
secretions.
Because of the difficulty of experimental studies in human infants, the coughing-rat 
model of pertussis has been used here.
The object of the proposed research was to determine the possible antibacterial effect 
of lung lavage fluids (LLF) from normal and B. pertussis- infected rats. Serum from these 
animals would also be tested in parallel.
The specific questions in the initial phases of the work were:
Q. 1. Are lung lavage fluids from normal rats able to kill B. pertussis ? Is normal rat 
serum bactericidal ?
Q.2. Are lung lavage fluids, or serum, from convalescent rats different from lavage 
fluids and serum from normal animals ?
If the answers to either questions was positive, the project would explore the mechanism(s) 
of the bactericidal systems. Further question envisaged were:
Q.3. Is activity located in humoral factors or in cellular components (presumably 
phagocytes) or both ?
Q.4. How do phase I and phase IV B. pertussis respond to LLF?
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BACTERIA, CULTURE MEDIA AND DILUENTS 
Bacteria
B. pertussis strains
A total of 13 strains of B. pertussis was used in this investigation. Most of the 
work was done with strain 18-323, the challenge organism used for assaying the protective 
potency of pertussis vaccines. This and the other strains are listed in Table 16. It will be 
noted that both virulent (phase I) and avirulent (phase IV) strains were used; also two 
vaccine strains, 18-334 and Tohama; a strain isolated from a case of whooping cough in 
Glasgow; and the strain lux which had luminescence genes inserted. Plate 1 illustrates the 
colonial appearance of B. pertussis strain 18-323 and lux on Bordet Gengou agar, while 
Plate 2 presents Phase I and Phase IV forms of strain 30042.
All the strains were received as stock cultures frozen in CAA-glycerol (see below) at 
- 70°C. From time to time fresh samples of these frozen stocks were prepared as required. 
Cultures were grown on Bordet-Gengou (BG) medium containing 15-20 % (v/v) horse 
blood, by spreading a portion of frozen inoculum over the surface and incubating for 3 d at 
37°C in a closed plastic box with a beaker of water to saturate the atmosphere.
Culture purity was checked by visual inspection and gram stain and initially, by 
agglutination with a B. pertussis hyperimmune rabbit IgG/IgA serum kindly supplied by Dr 
R. Parton. If these tests were satisfactory, a heavy inoculum (i.e. almost the whole growth 
on the 3-day plate) was transfered to a fresh BG plate and incubated for 24 h at 37 °C.
With B. pertussis lux, the above schedule was modified by having a single-stage, 
2-day 37 °C grown culture, which gave satisfactory results. The phase status of B. 
pertussis strains was checked by inoculation on to brain heart infusion agar (BHIA) and 
incubating for 24 h, or longer, at 37 °C. Phase IV strains gave heavy growth under these 
conditions while phase I organisms failed to grow.
For storage, a loopful of pure bacterial culture was suspended in 1.6 ml of sterile 
casamino acids (CAA) and 0.4 ml sterile glycerol (BDH). The mixture was given a few 
seconds on a whirlimixer (Fisons) and 100 |il aliquots were put into washed, sterilized 2
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Plate 1. Colonial appearance of B. pertussis on Bordet Gengou agar A) 5-day growth of 
strain 18-323; B) 5-day growth of strain lux.
A
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Plate 2. Colonial appearance of B. pertussis 30042 on Bordet Gengou agar after 5-day 
growth of A) Phase I ; B) Phase IV.
A
B
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Table 16. Strains of B. pertussis (all from departmental stocks) used in this study.
Strain Phase Remarks
18-323 A6
18-323 EH1
18-323 EH2
18-334
Tohama
Standard challenge strain in mouse and rat infection 
experiments.
Obtained by passage of 18-323 A6 through rats in 
1991.
Obtained by passage of 18-323 A6 through rats in 
1994.
Standard vaccine strain (Connaught Laboratories, 
Canada).
Japanese vaccine strain
BP347
L-84
L-84
44122/7S
44122/7R
lux
77/18319
30042
30042
IV
IV
Transposon mutant vir" (from Tohama) equivalent 
to phase IV (originally from A. Weiss).
Lister Institute: virulent strain (originally from J. 
Dolby)
Lister Institute: avirulent strain (originally from J. 
Dolby)
Streptomycin-sensitive (originally from P. 
Branefors)
Streptomycin-resistant (originally from P. 
Branefors)
Bioluminescent strain, derived from 44122/7R 
Glasgow pertussis case 
Originally from J. Dolby 
Originally from J. Dolby
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ml-volume polypropylene plastic vials with 'O' ring screw-cap (Elkay Lab Products UK 
Ltd) and stored at - 70 °C.
Other bordetellae
Bordetella bronchiseptica, NCTC 5376, and B. parapertussis, NCTC 10520, were 
received from departmental stock as - 70 °C frozen suspensions and were treated in the 
same way as B. pertussis, except that only a one-stage culture procedure was used. For B. 
bronchiseptica, the incubation time was 24 h at 37 °C and for B. parapertussis, 2 d. Culture 
purity of B. bronchiseptica was checked by Gram stain and by ability to grow on BHIA 
and MacConkey agar, and for B. parapertussis also by Gram stain and growth ability on 
BHIA.
Other bacteria
These were received as plate cultures and were converted into -70 °C glycerol-CAA 
suspensions as done above for B. pertussis, after growth in appropriate media as listed 
below.
Staphylococcus aureus and Streptococcus pyogenes were from departmental 
stock; Micrococcus luteus and E. coli Lilly were received from Prof. A. C. Wardlaw and 
E. coli lux WA 803 and E. coli lux DH5a were from Dr R. Parton. The culture purity was 
tested by visual inspection and Gram stain. All the bacteria were grown for 24 h at 37 °C, 
except M. luteus which was grown for 2 d at 30 °C and the culture purity was checked by 
visual inspection and Gram stain.
M. luteus, this classic, lysozyme-sensitive strain (NCTC 2665) was grown on 
BHIA. E. coli Lilly, a complement-sensitive strain (NCIMB 11888) was grown on BHIA. 
E. coli lux WA 803, a luminous construct was grown on BG agar medium with 25 Jig/ml 
kanamycin. E. coli lux DH5a, another luminous construct of a standard laboratory strain 
was grown on nutrient agar (NA) with 50 |ig/ml ampicillin. S. aureus, Oxford NCTC 6571 
strain was grown on blood agar (BA). S. pyogenes, NCTC 5763 was grown on 
MacConkey agar.
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Culture Media 
Bordet-Gengou (BG) agar
BG agar medium was prepared by dissolving 20 g of BG agar base (BBL, Becton- 
Dickinson) in 500 ml of distilled water (DW) containing 1% (v/v) glycerol by steaming at 
100°C. It was then sterilized for 15 min at 121°C. After cooling to about 50 °C, 15-20 % 
(v/v) defibrinated horse blood (Becton-Dickinson, Cowley) was added aseptically, in a 
laminar flow hood.
The mixture was swirled gently, avoiding the introduction of air bubbles, and about 
25 ml portions poured into 90 mm sterile petri-dishes (Sterilin). Solidified BG agar plates 
were labelled, packed in a sterile plastic sleeve, stored at 4°C, and discarded after three 
weeks if not used.
For BG with kanamycin, 100 |il of filter sterilized 2.5 % (w/v) kanamycin A 
(Sigma) in DW was added to 100 ml of cooled (45-50°C) BG agar medium, before adding 
the horse blood, after which the procedure for plain BG medium was followed.
Other media
The following media were obtained from Oxoid and were dissolved and sterilized 
according to manufacturer's instruction: Brain heart infusion agar; Nutrient agar; Nurient 
broth; Blood agar base and MacConkey agar. For blood agar, the melted base in 500 ml 
portions was cooled to 45-50 °C and 50 ml fresh defibrinated sheep blood (E&O, 
Laboratories Ltd) added.
Diluents 
Phosphate buffered saline (PBS)
At the beginning of the experimental work, PBS was prepared by dissolving 10 
PBS tablets (Oxoid) in 1 litre of DW, the pH was checked and found in most cases to be 
approximately 7.3. The addition of small amount of acid was needed to adjust the pH to 
7.2. PBS was sterilized and stored at 4 °C.
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However, the PBS which was used in most of the experimental work was prepared 
by dissolving analytical grade chemicals, 7.99 g NaCl (BDH), 1.196 g Na2HPC>4 (BDH), 
0.212 g KH2PO4 (Fisons)? and 0.199 g KC1 (Fisons) in 1 litre of DW. If necessary, the 
pH was adjusted to 7.2 by addition of small amounts of alkali or acid. In some experiments, 
PBS either at pH of 7.3 or 7.4 was used.
Casamino acids (CAA)
CAA 1% (w/v) solution was made by dissolving 10 g casein hydrolysate (Gibco- 
BRL), O.lg MgCl2 6H20  (BDH), 0.016g CaCl2 (Fisons) and 5g NaCl in 1 litre DW. The
pH of the mixture was adjusted to 7.1 by addition of NaOH, and the fluid sterilized and 
stored at 4 °C. It was discarded after two months if not used.
Cyclodextrin liquid (CL) medium
CL-medium was prepared as described by Imaizumi et al. (1983a) with minor 
modification, by dissolving 10.7 g L-glutamate acid (Sigma) [instead of L-glutamic acid 
sodium salt (BDH) as mentioned by Imaizumi et al., 1983], 2.5 g NaCl, 0.5 g KH2PO4 , 
0.1 g MgCl2 . 6H2 O, 0.02  g CaCl2 , 0.2 g KC1 (Fisons), 6.25 g Tris (Boehringer 
Mannheim GmbH), 10 g casein hydrolysate, 0.24 g L-proline (Sigma) and 1 g dimethyl-p- 
cyclodextrin (J. Shimizu, Teijin Ltd., Tokyo, Japan) in 1 litre of DW. The pH was adjusted 
at 7.4 with 1 N NaOH. The CL- medium base was sterilised and stored at 4 °C.
A supplement was prepared by dissolving 0.01 g FeS04 (BDH), 0.04 g L-cysteine, 
0.004 g niacin, 0.15 g glutathione (all from Sigma) and 0.4 g ascorbic acid (Lancaster 
Synthesis Ltd) in 10 ml DW, which then sterilised by passage through a membrane (0.45 
pm pore size) filter (Sartorius). It was added to the CL-medium base immediately before 
use in a volume of 50 pi (instead of 100 pi as mentioned by Imaizumi et al. , 1983a) per 10 
ml of medium. The supplement was stored at -20 °C, and discarded after two months if not 
used.
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Special cleaning of glassware and plasticware
All 7 ml-volume thin-wall glass Bijoux (L.I.P, Equip & Services Ltd) were 
immersed in concentrated nitric acid (which was handled with great care by using stainless 
steel clamp forceps, special eye safety glasses, and latex examination gloves) for 24 h. They 
were then rinsed ten times with DW, soaked in DW for a further of 24 h, and finally rinsed 
with DW, to ensure that the acid was completely removed by showing that the rinsing had 
the same pH as freshly made DW. The glass bijoux were then dried in a hot (about 80 °C) 
oven for a few hours, sterilized for 15 min at 121 °C, and stored in a covered container 
away from dust.
Plastic items such as the plastic screw caps of glass bijou bottles, Gilson pipette 
plastic tips, 1.5-ml volume plastic microfuge tubes (Greiner Labortechnik Ltd) and 2-ml 
volume screw cap plastic vials were boiled for 30 min in DW. Then they were dried at 80 
°C for a few hours, sterilised for 15 min at 121 °C. Latex examination gloves were worn 
when handling washed glass and plastic ware before and after autoclaving to keep the items 
clean.
COLLECTION AND PROCESSING OF TEST FLUIDS 
Lung Lavage Fluids (LLF) and Serum
Rats
Male and female barrier-reared Sprague Dawley rats "viral antibody free plus status" 
were obtained from Charles River UK Ltd (Manston Road, Margate) or from Harlan Olac 
Ltd (Shaws Farm, Backthorn, Bicester). Each batch of rats was certified free from a range 
of protozoal, viral, and bacterial pathogens including B. bronchiseptica, according to the 
health-status certificate.
Rats were ordered by weight around 150-200 g (Figure 4) equivalent to about 6 to 
8 weeks old and were kept in groups of 8-10 in flat bottomed cages with wood shavings as 
bedding in air filtered rooms. The animals were given free access to diet and water. To 
provide the cages units with filtered air, prefilters and main filters were used. Air passed
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through prefilters to remove particles of > 5 pm and then through main filters to remove 
particles of > 2 pm size.
Rats either normal, sham-operated, vaccinated and challenged, or convalescent from 
Bordetella pulmonary infection were used as a source of LLF and serum and were made 
available by Dr E. Hall. The animals at the time of obtaining these fluids were 
approximately 7-12 weeks old and weighed in the range of 180 - 350 g.
Infected rats (see Appendix 1) were housed as 2 per cage. In addition to Sprague 
Dawley, Lewis, Brown Norway and Hooded Lister rats were used in this study and were 
from the same source (Harlan-Olac).
Euthanasia
Various methods (A,B,C,D) of killing the rats before collecting LLF and serum 
were examined. Of these, method D used in later experiments appeared to be the best.
Euthanasia method (A) consisted in anaesthetising the rats with 2-2.5 % of 
halothane (RMB Animal Health Ltd, Dagenham) mixed with oxygen for about 3 - 5  min, 
killing them by transferring them to a 10 litre plastic jar containing CO2 from a piped 
source. Blood was then taken by heart puncture followed by LLF collection.
In the second method (B), rats were killed directly with CO2 without anaesthesia 
before collection of blood and LLF. In method (C), an overdose of halothane / oxygen was 
given to the rats for about 15 min as a way of killing followed by blood and LLF collection.
The standard euthanasia method (D) consisted in anaesthetising the rats with 
halothane / oxygen for about 3 -5  min. Blood was taken by heart puncture, then the animal 
was killed by cervical dislocation, after which the LLF was taken. See Table 17 for a 
summary of the different methods of euthanasia.
Rat serum
Blood was collected by inserting a 0.6 in x 25 gauge needle (Becton Dickinson) on 
a 10 ml syringe (Becton Dickinson) into the heart to yield about 10 ml blood, which was
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Figure 4. Relationship between age and weight of male and female outbred Sprague 
Dawley rats. Values are means ± standard deviation. (Data from Harlan-Olac)
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placed in a sterile thick-wall glass universal bottle (LAB SUPPLIES, University of 
Glasgow). Pooled bloods were centrifuged (MSE, Mistral 6 L) for 15 min at 2000 rpm at 
10 °C. The fluids were filter sterilized (0.45 jam membrane filter, Sartorius) and stored in 1 
ml amounts in washed, sterilized 2-ml plastic vials for 24 h at -20 °C, and then transferred 
to -70 0 C.
Rat LLF
The rats which had just been bled by heart puncture were immediately used as a 
source of LLF. The animals were placed on the operation table on their backs and fastened 
with strips of autoclave tape over their legs. About a 3 cm longitudinal incision was made in 
the throat at the site of the trachea, after which, the trachea was exposed, punctured with 
sterile 12 cm curved scissors, and 5 ml of sterile PBS injected with a 5 ml-syringe fitted 
with a special cannula (Figure 5). This was made from a standard 50 mm plastic "yellow 
tip, Sarstedt" from which 5 mm had been cut at a slant from the narrow end and at 10 mm 
uniformly around from the wide end.
The PBS was injected and rinsed by drawing up the barrel of the syringe 3 times. 
The final yield was about 3 ml crude lung washings per animal which were placed in a 
sterile plastic universal (Sterilin) on ice. Pooled lung washings from several rats were 
centrifuged for 15 min at 2000 rpm (in later experiments, this was reduced to 500 rpm 
which is enough for depositing the cells and debris, also to reduce the amount of active 
material being passed into the deposit fraction in which the bactericidal activity was found) 
at 10 °C.
Filtration and storing procedures of the supernate were as with serum. The 
collection procedures of serum and LLF were done in the same day to avoid the 
deterioration of the fluids and loss of activity.
The pH of 2 LLF batches number 15 and 34 as a sample from normal and 
convalescent rats were examined with pH indicator paper (Whatman) and found to be at pH 
7.
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Table 17. Summary of four different euthanasia methods before collection of rat serum and 
LLF.
Method Procedure prior to collection of LLF
Halothane/ CO2 Bleeding out Cervical Bleeding out LLF
oxvgen by heart dislocation by heart batch
under alone puncture before puncture after no.
anaesthesia death death
A + + - + 15,16,17
21,33
B + + 34,35
37,38.1
C + - + 38.2
D + + + 39,40,41
42,43,45,
55,56,58
Figure 5. Schematic diagram of how a Sarstedt yellow tip was cut with sharp 
scissors to make a rat tracheal cannula.
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Other animal species and human LLF
Other animal species and human LLF were used in this study. The species were 
mouse, horse, rabbit, sheep, chicken, and dog bronchial lavage specimens and had been 
stored at -20 °C (Appendix 2). They had been collected by J. Porter during his Ph. D study 
in 1991 on the growth of Bordetella species in LLF and other low-nutrient fluids (Porter 
and Wardlaw, 1994). One of the human LLF was provided by Dr. Neil Thompson and Dr. 
Hulk of Glasgow Western Infirmary. This sample was taken from an elderly patient (by 
bronchial lavage with saline) who had some form of non-infectious lung or bronchial 
disorder.
In addition to these stored samples, calf LLF was obtained from normal calves 
provided by Glasgow University Veterinary School. The lungs from the freshly slaughtered 
animals were removed and the trachea filled with approximately 1 litre of sterile PBS. The 
lungs were shaken up and down for mixing and then inverted to allow the lavage fluid to 
drain out. Approximately 450 ml fluid was recovered from each set of lungs. It was 
centrifuged for 15 min at 2000 rpm and a portion of the supemate was membrane filtered 
(0.45 pm pore size). This was then stored as 1 ml portions in a sterile 2-ml volume plastic 
vials for 24 h at -20 °C before transfer to -70 aC for long-term storage.
Long-Chain Fatty Acids and Phosphatidylcholine
Long-chain fatty acids (FA)
These were purchased from Sigma, and consisted of palmitic acid and myristic acids 
(sodium salts), and the remainder as free acids: elaidic, oleic, palmitoleic, linoleic, 
arachidonic, petroselinic and pentadecanoic.
Petroselinic and pentadecanoic acids were dissolved by sonication for 3 x 30 sec 
at 10 % amplitude with a microprobe (Jencons, Sonics & Materials Inc.) in 10 mM NaOH 
to a FA concentration of 10 mM, which was then diluted in 1 % CAA to a final range of 
concentrations of 1 mM - 0.1 pM. These were stored in washed and sterilized glass Bijous 
in volumes of 2.7 ml at -20 °C.
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Palmitic and myristic acids were dissolved in methanol (Fisons) and diluted with 
chloroform (Prolabo) to give 10 mM, which was then further diluted in chloroform to the 
same final concentrations as above and stored in the same way.
The other FA were dissolved to 10 mM in chloroform, which was then diluted in 
chloroform to final concentrations of 1 mM - 0.1 jiM and stored as before.
When required for bactericidal test, the chloroform solutions were placed in a 
container of warm water in a fume cupboard, and dried under a slow stream of nitrogen 
delivered through a plugged pasture pipette with its tip near to the top of the solvent surface. 
The dried FA were reconstituted with 2.7 ml of 1 % CAA and exposed to brief sonication 3 
x 30 sec at 5-10 % amplitude to aid dissolution.
Petroselinic and pentadecanoic acids were taken out from the freezer and left on the 
bench to warm then dissolved with sonication as above.
Methanol or chloroform solvents without FA, were subjected to the same 
procedures, for use as control fluids.
Phosphatidylcholine (PC)
PC (Sigma) was obtained in a small vial containing 25 mg in chloroform at 10 
mg/ml. This was diluted in chloroform to a final concentrations range of 500 - 15.6 |Lig/ml 
(0.59 - 0.02 mM), after which aliquots were dried under nitrogen gas, reconstituted with 1 
% CAA to its original volume then exposed to brief sonication 3 x 30 sec at 5-10 % 
amplitude.
BACTERIAL VIABILITY AND LUMINESCENCE 
Standardization of Bacterial Suspensions
For use in bactericidal tests, suspensions of B. pertussis and other bacteria were 
standardized to an absorbancy A = 0.45 at 540 nm in a 1 cm cuvette (as described by Porter 
et al. 1991). In most instances PBS was used as the suspending fluid except in the later
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experiments with B. pertussis and the other bordetellae when CAA was employed. This 
was because of better maintenance of viability.
The subsequent dilution (Figure 6) of the standardized suspension then varied 
according to the bacterial strain and species, and type of test. In viable count experiments 
the A540nm  = 0-45 suspension was diluted between 1/2000 and 1/ 40,000. For 
luminescence, the standard suspension was used undiluted and at 1/40.
In three experiments, the B. pertussis 18-323 was washed by centrifugation 
according to the method of Porter et al. (1991), the other aspects of preparation being 
unaltered. The washing was done by centrifuging (Biofuge 13, Heraeus Sepatech) 1 ml of 
A540nm = 0-45 suspension for 15 min at 10500 rpm, the supernatant was discarded and 
the pellet resuspended in 1 ml PBS and the washing process repeated another 2 times. The 
washed bacterial suspension was diluted in PBS to 1 in 2000.
Bactericidal Test 
Viable count method
Fluids to be tested for bactericidal activity were placed as 480 pi aliquots in 
washed, sterile 2-ml plastic vials and 20 pi of standardized, diluted bacterial suspension 
was added and mixed in. A sample of 20 pi was taken immediately and plated onto BG agar 
medium for the time-zero viable count. The vials were then incubated at 37 °C on a MK lllb  
shaker (LH Engineering Co. Ltd) at 110 rpm.
To determine survival and death of bacterial cells at 37 °C, samples of 20 pi were 
taken from the test mixtures at 15, 30, 60, 120, and 1440 min, and at 2880 min in some 
experiments. They were plated onto BG agar medium, which was then incubated for 3-5 
days at 37 °C, after which colonies were counted.
Luminometry method
Equipment: Luminometer (LKB, Walac 1251) was a bench-top (Figure 7) luminescence 
photometer intended for the measurement of all types of luminescence.
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Figure 6. Scheme of dilutions for preparing a bacterial suspension for bactericidal tests based on 
viable count (VC) or luminometry (Lum). The dilution of primary thick suspension needed to give an 
absorbancy of 0.45 at 540 nm was determined by its stepwise addition to PBS or 1 % CAA in a trial 
cuvette. This dilution was then used to prepare the main dilution series, with sterile precautions .
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Figure 7. A) General picture of the luminometer; (luminescence photometer); B) 
Another general picture showing the position of a 25-cuvette capacity measuring 
chamber; C) Instrument keyboard.
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The sample holder was a 25-position carousel-type metal dish, and the addition of 
reagents was done manually in the measuring chamber. The cover of the sample holder was 
closed except when applying the sample cuvettes, so as to avoid change of incubation 
temperature, quick evaporation of aldehyde or accumulating of dust inside the sample 
holder. The sample was mixed by continuous mixing through a motor which rotated the 
sample cuvette.
The sample changing and measuring section was used to convey samples to the 
measuring chamber into which the sample cuvette was raised by elevator and the light 
emitted from the sample was detected. The photomultiplier detected light accurately at a 
wavelength of between 300 and 600 nm. The photomultiplier converted the light into an 
electrical signal which was then amplified and recorded.
Conduct o f  test: The temperature in the luminometer was adjusted to 37 °C and a PC- 
computer (IBM) running on Multi-Use software (Bio-OrbitOy, Turku, Finland) was used to 
control the instrument.
Standardized B. pertussis lux (100 pi) was added to 400 |ll1 of test and control 
fluids in polystyrene luminometer cuvettes (Clinicon). These were incubated in the 
instrument with mixing for 1 h at 37 °C. To observe luminescence, it was necessary to add 
highly diluted decanal. A 20 % (v/v) stock solution, prepared fresh, consisted of 100 pi 
decanal (n-decylaldehyde, Sigma) and 400 pi dimethyl sulphoxide (DMSO, Fisons). This 
was diluted to 1: 220 in DW at room temperature by adding 10 pi of the 20 % stock solution 
to 2.190 ml DW. To each test mixture in the luminometer, 20 pi of the 1 : 220 dilution of 
decanal was added, so that the final amount of the aldehyde was 0.018 pi (or 18 nl) per 0.5 
ml test mixture.
The light output in millivolt (mv) from each sample in turn was measured, 
recorded, saved, and displayed on the computer screen in the form of graph of light output 
against time and as a Table. Usually, measurement were taken over a 10 min period and the 
peak value determined. In some experiments the 500 pi test mixture in the 2-ml plastic vials 
was incubated in a 37 °C water bath (Grant Instruments), then 500 pi of CL-medium was
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added to give a final volume of 1 ml. This was then transferred to the luminometer cuvettes, 
placed in the luminometer at 37 °C and given a complete run for approximately 150 sec, 
after which 20 pi of decanal solution was added.
In other experiments, the final decanal amount in the 20 |xl decanal solution (with 
DMSO and DW or PBS) was in the range from 0.01 to 0.1 p i  In other groups of experi­
ments the bioluminescence response in the test fluids was detected at 0, 15, 30, 45 and 60 
min incubation time, by adding 20 pi decanal solution at each incubation time to all test 
fluids.
CHARACTERIZATION OF RAT LLF 
Fractionation by Centrifugation
Cell-free LLF from either normal or treated rats was placed in a polycarbonate 
plastic ultracentrifuge tubes (about 10 ml size), and after balancing was spun in an 
ultracentrifuge (OTD Combi Ultracentrifuge, DU PONT) for 20 min at 29000 rpm (55000 
g) at 4°C. The supernate fraction was stored in a washed, sterilized, screw cap 2-ml plastic 
vial at - 70°C as a 1 ml portion.
The pellet (surfactant fraction) was reconstituted in sterile PBS to its original 
volume and transfered to a thick-wall glass universal. This was placed on ice and dissolved 
by sonication using an alcohol-cleaned microprobe kept clear of the glass. The treatment 
was done with 3 exposures of 2 min at 5-10 % maximum amplitude, after which it was 
stored as with supernate.
Incorporation of B. pertussis lux in agarose ± DM-p-CD
The incorporation (see Appendix 1) of 1 ml of standardized (A 540nm = 1.8 in 1 % 
CAA) B. pertussis lux in 1 ml of 4 % (w/v) agarose beads was as described by Hall et al. 
(1994). After this, 2 ml of 1 % CAA with or without 0.1 % (w/v) dimethyl-P-cyclodextrin 
(DM pCD) was added and the mixture homogenised for 15 sec at low speed. In 
luminescence (see above) test experiments, 100 pi of B. pertussis lux in agarose ± DM-p-
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CD, in DM-p-CD only and in DW were added to normal rat surfactant and PBS (as a 
control).
Artificial surfactant
A protein-free artificial surfactant (artificial lung expanding compound; ALEC 
pumactant) powder (Britannia Pharmaceuticals Ltd) consisted of dipalmitoylphosphatidyl- 
choline and phosphatidylglycerol in a ratio of 7 : 3 (Morley et al., 1981). ALEC 100 mg of 
sterile freeze-dried powder was suspended in 1.1 ml of 0. 85 % (w/v) saline (Oxoid) in 
DW, and mixed with a whirlimixer.
Biochemical and Serological Analysis 
Protein estimation
Total protein content of test samples was estimated according to Smith et al. (1985) 
using bicinchoninic acid (BCA). The protein used as standard was BSA (Sigma) which was 
vacuum dried at 500 millitor on a freeze-dryer apparatus for 18 h at 20 °C before use. It was 
dissolved at 20 mg / ml in DW and stored at -20 °C.
Reagent A contained 8% (w/v) anhydrous sodium carbonate (Fisons), 1.6 % (w/v) 
NaOH (BDH), and 1% (w/v) sodium tartarate (BDH) in 250 ml of DW, pH at 11.25 was 
adjusted with solid sodium hydrogen carbonate (Fisons) then diluted up to 500 ml as a final 
volume. Reagent B contained 10 ml of 4 % (w/v) 4,4' dicarboxy-2,2'biquinolin 
(bicinchoninic acid sodium salt, Sigma) in DW. Reagent C contained 4 % (w/v) Q 1SO4 
5H20 (BDH) in DW.
The stock BSA was serially diluted in DW to a range of 50 to 3.125 pg / ml and 
0.5 ml of standards, blank (DW) and diluted test sample was pipetted in a 7-ml volume 
plastic bijoux (Sterilin) in triplicate. To this was added 0.5 ml of working solution 
containing 10 ml of reagent B and 0.4 ml of reagent C. To this mixture an equal volume of 
reagent A was added.
71
All samples were incubated for 1 h in a 60 °C water bath, then they were cooled to 
room temperature, and their absorbancy measured at 562 nm versus a reagent blank. 
Standard protein concentrations were plotted against absorbancy and the concentrations of 
the unknowns determined by interpolation on to the standard curve (Figure 8).
Lysozyme detection and estimation
The bactericidal activity test (as above) was done using standardized and diluted 
Micrococcus luteus (ML, sensitive to lysozyme) as a test organism with 10-fold serially 
diluted LLF from normal and convalescent rats.
PBS, nutrient broth and hen's egg white lysozyme (HEWL, Sigma) at 
concentrations of 1 pg, 10 pg, and 100 pg / ml (w/v) in PBS were used as a positive and 
negative bactericidal controls.
The lysozyme content of 2.7 ml neat and diluted test samples in PBS normal and 
convalescent LLF was determined according to the spectrophotometric method described by 
Wardlaw and McHenery (1982), by measuring their bacteriolysis effect on 0.3 ml of 
standardized (A540nm = 4.5) M. luteus after a shaking incubation for 30 min at 30 °C. The 
absorbancy at A = 540 nm of the mixtures together with a diluted HEWL in PBS at 4 pg to 
0.125 pg / ml as a standard and PBS as a blank was measured, and plotted against the 
standard lysozyme concentrations (Figure 9).
Long-chain fatty acids (FA) estimation
FA were determined by the colorimetric assay of Duncombe (1963). Test samples 
(100 pi) were added to 2.4 ml of chloroform in a 10-15 ml volume glass centrifuge tubes 
with a suitable stopper, to which a 1.25 ml of a copper reagent [containing 9 volumes of 
aqueous 1M triethanolamine (Sigma), 1 volume of 1 N acetic acid (Fisons) and 10 volumes 
of 6.45 % (w/v) cupric nitrate (Sigma) in DW] was added.
The tubes were stoppered and mixed for two min using a whirlimixer, after which 
they were centrifuged for 5 min at 500 rpm at 10 °C. The supernate (upper phase) was 
removed carefully by pasteur pipette and discarded, 1.5 ml of chloroform (lower phase)
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Figure 8 . Standard curve for quantitation of protein. Data are the mean of triplicate 
tests. Error bars (SEM) were too small to project beyond the points.
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Figure 9. Lysis curve for diluted standard lysozyme. Absorbancy area between the two 
horizontal dotted lines indicates the region used for assay of unknowns. Data are the 
mean of duplicate readings and error bars are SEM which when small do not project 
beyond the points.
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was taken cleanly (not to touch the sides of the test tube) with a graduated glass pipette 
(volac) and delivered into a clean dry test tube. Then 0.25 ml of diethyl dithiocarbamate 
reagent [containing 0.1 % ( w / v )  solution of diethyl dithiocarbamic acid (sodium salt, 
Sigma) in butanol-2 (Riedel-De Haen AG Seelze-Hannover)] was added, after the solutions 
had been mixed, then the extinction was read at 440 nm in a 1 cm cuvette (lightpath cell) 
against a blank solution (consisting of 2.5 ml of Analar chloroform and 0.25 ml of diethyl 
dithiocarbamate reagent) that had been subjected to the same procedure.
Standard solutions of FA were prepared from a mixture of equal volumes of FA 
consisting of palmitic, myristic, elaidic, palmitoleic, linoleic, oleic and arachidonic acids. 
All FA were dissolved in chloroform except palmitic and myristic acids which were 
dissolved in Analar methanol. The standard FA were made up at a range of 10 - 100 |nM 
and the FA concentration values were obtained from the standard curve (Figure 10).
Antibodies to B. pertussis
The detection of antibodies to B. pertussis (Bp) sonicated cells, pertussis toxin 
(PT), and filamentous haemagglutinin (FHA) in normal and convalescent rat LLF and 
serum was carried out by ELISA assay according to the procedure described by Hall et al. 
1994. Each well of 96-well U-shape microtitre plate (Nunc Maxisorp, Life Sciences, 
Paisley) was coated with 0.1 ml of antigen preparation (Appendix 3) diluted in ELISA 
coating buffer containing Na2CC>3 1.59 g and Na HCO3 2.92 g dissolved in 1 litre DW, 
pH adjusted to 9.6, stored at 4 °C.
B. pertussis whole-cell sonicate stock suspensions were diluted 1 in 1000, FHA 
antigen was used at 2 |Lig of protein/ ml, and PT and fetuin (Sigma) used as a sandwich 
ELISA system at 1 |ng /ml. The coated plates were incubated overnight in a moist box at 4 
°C, then washed three times with washing buffer (WB) containing NaCl 8g, KH2PO4 0.2 
g, Na2HP0 4  1.15 g, and KC1 0.2 g dissolved in 1 litre DW, pH adjusted at 7.4, and 
Tween 20 (Sigma) added to WB to a final concentration of 0.05 % (v/v).
75
Figure 10. Standard curve for quantitation of long-chain fatty acids based on duplicate 
readings.
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The plates were blocked with 0.1 ml of 2 % (w/v) bovine serum albumin (Sigma) 
in WB for 1 h at 37 °C, except in the ELISA for PT in which 0.1 ml of PT 10 |Xg protein/ml 
in WB was applied. The plates were washed three times with WB, then 0.1 ml of neat (LLF 
only) and serially diluted at 10 fold dilution (LLF, serum, and controls at 1:10,1:100 and 
1:1000) test fluids in WB were added to duplicate wells.
The plates were incubated for lh at 37°C in a moist condition, then the plates were 
washed three times with WB, and 0.1 ml of horse radish peroxidase (HRP)-conjugated goat 
anti-rat IgG (Sigma) diluted 1 in 5000 in WB, was added to all wells and plates were 
incubated for lh at 37 °C in a moist condition, then plates were washed three times with 
WB. O-phenylenediamine substrate (0.1 ml), which consisted of OPD (Sigma) (34 mg/ ml) 
and 20 (il of 30 % hydrogen peroxide (Sigma) in 100 ml of citrate-phosphate buffer, pH 
5.0 consisted of 51 ml of 0.2 M (35.6 g/1) disodium phosphate and 49 ml of 0.1 M (21.01 
g/1) citric acid, was added to all wells.
After placing the plate in the dark for 20 min, the reaction was stopped by adding 
50 |il 12.5 % (v/v) H2SO4 (Prolabo) in DW to each well. Then the absorbancy was 
measured at 492 nm in a Titretek Multiscan MC ELISA reader (Flow Laboratories, 
Hertfordshire).
A reference serum which was used in the ELISA test as a positive control was also 
prepared by Hall et al. (1994) from a hyperimmune pool from two rats immunised 
intraperitoneally with 1 ml of B. pertussis whole-cell sonicate (equivalent to 2 x 10^ CFU / 
ml) followed by two further injections at intervals of 3 weeks and bled out 12 days after the 
last injection. The readings obtained for the reference preparation run on ELISA for the 
three different antigens were calculated, and enabled reproducibility to be checked. A pool 
of normal rat serum was used as a negative control, which together with a reference serum 
were included on every ELISA plate. The mean absorbancy of two sample readings was 
calculated and plotted against the log 10 dilutions of the sample. The dilution at an end-point 
of A492nm = 0-5 was taken as the titre of the test fluid.
Preparation of ELISA antigen and ELISA test for total IgE in LLF fluids were 
kindly done by E. Hall.
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Complement detection
Normal and convalescent rat LLF and serum were tested for bactericidal activity 
(BA) mediated by complement (Wardlaw, 1962) towards E. coli strain Lilly (sensitive to 
complement) at a final bacterial inoculum of approximately 4700 CFU/ ml. Neat and diluted 
(1/16 in PBS) guinea pig (GP) serum was taken as a source of complement, nutrient broth 
and PBS were used as controls. Also inactivated (for 30 min at 56 °C), neat or diluted GP 
serum was included as a control.
Treatment of LLF
LLF and its supernate and surfactant fractions were exposed to a variety of different 
physical and chemical treatments in order to characterize the substance responsible for their 
BA. When dilutions of LLF or its fractions were tested, the end points were taken at 50 % 
and 90 % reduction of luminescence or viable count, compared with controls. Respectively 
these end points were designated lum-50 and lum-90, and VC-50 and VC-90.
Physical treatments
Freezing and thawing: Supernate (SN) and surfactant (SUR) fractions of LLF were 
exposed to freezing and thawing once daily for 10 days by removing them from - 70 °C to 
room temperature for thawing, after which, they were returned to the -70 °C freezer.
Dialysis: SUR, SN, and PBS were dialysed through a size 1 dialysis tubing (6.3 mm 
diameter, Medicell International Ltd) which was boiled in DW for 10 min, and then kept in 
10 % (v/v) acetic acid in DW, ready for use when required, when it was washed with DW. 
Then 1 ml of test and control fluids were inserted and the tubing tied at both ends and 
dialysed against 500 ml of PBS in a beaker with magnetic stirring overnight at 4 °C.
Ultrafiltration: LLF fluids (2 ml) were placed in a microsep centrifugal concentrator 
(Filtron, Flowgen) with a pore size filter of 30 kDa. This was then placed in a rotor (Sorval 
SS-34 Rotor) of a fixed angle centrifuge (Sorval RC-5B superspeed refrigerated centrifuge,
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DUPONT) which was run for 60 min at 9000 rpm at 20 °C, after which, the filtrate, 
retentate fluids together with untreated samples were examined on the same day of 
treatment.
Heat: Test fluids were heated for 30 min at 56 °C in a waterbath or in boiling water for 
either 5 or 15 min.
Washing in PBS  : 1 ml of SUR was placed in a washed, sterile microfuge tube, 
centrifuged (Biofuge 28 RS, Heraeus SEPATECH) for 20 min at 17000 rpm at 4° C. After 
which the supernate was discarded and the pellet reconstituted with PBS to its original 
volume and centrifuged again as before. One and four times washed SUR was made.
Chemical and biochemical agents
pH: SUR, SN and PBS (as a control) were treated with NaOH and HC1 (Fisons) at a final 
concentration of 0.1 M of acid or alkali, which then incubated overnight at 4 °C. Then, the 
pH of test fluids and control was neutralized to approximately pH 7 (detected by Whatman 
pH indicator paper).
Bentonite: Bentonite (Sigma) treatment was performed according to La Force and Boose 
(1981). Stock bentonite solution was prepared according to Bloch and Bunim (1959). All 
glass bottles were washed with DW to ensure that all traces of detergents (used in cleaning 
glassware) were removed. The suspension of 0.5 g bentonite (Sigma) in 100 ml of DW was 
homogenised with a Silverson mixer-emulsifier (Silverson Ltd) for 1 min, the 
homogenising process was repeated after 5 min for another 1 min. The suspension was 
transferred to a 500-ml washed glass bottle, DW was added to a final volume of 500 ml, 
shaked and allowed to settle for one hour. Then 120 ml of supernate was distributed into six 
30-ml volume thick-walled glass universals, which were centrifuged for 15 min at 1300 
rpm. The pellet was discarded, and the supernate was recentrifuged for another 15 min at 
1600 rpm. Then the supernate was discarded and the pellet was resuspended to its original
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volume in DW, homogenized for 1 min, and kept at room temperature as stock bentonite 
suspension ready for use and stable as long as six month without losing its adsorptive 
properties.
Stock bentonite suspension (1 ml) was poured into a tared 1.5 ml volume microfuge 
tube, centrifuged (Biofuge 13, Heraeus Sepatech) for 10 min at 2300 rpm. The supernate 
was discarded and the pellet was weighed together with the microfuge tube to know the 
actual weight of bentonite pellet (found to be approximately 9.9 mg). 900 |xl of test fluid 
was added to the bentonite and the mixture rotated for 30 min at 37 °C. The microfuge tube 
was then centrifuged for 10 min at 2300 rpm, afterwhich the absorbed supernate together 
with untreated test fluids were examined.
Charcoal: Activated charcoal (Sigma) was reactivated (Pollock, 1947) as follows: it was 
made up in a 1 % (w/v) suspension in 10 ml PBS, and centrifuged (Megafuge 1, Heraeus 
Sepatech) for 10 min at 2000 rpm. Supernate was discarded and the pellet was resuspended 
and treated twice by boiling in 10 ml of 12 % (v/v) HC1 in DW; then the mixture was 
centrifuged for 10 min at 2000 rpm, the supernate was discarded and the pellet resuspended 
again in 10 ml PBS, washed in PBS for three times, and the pH was checked and found to 
be approximately 7.
To a tared microfuge tube, 1 ml of charcoal suspension was poured, centrifuged for 
10 min at 2300 rpm, the supernate discarded and pellet together with the microfuge tube 
was weighed (net weight of charcoal pellet found to be approximately 15 mg), and 0.9 ml 
of test fluid was added to the pellet. The mixture was rotated for 30 min at 37 °C, then 
centrifuged for 10 min at 2300 rpm and the test fluid removed.
Serum: Heated (for 30 min 56 °C) normal rat serum was added to the test fluids at a final 
serum concentration of 0.05 % in the test mixture. This was then incubated for 30 min at 37 
°C.
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Bovine serum albumin: 1 % (w/v) bovine serum albumin (BSA, Sigma) in DW was 
added to test fluids at a final concentration of 1 mg/ml, after which, the mixture were 
incubated for 30 min at 37 °C.
Starch: 1 % (w/v) starch (BDH) was dissolved by boiling for 5 min in PBS and added to 
test fluids at a final concentration of 1 mg/ml, after which, the mixtures were incubated for 
30 min at 37 °C.
Methylcellulose: 1 % (w/v) Methylcellulose (Sigma) in PBS was added to the test
fluids at a final concentration of 1 mg/ml, after which the mixtures were incubated for 30 
min at 37 °C.
Cyclodextrins: 1 % (w/v) of each of the following cyclodextrins: dimethyl-P- 
cyclodextrin (Teijin Ltd, Japan), p-cyclodextrin (Sigma) and a-cyclodextrin (Sigma) in 
PBS was added to the test fluids at a final concentration of 1 mg /ml. The test mixtures were 
incubated for 30 min at 37 °C.
Enzymes
Proteases: 1.5 % (w/v) in PBS of different proteases were tested: trypsin, chymotrypsin, 
subtilisin (Protease) and proteinase K (all from Sigma), were added to test fluids at a final 
enzyme concentration of 1.9 mg/ml in the test mixture, which was then incubated for 30 
min at 37 °C.
The proteolytic activity of proteases was checked by incubating 400 |Lil of proteases 
with 1 mg hide powder azure (Sigma) and 400 jil of PBS alone with hide powder as a 
control for 30 min at 37 °C. Also test fluids were incubated with hide powder to detect if 
there was any enzyme present in them. At the same time, test fluids were incubated with 
proteases for 30 min at 37 °C, then the mixture was incubated with hide powder for another 
30 min at 37 °C, to detect if there were any enzyme inhibitors in the test fluids.
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Phospholipase (Ph): Both Ph A2 and C (Sigma) were suspended in PBS, then added 
to the test fluids at a final concentration of 1.1 mg/ml for Ph A2 and 0.26 mg / ml for Ph C 
in the test mixture, which was incubated for 30 min at 37 °C after which the treated and 
untreated test fluids were examined.
Lipid extraction
Lipids were extracted from freshly prepared SUR from LLF as described by Bligh 
and Dyer (1959). The SUR pellets from 3 rats (approximately 12 ml LLF) were 
resuspended in 0.8 ml of PBS, and 3 ml of a mixture of chloroform and methanol at ratio of 
1:2 added. The mixture was dispersed with sonication for 1 x 30 sec at 5-10 % amplitude 
with the microprobe, then 1 ml of chloroform and 1 ml of DW was added to the mixture 
with sonication after each addition, after which the mixture was centrifuged for 5 min at 900 
rpm at 20 °C. The upper phase was discarded, and the inter phase was extracted again 
following the same procedure. The lower phases (mainly chloroform) from the two 
extractions were pooled and poured into a tared 7-ml volume thin-wall glass bijoux (which 
was placed under a source of nitrogen gas in a waterbath containing warm water), dried 
with a smooth flow of nitrogen gas. The weight of extracted lipids of each SUR pool (4 
pools) was measured and found to be 5.75 ± 0.9 mg/ 3 rats. Each pool of extracted lipids 
was dissolved in 2 ml of chloroform and stored at -70 °C. Then 0.5 ml of extracted lipids in 
chloroform was dried as before and resuspended in 1 % CAA by sonication for 3 x 30 sec. 
For bactericidal tests, 240 |il was mixed with 10 |il of B. pertussis 18-323 suspension 
containing 0.8 x 10^ CFU followed by incubation and plating out.
Column chromatography
Silicic acid column chromatography was done according to the method of Daniels 
et al. (1994). A mini-glass-column of 100 x 6.6 mm with Teflon type tubing and jointers 
(Whatman International Ltd) was filled with a slurry of a 0.678 g heat-activated (at 125 °C 
for 4 h) silicic acid (5030 h Silicic acid 325 mesh, Koch- Light Laboratories. Ltd) in 5 ml
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chloroform in a 7-ml volume thin-wall glass bijoux, which was placed in a desiccator (for 
degassing) under a vacuum pressure of 700 mm Hg for 10 min.
Then, 1.8 ml of the degassed silicic acid slurry was applied with a 1-ml graduated 
glass pipette to the column, the column was drained until the meniscus was about 1 mm 
above the resin (which was of 4 cm height), then the column was washed with 30 ml of 
chlorofom, the column was drained again until the meniscus was 1 mm above the resin. 
After which 1 ml of extracted lipid in chloroform (containing about 2.9 mg lipid) was 
applied gently and slowly (by the wall of the column without disturbing the resin bed 
surface) to the column. The column was drained again until the chloroform just entered the 
resin layer, then 1 ml of chloroform was added and the column was drained again until all 
the lipids entered the resin bed.
A dry clean sterile thick wall glass universal (as a reservoir) containing 24 ml of 
chloroform was placed in a position higher than the column connected to the column 
through a Teflon tube. The solvent was allowed to flow from the reservoir through the 
column into a dry clean sterile thick-wall glass universal (collection vessel) at a rate not 
more than 1 ml / min when nearly all the chloroform entered the resin bed.
The column was eluted respectively with 24 ml of acetone and 24 ml of methanol 
and the collection vessels were changed after each elution. After which each eluate was 
dried (until the total volume of elution was reduced to about 3 ml) under a smooth current of 
nitrogen gas in a waterbath containing warm water; then the 3 ml elution was mixed and 
transferred into a dry, clean, sterile thin-wall glass bijoux, which was well exposed to 
nitrogen gas for complete dryness. Each dried lipid was dissolved in 1 ml of its original 
solvent. After which 0.5 ml of each solvent eluate was dried under nitrogen gas and 
resuspended by sonication for 3 x 30 sec in 2 ml of 1 % CAA. Of this, 240 pi was mixed 
with 10 pi of B. pertussis 18-323 suspension containing 1.1 x 10^ CFU for BA.
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Electron Microscope (EM) Examination 
Sample preparation
The component of rat lung SUR, which was fractionated from normal rat LLF was 
stored overnight at 4 °C. Then 1 ml of prepared SUR was centrifuged for 20 min at 17000 
rpm at 4 °C, after which the deposit was examined by transmission electron microscopy 
(TEM).
B. pertussis 18-323 A6 was cultured on BG-medium agar for 3 days, subcultured 
for 24 h, suspended in 1 % CAA. The absorbancy was adjusted at either A540nm = 0.45 or 
0.9. For B. pertussis lux, the bacterial suspension in 1 % CAA was prepared from a 2 
days-old lawn plate culture, then the absorbancy was adjusted as with B. pertussis 18-323 
A6 .
Either standardized B. pertussis strain 18-323 A6 or lux suspension (200 pi) was 
added to 400 pi of each test fluids consisting of normal rat SUR, SN, serum or 
convalescent rat serum, together with PBS and CL-medium as a test control. At time-zero 
and after lh incubation at 37 °C, the test samples were then centrifuged for 15 min at 10000 
rpm .
Transmission EM (TEM)
The material was fixed in 3 % glutaraldehyde (in 0.2 M phosphate buffer) for 1 h. 
It was rinsed in 0.2 M phosphate buffer three times for 5 min, and post-fixed in 0.2 % 
osmium tetroxide for 1 h. The material was then stained in 0.5 uranyl acetate for 1 h, rinsed 
in DW twice for 5 min, and then embedded in agar, and cut into small pieces for further 
processing.
The pieces of agar containing the material was dehydrated through a graded ethanol 
series and embedded in spur resin; sections were cut with a diamond knife on a LKB III 
microtome at a thickness of 60 nm (silver coloured sections). The sections were picked up 
on copper grids (300 mesh), and stained in 2 % uranyl acetate (Reynolds, 1963) and lead
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citrate (Gibbons and Grimstone, 1960) for 5 min in each. The material was examined on a 
Zeiss 902 microscope.
R E S U L T S
8 6
-  DEVELOPMENT OF AN EXPERIMENTAL PROTOCOL
Preliminary Experiments
It was not known at the start of this investigation whether lung lavage fluid (LLF) or 
serum from normal rats would have bactericidal activity (BA) towards B. pertussis 18-323. 
Nor was there information on whether these body fluids when taken from animals that were 
convalescent from B. pertussis pulmonary infection might have heightened activity. A 
simple experiment was therefore done to test samples of rat LLF and serum, both normal 
and convalescent, for ability to kill the test strain of B. pertussis. As control fluids, 
cyclodextrin liquid (CL) medium and phosphate buffered saline (PBS) were used. CL 
medium was chosen because it supports growth of B. pertussis from small inocula 
(Imaizumi et a l , 1983), and PBS because it was the fluid used to wash out the rat 
tracheobronchial tree in order to obtain LLF. The test dose of B. pertussis was prepared 
according to the method of Porter et al. (1991) so as to allow direct plating of 20 |il aliquots 
from the bactericidal test mixtures without further dilution. This was achieved by adjusting a 
fresh suspension of the bacteria to A540nm = 0.45, followed by a 1/2000 dilution and 
adding 20 \i\ to 480 (il of test fluid in Bijoux bottles.
The mixtures were incubated with shaking at 110 rpm at 37°C and 20 (Lil samples 
removed at intervals and plated on Bordet-Gengou (BG) medium to determine the viable 
count. Colonies were counted after 5 days incubation at 37°C. The results of this 
preliminary experiment are presented in Table 18 and show the following:
1) Convalescent rat serum was the most highly bactericidal of all the fluids tested and gave 
a viable count of zero in the short time needed to plate out the time zero samples.
2) Next in bactericidal potency were normal rat serum and the normal and convalescent 
LLF, all of which had killed the inoculum by 120 min.
3) Survival for up to 120 min was satisfactory in both PBS and CL medium, although the 
latter had an unexplained high viable count at time zero.
4) At the longer incubation times, the bacteria in PBS eventually died out (between 240 and 
1440 min) while in CL medium they maintained viability but did not grow. Exactly the same
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Table 18. Comparison of bactericidal activity of normal (N) and convalescent (C) rat LLF 
and serum (S) towards B. pertussis 18-323. PBS and CL medium were used as non- 
bactericidal controls.
Test
fluid
Rat
batch*
No. of CFU / 20 jxl after exposure at 37°C for (min)
0 120 240 1440 2880
NLLF Al 28 0 0 0 nt
CLLF A2 18 0 0 0 nt
NRS Al 21 0 0 0 nt
CRS A2 0 0 0 0 nt
PBS - 26 24 6 0 0
CL - 47 26 19 57 44
*For further details on normal fluids see Appendix 9, and for convalescent fluids, 
Appendix 11. 
nt = not tested
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experiment was repeated about one week later but with LLF and serum from a different 
batch of rats. The results (Table 19) were essentially as before except that the CL medium 
on this occasion permitted actual growth of the B. pertussis. The difference between this 
finding and that in Table 18 where the bacteria merely retained their initial viable count, 
caused concern. The same batch of CL medium base and CL medium supplement were used 
on both occasions and the protocol for preparing the inoculum was not varied. Inadequately 
cleaned glassware was considered a possible explanation and was investigated subsequently 
as reported below.
Bacterial Suspension, Control Fluids and Test Vessels
Before presenting the detailed results of a large number of tests on the BA of rat 
LLF, it is convenient to summarize the accumulated information on protocol development 
and observations on the control fluids. The next few pages therefore describe a variety of 
control studies during the approximately 36 months of the main experimental work. These 
control studies comprised: relationship between CFU/ml of the B. pertussis suspension and 
its method of preparation and initial absorbancy; survival of the bacteria in PBS at 37°C; 
survival and growth of the bacteria in CAA and in CL medium; effect of different containers 
and effect of different volumes for bactericidal tests; and statistical analysis of the 
consistency of duplicate counts. The large number of data collected in the above are detailed 
in Appendices 5 and 6 , and presented here as summary charts.
Bordetella pertussis test suspension
During these investigations of the BA of rat LLF, a large number of control tests 
were done with CL medium to monitor the growth of B. pertussis from the small inocula 
that were used. Altogether 118 such tests were done in which time-zero counts were 
recorded, from CL medium as well as from the other fluids. In early tests, difficulty was 
experienced in having a known and reproducible number of viable B. pertussis at time 
zero. Thus the bacterial suspension adjusted to A540nm = 0-45 and then diluted by a fixed 
amount, yielded between as low as 15 and as high as 250 CFU when plated at time zero.
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Table 19TA second experiment on the bactericidal activity of normal (N) and convalescent 
(C) LLF and serum (S) towards B. pertussis 18-323. PBS and CL medium were used as 
non-bactericidal controls.
Test
fluid
Rat
batch*
No of CFU / 20 pi after exposure at 37°C for (min)
0 30 120 1440 2880
NLLF A2 14 1 0 nt nt
CLLF A5 7 0 0 nt nt
NRS A2 10 0 0 nt nt
CRS A5 0 0 0 nt nt
PBS - 13 10 6 0 0
CL - 14 13 11 185 228
*For further details on normal fluids see Appendix 9, and for convalescent fluids, 
Appendix 11. 
nt = not tested
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To get better standardization, different culture protocols for the test organisms and different 
master dilutions were used in the early months of this work. Also, around Experiment 
Ordinal No. 45, the substrain of B. pertussis 18-323 was changed from EH1 to A6.
Summary chart: A summary of these studies in the form of a chart of time-zero viable 
counts of B. pertussis 18-323 from CL medium is presented in Figure 11. It shows that the 
relatively high variability in time-zero counts in about the first 45 experiments was gradually 
reduced and brought within closer limits. The top section of the chart summarizes the 
various changes in experimental protocol that were introduced. Thus at Experiment Ordinal 
No. 34, the vessels for bactericidal test were changed from glass Bijou to 2-ml plastic vials. 
Prior to this, at Experiment Ordinal No. 27, extra washing of all glassware (Bijou) and 
plastic ware was introduced. The Bijous, used for making dilutions etc, were washed in 
concentrated nitric acid and throughly rinsed in distilled water, while the plastic ware (tips, 
bijou caps, and plastic vials and caps) were boiled in distilled water. After Experiment 
Ordinal No. 34 a standard protocol for growing the B. pertussis test cultures was adopted 
and not changed for the rest of the investigation. This consisted in a 3-day primary culture 
from frozen stock, followed by a heavy inoculum onto a fresh BG plate and incubation for 
24 h. This protocol replaced the single-stage 5-day and 7-day cultures and the 2-stage 5 day 
+ 24 h subculture.
Although individually, the above changes may not have had major and reproducible 
effects, collectively they seemed to improve the consistency of the time-zero counts and to 
bring most of them into the countable range of 50-150 colonies per plate. Between 
Experiment Ordinal No. 42 and 104, the master dilution of the A540nm = 0*45 suspension 
was increased slightly from 1/7000 to 1/9000, in response to rising counts.
Statistical analysis o f viable counts: Having developed the above s tan d a rd  
conditions, the time-zero counts from Experiment Ordinal No. 74 onwards were 
summarized in order to obtain an average value of the CFU/ml of B. pertussis in a 
suspension of A540nm = 0.45. The results of 45 such estimates are summarized in the
hsc 
= 
hours of subculture
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Minitab "analysis in Figure 12. The boxplot and histogram present pictorial summaries of the 
data, indicating a slightly asymmetric distribution around a median of about 70 x 10^ CFU / 
ml for an A540nm = 0.45 suspension in a 1 cm cell.
The summary statistics give the more accurate values (xlO^) as : 
median = 71
mean = 74.01
95 % confidence limits = 64.4 , 83.6
of the mean
Phosphate buffered saline (PBS)
Since PBS was the fluid used to wash out the rat tracheobronchial tree in order to 
obtain LLF, it was necessary to include PBS as a control fluid in the bactericidal tests. The 
approximately 800 observations on B. pertussis 18-323 survival in PBS during incubation 
times of 0, 15, 30, 60, 120, and 1440 min are recorded in Appendix 6.
In the early experiments, the PBS was prepared by dissolving 10 tablets (Oxoid) in 
1 litre of DW, adjusting to pH 7.2 if necessary, and sterilizing by autoclaving in 10 ml 
aliquots. However after Experiment Ordinal No. 11, it was decided to prepare the PBS 
from the individual analytical-grade chemicals and the tablets were no longer used. This 
change was made to see whether survival of the B. pertussis 18-323 during 120 min at 
37°C might be improved; minor changes in pH were also introduced, the initial value of 7.2 
being adjusted in later experiments to pH 7.4 and finally, pH 7.3.
Summary charts: the previously presented summary chart Figure 11, showed actual 
colony counts per 20 |il at time zero for each experiment. However to facilitate comparison 
of results of different experiments, it was decided to express viability as percent survival 
(Figures 13 and 14). For this purpose the time-zero count from CL medium was taken as 
100 % survival. This was done for the first 96 experiments over approximately 36 months, 
after which the use of CL medium as a control was discontinued (because it was decided to
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F ig u re d .  Minitab analysis of 45 observations on the viable count (x 10^) of B. 
pertussis 18-323 at A 540nm = 0-45 in a 1 cm cell.
A. Boxplot
>-------------- i ( +) i * * o
H------------------ 1------------------ 1------------------ 1-------------------1—  CFU/ml
0 50 100  150  2 0 0
Box = Quartiles
Whiskers = Range
Vertical line = Median
Curved brackets = 95 % Confidence limits of the median 
* * 0 = Outliers
B. Histogram
Midpoint Count
20 1
40 7
60 14
80 14
100  5
120 1
140  1
160  1
180  1
0 . 0
C. Summary statistics
N MEAN MEDIAN STD DEV SEM 95%CONFLIM TS
OF THE MEAN
45 74.0 71.0 31.9 4.8 64.4,83.6
4 . 0 8. 0 1 2 . 0 1 6 . 0
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terminateThe experiment at incubation time of 120 min). Thereafter, the time-zero count 
from PBS was taken as indicating 100 % survival. In addition to changes in the method of 
preparing PBS, there were other alterations in experimental procedure such as those relating 
to the bacterial suspension and the type of container. Thus Figures 13 and 14 show that 
none of the experimental manipulations had much consistent effect on the initial bacterial 
counts in PBS.
Although survival of B. pertussis 18-323 after 15, 30, and 60 min at 37°C in PBS 
was studied in some experiments (see Appendix 6), the standard exposure was 120 min. 
Many experiments were continued through to 1440 min exposure, but not all of these times 
were necessarily used in every experiment. These 120 and 1440 min exposures to PBS are 
summarized in Figures 15 and 16. As with the time-zero summary chart, it is difficult to 
attribute differences in B. pertussis survival to particular changes in protocol. It will be 
noted that sporadic survival in the region of 5-10 % at 1440 min was sometimes observed.
Statistical analysis: The numerous experiments in which PBS was used as a non- 
bactericidal control yielded a set of summary statistics of survival of B. pertussis 18-323 in 
this fluid at 37°C (Appendix 6). Figure 17. (A) presents the boxplots of % survival in PBS 
at each sampling time and show a regular decline in median survival as the time of 
incubation increased. Although the spread of observations at each time was quite large, as 
indicated by the width of the boxes and the lengths of the whiskers, the 95 % confidence 
intervals (of the medians) were mostly quite narrow because of the large number of 
observations.
At 120 min which eventually was selected as the time for terminating the bactericidal 
tests, the mean survival in PBS was 56.6 % (n =93) with 95 % confidence limits of 51.3 to 
61. 9. The recorded mean percent survival at 1440 min was 1.73 % but this value is not 
accurate since in many experiments, no viable bacteria were detected. Thus since Minitab 
does not accept" less than" data, an arbitrary value of 0.3 % survival was inserted to allow 
statistical evaluation. The lower section B of Figure 17 presents the summary statistics for 
the percent survival of B. pertussis in PBS.
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Figure F7r Minitab analysis of percent survival (based on time-zero CL medium counts) of
B. pertussis 18-323 in PBS during incubation at 37°C for various times.
A). Boxplot
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B). Summary statistics
IME (min) N MEAN MEDIAN STD DEV SEM 95 % CONF LIMTS 
OF THE MEAN
0 96 91.7 92.0 13.2 1.4 89.0, 94.4
15 57 83.7 88.0 16.7 2.2 79.3, 88.1
30 85 75.6 78.0 21.6 2.4 70.9, 80.2
60 26 71.3 72.5 27.6 5.4 60.2, 82.5
120 93 56.6 62.0 25.7 2.7 51.3, 61.9
1440 74 1.7 0.0 3.2 0.4 1.0, 2.5
100
Quantitative analysis o f  survival: The percent survival data of B. pertussis in PBS 
(Figure 17) are plotted against time in Figure 18. It will be noted that for the first 120 min at 
37°C, a strong decrease in percent survival from about 90 to 75 after 30 min was followed 
by a gradual decrease to about 56 at 120 min.
Casamino acids (CAA)
Casamino acids (CAA) 1 % (w/v) is used as a standard diluent for B. pertussis in 
animal-challenge experiments. It was also used in a majority of my experiments (from 
Ordinal No. 84, see Appendix 6.) as the suspending medium into which B. pertussis 18- 
323 was scraped from BG plates. It was the diluent for absorbancy standardization and for 
diluting the standardized suspension prior to its addition to test fluids. In view of the above, 
CAA was also used periodically as one of the non-bactericidal control fluids, sometimes 
alone but mostly in parallel with PBS and occasionally alongside CL medium.
Appendix 7 contains the viable count data from incubations of B. pertussis 18-323 
with CAA for up to 1440 min. These data are recalculated in Appendix 8 as mean % 
survival, based on the time-zero counts from PBS being taken as 100 %. For the graphic 
presentation of these results (Figure 19), a straight line connection has been drawn through 
the time-zero and 30 min points, and the 15 min time has been relatively neglected because 
there were only 2 observations.
Casamino acids, in its use as a non-bactericidal control fluid, allowed 85% (SEM 
3.61, N= 25) survival of B. pertussis 18-323 at 60 min, while at the standard incubation 
time of 120 min, the value was 55.3 % (SEM 11.0, N=7) which is very close to that 
observed with PBS. In only one out of 5 experiments did B. pertussis 18-323 survive for 
1440 min in CAA as judged by viable count from 20 (il (Appendix 8). The median % 
survival is presented as a boxplot and summary statistics in Figure 20. Since for Minitab 
purposes, almost-confluent plates were arbitrarily taken to have 300 colonies, in all 
probability the true count was much higher.
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Figure H?. Mean (±SEM) percent survival of B. pertussis 18-323 during incubation at 
37°C in PBS for 120 min. Data are from 96 experiments, the % survival calculation being 
based on CL time-zero counts.
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Figure 19: Loss of viability of B. pertussis 18-323 during incubation in 1% (w/v) CAA at 
37°C. Data are the means (± SEM) of 2 - 25 observations.
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Figure 20. Minitab analysis of percent survival of B. pertussis in 1 % CAA during 
incubation at 37°C for various times. The calculation of % survival was based on PBS time- 
zero counts.
A). Boxplot
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B). Summary statistics
TIME (min) N MEAN MEDIAN STD DEV SEMEAN 95 % CONF LIMTS
0 13 97.5 100.0 101.1 5.9
OF THE MEAN 
84.6, 110.5
15 2 83.0 83.0 83.0 0.0 83.0, 83.0
30 8 103.5 106.0 103.5 10.4 78.9, 128.1
60 25 85.1 87.0 85.4 3.6 77.6, 92.5
120 7 55.3 47.0 55.3 11.0 28.5, 82.1
1440 5 3.8 0.0 3.8 3.8 -6.8, 14.4
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Cyclodextrin liquid (CL) medium
In the present work, CL medium base was prepared, distributed as 10 ml portions in 
30 ml glass universals, sterilized, and stored at 4°C. For use, 50 |xl of CL supplement was 
added to make the complete CL medium. The full medium was used as a non-bactericidal 
control alongside PBS in most of the viable count experiments for approximately the first 2 
years of experimentation. The time-zero count in CL medium was used as a base for 
calculating the % survival for all incubation times and for all test fluids and controls.
Preliminary experim ents: In some very early experiments, CL medium as a non- 
bactericidal control failed to support viability and growth of B. pertussis 18-323. It was 
therefore decided to change the CL medium base by replacing L-glutamic acid sodium salt 
(BDH), with L-glutamic acid (BDH) and L-glutamic acid (Sigma), These three different 
batches were tested for their ability to support viability and growth of B. pertussis 18-323 
in two different experiments (Table 20). In these experiments, it was clearly noticed that the 
later two batches of CL medium base containing L-glutamic acid from (BDH) and (Sigma) 
both supported growth and survival of B. pertussis 18-323. Also a heavier confluent 
growth was noticed on a lawn BG plate agar inoculated from CL medium containing L- 
glutamic acid (Sigma) than the other one (BDH).
After this finding, L-glutamic acid (Sigma) was used in CL medium base for all later 
experiments. Despite this change in CL medium base, the problem of CL medium not 
always supporting survival and growth of B. pertussis 18-323 still existed. For this reason, 
further attempts to solve this problem were made. This time, the change was made by 
adding 50 pi (instead of 100 pi according to Imaizumi et al., 1983a) of CL medium 
supplement to 10 ml of CL medium base.
The results of two comparative experiments in Table 21 showed that 50 pi of CL 
supplement was better than 100 pi. From this point onwards, the problem of CL medium as 
a suitable control fluid was overcome. By all the above-mentioned changes, in both CL 
medium base and supplement together with other changes concerning type and cleaning of 
test container, age of bacterial culture, the use of different dilutions and diluent
Table 20.-Survival and growth of B. pertussis 18-323 in CL medium made with different 
batches of L-glutamic acid or glutamate. Data of two experiments, each in duplicate.
CL from Mean CFU/20 pi ±SEM after exposure at 37°C for (min)
L-glutamic _______________________________________________________________
acid batch* 0 15 30 120 1440 2880
A 59±8 50±9 60±9 58±9 240±29 ac
B 50±7 52±8 50±7 59±11 ac c
C 56±7 51±7 52±12 56±9 ac c
Batch* A = L-glutamic acid sodium salt (BDH); B = L-glutamic acid (BDH); C = L-
glutamic acid (SIGMA); ac = almost confluent, c = confluent
Table 21. Survival and growth of B. pertussis 18-323 in CL medium with two different 
concentrations of CL medium supplement.
Concentration of No of CFU/20 pi after exposure at 37°C for (min)
supplement ____________________________________________________________
(p i/1 0  ml) 0 15 30 60 120 1440 2880
50 52,30 40,48 43,48 4 3 ,4 8  51,36 a c , ac c , c
100 5 8 ,3 6  4 6 ,5 3  4 5 ,4 0  5 8 ,3 6  5 1 ,41  n t , 52 3 2 ,2 0
ac = almost confluent growth, c = confluent growth, nt = not tested.
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in preparing test suspension, and a different substrain of 18-323 (Appendix 5) CL medium 
as a non-bactericidal control gave satisfactory results.
Summary charts: The results of 118 experiments where CL medium used as a non- 
bactericidal control are summarized in Figures 21 and 22 as a percent survival of B. 
pertussis 18-323 after 120 and 1440 min of incubation at 37°C. The arrows on the upper 
side of the Figures 21 and 22 showed the locations where the different changes were made. 
From Experiment Ordinal Number 1 up to 41, with a few exceptions, CL medium failed to 
support the survival and growth of B. pertussis 18-323. But, from Experiment Ordinal 
Number 41 through to 118, CL medium was satisfactory as a non-bactericidal control, by 
showing no, or very little, reduction in percent survival, and different rates of succesful 
growth were noticed through a 24 h incubation. This improvment in CL medium action 
appeared to be due to a combination of changes which were made at an early stage of the 
experimental work, but not due to one change only.
Statistical analysis: Minitab analysis in Figure 23 of all data of % survival of B. 
pertussis 18-323 in CL medium are summarized as before.
Survival during incubation: The summary data of % survival of B. pertussis 18-323 
in CL medium from the same 118 experiments is presented in Figure 24 A, B and C. From 
the figure it is obvious that there was a gradual decrease in mean % survival from 100 % at 
time zero to about 80 % at 120 min. A 20 % decline mostly occured during the first 41 
experiments, during which CL medium was used as a non-bactericidal control before the 
various problems were overcome. In the later 77 experiments the median survival increased 
to 95 %.
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Figure 23r Minitab analysis of percent survival (based on time-zero CL medium counts) of 
B. pertussis 18-323 in CL medium during incubation at 37°C for various times.
A). Boxplot
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MEAN MEDIAN STD DEV SEM 95 % CONF LIMTS
0 118 100.0 100.0 0.0 0.0
OF THE MEAN 
100.0, 100.0
15 59 96.6 97.0 14.1 1.8 93.0, 100.3
30 89 95.0 96.0 18.8 2.0 91.1, 99.0
60 25 93.1 87.0 17.7 3.6 86.0, 100.6
120 114 79.8 88.0 28.0 2.6 74.6, 85.0
1440 96 286.4 275.5 231.7 23.6 239.4, 333.3
2880 56 482.2 444.0 411.1 54.9 372.0, 592.3
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Figure-24. Mean (±SEM) percent survival of B. pertussis 18-323 in CL medium 
up to 120 min at 37°C. Data are presented in relation to method of experimentation 
and standardization.
110
A = All results 
(Data of 118 experiments)
100
90
80
70
100 1500 50
110 B = During phase of method 
experimentation 
(Data of first 41 experiments)100
90
80
70
60
50
100 1500 50
110
C = During phase of method 
standardization 
(Data of last 77 experiments)
100
90
80
50 1500 100
Time (min)
Il l
Direct comparison of PBS with CAA and CL Medium
In a few experiments a direct comparison was made of the survival of B. pertussis 
18-323 at 37°C in PBS, CAA and CL medium, tested in parallel. Table 22 shows that loss 
of viability took place at very similar rates in PBS and in CAA, while in CL medium, the 
count did not decline appreciably during the first 120 min, and at 1440 min had definitely 
increased. The figure of 372 % survival in CL medium at 1440 min was slightly lower than 
usual.
Type and size of test container
At the start of the experimental work, sterile, washed, 7 ml-volume thin-wall glass 
Bijous with a plastic screw cap were used as the containers for bacterial suspensions and for 
the test mixtures. However an unexpected reduction in percent survival of B. pertussis 18- 
323 in CL medium and in PBS was found after 120 min of incubation at 37°C in these 
containers. Attention was then focused on the type and the size of the containers which have 
a direct contact with the bacterial suspension. These included sterile U-shaped 96-well 
microtitre plates and sterile washed screw-cap plastic vials (2-ml volume), with 500 p.1 
volumes of test mixture. Sterile, washed 7 ml-volume thin-wall glass Bijoux were the 
standard containers for the bacterial suspensions of 3 ml volume.
According to the results presented in Table 23, there was an obvious gradual 
reduction in viability (86 %) of B. pertussis 18-323 incubated in PBS after 120 min with 
the glass bijoux. No reduction in viability was noticed in PBS after 120 min incubation in 2- 
ml volume plastic vials, whereas a 16.3 % reduction in viability was noticed in PBS after 
120 min incubation in U-Shaped 96-well microtitre plates. There was also a reduction 
(about 67 % after 120 min) in viability of B. pertussis 18-323 in CL medium incubated in 
glass bijoux for 120 min and no growth was detected after 1440 min. In contrast, good 
survival of the same bacteria was found after corresponding incubation in CL medium in 2- 
ml volume plastic vials, and good growth was achieved after 1440 min. With a microtitre 
plate, B. pertussis 18-323 showed about 26 and 72 % reduction in viability respectively
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Table 22^Percent survival of B. pertussis 18-323 in phosphate buffered saline (PBS), 
casamino acids (CAA) and cyclodextrin liquid (CL) medium.
Test Mean % survival ± SEM (No. of experiments) based on PBS time-zero count
Fluid ____________________________________________________________________
0 15 30 60 120 1440 min
PBS 100±0 87±2 98±11 93±32 63±26 4±4
(4) (2) (4) (2) (4) (4)
CAA 102±12 84±24 85±13 97 ±9 50±20 5±5
(4) (2) (4) (2) (4) (3)
CL 113±15 107±7 131±12 104±4 80±18 372±21
(4) (2) (4) (2) (4) (4)
Table 23-.-Effect of type of container used with the test mixture on the survival and growth 
of B. pertussis 18-323 in PBS and CL medium.
Test
fluid
Type of* 
container
No. of CFU / 20 |jl1 (SEM) after exposure at 37°C for (min) 
[Percent reduction in viability]
0 30 60 120 1440
PBS Bijou 9 0 ,8 6 32 , 38 15 , 11 12, 12 0 , 0
bottle
(g>
[0] [60.2] [85.2] [86.4] [100]
PBS Vial 62 , 70 68 ,62 62 ,5 8 76 , ± 56 1.0, 0.0
(P) [0] [1.5] [9.1] [0] [99.2]
PBS Microtitre 88, 108 nt nt 8 0 ,8 4 0 , 0
well
(P)
[0] - - [16.3] [100]
CL Bijou 8 4 ,7 2 56 , 54 5 2 ,5 3 22 , 30 22 , 24
bottle
(g)
[0] [29.5] [33.3] [66.7] [70.5]
CL Vial 7 2 ,8 8 7 4 ,7 2 6 7 ,8 0 7 2 ,7 2 ac
(P) [0] [8.8] [8.8] [10] [< 275]
CL Microtitre 112, 108 nt nt 80, 82 2 6 ,3 4
well
(P)
[0] [26.4] [72.7]
* g = glass, p = plastic; nt = not tested, ac = almost confluent
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after 120 and 1440 min of incubation. According to these findings, plastic vials were used 
as test mixture containers in all further experimental work.
Consistency of duplicate counts
Reference to the various Appendices (5, 6, 7 and 9), in which the full data of 
bacterial viable counts are recorded, shows that duplicate samples were taken for counting 
on about one-half of all occasions. To check the consistency of these duplicates, a 
representative set of N = 65 pairs of counts from LLF (Appendix 9) experiments was 
chosen for further analysis. Very low (< 15) and very high (> 180) counts were excluded 
on grounds of reduced reliability. A Chi-square value for each of the 65 pairs of counts was 
calculated on Minitab and summarized as a histogram in Figure 25. This shows close 
conformity to expectations on the assumption that the differences between duplicate counts 
were due to random-sampling fluctuations and there was no detectable additional component 
of volumetric error. There were 2 out of 65 Chi-square values >3.84 (the 5 % point of the 
Chi-square distribution) whereas the expected number is 3.1, a reasonable agreement.
EFFECT OF LLF ON BACTERIAL VIABILITY 
Bordetella pertussis 18-323 as Test Organism
Having established that B. pertussis strain 18-323 was killed by normal and 
convalescent rat lung lavage fluid (LLF), the effect of certain variables was then explored. 
These included batch-to-batch variation in LLF, method of killing of the rats and different 
strains of rats.
Batch-to-batch variation of LLF from normal rats
During the course of these studies, four methods of euthanasia were used to kill 
normal rats prior to obtaining blood and LLF and three of these methods were also applied 
to convalescent rats. In brief the methods were:
A : Halothane/02 anaesthesia followed by CO2 euthanasia, then bleeding out by heart 
puncture;
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F ig u re d . Histograms of Chi-square values from 65 pairs of viable counts from 
experiments on the bactericidal activity of rat lung lavage fluid (LLF), compared with 
65 theoretical Chi-square values for 1 degree of freedom.
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B : C02Talone euthanasia, then bleeding out by heart puncture;
C : Overdose of halothane / 02, then bleeding out by heart puncture;
D : Halothane / O2 anaesthesia, bleeding out by heart puncture followed by cervical 
dislocation.
Sixteen different batches of LLF from normal rats were tested against B. pertussis 
18-323 in 90 experiments, of which the detailed results are presented in Appendix 9. The 
results are re-expressed as the median % survival in Appendix 10, and summarized in 
Figures 26, 27 and 28 as boxplots.
The boxplots of Figure 26 show that all 5 batches of LLF which had been obtained 
by euthanasia method A were active, ie. the upper 95 % confidence limit of the median % 
survival was less than the lower 95 % confidence limit of PBS; also, a progressive loss of 
viability between 30 and 120 min was apparent. According to the boxplots in Figure 27, 
little or no BA was found with any of the 4 batches which had been obtained by euthanasia 
method B, while the only one batch which had been obtained by euthanasia method C was 
active at 30 and 120 min. In Figure 28, all 6 batches which had been obtained by euthanasia 
method D were highly active at 120 min and most of them were highly active at 30 min. 
Most later batches of LLF were collected by euthanasia method D.
Effect o f  age o f  rats: LLF from rats aged between 40 and >92 days old, and with 
mean weights from 126 to 455 g was examined. All samples had been collected by 
euthanasia method D. The results in Table 24 show very little differences in LLF BA related 
to age. Thus the LLF from 40 and >92 days old rats both gave complete killing after 30 
min. Overall therefore, the age of the rat was not a major determinant of LLF BA.
Convalescent LLF
Experimental variables: With 7 of the batches of Sprague Dawley rats from which 
normal LLF had been obtained, there was also the opportunity to collect samples of LLF 
from animals that had been exposed to various infection andI or vaccination procedures.
Figure 26. Boxplots of bactericidal activity of normal rat LLF (collected by euthanasia 
method A) towards B. pertussis 18-323 after 30 and 120 min incubation. The results are 
presented in chronological order of LLF batch collection, and the activities of PBS and CL 
medium are shown at the bottom.
LLF Time No of
batch (min) observations
no
15 30 9 K , t ..1---- >—
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Figure 27. Boxplots of bactericidal activity of normal rat LLF (collected by euthanasia 
method B, except for 38.2 for which method C was used) towards B. pertussis 18-323 
after 30 and 120 min incubation. The results are presented in chronological order of LLF 
batch collection, and the activities of PBS and CL medium are shown at the bottom.
LLF Time No of 
batch (min) observations 
no
34 30 6
34 120 10
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35 120 2
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Figure 28. Boxplots of bactericidal activity of normal rat LLF (collected by euthanasia 
method D) towards B. pertussis 18-323 after 30 and 120 min incubation. The results are 
presented in chronological order of LLF batch collection, and the activities of PBS and CL 
medium are shown at the bottom.
LLF Time No of
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no
39 30 9 t<I>0
39 120 9
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45 30 2 t
45 120 2 t
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PBS 120 93 ■-----------1—<-U
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Table 24-.-Percent survival of B. pertussis 18-323 treated with LLF from rats of different 
ages. Data are the mean of three experiments.
Rat weight mean 
batch/ (SEM) 
(No. of 
rats)
Age*
(days)
Mean (SEM) % survival** after incubation 
at 37°C for time (min)
0 30 60 120 1440
39 126±4 40 97±12 0 0 0 0
(5)
39 253±2 62 120±14 8±17 7±3 1±1 0
(5)
39 350±6 88 91±3 2±1 0 0 0
(2)
40 355±4 92 98±16 11±6 0 0 0
(15)
40 456±31 >92 94±4 0 0 0 0
(4)
* Data derived from Sprague Dawley rats growth chart, which was prepared from growth 
charts supplied by animal house.
** Based on time-zero PBS counts.
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These animals were killed at between 3 and 6 weeks after infection, with LLF from 
normal control rats being of the same original delivery batch obtained on the same day.
Three different euthanasia methods were used, but on any particular occasion, both 
normal and convalescent rats were subjected to the same euthanasia procedures. Collection, 
processing, and storing procedures were the same as with LLF from untreated rats.
All the infection experiments involved the intratracheal administration (under 
Hypnorm and Hypnovel anaesthesia) of 10^ B. pertussis 18-323 (except in a few 
experiments where other B. pertussis strains were used) in 0.1 ml of agarose bead 
suspension, except in a few experiments where alginate or carrageenan were used in a place 
of agarose. As controls, the beads without live B. pertussis were given to "sham-operated" 
rats. In most experiments, after depositing the beads in the lungs, the animals were exposed 
for 2 min to ether, before being allowed to recover.
For challenge, different B. pertussis 18-323 phase I substrains (A6, EH1 and EH2), 
Tohama, transposon mutants (BP 1809 HLT ", BP 357 PT _), L84 phase IV and B. 
parapertussis strain 10520. In vaccination experiments, the animals were injected 
intraperitoneally with 0.5 ml of DPT vaccine 21 days before infection. Thus at the time of 
euthanasia, the rats were usually 9 to 12 weeks of age. Usually, pooled LLF from 8 rats 
for each group was used.
Results of median % survival of B. pertussis 18-323 in convalescent LLF after 30 
and 120 min incubation are presented here as 7 figures and explained batch by batch. They 
were based on between 2 and 17 bactericidal tests. See Appendices 11 and 12 for detailed 
records. Note that the vaccination and challenge of all these rats were done by my 
colleagues E. Hall, R. Parton and A. C. Wardlaw.
Effect o f  B. pertussis challenge: Rats in this batch were divided into two groups, 
one untreated and the other challenged with B. pertussis 18-323 substrain EH1 in agarose 
beads and then exposed to ether. Euthanasia method B was used before collecting LLF. 
Bactericidal results in Figure 29 showed a weak or no activity of LLF from untreated rats,
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whereas, a high decrease in % survival at 30 min and a complete killing at 120 min were 
noticed with LLF from convalescent rats.
Effect of rat sex and various B. pertussis strains: The 40 rats in this batch were 
used to compare the effect of rat sex and phase I and phase IV B. pertussis challenge 
suspension, and the influence of ether. The LLF bactericidal results in Figure 30 show that 
the normal LLF was more active than any of the LLFs from the convalescent animals. There 
were, however differences in the latter, in that the LLF from rats challenged with phase IV 
B. pertussis was more bactericidal than that from rats challenged with phase I. No effect of 
ether was detected.
Effect of agarose and alginate, ± B. pertussis challenge: Five rat groups in this 
experiment were exposed to euthanasia method D, one untreated, two were sham-operated 
(one with agarose and the other with alginate) with no bacteria, and the other two were 
challenged, with B. pertussis 18-323 substrain EH2, one in agarose beads and the other in 
alginate. All treated rats were exposed to ether. BA results of these LLF fluids towards B. 
pertussis 18-323 were presented in Figure 31, which showing a high activity of LLF from 
untreated and sham-operated rats, and no activity was noticed with LLF from challenged 
and convalescent rats.
Effect o f various B. pertussis challenges (alginate or agarose, ± ether): All
treated rats in this experiment were challenged with B. pertussis 18-323 substrain EH2, 
which was in agarose beads for 2 groups and in alginate for the other 2. Also 2 groups were 
exposed to ether, and the other 2 with no ether treatment. According to the bactericidal 
results in Figure 32, high BA of LLF from untreated and challenged rats with no ether 
treatments was observed and weak or no activity with LLF from the other challenged rats 
which exposed to ether treatment was found.
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Figure 29: Effect of B. pertussis challenge, followed by convalescence, on the bactericidal 
activity of rat LLF (rat batch no. 34). Diagram shows the median % survival of B. 
pertussis 18-323 after 30 (diagonal line) and 120 (solid block) min at 37°C. Euthanasia of 
the rats was by method B. The horizontal dotted line indicates the detection limit. Error bars 
are the upper 95 % confidence limits.
1000 -
100 -
N C l
Chall  
B. p 
EH1 
Ether
Treatment of rats
N : Male normal rats.
Cl : Male rats challenged with B. pertussis 18-323 substrain EH1 in agarose, with 
ether and sacrified 4 weeks later.
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Figure^O. Effect of rat sex and various B. pertussis challenges (Phase I or IV, ± ether) on 
the bactericidal activity of rat LLF (rat batch no. 15). Diagram shows the median % 
survival of B. pertussis 18-323 after 30 (diagonal line) and 120 (solid block) min at 37°C. 
Euthanasia of the rats was by method A. The horizontal dotted line indicates the detection 
limit. Error bars are the upper 95 % confidence limits.
1000 1
C l C 2 C3 C4
Chall Chall Chall Chall
Ph IV Ph I Ph I Ph I
Female Female Male Female
Ether Ether Ether No Ether
Treatment of rats
N : Female normal rats.
Cl : Female rats challenged with B. pertussis L-84 (Phase IV), with ether 
C2 : Male „ „ „ „ 18-323 EH 1 (phase I), with ether
C3 : Female „ „ „ „ „ „ , with ether
C 4 . ,, ,, ,, ,, ,, ,, ,, , no ether
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Figure -3i. Effect of various B. pertussis challenges (alginate or agarose) on the 
bactericidal activity of rat LLF (rat batch no. 41). Diagram shows the median % survival of 
B. pertussis 18-323 after 30 (diagonal line) and 120 (solid block) min at 37°C. Euthanasia 
of the rats was by method A. The horizontal dotted line indicates the detection limit. Error 
bars are the upper 95 % confidence limits.
1000 “
SO 1 SO 2 C l C 2
Sham Sham Chall Chall
agarose alginate EH2 EH2
Ether Ether agarose alginate
Ether Ether
Treatment of rats
N : Female normal rats.
SO 1 : „ rats given agarose with no bacteria.
SO 2 : „ „ „ alginate „ „
Cl : „ „ challenged with B. pertussis 18-323 EH2 in agarose.
C2 : „ „ „ „ „ „ „ alginate.
All treated rats exposed to ether.
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Figure 32*. Effect of various B. pertussis challenges (alginate or agarose, ± ether) on the 
bactericidal activity of rat LLF (rat batch no. 43). Diagram shows the median % survival of 
B. pertussis 18-323 after 30 (diagonal line) and 120 (solid block) min at 37°C. Euthanasia 
of the rats was by method D. The horizontal dotted line indicates the detection limit. Error 
bars are the upper 95 % confidence limits.
1000 -q
C l C2 C3 C4
Chall Chall Chall Chall
EH2 EH2 EH2 EH2
alginate alginate agarose agarose
no ether ether no ether ether
Treatment of rats
N : Female normal rats.
Cl : „ rats challenged with B. pertussis 18-323 EH2 in alginate, no ether.
C 2 : „ „ „ „ „ „ in alginate, with ether.
C3 : „ „ „ „ „ „ in agarose, no ether.
C 4 : „ „ „ „ „ „ in agarose, with ether.
127
E ffec t -of various Bordetella challenges (± carrageenan): This experim ent 
consisted of five groups of rats. Two groups were challenged with virulent B. pertussis 
strains, one with Tohama and the other with 18-323 substrain A6. Other two groups were 
challenged with B. pertussis transposon mutants, one with BPM 1809 HLT “ and the other 
with BP 357 PT ". The fifth group was challenged with B. parapertussis 10520. All the 
bacterial inocula were introduced in a mixture of agarose and carrageenan. All treated rats 
were exposed to ether.
The bactericidal results in Figure 33, shows that all LLF from challenged and 
convalescent rats with B. pertussis HLT ”, PT '  and B. parapertussis 10520 were active. 
No activity was found with LLF from rats challenged with Tohama. LLF from untreated 
rats was less active after 30 min. A low percent survival was achieved after 120 min.
Effect o f  vaccination and various challenges: Two rat groups of this experiment 
were vaccinated, one of which was challenged with B. pertussis 18-323 substrain A6 and 
the other challenged with substrain EH1. The other two groups were only challenged, one 
with B. pertussis 18-323 A6 and the other with EH1.
According to the results in Figure 34, the highest BA was noticed with normal , 
vaccinated and challenged group 1, 2 and convalescent group 2, while weak or no BA was 
detected with convalescent LLF group no. 1. In all cases, loss of bacterial viability after 120 
min was more than that at 30 min.
E ffect o f  sham-operation, vaccination and various challenges: There were no 
completely normal rats in this batch, since in place of untreated animals, a group of 8 sham- 
operated rats was included. These had been through the complete tracheotomy and insertion 
of agarose beads, but the beads were sterile. As shown in Figure 35, the LLF from these 
animals was very similar to the normal LLF from batch no. 15.
The other animals in this experiments had all been challenged with B. pertussis 18- 
323 EH1, but two of the groups had also been vaccinated 3 weeks before. The experiment
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Figure 3-3-. Effect of various Bordetella challenges (± carrageenan) on the bactericidal 
activity of rat LLF (rat batch no. 21). Diagram shows the median % survival of B. 
pertussis 18-323 after 30 (diagonal line) and 120 (solid block) min at 37°C. Euthanasia of 
the rats was by method A. The horizontal dotted line indicates the detection limit. Error bars 
are the upper 95 % confidence limits.
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Treatment of rats
N : Male normal rats.
Cl : „ rats challenged with B. pertussis Tohama in agarose + carrageenan
C2 : „ „ „ „ „ BPM 1809 HLT ~ in agarose + „
C3 : „ „ „ „ „ 18-323 A6 in agarose + „
C4 : „ „ „ „ B. parapertussis 10520 in agarose + „
C5 : „ „ „ „ B. pertussis BP 357 P T " in agarose + „
All treated rats were exposed to ether.
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Figure-34. Effect of vaccination (V) and various challenges (C) on the bactericidal activity 
of rat LLF (rat batch no. 17). Diagram shows the median % survival of B. pertussis 18- 
323 after 30 (diagonal line) and 120 (solid block) min at 37°C. Euthanasia of the rats was 
by method A. The horizontal dotted line indicates the detection limit. Error bars are the 
upper 95 % confidence limits.
1000 1
VC1 C l VC 2 C2
Vacc+ Chall Vacc+ Chall
Chall Bp A6 Chall Bp EH1
Bp A6 Ether Bp EH1 Ether
Ether Ether
Treatment of rats
N : Male normal rats.
VC1 : „ rats vaccinated + challenged with B. pertussis 18-323 A6 in agarose.
Cl : „ „ challenged with B. pertussis 18-323 A6 in agarose.
VC2 : „ „ vaccinated + challenged with B. pertussis 18-323 EH1 in agarose.
C2 : „ „ challenged with B. pertussis 18-323 EH 1 in agarose.
All treated rats exposed to ether.
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Figure 35^  Effect of sham-operation (SO), vaccination (V) and various challenges (C) 
on the bactericidal activity of LLF (rat batch no. 16). Diagram shows the median % 
survival of B. pertussis 18-323 after 30 (diagonal line) and 120 (solid block) min at 
37°C. Euthanasia of the rats was by method A. The horizontal dotted line indicates the 
detection limit. Error bars are the upper 95 % confidence limits.
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Agarose Agarose  
Ether Carrag.
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Treatment of rats
SO : Male rats given agarose and carragenaan only (no bacteria)
VC1 : „ „ vaccinated + challenged with B. pertussis 18-323 EH 1 in agarose
V C 2: „ „ „ + „ „ „ „ in agarose + carrageenan.
Cl : „ „ challenged with B. pertussis 18-323 EH 1 in agarose
C2 : „ „ „ „ „ „ „ „ + carrageenan.
All treated rats exposed to ether.
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also examined the effect of adding carrageenan to the agarose. The bactericidal results in 
Figure 35 contain an anomalous observation in that the 120 min survival was apparently 
higher than the 30 min [Total observations were 17 at time zero, 10 at 30 min and 14 at 120 
min].
Summary analysis o f  effect o f  experimental treatments on LLF  activity: For
further analysis of the accumulated results (Appendix 13) of experimental treatment of the 
rats and the BA of their LLF towards B. pertussis 18-323, Figure 36 shows that there was a 
lot of variation between individual pools of LLF but sex did not appear to be a factor. A 
general observation was that normal rats gave more bactericidally active LLF than 
convalescent animals but with much variation between individual pools of LLF, especially 
from convalescent rats.
Similarly (Figure 37), a lot of variation was also found in the activity of LLF from 
rats exposed to sham-operation ± ether and also in respect of the euthanasia method. LLF 
from treated and untreated rats collected after different times after infection showed (Figure 
38) also much variation, with the day 23 and 28 samples giving the highest activity. Rats 
infected with different organisms (Figure 39) also gave LLF with different BAs. LLFs from 
rats challenged with B. pertussis 18-323 substrains (A6, EH1 and EH2) and Tohama 
showed a lot of variation in their BA.
Of particular interest was the very high activity (low % survival) of fluids from 
animals infected with the Phase IV, HLT ", PT " strains of B. pertussis or with B. 
parapertussis.
Summary analysis of euthanasia data
Altogether 43 batches of LLF were collected, of which 16 were from normal (N) 
and 27 from convalescent (C) animals. Method A of euthanasia was used mainly for early 
studies and method D in the later work.
Bactericidal tests with B. pertussis 18-323 were applied to all different batches of 
LLF and the results summarised in Table 25 for the 30 min results and Table 26 for the 120
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Figure 36. Bactericidal activity of LLF from male and female rats compared with LLF 
from normal (o) and convalescent (•) animals. Percent survival data were at 30 min.
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Figure 2Fh Effect of sham operation, euthanasia method and ether treatment of rats on 
the bactericidal activity of their LLF towards B. pertussis 18-323. Percent survival data 
were at 30 min.
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Figure 38. Bactericidal activity towards B. pertussis 18-323 of LLF collected from 
normal (o) and convalescent ( •)  rats at various times after infection or from matched 
controls. Percent survival data were at 30 min.
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Figured. Effect of vaccination and challenge with different organisms on the bactericidal
activity of LLF towards B. pertussis 18-323 after 30 min incubation.
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min. The data are divided into 4 categories of BA, expressed as median % survival. Details 
of all the individual bactericidal tests may be found in Appendix 9.
Survival o f  B. pertussis after 30 m in : The LLF batches of greatest interest were 
those that gave complete killing of the bacterial inoculum i.e. a median survival of 0 % after 
30 min. Eleven of the 42 batches fell into this highest-activity category. Of these, 5 (IN and 
4C) had been obtained by euthanasia method A and 6 (4 N and 2 C) by method D.
In the next highest BA category (median survival 1-20 %) there was a total of 8 
batches, of which 5 (1 N and 4 C) had been obtained by euthanasia method A, IN by 
method C and 2 (1 N and 1C) by method D.
The table shows that 7 batches of LLF gave median survivals in the range 21-60 % 
i.e. were of moderate BA. These were distributed as method A : (3 N and 1 C); method B: 
(IN and 1C); and method D: (1C).
Finally, there were 16 relatively inactive batches of LLF that gave median survival 
of > 61 % and which were of less use for exploration of BA. These batches were 
distributed as method A: 8 (0 N and 8 C); method B : 3 (3 N and 0 C); method C none and 
method D : 5 (1 N and 4 C).
The overall conclusion from these results was that methods A and D of euthanasia 
were both satisfactory (in giving LLF of a strong BA) for killing the rats before collection of 
LLF and that there was a suggestion that method D might be the better of the two.
Survival o f  B. pertussis after 120 min: As with the 30 min results, attention was 
focused on those LLF batches which gave complete killing of the bacterial inoculum (a 
median survival of 0 %) at 120 min. Table 26 shows that nineteen of the 42 batches were in 
this highest-activity category. Of these, 9 (3 N and 6 C) were from rats killed by euthanasia 
method A, 1 (1 C) by method B, and 9 (5 N and 4 C) by method D.
Nine batches are categorised in the next highest BA (median survival 1-20 %), of 
which, 7 (2 N and 5 C) had been obtained by euthanasia method A, 1 (1 C) by method C 
and 1 (1 N) by method D. In the category of moderate BA (a median survival of 21-60),
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Table 25rSummary of percent survival of B. pertussis 18-323 incubated for 30 min in
different batches of LLF from rats killed by four different euthanasia methods.
Method
of
Type of 
LLF**
Total no. 
of
No. of batches of LLF with median % survival in range:
euthanasia* Total batches 0 1-20 21-60 >61
A N 5 1 1 3 0
C 17 4 4 1 8
T 23 5 5 4 8
B N 4 0 0 1 3
C 1 0 0 1 0
T 5 0 0 2 3
C N 1 0 1 0 0
D N 6 4 1 0 1
C 8 2 1 1 4
T 14 6 2 1 5
Total N 16 5 3 4 4
C 26 6 5 3 12
T 42 11 8 7 16
* A : Halothane/C>2 anaesthesia followed by CO2 euthanasia, then bleeding out by heart
puncture;
B : C02-alone euthanasia 
C : Overdose of halothane / O2
D : Halothane/02 anaesthesia, bleeding out by heart puncture followed by cervical 
dislocation.
**N = normal, C = convalescent, T = total
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there was~a total of 7 batches, of which, 2 (2 C) were from rats killed by euthanasia method 
A, 3 (3 N) by method B and 2 (2 C) by method D.
Finally, seven batches gave a median survival of > 61 %, of these, 4 (4 N) are from 
rats treated by euthanasia method A, 1 (1 N) by method B and 2 (2 C) by method D.
Taking the results Table 27 at 30 and 120 min where the median survival was 0 %, 
it was concluded that euthanasia method D was best and accordingly was chosen as the 
standard method for killing the rats before collection of LLF. However, method A was 
almost as satisfactory.
Different strains of rats
During the early period of investigating the BA of LLF, only rats of the Sprague 
Dawley strain were used. Subsequently, there was an opportunity to test other rat strains, 
namely Lewis, Brown Norway, and Hooded Lister. After killing the animals by euthanasia 
method D, LLF was obtained from both normal and convalescent animals, with Sprague 
Dawley rats being tested in parallel. Two batches of LLF from normal rats of each strain 
were collected.
Normal LLF: The animals were of two different age ranges and their fluids were 
examined for BA towards B. pertussis 18-323 substrain A6. The results (Table 28) show 
that LLF from the Sprague Dawley rats had typical BA, with some killing apparent at time 
"zero" and no detectable colonies thereafter. The other three rat strains were very similar, 
with the LLF from Lewis being the most active (and more active than Sprague Dawley), and 
Brown Norway the least. The 1 % survival in 6 - 7 week Lewis LLF was exceptionally 
high, and was never equalled by Sprague Dawley LLF in the whole of this research.
The age of rat from which LLF was obtained had no consistent influence across the 
strains. Thus with Brown Norway and Hooded Lister, the younger animals yielded the 
most active fluid, whereas, with Sprague Dawley and Lewis the opposite was observed. 
The bottom line of Table 28 shows that survival of the B. pertussis in PBS was within 
normal ranges at the different sampling times.
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Table 26rSummary of percent survival of B. pertussis 18-323 incubated for 120 min in
different batches of LLF from rats killed by four different euthanasia methods.
Method Type of Total no. No. of batches of LLF with median % survival in range:
of LLF** of
euthanasia* Total batches 0 1-20 21-60 >61
A N 5 3 2 0 0
C 17 6 5 2 4
T 22 9 7 2 4
B N 4 0 0 3 1
C 1 1 0 0 0
T 5 1 0 3 1
C N 1 0 1 0 0
D N 6 5 1 0 0
C 8 4 0 2 2
T 14 9 1 2 2
Total N 16 8 4 3 1
C 26 11 5 4 6
T 42 19 9 7 7
* A : Halothane/02 anaesthesia followed by CO2 euthanasia, then bleeding out by heart
puncture;
B : C02~alone euthanasia 
C : Overdose of halothane / O2
D : Halothane/02 anaesthesia, bleeding out by heart puncture followed by cervical 
dislocation.
**N = normal, C = convalescent, T = total
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Table Th.Comparison between bactericidal activity of LLF obtained by euthanasia methods 
A and D towards B. pertussis 18-323 after 30 and 120 min incubation.
Method
of
euthanasia*
Type of 
LLF** 
Total
Total no.
of
batches
No. of batches of LLF with median of 
0 % survival after incubation time:
30 120
A N 5 1 3
C 17 4 6
T 22 5 9
D N 6 4 5
C 8 2 4
T 14 6 9
**N = normal, C = convalescent, T = total
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Table 28rBactericidal activity towards B. pertussis 18-323 substrain A6 of LLF* from 
normal rats of different strains and ages. PBS was used as a non-bactericidal control.
Strain
of
rat
Age
(weeks)
% Survival** in duplicate tests after exposure 
at 37 °C for (min)
0 30 60 120
Sprague Dawley (4-5) 46,  30 0 , 0 0 , 0 0 , 0
(6-7) 24,  16 0 , 0 0 , 0 0 , 0
Lewis (4-5) 1 0 , 6 0 , 0 0 , 0 0 , 0
(6-7) 1 , 1 0 , 0 0 , 0 0 , 0
Brown Norway (4-5) 3 4 , 3 6 0 , 0 0 , 0 0 , 0
(6-7) 80 , 89 0 , 0 0 , 0 0 , 0
Hooded Lister (4-5) 3 , 3 0 , 0 0 , 0 0 , 0
(6-7) 41 , 32 0 , 0 0 , 0 0 , 0
(PBS control) - 100, 100 9 4 , 7 7 59 , 52 43 ,2:
*LLF pooled from 8 rats of each strain.
** calculation of % survival values was based on PBS time-zero count.
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Convalescent LLF : Rats were infected intratracheally with B. pertussis 18-323 encased 
in agarose beads with dimethyl p-cyclodextrin, and the LLFs were obtained at the 
convalescent stage. In marked contrast to the above results with LLF from normal rats, the 
corresponding convalescent LLFs were mostly much less active (Table 29). With Sprague 
Dawley convalescent LLFs of both ages, the results were consistent with those reported 
previously (Figure 30). Similar to Sprague Dawley were the older Lewis and the younger 
Hooded lister, As before, with the normal LLFs, Brown Norway convalescent LLF was the 
most active and at both ages. LLF from the 6 - 7 week Lewis and the 4 - 5  week Hooded 
Lister had no BA. Indeed the Hooded Lister LLF appeared to act as a growth medium.
To facilitate further comparison of possible rat strain and age effects in BA of LLF, 
the 30 min results already presented in Tables 28 and 29 are retabulated in Table 30. This 
highlights the general conclusions that 1) with various ages and strains of rats, normal LLF 
is more bactericidal than convalescent; 2) that Brown Norway rats may have LLF that is 
more active than LLF from the other strains ; and 3) that convalescent Hooded Lister LLF 
may be the least active. The 30 min incubation time chosen for these comparisons allowed 
close to 100 % survival of the B. pertussis in PBS.
LLF from other animal species and human
LLF was obtained from 7 animal species and from a human patient, and tested for 
BA towards B. pertussis 18-323 substrain A6. One LLF batch from each species was 
available and was tested against normal rat LLF as a positive control. PBS was the negative 
control. These studies were not all done on the same occasion and batch nos 15, 33, and 40 
of rat LLF were used.
The results in the various sections of Figure 40 show that none of the other animal 
species yielded LLF as active as that from the normal rat. In fact, the only species where 
any BA was detected were human (Figure 40 A) and calf (Figure 40 E). LLF with no BA 
towards B. pertussis was obtained from chicken, rabbit, horse, sheep, dog and mouse.
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Table 29rPercent survival of B. pertussis 18-323 substrain A6 treated with LLF from 
convalescent rats of different strains and ages. PBS was used as a non-bactericidal control.
Strain
of
rat
Age
(weeks)
% Survival* in duplicate tests after exposure 
at 37°C for (min)
0 30 60 120
Sprague Dawley (4-5) 101, 97 68 ,43 27 , 37 19, 23
(6-7) 82 , 83 18 , 24 6 , 6 8 , 14
Lewis (4-5) 118 , 105 26,21 8 , 0 6 , 9
(6-7) 113 , 113 67, 66 108 , 84 83 , 136
Brown Norway (4-5) 5 , 8 0 , 0 0 , 0 0 , 0
(6-7) 53 ,44 0 , 0 0 , 0 0 , 0
Hooded Lister (4-5) 119 , 104 113 , 129 229 , 184 267 , 364
(6-7) 87 ,73 9 0 , 9 7 67 , 61 25 , 50
(PBS control) - 100, 100 9 4 , 7 7 59 , 52 43 ,22
* calculation of % survival values was based on PBS time-zero count.
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Table 307~Comparison of percent survival of B. pertussis 18-323 substrain A6 after 30 min
at 37°C in LLF from normal and convalescent rats of different strains and ages.
Strain
of
rat
% Survival*
Normal Convalescent
4-5 6-7 4-5 6-7 week
Sprague Dawley 0 ,  0 0 ,  0 68 , 43 18 , 24
Lewis 0 ,  0 0 ,  0 2 6 , 21 67 ,66
Brown Norway 0 ,  0 0 ,  0 0 ,  0 0 ,  0
Hooded Lister 0 ,  0 0 ,  0 113 , 129 9 0 , 9 7
(PBS control) 94, 77 94, 77 94, 77 94, 77
* calculation of % survival values was based on PBS time-zero count.
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Figure 40. Bactericidal activity of different normal animal and human LLF towards B. 
pertussis 18-323 substrain A6. PBS was used as a non-bactericidal control. Data are the 
mean of 2 to 3 experiments. Error bars are SEM which when small do not project beyond 
the points.
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Figure 40 continued
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Other Strains of Bordetella pertussis
After the confirmation of the BA of normal and treated rats LLF towards B. 
pertussis 18-323 was established, the idea of testing other strains of B. pertussis phase I 
and IV was raised to see whether they have the same sensitivity to the bactericidal effect of 
LLF from normal and treated rats as with B. pertussis 18-323.
Phase I strains, including B. pertussis lux
Twenty two experiments were done to test the BA of LLF towards 11 B. pertussis 
phase I strains, the bacterial suspensions being prepared, standardised and diluted as with 
B. pertussis 18-323. PBS was included in all experiments as a non-bactericidal control. All 
B. pertussis strains were tested with normal and convalescent rat (exposed to euthanasia 
method A) LLF batch no. 15 group 1, except strain 30042 phase I which was tested with 
LLF from both normal and convalescent rats (exposed to euthanasia method B) batch no. 
34.
Convalescent rats batch no. 15 group 1, were challenged with B. pertussis L84 
phase IV encased in agarose beads and exposed to ether inhalation for 2 min, and LLF then 
collected 28 days after infection. The convalescent rats batch no. 34, had been challenged 
with B. pertussis 18-323 EH1 phase I incorporated in agarose beads, then the animals were 
exposed to ether inhalation for 2 min and, LLF obtained 28 days after infection.
It should be noted that the rats of batch no. 34 were exceptional in giving normal 
LLF that had less BA than the fluid from convalescent animal towards both phase I and 
phase IV test organisms. The only feature of those animals that might be responsible was 
the collection of LLF by euthanasia method B.
According to the results presented in Figures 41, all B. pertussis phase I strains 
showed between low and moderate loss of viability during incubation in normal rat LLF. 
With LLF from convalescent rats, the loss of viability was faster. However this particular 
convalescent LLF had come from rats infected with phase IV B. pertussis.
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Figure~4l. Bactericidal activity of normal (N) and convalescent (C) rat LLF towards 
different strains of B. pertussis phase I, with PBS as the non-bactericidal control. Data are 
the mean of two experiments with one duplicate of each. Error bars are SEM which when 
small do not project beyond the points.
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Figure 41. continued
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Table 31. Comparison of bactericidal activity of LLF towards Bordetella pertussis 18-323 
sub-strain A6 and B. pertussis lux. CL medium and PBS were used as non-bactericidal 
controls.
B. pertussis 
strain
Test
fluids
% Survival** after exposure at 37°C for (min)
0 30 60 120 1440
18-323 A6 LLF* 119,65 0 , 0 0 , 0 0 , 0 0 , 0
CL medium 141 , 94 131 , 100 125 , 82 147 , 97 406, 394
PBS 100 , 100 94 , 82 113 , 124 88 ,7 6 0 ,9
Lux LLF* 96 , 101 1 ,0 1 , 1 1 ,0 0 , 0
CL medium 8 8 , 7 9 9 0 , 9 2 99 , 101 71 ,76 221 , 214**=
PBS 100 , 100 99 , 84 6 6 , 7 7 63 , 87 3,2
LLF* = Batch no. 40
* Calculation of % survival was based on PBS time-zero count data.
*** Both of these numbers are the outcome of dividing 300 (no. of cells assumed to be 
equal to almost-confluent growth) by the PBS time-zero count and multiplying by 100.
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Further viable count examination of the BA of LLF from rats (euthanasia method D) 
batch no. 40 towards B. pertussis 18-323 A6 and lux was performed. CL medium and 
PBS were included as a control fluids. The results in Table 31, showed a complete killing 
of both B. pertussis strains after 30 min of incubation. No or very little loss of viability 
during 120 min incubation in CL medium was found, and a growth of both strains was 
achieved after 1440 min. Strain 18-323 grew better in CL medium than lux. Moderate 
reduction in percent survival of both strains in PBS was observed.
Phase IV strains
Two phase IV strains of B. pertussis were used in the following experiments, but 
because they were tested several months apart, different batches of LLF were used. Also the 
euthanasia methods with which the LLFs were collected were different.
In the bactericidal tests, the results (Table 32) include PBS as the usual control. The 
most interesting observation with both of the phase IV strains and both batches of normal 
LLF was the absence of BA. In fact, the LLFs acted as growth media, in that there was little 
or no loss of viability at 120 min and an apparent increase in viable count at 1440 min. It 
should be noted that in contrast with phase I B. pertussis, normal LLF of batch no. 15 (c. f. 
Figure 30) gave little activity compared with the activity of batch no. 34.
The convalescent LLFs were different from the normal fluids collected at the same 
time in showing moderate to strong BA. The convalescent LLF collected by euthanasia 
method B was more active than the fluid collected by method A. This result was similar to 
that previously observed with Phase I B. pertussis (Figure 29 and 30). Both phase IV 
strains slowly lost viability in PBS during 120 min at 37°C, but there were still a few viable 
cells at 1440 min. Other than batch no. 34, none of the other 11 LLF batches (3 normal and 
8 convalescent) which had been tested for their BA towards B. pertussis 30042 IV, was 
active.
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Table 32rSurvival of B. pertussis phase IV strains L84 and 30042 in normal (N) and 
convalescent (C) rat LLF. PBS was used as a non-bactericidal control. Data of two 
experiments each with one duplicate.
B. p  Test 
phase IV fluids 
strain
Mean (±SEM) % survival* after exposure at 37°C for (min)
0 15 30 120 1440
L84 NLLF** 104.8 ± 2.5 102 ± 5.4 98.7 ± 4.4 89.8 ± 6.0 131.9 ±32.3
CLLF** 103.5 ± 3.3 93.2 ± 3.4 87.8 ± 3.3 65.5 ± 4.0 3.13 ±2.5
PBS 100 ±0.0 102.9 ± 4.5 91.7 ± 3.2 83.3 ± 4.2 46.2 ± 6.9
30042 NLLF*** 98.8 ± 2.9 97.2 ±3.1 94.4 ± 3.4 90.8 ± 3.7 167.8 ± 12.5
CLLF*** 96.6 ± 2.6 12.2 ±3.5 3.5 ± 0.5 0.31 ±0.3 0 ± 0
PBS 100 ± 0.0 95.8 ± 2.5 95.6 ± 3.9 84.2 ± 1.4 3.6 ±2.1
Calculation of % survival was based on PBS time-zero counts. 
**NLLF batch no. 15, see Appendix 9 footnote for code Ai 
**CLLF batch no. 15, see Appendix 11 footnote for code A] 
***NLLF batch no. 34, see Appendix 9 footnote for code A6 
***CLLF batch no. 34, see Appendix 11 footnote for code A is
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Comparison of LLF and serum with phase IV
For the comparison of BA of LLF and serum, the single phase IV strain 30042 was 
used. Also a single batch of rats and a single euthanasia method was used as the source of 
normal and convalescent LLF and serum. This batch was the same as used in lower half of 
Table 32. In addition CL medium was used as a further control.
In confirmation of the previous observation, normal LLF (Table 33) acted as a 
growth medium for phase IV B. pertussis and was indistinguishable from CL medium for 
up to 1440 min. The convalescent LLF was, as before, quite strongly bactericidal but not 
nearly as active as the two sera. Normal rat serum was so active as to give a low count at 
zero time, indicating killing during the few minutes of initial sampling. Convalescent rat 
serum was even more active. PBS was slowly bactericidal during the 120 min of 
observation.
A summary comparison of survival of B. pertussis strain 18-323 A6 Phase I and 
30042IV in LLF and serum from normal and convalescent rats batch no. 34 is presented in 
Table 34. CL medium and PBS both were used as a control fluids.
Loss of viability of phase I during 120 min incubation in normal LLF and complete 
killing after 1440 min were found, whereas no reduction in percent survival of phase IV 
throughout 120 min incubation with a significant growth after 1440 min were recorded. 
Both B. pertussis strains failed to survive in LLF from convalescent rats.
Serum from both normal and infected rats of the same batch was highly bactericidal 
towards both B. pertussis strains. A good survival and growth of both strains in CL 
medium were noticed. Slow and no reduction of cell viable count respectively of phase I 
and IV was demonstrated.
Summary comparison of phase I and IV
B. pertussis phase I and IV strains (All strains tested with LLF from rats batch no. 
15, except strains 30042 I and IV which were tested with LLF batch no. 34) were compared 
for bactericidal sensitivity towards LLF from normal and convalescent rats, with PBS as a 
control.
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Table 33:Bactericidal activity of lung lavage fluids (LLF) and serum from normal (N) and 
convalescent (C) rats batch no. 34 towards B. pertussis 30042IV. PBS and CL medium 
were used as a non-bactericidal control.
Test
Fluids
Mean % survival* ±SEM (No. of experiments) during 
incubation at 37°C for a time of (min)
0 15 30 60 120 1440
NLLF 103.5±4.4 97.3±3.1 100.8±4.4 100.3±4.3 91.0±4.4 168.0±12.5
(8) (4) (8) (3) (7) (4)
CLLF 93.9±1.5 12.3±3.6 5.4±1.2 1.6±0.9 0.27±0.2 0
(10) (4) (10) (5) (9) (4)
NRS 15.3±4.1 0.13±0.1 0.13±0.1 nt 0 0
(4) (4) (4) - (4) (4)
CRS 3.5±0.9 0 0 nt 0 0
(4) (4) (4) - (4) (4)
CL medium 100.8±3 98.5±1.7 99.6±4.3 99.8±7.9 91.9+3.1 170.5±10.6
(8) (4) (8) (4) (8) (4)
PBS 100±0.0 nt 100.8±3.1 93.2±6.2 86.4±7.5 nt
(6) - (6) (5) (5) -
Calculation of % survival was based on PBS time-zero count.
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Table 34. Comparison of percent survival between B. pertussis 18-323 A6 phase I and B. 
pertussis 30042 phase IV in LLF and serum (RS) from normal (N) and convalescent (C) 
rats batch no. 34.
Test Mean % survival*±SEM (No. of experiments) during
Fluids incubation at 37 °C for a time of (min)
B.pertussis 18-323 A6 I B.pertussis 30042 IV
30 120 1440 30 120 1440 .
NLLF 45.0±13.2 6.7±6.7 0 100.8±4.4 91.014.4 168.0112.5
(3) (3) (2) (8) (7) (4)
CLLF 24.1±4.7 1.4±0.6 0 5.4±1.2 0.2710.2 0
(7) (7) (2) (10) (9) (4)
NRS 3.0±1.7 0 0 0.1310.1 0 0
(3) (3) (2) (4) (4) (4)
CRS 1.0±1.0 0 0 0 0 0
(3) (3) (2) (4) (4) (4)
CL medium 98.6±4.3 94.7±6.9 60010.0** 99.614.3 91.913.1 170.5110.6
(7) (7) (2) (8) (8) (4)
PBS 93.5±4.1 76.6±2.5 nt 93.216.2 100.813.1 nt
(6) (6) - (5) (5) -
Calculation of % survival was based on PBS time-zero count data.
** This large number is the outcome of dividing 300 (no. of cells assumed to be equal to 
almost-confluent growth) by the PBS time-zero count data and multiplying by 100.
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Table 35 show that all B. pertussis phase I strains showed a 50 % reduction in 
viability in normal rat LLF as early as 12 min, and as late as 92 min. A 90 % reduction was 
seen as early as 33 min, and as late as > 120 min. However, the 50 % reduction in viability 
in convalescent rats LLF was as early as 4 min, and as late as 32 min, and 90 % reduction 
in the same fluids was as early as 9 min and as late as > 120 min.
For B. pertussis phase IV strains, no BA of normal LLF was detected towards 
either of the two strains (L84 and 30042). While, in convalescent LLF, a 50 and 90 % 
reduction in viability of strain 30042 IV (tested with LLF of batch no. 34) was achieved 
respectively after 7 and 21 mins, compared with no BA of LLF from rats batch no. 15 
towards strain L84 IV was found. In PBS as a non-bactericidal control, all B. pertussis 
strains (phase I and IV) show a good survival and >120 min was needed for a 50 and 90 % 
reduction in viability.
EFFECT OF LLF ON BACTERIAL LUMINESCENCE 
Development of Method
Preliminary experiments
For rapid testing, the effect of rat LLF on bacterial luminescence was explored, 
since experiments could be completed within a few hours instead of waiting 5 days for B. 
pertussis 18-323 colonies to be ready for counting. For this purpose, a standardized 
(A540nm = 0.45) suspension of B. pertussis lux was incubated with test and control fluids 
for 1 h at 37°C. Then the test mixtures were transfered to the luminometer cuvettes, placed 
in the luminometer and decanal added. The decanal was added as 20 (ill of 0.5 % (v/v) 
solution in DMSO and PBS so that the volume of the undiluted aldehyde per test was 100 
nl. The peak luminescence (light output) in millivolts was then determined over a 10 min 
period.
Table 36 shows that there was little reduction in bacterial luminescence by either 
normal or convalescent rat LLF. In contrast, a large reduction in luminescence was 
produced by normal and convalescent rat serum. In experiment 3 of Table 36, the use of an
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Table 35'.~Summary comparison of percent survival of B. pertussis phase I and IV strains
incubated in normal and convalescent rat LLF and PBS.
Strain Phase Time (min) for killing %
Normal Convalescent PBS
50 90 50 90 50 90
18-323 EH1 I 30 108 10 32 106 >120
18-323 A6 I 55 >120 7 15 >120 >120
18-334 I 92 >120 6 12 >120 >120
44122 7S I 18 49 14 65 >120 >120
44122 7R I 24 99 32 96 >120 >120
Lux I 16 48 24 120 >120 >120
Tohama I 12 73 4 9 >120 >120
347 I 22 >120 4 9 >120 >120
77/18319 I 22 >120 7 19 >120 >120
L84 I 18 33 4 13 >120 >120
L84 IV >120 >120 >120 >120 >120 >120
30042 I 29 >120 5 18 >120 >120
30042 IV >120 >120 7 21 >120 >120
1 6 0
Table 367 Effect of normal (N) and convalescent (C) rat LLF and serum (RS) on the
luminescence of B. pertussis lux with 100 nl of decanal after 1 h incubation at 37°C. PBS
was used as a non-bactericidal control.
Expt
no
Age of 
decanal
Luminescence (mv) after lh incubation in test fluid
solution NLLF CLLF NRS CRS PBS
1 Fresh 140 140 58 66 200
2 Fresh 160, 180 160, 180 55, 55 55, 55 150, 154
3 > 4 days 
old
8, 8 14, 14 14, 16 14, 16 8, 10
NLLF & NRS batch no 15, see code A1 in Appendix 9 footnote for more details. 
CLLF & CRS batch no 15, see code A1 in Appendix 11 footnote for more details.
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old solution of decanal was associated with low luminescence. Also in early experiments 
there was much unexpected variation in the light output of the same -70°C stock of B. 
pertussis lux when incubated in PBS. For example, the luminosity ranged from 100 mv 
down to 10 mv for no apparent reason. It was therefore clear that the method for studying 
death or survival of B. pertussis lux in experimental fluids required further development.
Age of bacterial culture
Standardized (A540nm = 0.45) B. pertussis lux suspension (in 1 % CAA instead of 
PBS) of 36, 48, 60, 72 and 84 h old lawn-grown cultures at 37°C were prepared, and 100 
jLtl of each was added to 400 pi of PBS. The experiment, in addition to examining different 
ages of culture, also had a change in decanal concentration from that used above. Instead of 
having 100 nl of the aldehyde, 18 nl was used. The test mixtures were incubated for 1 h at 
37°C in the luminometer, after which, 20 pi of 0.09 % (v/v) of decanal in DMSO and DW 
was added (to deliver 18 nl of neat decanal). The highest level of luminescence (Figure 42) 
of B. pertussis lux was from 48 h-grown cells. This age of culture was significantly better 
than 36 h, or 60 h or older cultures. Accordingly, 48 h-grown cells were used for all later 
experiments. In 27 observations, B. pertussis lux suspended in 1 % CAA survived well in 
PBS at 37°C for 1 h in that a median % survival of 82 with upper 95 % confidence limit of 
87.2 was found.
Bacterial concentration
A series of experiments was done in which the A540nm = 0.45 bacterial suspension 
was added in volumes from 12.5 to 100 pi to the PBS to give a final volume of 1.0 ml. 
Luminescence varied in an approximately linear fashion with the log (quantity of luminous 
bacteria) as shown in Figure 43. In subsequent experiments, 100 pi of the standardized 
suspension was added to all test and control fluids.
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Figure 42. Effect of bacterial culture age on the luminescence of B. pertussis lux. Data 
are the mean (±SEM) of 2 observations in the same experiment.
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Figure 43\ Effect of different B. pertussis lux (A540nm = 0.45) volumes incubated in 
PBS (to give a final volume of 1ml of test mixture) for 1 h on the extent of luminescence. 
Data are the mean (±SEM) of three experiments.
1000 n
0>
8Vun
100 -
10
100 50 25 12 .5
Volume of bacterial suspension (pi)
/
1 6 4
Decanat~concentration and age
A problem in the early experiments was that decanal and DMSO, if used at too high 
concentrations, appeared to kill B. pertussis lux suspended in PBS. This interpretation was 
reached from tests in which a second dose of decanal (dissolved in DMSO) failed 
completely to stimulate luminescence.
Therefore, attention was directed at the adjustment of decanal and DMSO 
concentrations to stimulate strong luminescence and allow frequent addition of decanal at 
different times without harming the bacteria. For this purpose, two different solutions of 10 
% and 20 % (v/v) decanal dissolved in DMSO were prepared after which both mixtures 
were further diluted in PBS or DW giving a different range of final decanal volumes of 100 
to 18 nl, and final DMSO volumes of 900 to 72 nl.
Three of the 10 different dilution schemes tested are described in Table 37. 
Preparation method A (Figure 44), shows a reduction in luminescence of B. pertussis 
incubated in PBS. Whereas, an increase of light output of bacteria incubated in CL medium 
was detected.
In method C, an improvement of bacterial luminescence in PBS and CL medium 
was detected, while, a decrease in 1 % CAA was observed. In preparation method J, no 
decrease in bacterial luminescence incubated in PBS and an increase in CL medium were 
found. In 1 % CAA, an improvement was found. Finally it should be noted that method C 
was the best. All the different dilution schemes are in Appendix 14 and 15. Full results of 
the effect of frequent addition of decanal (at different volumes) on the luminescence of B. 
pertussis incubated in PBS, CL medium and 1 % CAA at 37°C for various time are in 
Appendix 16.
Even after these successful suitable final decanal concentrations had been 
determined, a gradual decrease in light output of B. pertussis lux from the same - 70°C 
stock was noticed in PBS. Attention was focused on the age of the prepared decanal which 
usually was at about 2, 3 and > 4 days old. An experiment was done testing the bacterial 
luminescence of B. pertussis lux treated with 1 and 48 h prepared decanal. More 
luminescence from bacteria treated with fresh (1 h old) prepared decanal than from bacteria
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Table 37. Three different dilution schemes of 10 and 20 % (v/v) decanal dissolved in 
dimethyl sulphoxide (DMSO) as the primary solvent and diluted in PBS or DW as the 
secondary diluent.
Decanal Secondary Final volume (nl) per test
reagent diluent _________________________
method Decanal DMSO
A PBS 100 900
C DW 20 180
J DW 18 72
1 6 6
Figure~44. Effect of three of the ten different dilution schemes for decanal on the 
luminescence of B. pertussis lux when incubated in PBS, CL medium and, with methods 
C and J, in CAA. Data are the mean of one to three observations. Error bars are SEM 
which when small do not project beyond the points.
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Figure 44. continued
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treated with 48 h old prepared decanal was found.
Batch Variation of LLF
Extensive tests by luminometry, similar to those by viable counting with 18-323, 
were made to find out whether there were differences between LLF samples obtained from 
different batches of normal and convalescent rats. In collecting these samples, different 
methods of euthanasia had been used. Thus, thirteen LLF batches from normal rats and 2 
from convalescent rats were tested as neat and four-fold dilutions to 1/64 in PBS.
Results of the effect of these different LLF batches on bacterial luminescence are 
summarised in Table 38, with details in Appendix 17. LLF obtained from rats treated with 
euthanasia method D were mostly slightly more active than LLF from euthanasia method A. 
Euthanasia method C was only used on one occasion and although it gave LLF less active 
than A or D it is difficult to draw firm conclusion. Whereas, no activity was found with 
Euthanasia method B. There was more BA with LLF from normal rats than from 
convalescent animals.
The footnote to Table 38 indicates that the use or avoidence of ether, at the time the 
rats were given their intrabronchial infection with B. pertussis did not influence the non- 
bactericidal activity of the convalescent LLF obtained several weeks later.
B. pertussis Lux Luminescence Compared with 18-323 Viable Counts
Having shown above that LLF reduced the luminescence of B. pertussis lux and (in 
previous section) the viable count of B. pertussis 18-323, it was felt necessary to make 
more direct comparisons. It should be noted that the viability test with B. pertussis 18-323 
used the bacteria at an initial concentration of 3000 / ml whereas luminometry with B. 
pertussis  lux required approximately lO^-times higher concentration. A series of 
experiments was done using LLF from 4 different batches of normal rats (exposed to 4 
different euthanasia methods) and 2 different batches of convalescent rats (euthanasia 
method D).
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Table 38rBatch to batch variation of LLF from normal (N) and convalescent (C) rats in 
bactericidal activity towards B. pertussis lux.
LLF Method Treatment Bactericidal activity (jil)*
batch of of _________________________________________
no. euthanasia rats Reduction of luminescence (% DEP)
Lum 50 Lum 90
15 A N 6 ,3 0 90 , 145
17 A N 15 285
33 A N 3 ,37 75 , 245
34 B N 135 , >400 >400 , >400
35 B N >400 , >400 >400 , >400
37 B N >400 >400
38.1 B N >400 , >400 >400 , >400
38.2 C N 72 , 83 310, >400
39 D N 7 , 12 70 , 205
40 D N 5 ,20 75 , 207
41 D N 70 , 205 >400 , >400
42 D N >400 , >400 >400 , >400
43 D N 5 ,25 55 , 107
43 D C3 195 , >400 >400 , >400
43 D C4 >400 , >400 >400 , >400
* Volume of test fluid required to give either 50 % or 90 % reduction of luminescence 
(Lum)[ (ie. 50 % or 90 % inactivation endpoint [IEP]).
C3 = No ether treatment, at the time of infection.
C4 = With ether treatment, at the time of infection.
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Table 39 shows that LLF from normal rats was more active than from convalescent 
animals. Taking the 50 % end points, parallel activity of LLF from normal rats towards both 
bacteria was observed, ie. the batch 43 was approximately equal to batch 15 in both test 
systems, and both were more active than batch 38 which, in turn was more active than batch 
34. The last-mentioned was in fact inactive, as were the two batches of convalescent LLF. 
The 90 % end points gave the same pattern of activity, but were shifted to larger volumes 
eg. batch 15 required a 3 to 4 times greater volume to give a 90 %, compared with a 50 %, 
end point in the two test systems. Of the 4 euthanasia methods, D and A gave similarly 
active LLFs from normal rats (except no. 42), while B was much less satisfactory. The 
single LLF collected by method C had intermediate activity.
CHARACTERIZATION OF RAT LLF 
Fractionation by Centrifugation
As a first step in characterizing the substances responsible for the BA of LLF, the 
fluid (after low-speed deposition of cells) was ultracentrifuged at 29,000 rpm (55,000 g) for 
20 min, at 4°C, and the supernate (SN) and deposit (surfactant, SUR) separated. The 
deposit was dispersed in PBS to the original volume of the LLF and both fractions stored 
frozen. They were then examined for their BA towards bordetellae and other bacteria.
Viable count experiments
B. pertussis 18-323: A series of tests was done on the SN and SUR fractions for their 
BA towards B. pertussis 18-323. Eight LLF batches from normal rats and two from 
convalescent rats were used. With fluids from normal rats, Figure 45 shows that the SUR 
fraction was more bactericidally active than the SN, after both the 30 and 120 min 
incubations. The longer incubation, as expected, gave greater reduction in % survival of the 
bacteria in the SN.
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Table 39: Comparison of percent reduction of both B. pertussis 18-323 A6 and lux 
incubated in different batches of normal (N) and convalescent (C) rat LLF at 37°C for 60 
min. Data are the mean of duplicates in the same experiment.
LLF batch 
no./Method 
of euthanasia
Treatment*
of
rat
% Reduction (50 % and 90 %) end point (|il)* 
after exposure at 37°C for 60 min
lux 18-323 A6
VC-50 VC-90 VC-50 VC-90
15/A N 60 245 25 75
34 /B N >400 >400 >400 >400
38 /C N 140 >400 130 245
43 /D N 45 165 25 65
43 /D C3 >400 >400 >400 >400
43 /D C4 >400 >400 >400 >400
* Volume of test fluid required to give either 50 % or 90 % reduction of viable count (VC)[ 
(ie. 50 % or 90 % inactivation endpoint [IEP]).
C3 = no ether treatment, at the time of infection.
C4 = with ether treatment, at the time of infection.
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Figure 45. Bactericidal activity of normal rat LLF fractions (supemateo and surfactant*) 
collected by euthanasia method D towards B. pertussis 18-323 after 30 and 120 min at 
37 °C. Data from 1 to 6 observations at each point.
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With another batch of rats, the SUR fluids from normal and sham-operated animals 
were both highly active, whereas little activity was found with the corresponding SNs 
(Figure 46). Convalescent rats, on the other hand, yielded LLF in which neither the SUR 
nor the SN fluids had BA. An exception was group C3, whose surfactant showed a strong 
activity compared with little or no activity in the SN. Normal fluids from rat batch no. A 16 
and 18 in Figure 45 are the normal fluids in Figure 46 for comparison with the treated 
fluids.
The footnotes in Figure 46 indicate that the sham-operated and the convalescent rats 
had been exposed to a variety of different procedures at the time of infection with B. 
pertussis. The important observations were that a) sham-operated animals gave LLF 
fractions that were similar to normal in their BA, and b) that inclusion of B. pertussis in the 
challenge doses gave inactive LLF fractions, except as noted above.
Thus the use of alginate, as against agarose, or the use or non-use of ether had no 
consistent effects. It should be emphasised that the convalescent LLF had been collected at 
21-23 days after infection, indicating that exposure of the rat respiratory tract to live B. 
pertussis caused long-lasting abolition of BA of LLF and/or its fractions.
For more detailed information, the viable count results with B. pertussis 18-323 
incubated in normal and convalescent SUR and SN at various times are presented in 
Appendices 18, 20, 22 and 24. The same results expressed as median % survival are 
in Appendices 19, 21, 23 and 25. It was concluded that the SUR fraction contain most of 
the BA, whereas, the SN had little activity. Instead of whole LLF, SUR and SN were used 
as test fluids in all later experiments.
Other bordetellae: Attention was next turned to other bordetellae for their sensitivity to 
the BA of normal rat surfactant and supernate when tested under similar conditions. B. 
pertussis 18-323 was included for comparison.
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Figure 46. Effect of various B. pertussis challenges (in alginate or agarose) on the bactericidal 
activity of rat LLF fractions (supemateo and surfactant*). Diagram shows the median % survival 
of B. pertussis 18-323 after 30 min at 37°C. Data from 2 to 3 observations at each point.
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Table 40.T3actericidal activity of surfactant (SUR) and supemate (SN) from rats batch no.
45 towards Bordetella species. PBS was used as a non-bactericidal control.
Bordetella 
species and 
strain
Test
fluid
No. of CFU/20 pi after exposure at 37°C for min
0 60 120 1440
pertussis SUR 36 , 32 0 , 0 0 , 0 0 , 0
18-323
SN 38 , 32 0 , 0 0 , 0 0 , 0
PBS 4 0 ,4 6 3 2 ,2 0 32 ,31 0 , 0
parapertussis SUR 48 , 57 0 , 0 0 , 0 0 , 0
10520
SN 68 , 52 0 , 0 0 , 0 0 , 0
PBS 5 6 ,4 2 5 2 ,4 2 5 6 ,4 9 2 , 0
bronchiseptica SUR 34,44 33,45 53,40 ac,ac
5376
SN 6 0 ,4 4 36 ,44 44 , 68 c , c
PBS 43 ,50 3 0 ,3 5 37 , 54 ac , ac
c = confluent growth; ac = almost confluent growth.
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The tests reported in Table 40 show that B. parapertussis was indistinguishable 
from B. pertussis i.e. rapid killing (in less than 60 min) in SUR and SN and (with B. 
pertussis) a slow loss of viability in PBS. In contrast, B. bronchiseptica was quite 
different, in that there was no killing in the LLF fractions and the organism grew in all three 
test fluids, including PBS. The only difference was in the SN, after 1440 min incubation, 
when confluent growth was observed. Thus B. bronchiseptica, unlike the other two species 
was able to use the two LLF fractions as growth media (and PBS also).
Other bacterial Tests similar to the above were made with a few non-bordetella bacteria, 
namely two gram positive species and 3 strains of E. coli. B. pertussis 18-323 was 
included as a control.
With Staphylococcus aureus 'Oxford', there was a slow loss of viability in SUR 
which paralleled the loss of viability in PBS (Table 41). This was possibly due to lack of 
nutrient. In contrast, the viable count did not decline during 120 min in SN, and the 
organism subsequently grew, as evidenced by the confluent result at 1440 min. Unlike S. 
aureus, Streptococcus pyogenes 5763 grew in both the SUR and SN fractions of rat LLF. 
However, like the staphylococcus, it lost viability slowly in PBS. The control, B. pertussis 
responses to these test fluids were typical of those reported above.
Tests with 3 strains of E. coli were done similarly except that normal rat serum 
(NRS) was included as an additional test fluid, since E. coli Lilly is very sensitive to it. In 
addition, B. pertussis lux was used as a control because two of the E. coli strains were 
lux constructs. They differed in that WA803 requires addition of decanal for luminescence 
(as does B. pertussis lux) whereas E. coli lux DH5a is spontaneously luminescent 
without exogenous decanal.
The results in Table 42 show that the LLF SUR of batch 55 was similar to that of 
the batch no. 45 reported in Table 41 in being highly bactericidal towards B. pertussis 18- 
323. However, the SN fraction was much less active and allowed about 25 % survival at 
120 min. B. pertussis lux was much less sensitive than 18-323 in having 100 % survival 
in SN at 120 min and only about 30 % killing in SUR. Both B. pertussis strains showed
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Table 41. Bactericidal activity of surfactant (SUR) and supemate (SN) from rat batch no.
45 towards B. pertussis and other bacteria. PBS was used as a non-bactericidal control.
Bacterial Test No. of CFU/20 (il after exposure at 37°C for min
species and fluid _________________________________________
strain 0 30 60 120 1440
B. pertussis SUR 42 , 24 0 , 0 0 , 0 0 ,0 0 , 0
18-323
SN 42 , 44 0 , 0 0 , 0 0 ,0 0 , 0
PBS 55 , 61 58 , 54 n t , nt 38 , 30 0 , 0
Staphylococcus SUR 23, 20 14, 19 9 , 10 8 ,7 4 , 2
aureus 'Oxford'
6571 SN 20, 22 14, 24 15, 27 27 ,27 c , c
PBS 18, 24 12, 22 16, 16 15 , 10 2 ,1
Streptococcus SUR 27, 31 20 , 26 28 , 24 23 , 28 ac , ac
pyogenes 5763
SN 20, 18 20 , 18 36 , 26 30 , 50 c , c
PBS 23, 21 25 , 17 15, 12 13 , 13 2 , 0
c = confluent growth; ac = almost confluent growth.
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Table 42r-Bactericidal activity of surfactant (SUR), supemate (SN), and serum (NRS) from
normal rats batch no. 55 towards B. pertussis and E. coli strains. PBS was used as a non-
bactericidal control.
Bacterial Test No. of CFU/20 pi after exposure at 37°C for min
species fluids __________________________________________
0 30 60 120
B. pertussis SUR 26, 24 0 0 0 , 0 0 , 0
18-323
SN 106,80 52 62 4 4 ,3 4 3 0 ,3 2
NRS 96 , 80 28 26 1 6 ,2 0 9 , 9
PBS 76 , 86 76 72 8 6 ,6 2 52 ,4 0
B. pertussis SUR 122 , 104 58 50 52 , 54 38 ,4 0
lux
SN 158 , 148 156 126 154, 146 158,130
NRS 146 , 138 158 122 124, 120 116, 120
PBS 170 , 160 130 134 134 , 100 108 , 84
E.coli SUR 68 , 88 78 68 68 ,66 9 0 ,5 6
Lilly
SN 8 2 ,7 8 64 80 a c , ac c , c
NRS 28 , 22 0 0 0 , 0 0 , 0
PBS 84 , 90 94, 106 78 ,94 88 , 62
E.coli SUR 6 0 ,6 2 48 58 30 , 38 6 6 , 6 2
luxWA803
SN 84 , 64 68 64 78 , 104 104 , 124
NRS 2 ,2 0 0 0 , 0 0 , 0
PBS 54 , 84 48 42 3 6 , 3 8 3 6 , 4 2
E.coli SUR 7 4 , 4 2 34 24 1 6 , 8 10,  16
lux DH5a
SN 30 , 36 34 32 52 ,46 86 , 112
NRS 24 , 18 0 0 0 , 0 0 , 0
PBS 4 6 , 4 8 36 ,46 52 ,46 4 4 , 4 8
c = confluent growth; ac = almost confluent growth.
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similar loss of viability in PBS, about 45 % at 120 min. With normal rat serum (from the 
same rats as gave the LLF fraction) B. pertussis 18-323 was 90 % killed at 120 min, 
whereas B. pertussis lux showed only about 30 % killing.
The three E. coli strains were qualitatively similar to each other in a) being killed 
rapidly by normal rat serum; b) maintaining, over 120 min, a steady count in PBS, and c) 
treating the LLF SN as a growth medium. They differed, however, in response to SUR, 
with DH5a showing about 75 % loss of viability, while the other two strains were without 
significant loss.
E ffec t o f  dilution o f  normal LLFf surfactant and supernate: LLF and its
ultracentrifuge fractions were subjected to dilution assay of their BAs, with the fluids tested 
from undiluted to 1/64. "Undiluted" means that in the 250 pi test mixture, 240 pi was the 
test fluid and 10 pi the standard inoculum of bacteria. Dilutions 1/2 to 1/64 were made by 
dispensing the undiluted fluid in volumes from 120 pi down to 3.75 pi and adjusting the 
volume to 240 pi with PBS.
After incubation for lh at 37°C and plating out, the results were expressed as % 
survival, based on the survival in PBS at that (1 h) time. A typical assay, with both a 
volume scale and a dilution scale on the abscissa, is presented in Figure 47. Dotted lines 
have been inserted to enable the 50 % and 90 % killing end points to be read. With this 
particular batch (no. 55) of LLF, the 50 % end point was at a 1/24 dilution, corresponding 
to 9.9 pi of undiluted LLF in the test mixture. Likewise, the 90 % killing end point was 
given by a 1/11 dilution, equivalent to 21 pi in the test mixture.
The same procedure was used to assay the BA of various batches (nos. 45 and 55) 
of SUR (Figure 48) and SN (Figure 49). With the former, a typical 50 % end point was 1/ 
34 (7 pi) while with the latter, a value of 1/1.8 (135 pi) was observed. Because various 
different batches of LLF, SUR and SN were assayed, due to the work being done at 
different times, exact estimates of yield of activity in the two fractions are not possible. 
However, it appeared that SUR could be obtained without significant loss by ultracentrifug-
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Figure 477 LLF assay: Mean (±SEM) percent survival of B. pertussis 18-323 incubated 
for 1 h at 37°C in neat and diluted LLF from normal rats batch no. 55. Calculation of % 
survival was based on PBS time-lh counts of 2 observations at each point. Dotted lines 
indicates the procedure for reading 50 % (------- ) and 90 %(--------) killing end-ponts.
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Figure 48. Surfactant assay: Mean (±SEM) percent survival of B. pertussis 18-323 
incubated for 1 h at 37°C in neat and diluted surfactant fraction of LLF from normal rats 
batches no. 45 and 55. Calculation of % survival was based on PBS time-lh counts of 12 
observations (with 2 batches with very similar results) at each point. Dotted lines indicates 
the procedure for reading 50 % ------ ) and 90 % (--------) killing end-ponts.
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Figure 49. Supernate assay: Mean (±SEM) percent survival of B. pertussis 18-323 
incubated for 1 h at 37°C in neat and diluted supernate fraction of LLF from normal rats 
batches no. 45 and 55. Calculation of % survival was based on PBS time-lh counts of 
10 observations (with 2 batches with roughly similar results) at each point. Dotted lines 
indicates the procedure for reading 50 % (----------) killing end-pont.
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ation of LLF and that it was about 20 times more active than SN. This can also be expressed 
by saying that about 95 % of the initial BA of the LLF was in the SUR and 5 % in the SN.
E ffec t o f  m em brane filtra tio n  on surfactant activity: At the start of the 
experimental work on LLF, the fluid was sterilized by membrane filtration (0.45 |im pore 
size). This was done with approximately the first 50 % of all LLF batches collected. 
However, the filtration was stopped after the experiment about to be described in which the 
BA of the redispersed SUR fraction was found to be greatly (60- 90 %) reduced by 
filtration.
These data (Table 43) with 5 preparations of SUR (all from rats batch no 41), show 
that filtration of SUR removed most of its BA. This was seen with preparations from 
normal, sham-operated and convalescent animals (the last mentioned having low activity to 
start with). Although only a few tests were done, it seemed that unfractionated LLF did not 
lose activity by filtration, at least not to this extent.
Presumably, therefore, the SUR after ultracentrifugation did not disperse 
sufficiently when resuspended, to allow it to pass through the pores of a 0.45 Jim 
membrane filter. The later batches of (unfractionated) LLF were also not filtered and this did 
not result in significant background contamination.
Luminescence experiments
B. pertussis and other lux bacteria: SUR and SN of LLF from normal rats batch no. 
55 were tested for their effect on the luminescence of B. pertussis lux, E. coli WA 803 and 
E. coli DH5a. Diluted serum (1/16) was also included as a positive control from the same 
batch of rats previously used (Table 42).
With SUR, and in a comparison with results in PBS, Table 44 shows that around 
80 % reduction in light output was observed with B. pertussis lux after lh incubation, 
whereas there was no reduction in luminescence of either E. coli strain. SN gave a 
reduction of about 70 % in luminescence of B. pertussis lux, whereas no reduction of the
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Table 43: Effect of filtration (0.45 J i m  pore size membrane filter) on the bactericidal activity 
of surfactant from normal (N), sham-operated (SO) and convalescent (C) rats batch no. 41. 
CL medium and PBS were used as non-bactericidal controls.
Treatment
of
rats
Filtration No of CFU/20 |il after exposure at 37°C for min
0 15 30 120 1440
SOI + 93 , 100 7 4 , 7 8 7 2 , 6 0 23 , 36 0 , 0
- 28 ,43 0 , 0 0 , 0 0 , 0 0 , 0
S02 + 114 , 100 100 ,74 9 6 , 7 3 78 ,58 3 , 1
- 4 , 4 1 0 , 0 0 , 0 0 , 0 0 , 0
Cl + 124 , 97 104 , 106 118 ,67 9 6 , 7 5 3 , 4
- 82 , 101 99 ,70 84 , 58 4 , 1 0 , 0
C2 + 130 , 104 98 , 100 104 ,92 9 4 , 8 6 0 ,  1
- 9 2 , 9 9 98 ,73 7 4 , 6 8 9 , 17 0 , 0
N + 110,98 112,78 120 , 69 6 6 , 4 8 3 , 1
- 8 , 28 0 , 0 0 , 0 0 , 0 0 , 0
PBS 94 , 97 72 ,70 9 0 , 6 0 49 , 30 3 , 1
CL medium 95 , 80 90 ,8 8 110,80 114,74 a c , ac
SOI = rats were given agarose; S02 = rats were given alginate; Cl = rats were challenged 
with B. pertussis 18-323 EH2 in agarose; C2 = rats were challenged with B. pertussis 18- 
323 EH2 in alginate.
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light output was found with E. coli WA 803, and very high luminescence of E. coli 
DH5a was retained. In serum, about 70 % of B. pertussis lux light output was lost, while 
little decrease of E. coli WA 803 luminescence was seen, compared with very high light 
output of E. coli DH5a.
With regard to serum-sensitivity of E. coli lux, the two strains gave similar 
responses in the luminometer, ie. were not killed (Table 44). This was different to the 
responses (Table 42) when both strains were killed by normal rat serum, however; it should 
be noted a) that the serum was used undiluted in the viable count experiments, and at 1/16 in 
luminometery; b) the test doses of bacteria in the luminescence experiments were about 
1000-times higher than those for viable counting. If further experiments were to be done, it 
might be desirable to interchange the serum concentrations and bacterial dose in the two 
types of test system.
Effect o f  dilution o f  normal LLF, surfactant and supernate: Similar to the viable 
count experiments, dilution assays of the effect of undiluted to 1/64 LLF, SUR and SN on 
the luminescence of B. pertussis lux were performed. A standard bacterial inoculum (100 
pi) was added to 400 pi of test fluids to give the undiluted test mixture. Dilutions 1/2 to 
1/64 were made as before. After incubation in the luminometer for lh at 37°C, decanal was 
added and the light output read and the results were expressed as % survival, based on the 
survival in PBS at lh.
A specific assay, with both a volume and a dilution scale, is presented in Figure 36. 
As with viable count assays, the 50 and 90 % end points were read by interpolation of 
dotted lines. Results (Figure 50) show that LLF gave a 50 % inactivation end point at a 1/50 
dilution equal to 8 pi of undiluted LLF in the test mixture. Correspondingly, the 90 % 
inactivation end point was achieved by a 1/ 4.8 dilution, approximating to 83 pi in the test 
mixture.
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Table 44. Effect of surfactant (SUR), supernate (SN), and 1 in 16 normal serum (NRS) 
from rats batch no. 55 on the luminescence of B. pertussis lux and E.coli lux strains WA 
803 and DH5a. PBS was used as a non-bactericidal control. A and B are duplicates.
Bacterial 
species and 
strains
Test fluid Luminescence (mv) after lh incubation
A B
B. pertussis SUR 17.5 23.6
lux
SN 33.2 33.9
NRS 30.7 38.4
PBS 118 115
E. coli lux SUR 151 124
WA 803
SN 290 284
NRS 91.4 105
PBS 121 127
E. coli lux SUR 417 377
DH5a
SN 1260 1290
NRS 1320 1260
PBS 143 141
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The same procedure was applied to assay the effect of various batches (nos. 44 and 
45) of SUR (Figure 51) and SN (Figure 52) on bacterial luminescence. With SUR, a typical 
50 % end point was at 1/67 dilution (6 pi) whereas, the 90 % end point was at 1/12.5 (32 
pi).
With SN, a value of 1/5.1 (79 pi) was obtained for the 50 % end point, while the 
90 % end point was at 1/1.4 (290 pi). Because the various different batches of LLF, SUR, 
and SN were examined at different times, exact comparions of 50 and 90 % inactivation end 
points are difficult. Despite that, it appeared that SUR had activity about 10 times that of 
SN.
Effect o f ether on the bactericidal activity o f LLF and its fractions: A n
experiment was done with LLF, SUR and SN collected from normal rats (batch no. 58) 
which had been exposed to ether immediately before euthanasia. This was done to see if 
recent (after 6 days of treatments) inhalation of ether had an effect on the BA of the fluids 
towards B. pertussis 18-323.
According to the results (Table 45), LLF and SUR from untreated rats showed a 
high activity, whereas, no activity was found with SN from the same rats.
With the ether-treated rats, the BA of LLF and SUR was not different from the 
untreated rats, while the activity of the SN was enhanced by the ether treatment. This 
enhanced activity might have been due to residual dissolved ether in the SN, or to release 
into the SN of BA from the still-living rat.
Luminescence of bacteria in agarose with DMpCD: Standardized B. pertussis lux 
suspension in 1 % (w/v) CAA was incorporated into agarose gel beads with or without 
dimethyl-p-cyclodextrin (DMPCD). The preparation was added to PBS or SUR at a final 
concentration (v/v) of 1/5, and incubated in the luminometer for lh at 37°C in the usual 
way. Bacteria without either or both agarose or DMPCD were run in parallel.
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Figure 50". LLF dilution assay by luminometry: Mean (±SEM) percent luminescence of 
B. pertussis lux incubated for 1 h at 37°C in neat and diluted LLF from normal rats. 
Calculation of % luminescence was based on PBS time-lh values of 3 observations at
each point. Dotted lines indicates the procedure for reading 50 % (------- ) and 90 %
(------- ) killing end-ponts.
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Figure 51. Surfactant dilution assay: Mean (±SEM) percent luminescence of B. pertussis 
lux incubated for 1 h at 37°C in neat and diluted surfactant fraction of LLF from normal 
rats batches no. 44 and 45. Calculation of % luminescence was based on PBS time-lh 
values of 7 observations (with 2 batches with very similar results) at each point. Dotted 
lines indicates the procedure for reading 50 % (------- ) and 90 % ( --------) killing end­
points.
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Figure 52. Supernate dilution assay: Mean (±SEM) percent luminescence of B 
pertussis lux incubated for 1 h at 37°C in neat and diluted supernate fraction of LLF 
from normal rats batches no. 44 and 45. Calculation of % luminescence was based on 
PBS time-lh values of 7 observations (with 2 batches which very similar results) at
each point. Dotted lines indicates the procedure for reading 50 % ( ------- ) and 90 %
(------- ) killing end-points.
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Table 45:13actericidal activity of LLF, supernate (SN), and surfactant (SUR) from normal 
rats (batch no. 58) exposed to ether vapour for 2 min immediately before euthanasia method 
D. B. pertussis 18-323 was the test organism and PBS was used as a non-bactericidal 
control.
Test Fluids Ether No. of CFU/20 |xl after exposure at 37°C for min
treatment ________________________________________
0 30 60 120
LLF - 76 , 80
oo
0 , 0 0 , 0
+ 80,, 86 0 , 0 0 , 0 0 , 0
SN - 158 , 162 122 , 138 138 , 114 98 , 104
+ 116 , 150 10 , 8 1 , 1 0 , 0
SUR - 66,,64 0 , 0 0 , 0 0 , 0
+ 114 , 102 0 , 0 0 , 0 0 , 0
PBS 132 , 158 98 , 102 8 2 ,9 8 5 4 ,7 6
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The resulfs in Figure 53 show :
1) Incorporation of B. pertussis lux in agarose beads or addition of DMpCD caused a 
reduction of bacterial light output. The lowest light output was when both were present.
2) DMPCD cased a reduction in antibacterial effect of SUR, and reduced the luminescence 
of the bacteria in PBS.
M easurement o f  B. pertussis 18-323 half-life in experimental flu id s : D uring  
the course of these studies on BA of rat LLF, its fractions, and the various control fluids, a 
large number of replicate observation was collected. For example with PBS, there were 96 
experiments on the decline in viable count of B. pertussis 18-323 at 37°C during 120 min 
incubation. Similarly, with CL medium, there were 118 experiments, with 1 % CAA 13, 
and various numbers with the different normal and convalescent rat fluids. All these data 
were subjected to linear regression analysis with the results given in the 9 diagrams of 
Figure 54.
It will be seen that with all the fluids, the loss of viability (on a log scale) of B. 
pertussis 18-323 approximated to a straight line when plotted against time on an arithmetic 
scale.
With each fluid, a regression equation was obtained from which the half-life of B. 
pertussis in each fluid at 37°C was calculated. For convenience of comparison, these 
parameters are summarized in Table 46.
Theoretically, the intercept of the survival line should be at 2.00 (the logio of 100 % 
survival) and most fluids gave parameters close to this figure (column 2 of Table 46). 
However, the slopes showed much greater variation and, in turn, the half-life values were 
correspondingly different. The longest half-life, of 386 min, or about 6.5 h, was in CL 
medium which is well known to support growth of B. pertussis from small inocula. A 
surprizing result was that PBS and 1 % CAA gave similar half-lives of 147 and 155 min 
respectively. Much shorter half-lives were seen with the bactericidal fluids: normal rat LLF 
gave 47 min, while normal rat SUR was less than 10 min, an exact value not being 
obtainable because of the non-linearity of the survival curve. There was longer (70 min)
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Figure 53. Sensitivity of B. pertussis lux incorporated with or without 4 % (w/v)
agarose in beads and 0.1 % (w/v) Dimethyl-p-cyclodextrin (DM pCD) to the antibacterial
activity of LLF fraction (Surfactant). PBS was used as a non-bactericidal control. Data 
are the mean (±SEM) of two observations in the same experiment.
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Figure-54. Quantitation of survival of B. pertussis 18-323 at 37°C in various fluids and 
the fitting of linear regression lines. Error bars are the 95 % confidence limit of the mean.
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Figure"54. continued
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Figure 54. continued
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Table 46.~Summary of regression parameters and half-life of B. pertussis 18-323 at 37°C
in various fluids.
Fluid Intercept Slope 
x 1000
Half-life* (min)
PBS 1.9470 - 1.6667 149
1 % CAA 2.0073 - 1.9833 155
CL medium 2.0013 - 0.7833 386
NLLF 1.8380 - 12.400 11.2
CLLF 1.9660 - 13.371 20.0
NSUR nc nc nc
CSUR 1.8363 - 7.9167 17.3
NSN 1.7365 - 5.8333 64.3
CSN 1.9530 - 3.9333 64.6
nc : not calculated because of non-linearity of the relationship.
1 9 8
half-life-of bacteria in convalescent rat LLF than in normal LLF, whereas, convalescent rat 
SUR gave only 17 min. The half-lives of bacteria in normal and convalescent rat SN were 
indistinguishable.
Artificial surfactant: Commercially prepared artificial surfactant (ALEC) as used to treat 
premature babies with respiratory destress syndrome, was tested for BA towards B. 
pertussis strains 18-323 and lu*. Normal rat SUR, PBS and 0.85 (w/v) saline were 
included as controls.
Table 47 shows that the artificial surfactant had no bactericidal effect on B. pertussis 
18-323, compared with the strong bactericidal effect shown by rat SUR. Towards B. 
pertussis lux, both rat and artificial surfactant gave a roughly similar reduction of bacterial 
luminescence. This could have been due to the bactericidal effect of rat LLF or, in case of 
the artificial surfactant, to optical interference with luminescence. It is therefore, possible 
that artificial surfactant may have a slight BA towards B. pertussis lux.
Biochemical and Serological Analysis
Since it is well known that lysozyme and free fatty acids have a BA towards some 
bacteria, LLF and its fractions were analysed for these substances. Also, since the killing of 
some bacteria is mediated by antibodies and complement, LLF was tested serologically for 
these components. LLF and its fractions were also assayed for total protein.
Protein determination
LLF and its fractions were assayed for protein by the bicinchoninic acid (BCA) 
method (Smith et al., 1985) which was chosen because of its high sensitivity. Figure 55 
show that LLF collected from convalescent rats had more protein than LLF from normal 
animals. Euthanasia method B gave LLF with slightly more protein than euthanasia method 
D. This in turn was higher in protein than LLF of method A. The lowest protein 
concentration was found with the LLF collected from a single rat batch by method C.
1 9 9
Table 47v"Percent survival* of B. pertussis 18-323 (viable count) and lux (luminescence) in 
rat LLF surfactant and artificial surfactant after incubation for 1 h at 37°C.
Dilution % Survival & luminescence after lh incubation 
time at different dilution
Rat surfactant Artificial surfactant
Viable count Luminescence Viable count Luminescence
1/1 0 , 0 9 71 ,95 5.2
1/4 0 , 0 44 146, 185 33
1/16 3 2 ,4 2 87 138 , 185 103
1/64 76 , 113 107 125 , 150 132
* % survival calculation was based on PBS time-lh count for rat surfactant and saline time- 
lh count for artificial surfactant.
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Figure 55. Biochemical characterization of LLF in relation to the euthanasia methods A, B, 
C and D, infectious status and batch number. Clustering of data points is reinforced by area 
outlining and shadowing. Solid points and shaded areas are for convalescent LLF, plain 
points and areas for normal LLF. o •  (A); AA (B); □ (C); o ♦ (D).
Protein
800
600
200
4030200 10
1
Sf Lysozyme
120  -
600
>  108 :
100  -
80 -
400
60 -
40 -
200
20  -
0  H---------------1---------------1---------------1---------------1--------------- 1---------------1 1 i
0 10 20 30 40
Batch of LLF, in numbered sequence
2 0 1
“Figure 55. continued.
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Nearly similar protein concentrations in LLF from normal and sham-operated rats 
was found (Table 48), which in turn were lower than the protein concentration in LLF from 
convalescent rats. Approximately 85 % of LLF protein was in the SN fraction, whereas, 
only 3 % was in the SUR fraction. Also, less protein was found in membrane (0.45 (im 
pore size ) filtered SUR than in unfiltered material. Appendix 26 has more detailed results.
Lysozyme detection by viable counting
A series of experiments was done to detect whether there was lysozyme in LLF. For 
this purpose, Micrococcus luteus (sensitive to lysozyme) together with B. pertussis 18- 
323 as a test organisms were standardized (A540nm = 0.45), incubated for various time in 
neat and diluted LLF. Egg hen's white lysozyme at different concentrations, nutrient broth, 
and PBS were used in all experiments as test controls. Bentonite as adsorbing agent for 
lysozyme also was applied as a control.
Results (Table 49) revealed that LLF from both normal and convalescent rats had 
high BA towards M. luteus. This activity was higher in LLF from the convalescent animals, 
but with the exception that M. luteus survived better during 1440 min in 1/100 of LLF of 
convalescent rats than in LLF of normal animals. Complete killing of the bacteria in LLF, at 
dilutions up to 1:100, from both normal and convalescent rats was observed after 120 min 
of incubation at 30 °C. The amount of lysozyme in both undiluted test fluids was > 10 
jig/ml.
There was gradual loss o f viability o f M. luteus in lysozym e at 1 (ig/ ml but 
com plete and rapid killing at 10 |Lig/ml lysozym e. Incubation of the bacteria in bentonite- 
treated lysozym e yielded as good survival as in nutrient broth. B. pertussis 18-323 was not 
killed at up to 100 |Lig/ml lysozym e.
Lysozyme estimation by spectrophotometry
LLF and its fractions were assayed for lysozyme by the spectrophotometric method 
described by Wardlaw and McHenery (1982). Figure 55 shows that there was more lysozy-
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Table 4S: Protein concentration in LLF from normal (N) sham-operated (SO) and 
convalescent (C) rats. The fluid was either membrane (0.45 pm pore size) filtered (F) or 
unfiltered (UF). Data for supernate and surfactant fractions are also given.
LLF
Batch
no
Treatment
of
rats
Protein (pg/ml)±SEM 
[% yield]
LLF
F
supernate
F
surfactant
F UF
37 N 635±10 540±9 141±1 nt
[85] [22]
40 N 390±3 275±3 19±1 _
[71] [5]
41 N 480±6 407±4 10±2 24±2
[85] [2] [5]
SOI 460±3 345±3 11±2 29±2
[75] [2] [6]
S02 450±3 352±2 9±2 24±1
[78] [2] [5]
Cl 755±10 670±6 14±1 29±2
[89] [2] [4]
C2 577±9 268±2 13±2 24±1
[46] [2] [4]
42 N 400±3 392±2 nt 36±1
[98] [9]
45 N 445±2 407±3 _ 52±1
[[92] [12]
Median 460 392 14 29
[% yield] [100] [85] [3] [6]
SO I: Female rats given agarose with no bacteria, with ether.
S02:   alginate   , "
C l :  " " challenged with B. pertussis EH2 in agarose, with ether
C2 : " "   " "alginate,
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Table 49. Percent survival of both Micrococcus luteus (Ml) and B. pertussis (Bp) 18-323 
in LLF from normal (N) and convalescent (C) rats. Bentonite treated and untreated egg hens 
white lysozyme (LZ), PBS and nutrient broth (NB) were used as controls.
Test Bacteria No. of Mean % survival* (No. of observations) at
fluids Species experiments incubation time (min)
and _________________________________________
Temperature (°C) 0 30 60 120 1440
NLLF Ml (30) 12 2±1 (12) 0(10) 0(2) 0(12) 0(6)
1/10 NLLF 5 33±20 (5) 0(5) 0(5) 0(5) 0(5)
1/100 NLLF 5 89±5 (5) 49±17 (5) 59±13 (2) 51 ±23 (5) 0(3)
CLLF 11 0(11) 0(2) 0(9) 0(2) 0(11)
1/10 CLLF 5 0(5) 0(5) 0(2) 0(5) 0(3)
1/100 CLLF 5 77±8 (5) 62±16 (5) 71 ±0(2) 24±10 (5) 19±19 (3)
LZ 10 pg/ml 4 1±0 (4) 0(2) 0(4) 0(2) nt
L Z lpg /m l 9 83±8 (9) 30±10 (8) 54±4 (2) 17±7 (9) 1±1 (6)
LZ 10 p,g/ml 
+ bentonite
2 105±3 (2) 82±12 (2) 89±12 (2) 96±10 (2) nt
NB 11 101±3 (11) 99±3 (10) 100±7 (2) 93±7 (11) 556±36 (6)
LZ 10 |ig/ml Bp (37) 2 86±4 (2) 83±1(2) 85±1(2) 64±3 (2) nt
LZ 100 p,g/ml " 2 85±6 (2) 70±7 (2) 67±6 (2) 59±4 (2) nt
PBS 2 100±0 (2) 80±10 (2) 73±3 (2) 56±4 (2) nt
* % Survival calculations were based on nutrient broth time-zero count for test fluids tested 
with M. luteus, and on PBS time-zero count for fluids tested with B. pertussis 18-323.
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of LLF Collected from rats by euthanasia method B, which was less than that of method D. 
LLF from only a single batch of normal rats killed by euthanasia method C was similar to 
method B.
Results in Table 50 shows that almost all (around 100 %) of the LLF lysozyme was 
in the SN fraction and less than 5 % was in the SUR. There was less lysozyme in 
membrane (0.45 pm pore size) filtered SUR than in the unfiltered material. For more 
detailed results see Appendix 27.
Long-chain fatty acids (FA)
The colorimetric assay of Duncombe (1963) was used to estimate FA in LLF and its 
fractions. Figure 55 show that there were no significant differences in concentration of FA 
in LLF from normal and convalescent rats. The highest concentration (170 pM) was 
observed with one out of 6 batches of LLF obtained by euthanasia method D. There were 
no significant differences between the other 5 LLF batches of euthanasia method D and LLF 
batches of both method A and B. On the other hand, the single batch of LLF obtained by 
euthanasia method C gave a low FA concentration (16 pM). The median FA concentration 
in LLF was 46 pM.
There were variable amounts of FA, with no significant differences, in LLF from 
normal, sham-operated and convalescent rats (Table 51). Most (44 %) of the LLF FA were 
detected in the SUR fraction, whereas only 17 % was in the SN fraction (LLF batch no. 
45). Also, with 4 other LLF batches, more FA were in the SUR than in the SN. Filtered 
LLF (batch no. 43) had only about one-half the FA of unfiltered fluids (see footnote).
LLF from species other than the rat were analysed for protein, lysozyme and FA. 
In addition, the killing of B. pertussis by these fluids was determined. Table 52 shows that 
the highest protein concentration was detected in mouse LLF, whereas the highest lysozyme 
was found in rat LLF. LLF from human and rats had similar protein and FA concentrations.
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Table Sfr^field of lysozyme in normal (N) and convalescent (C) rat LLF, either membrane 
(0.45 pm pore size) filtered (F) or unfiltered (UF) and in supernate and surfactant fractions 
after ultracentrifugation.
LLF Treatment Lysozyme (pg/ml)±SEM
batch of [% yield]
no. rats
LLF supernate surfactant
F F F UF
37 N 47±1 45±1
[96]
<5±0
[<H]
nt
40 N 99±1 111±5 
[112]
<5±0
[<5]
-
41 N 88±1 99±1
[113]
5 ±2 
[6]
-
41 Cl 107+1 >108±0
[>101]
<5±0
[<5]
-
42 N >108±0 nt nt 36+1
[>33]
45 N 105±1 107±7
[102]
- <5±0
[<5]
Median 102 107 <5 <21
[% yield] [100] [105] [<5] [<21]
Cl : Female rats challenged with B. pertussis EH2 in agarose, with ether.
2 0 7
Table 5 IvLong-chain fatty acids (FA) quantitation in filtered (F) and unfiltered (UF) LLF, 
and in supernate and surfactant fractions from normal (N), sham-operated (SO) and 
convalescent (C) rats by different method of euthanasia. Data are the means of duplicate
observations.
LLF
batch
Treatment
of
Method
of
FA pM (±SEM) in 0.5 ml of
no. rats euthanasia Unfractionated
LLF
F
Supernate 
(% yield)
F
Surfactant 
(% yield)
NF
15 N A 26±1 nt nt
Cl A 32±0 - -
C2 A 22±2 - -
16 SO A 50±6 - -
33 N A 50±4 - -
34 N B 46.0 - -
C B 61±16 - -
35 N B 48±4 - -
38 N B 31 - -
N C 16±1 - -
39 N D 13±1 - -
40 N D 60±9 - -
41 N D 57±1 - -
42 N D 47 - -
43 N D 32±0* - -
44 N D nt 8±2 55±10
45 N D 170±25 29+1
(17)
75+4
(44)
50 N D nt 19 104±6
55 N D - 3±0 91±11
Median 46 14 65
* Unfiltered fluids gave 83±23 (liM.
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Table 52: Analytical characteristics and bactericidal activity of human and animal LLF
towards B. pertussis 18-323.
Human Protein Fatty acids Lysozyme Mean (±SEM) % survival* after
and (pg/ml) (jLiM) (Mg/ml) exposure at 37°C for (min)
animal (±SEM) (±SEM) (±SEM)
LLF [no. of 0 30 120
experiments]
Human 367±4 61 >36±0 91 ±5 61±10 18±2
[3] [1] [2] [3] [3] [3]
Rat 377±33 50±11 75±7 66±16 0 0
[18] [12] [14] [3] [3] [3]
Horse 630±6 24 6±1 95±6 138±18 75±17
[3] [1] [2] [2] [2] [2]
Mouse 563±9 nt 22±1 84±4 79±3 77±3
[3] [1] [2] [3] [3] [3]
Rabbit 212±4 nt 6±1 85±4 76±2 61±6
[3] [1] [2] [3] [3] [3]
Sheep 322±4 11 12±2 82±0 76±3 73±5
[3] [1] [2] [3] [3] [3]
Dog 533±12 nt 17±1 119±6 144±20 42±15
[3] [1] [2] [2] [2] [2]
Calf 417±4 26±4 1±0 85±10 100±9 28±1
[3] [2] [2] [2] [2] [2]
* % Survival based on CL-medium time-zero count.
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The lowest protein and lysozyme concentration were found in rabbit LLF. B. 
pertussis 18-323 survived well in the LLF from other than the rat, except that there was 
gradual decrease in viability in the human and calf fluids.
Detection of antibodies
An ELISA method was used to examine the presence of specific antibody classes 
IgG and IgA against whole cell sonicate of B. pertussis or its active component namely 
pertussis toxin (PT) and filamentous haemagglutinin (FHA) in rat LLF and serum. Also, 
ELISA tests for total IgE in LLF were done. Neat and 10-fold dilutions of LLF and serum 
were obtained from normal, sham-operated (agarose ± carrageenan), vaccinated and 
challenged (B. pertussis L84IV and / or 18-323 I) rats.
Test fluids from two different rat batches, batch no. 15 (fluids collected 28 days 
after treatment) and batch no. 16 (fluids collected 42 days after treatment). Rats of these two 
batches were subjected to euthanasia method A.
As a positive control, a hyperimmune reference serum from two rats was used, and 
a pool of normal rat serum provided a negative control. Both controls were included in each 
ELISA plate. Table 53 presents the results of test fluids from rat batch no. 15 and Table 54 
for batch no. 16. High titres (Table 53) of IgG to BP sonicate, FHA and PT were observed 
in serum from convalescent rats. Only very low titres of IgG antibody against the same 
antigens were found in LLF from the same convalescent rats. No, or very low, titres of IgG 
and IgA antibodies against the three antigens were observed in either serum or LLF.
Serum and LLF from rats challenged with L84 phase IV gave lower or no titre of 
antibody of both classes towards respectively Bp sonicate, and FHA or PT. Rats infected 
with B. pertussis 18-323 phase I yielded fluids of a higher titre of antibody of both classes 
against the same antigen. Serum and LLF from sham-operated (Table 54) rats gave roughly 
the same titres as with fluids from normal rats (Table 53), while higher titres of both IgG 
and IgA against the three antigens was found with fluids from vaccinated and challenged 
animals.
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Table 53. Detection of antibodies to BP sonicate, FHA, and PT antibodies in both normal 
(N) and convalescent (C) rat LLF and serum batch no. 15. Hyperimmune serum from rats 
injected with B. pertussis sonicate was usedas a positive control and normal rat serum as a 
negative control (Data are the means of duplicate observations).
Test
fluid
Rat
Treatment
ELISA titre
IgG IgA
BP
sonicate
FHA PT BP
sonicate
FHA PT
LLF Cl <10 <10 <10 <10 <10 37
C2 14 18 52 18 <10 26
C3 <10 14 41 20 <10 26
C4 <10 <10 16 <10 <10 30
N <10 <10 <10 <10 <10 nt
Positive control - 55000 43000 500 500 360 10000
Negative control - <10 <10 <10 <10 <10 5000
Serum Cl 1600 <10 <10 73 <10 nt
C2 4000 5000 9900 90 <10 nt
C3 1200 890 5800 55 <10 nt
C4 3400 1800 3900 60 <10 nt
N 50 <10 <10 39 <10 nt
Positive control - 220000 90000 1700 920 19 nt
negative control - 10 <10 <10 79 <10 nt
C 1 = Female rats given B.pertussis L84IV in agarose beads, with ether 
C2 = Female rats given B. pertussis 18-323 I in agarose beads, with ether 
C3 = Male rats given B. pertussis 18-323 I in agarose beads, with ether 
C4 = Female rats given B. pertussis 18-323 I in agarose beads, no ether
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Table 54. Detection of antibodies to BP sonicate, FHA, and PT in both sham-operated (SO) 
and convalescent (C) rat LLF and serum batch no. 16. Hyperimmune serum from rats 
injected with B. pertussis sonicate was used as a positive control and normal rat serum as a 
negative control (Data are the means of duplicate observation).
Test
fluid
Rat
Treatment
ELISA titre
IgG IgA
BP
sonicate
FHA PT BP
sonicate
FHA PT
LLF Cl 36 18 <10 <10 <10 18
C2 30 23 <10 <10 <10 <10
C3 <10 15 <10 <10 <10 <10
C4 <10 <10 <10 <10 <10 <10
SO <10 <10 <10 <10 <10 17
Positive control - 30800 37000 120000 500 360 10000
Negative control - <10 <10 <10 <10 <10 5000
Serum Cl nt nt nt nt nt nt
C2 16000 7300 4500 330 17 nt
C3 3600 1800 900 60 <10 nt
C4 2500 630 1300 59 <10 nt
SO 24 <10 <10 60 <10 nt
Positive control - 170000 100000 <1000 850 26 nt
negative control - <10 <10 <10 100 <10 nt
Cl = Male rats given DPT vaccint+B.pertussis 18-323 EH1 in agarose beads, with ether. 
C2= " rats given DPT vaccinz+B.pertussis 18-323 EH 1 in carrageenan+agarose 
beads, with ether.
C3 = Male rats given B.pertussis 18-323 EH1 in agarose beads, with ether.
C4 = " rats given B.pertussis 18-323 EH 1 in carrageenan+agarose beads, with ether.
SO = Male rats given agarose beads, with ether.
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Infection of unvaccinated rats yielded fluids with lower titres of both IgG and IgA 
towards the same antigens. The overall conclusion was that serum gave higher titres of IgG 
and IgA against BP-sonicate, FHA and PT than LLF, except that the LLF IgA titre against 
FHA was higher than that of serum IgA towards the same antigen. Anti-5, pertussis total 
IgE in undiluted LLF was examined and only very low titres detected.
Complement detection
It is well known that the serum killing of many gram-negative bacteria is mediated 
by complement, which might act similarly against B. pertussis 18-323 in the LLF. 
Accordingly a series of experiments was done to test for complement. For this purpose E. 
coli Lilly was applied in all experiments due to its sensitivity to complement. As controls, 
nutrient broth, PBS, untreated, neat, diluted (1/16) and inactivated guinea pig serum (as a 
source of complement) were used.
Results (Table 55) showed that there was no reduction in viability of E. coli Lilly 
in LLF or its fractions after 120 min of incubation. In serum, complete killing of the bacteria 
was found after only 15 min incubation. Unfractionated LLF supported the survival and 
growth of the bacteria, which survived and grew better in both the SN and nutrient broth.
SUR acted similarly as PBS towards E. coli Lilly, which was completely killed in 
both 1/16 and neat guinea pig serum after 30 min of incubation. Heat inactivation of guinea 
pig serum yielded a good survival and growth of the bacteria in the inactivated serum. 
Complete killing of the bacteria in diluted guinea pig serum confirmed the high level of 
complement present in that fluid. It was concluded that LLF and its fractions contained no 
detectable amount of complement.
Effect of Various Treatments
NLLF and its ultracentrifuged (29, 000 rpm; 55, 000 g) fractions were exposed to 
various physical, chemical, biochemical and enzyme treatments in order to characterize the 
substance(s) which might be responsible for the bactericidal effects on B. pertussis. In 
choosing batches of LLF for these studies it was desirable to have batches of the highest
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Table 55v~Bactericidal activity of LLF, surfactant (SUR), supernate (SN) and serum (S) 
from normal (N) and convalescent (C) rats towards E. coli Lilly during incubation for 24 
h at 37°C. PBS, nutrient broth (NB) and guinea pig serum (GPS) were used as negative 
and positive controls respectivley.
Test
fluids
No. of 
experiments
Mean % survival* (No. of observation) at 
incubation time (min)
0 15 30 60 120
NLLF 10 102±5 (10) 112±13 (5) 98±6 (9) 137±21 (4) 203±17 (10)
NSUR 2 90±9 (2) nt 85±9 (2) 77±4 (2) 85±23 (2)
NSN 2 93±6 (2) nt 83±7 (2) 345±12 (2) 691±24 (2)
NRS 7 10±3 (7) 0(5) 0(5) nt 0(7)
CLLF 23 95±2 (23) 114±11 (2) 96±3 (22) 147±5 (20) 214±6 (23)
CRS 4 9±5 (4) 0(2) 0(2) nt 0(4)
GPS 1 117(1) nt 0(1) 0(1) 0(1)
1/16 GPS 3 91±11 (3) 0(3) 0(3) nt 0(3)
In/GPS 1 200(1) nt 208(1) 208 (1) 442(1)
In 1/16 GPS 1 175(1) nt 177(1) 238 (1) 429(1)
NB 4 100±0 (4) 100±7 (3) 104±6 (4) 141(1) 358±34 (4)
PBS 5 100±0 (5) 87±13 (5) 98±5 (5) 111±5 (5) 103±8 (5)
* % survival calculations for all test and control fluids were based on time-zero of nutrient 
broth, and on PBS time-zero count for PBS only.
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activity-and obtained by euthanasia method D. Batches nos 44, 45 and 55 met this 
requirement. These studies used luminometry measurements with strain lux and viability 
counting with strain 18-323. Table 56, which presents Lum-90 and Lum-50 end points, 
shows that the SUR fraction of NLLF batches nos. 44 and 45 had about 10 times higher 
BA towards strain lux as the SN fraction. The low activity in SUR from NLLF batch 50 
could not be explained.
Essentially parallel information was obtained with viable counts of strain 18-323, 
and VC-90 and VC-50 end points (Table 57). For more detailed information, see Appendix 
29 and 30.
Physical and chemical treatments of NLLF
In preliminary experiments, three different batches of NLLF were exposed to 
heating at 56 and 100°C, dialysis and ultrafiltration and acid and alkali treatments. The 
samples were then tested undiluted for ability to reduce the viable count of B. pertussis 18- 
323 during 30 min at 37°C. The results in Table 58 indicate that the BA was slightly 
affected by 30 min at 56°C and destroyed to a considerable extent by 5 min at 100°C. The 
dialysis and ultrafiltration experiments showed that the BA in the LLF was mainly due to 
factor(s) of high molecular weight.
Finally, the activity was only slightly affected by 18 h exposure to 0.1 M HC1 or 
NaOH at 4 °C. For further details see Appendix 28.
Sonication and washing of surfactant
Since the surfactant (NSUR) fraction of normal LLF contained the major part of the 
BA, a few experiments were done to determine the best method of preparing this material. 
In particular, it was necessary to know whether the sonication that was used to disperse the 
resuspended pellet had a detrimental effect on its activity. Also whether the ultracentrifuge 
pellet could be resuspended in PBS and recentrifuged, i. e. "washed", in PBS so as to get a 
cleaner separation from the supernate (NSN) fraction. The effect of these treatments was 
studied by both luminometry and viable counting as shown in Table 59. It was clear that
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Table 56rComparison of B. pertussis lux inactivating potency of 55,000 g supemate and
surfactant fractions of normal rat LLF. (original data in Appendix 29).
LLF
Batch
No.
Luminescence (Lum-90 and Lum-50) end points (pi)* 
in individual experiments and [Median]
Supemate Surfactant
Lum-90 Lum-50 Lum-90 Lum-50
44 350, >400, 120, 165 40, 75, 20, 20
250, 250 135, 90 55, 50 20, 20
[300] [122.5] [52.5] [20]
45 175, 265 30, 65 30, 30, 20, 20
400 70 80, 290 25 ,3 0
[265] [65] [30] [22.5]
50 nt nt >400 260
*Volumes of test fluids requred to inactivate 50 % or 90 % of standard inoculum of B. 
pertussis lux.
Table 57. Comparison of B. pertussis 18-323 inactivating potency of 55,000 g supernate 
and surfactant fractions of normal rat LLF. (original data in Appendix 30)
LLF Bactericidal activity (VC-90 and VC-50) end points (|il)*
Batch in individual experiments and [Median]
No. ___________________________________________________________
Supemate Surfactant
VC-90 VC-50 VC-90 VC-50
55 >240, 132, 165 215, 90, 130 60, 25, 30 30, 8, 15
160, >240, >240 126, 125, 60 30, 20, 15, 15, 10, 5
200, 180, >240 120, 90, 150 15, 10, 20 5, 5, 10
[200] [125] [20] [10]
45 nt nt 30 20
*Volumes of test fluids requred to inactivate 50 % or 90 % of standard inoculum of B. 
pertussis 18-323.
Table 5#r Summary of effect of various treatments of LLF on its bactericidal activity
towards B. pertussis 18-323 after 30 min of incubation.
Treatment LLF batch no. No. of observations % Survival* [Range]
Nil 33,40,43 8 0 [0-0]
H eat: 56 °C for 30 min 33 2 4.5 [0-9]
H eat: 100 °C for 5 min 33 1 55
Dialysis (retentate) 33 2 0 [0-0]
Ultrafiltration 30 kDa filtrate 43 2 72.5 [54-71]
Ultrafiltration 30 kDa retentate 43 2 0 [0-0]
HC1 : 0.1 M, 18 h 4 °C 40 2 2.5 [0-5]
NaOH: 0.1 M, 18 h 4 °C 40 2 8 [3-13]
* % survival calculations were based on CL-medium time-zero count data.
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sonicatioiT had little deleterious effect but that washing in PBS caused unacceptable losses. 
From these results and the previously reported adverse effect of membrane filtration (Table 
43), a standard procedure emerged for making NSUR. First, the LLF was collected as 
sterile as possible, ultracentrifuged in clean tubes and the final pellet sonicated, not further 
washed, and stored in small aliquots at -20 °C for 24 h, then at - 70 °C.
Physical and chemical treatments of NSN and NSUR
The same physical and chemical treatments which were applied to unfractionated 
NLLF were now given to NSN and NSUR and tested by luminometry with strain lux and 
by viable count with strain 18-323. Dilution assays were used in both test systems and both 
50 and 90 % inactivation end points obtained. Three different batches of NLLF were used 
for these experiments.
Inactivation o f  NSN: The results in Table 60 show that the BA of the NSN fraction 
was partly destroyed at 56 °C and there was no detectable residual activity after heating at 
100 °C. Similar extensive inactivation was produced by overnight exposure at 4 °C to either 
0.1 M HC1 or NaOH. Both the luminometry and the viable count methods gave consistent 
results with the NSN fractions exposed to these treatments. In contrast 10 cycles of freezing 
and thawing caused about 50 % inactivation as judge by luminometry while giving an 
apparent 20 % increase in BA by viable counting. A similar pattern of results was obtaind 
by dialysis, where the retentate fraction had no loss by luminometry but had more than dou­
bled (- 127 % increase) in BA by viable counting. This pattern was again repeated by 18 h 
storage at 4 °C where there was a small loss in activity by luminometry and 3-fold increase 
by viable count.
It was concluded from these results that NSN contained a non-dialysable, heat-labile 
antibacterial substance which was also acid- and alkali-labile, and probably therefore 
protein. The observed increases in BA by viable counting with strain 18-323 suggested that 
the NSN fraction might contain an antibacterial substance in precursor form which could be
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Table 59TEffect of sonication and washing (in PBS) of surfactant fraction on its bactericidal 
activity towards both B. pertussis lux and 18-323. The table shows the 50 % endpoints in 
|il (as lum-50 for luminescence experiments and VC-50 for viable count experiments) and 
the % inactivation (I). Data are the mean of two experiments.
Treatment* Activity and effect of treatment
Lum-50 VC-50
V* % I 1*1
l-H
Nil* 30 0 20 0
Sonication 20 -50 20 0
Nil** 260 0 5 0
Washed in PBS once >400 >35 15 67
Washed in PBS 4 times >400 >35 35 86
* LLF batch 45 was used in both test systems.
** LLF batch 50 was used for luminometry and batch 55 for viable counts.
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activatecTby freezing and thawing, storage at 4 °C and possible removal of a low molecular 
weight accessory component by dialysis.
Inactivation o f  NSUR: Assays of the effects of the various physical and chemical 
treatments on the NSUR fraction are also presented in Table 60. In both test systems the 
NSUR was considerably more active than the NSN. In the luminometry system the ratio of 
NSN/NSUR endpoints ranged from 1.5-fold to 8-fold (average 5-fold), while in the viable 
counting system the range was from 8.3-fold to 24-fold, with an average of 14-fold. The 
viable counting results are probably the more reliable for these ratios, since luminometry 
had various technical problems such as optical quenching due to sample turbidity. Heating 
at either 56 or 100 °C had much less destructive effect on NSUR than it had on NSN, the 
100°C treatment still leaving between 30 and 50 % of the initial activity. The acid and alkali 
treatments caused about 33 % loss of activity as judged by luminometry and 67 % by viable 
counting, the latter being taken as the more reliable figure. Neither freezing and thawing nor 
dialysis had any significant destructive effect on BA of NSUR. The increases in activity 
produced by some of the treatments when applied to NSN were not seen with NSUR.
It was concluded that the bactericidal substance(s) in NSUR, although also of high 
molecular weight, was qualitatively different from that in NSN as well as having a higher 
titre.
Non-enzymic biochemical agents
NSN and NSUR were treated with a variety of biochemical agents choozen for 
ability to remove lysozyme or growth inhibitors of phase I B. pertussis. The list thus 
included bentonite, charcoal, heated rat serum, bovine albumin serum, starch, 
methylcellulose and various forms of cyclodextrins. The untreated and treated test fluids 
were assayed for BA, but only with the viable counting system. This was partly because of 
complications with luminometry and partly because of shortage of NSN and NSUR 
samples. The NSN and NSUR fractions were from LLF batches nos. 45 and 55 (as above).
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Table 60: Effect of physical and chemical treatments of supemate (NSN) and surfactant 
(NSUR) fractions of various batches of rat LLF on its bactericidal activity against B. 
pertussis lux and 18-323. The table shows the 50 % endpoints in p,l (as Lum-50 for 
luminescence experiments and VC-50 for viable count experiments) and the % inactivation 
(I). Data are the mean of two experiments.
Treatment* Activity and effect of treatment
NSN NSUR
Lum-50 VC-50 Lum-50 VC-50
|il % I |ll % I % I % \
Nil* 120 0 125 0 20 0 10 0
H eat: 56°C for 30 min 255 53 >240 >48 30 33 15 33
H eat: 100°C for 15 min >400 >70 >240 >48 70 71 20 50
Nil* 165 0 120 0 20 0 5 0
0.1 M HC1, 4 °C for 18 h 320 48 >240 >50 30 33 15 67
0.1 M NaOH, 4 °C for 18 h 380 57 180 33 30 33 15 67
4 °C for 18 h 210 21 40 -200 30 33 5 0
Nil* 90 0 60 0 20 0 5 0
Freezing & thawing 10 x 165 45 50 -20 20 0 5 0
Nil** 30 0 125 0 20 0 15 0
Dialysis (retentate) 30 0 55 -127 20 0 20 25
* LLF batch 44 was used for luminometry and batch 55 for viable counts.
** LLF batch 45 was used for luminometry and batch 55 for viable counts.
2 2 1
Inactivation o f NSN  All of the treatments listed in Table 61 caused at least some loss of 
the BA of NSN. In most instances the extent of this loss could not be properly quantitated 
because of the low initial activity of this fraction. Even 30 min incubation at 37°C (a control 
treatment) caused 30 % inactivation. It was notable that inactivation was caused by such a 
wide variety of substances, namely: insoluble agents (bentonite and charcoal), high 
molecular weight substances (heated serum, BSA, starch and methylcellulose) and the 
small-molecular cyclodextrins.
Inactivation o f  NSUR : Table 61 also shows that all of the above biochemical treatments 
(including 30 min at 37 °C control incubation) had a measurable effect on the BA of NSUR, 
although only a few of them caused essentially complete loss. The highly inactivating agents 
were charcoal and DMpCD which gave >97 % inactivation of NSUR BA. It was 
considered significant that unmethylated pCD and aCD were relatively inactive, just as they 
are ineffective in culture media designed to promote growth of B. pertussis from small 
inocula (Imaizumi et al. 1983a).
Protease treatment
To explore a possible role of proteins in the BA of LLF, the fluid was treated with 
three different proteases at a final concentration of 1.9 mg/ml. Luminometry with B. 
pertussis lux was used to monitor the results (Table 62). There was no significant loss of 
activity brought about by trypsin, chymotrypsin or subtilisin, leading to the conclusion at 
that time that proteins in LLF had little involvement. However, the Table shows that the 
enzymes alone, in control tests, had an apparent enhancing effect on luminescence. This 
complicates the interpretation of any possible destructive effect of the proteases on proteins 
in the LLF.
To confirm that the proteases were enzymically active, they were incubated with 
hide powder azure at 37 °C for 30 min and the release of dye demonstrated. Control 
experiments showed that there was no detectable amount of protease or protease inhibitors 
in LLF.
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Table 6tTEffect of treatment of supernate (NSN) and surfactant (NSUR) fractions of rat 
LLF batch no. 55 with non-enzymic biochemical agents on its bactericidal activity against 
B. pertussis 18-323. The table shows the 50 % endpoints in p.1 (as VC-50 for viable count 
experiments) and the % inactivation (I). Data are the mean of two experiments.
Treatment Activity and effect of treatment
NSN (VC-50) NSUR(VC-50)
% I % I
Nil 90 0 5 0
Bentonite (11 mg/ml) >240 >63 15 67
Charcoal (16.9 mg/ml) >240 >63 >240 >98
37 °C for 30 min 130 31 15 67
Nil 130 0 15 0
Heated rat serum (0.05%) >240 >46 55 73
BSA (1 mg/ml) >240 >46 65 77
Starch (1 mg/ml) 215 40 20 25
37 °C for 30 min 190 32 20 25
Nil 150 0 5 0
Methylcellulose (1 mg/ml) >240 >38 15 67
37 °C for 30 min 205 27 15 67
Nil 90 0 8 0
DMpCD (1 mg/ml) >240 >63 >240 >97
pCD (1 mg/ml) >240 >63 16 50
aCD (1 mg/ml) >240 >63 16 50
37 °C for 30 min >240 >63 16 50
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Table 62rEffect of protease treatment of rat LLF batch no. 40 on its effect on luminescence 
of B. pertussis lux after incubation for lh at 37 °C. Data are single observations.
Test fluid* % Luminescence
PBS 100
Untreated LLF 3
LLF treated with trypsin 2
LLF treated with chymotrypsin 2
LLF treated with subtilisin 1
Trypsin in PBS 127
Chymotrypsin in PBS 122
Subtilisin in PBS 142
* All enzymes were tested at 1.9 mg/ml final concentration.
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Inactivation o f  N SN : The same protease treatments which had been applied to LLF 
without significant effect were next used with the NSN fraction. In addition, proteinase K 
and two phospholipases (to explore phospholipid involvement) were tested, and most 
samples were assayed for BA in the two test systems. As judged by luminometry, trypsin, 
chymotrypsin and subtilisin had no destructive effect, while proteinase K caused significant 
but not complete inactivation (Table 63). This variation in result between the former three 
proteases and proteinase K is possibly due to differences in their action in hydrolyzing the 
substrate molecules. Trypsin, chymotrypsin and subtilisin cleave bonds within the peptide 
chain with varying degrees of specificity for particular amino acyl residues, while proteinase 
K attacks at different parts of the peptide chain.
Exact comparison of the luminometry and viable counting results is made difficult 
by the NSN having come from two different batches of LLF. However, it appeared by 
viable counting that none of the four proteases had much destructive effect on the BA of 
NSN. Simple incubation at 37 °C appeared to have a slight inactivations effect. Of the two 
phospholipases, A2 had a destructive effect whereas C did not. With the former however, 
there was at least 94 % loss of BA in NSUR after treatment.
Inactivation o f  NSU R : Luminometry experiments (Table 63) indicated that the four 
proteases caused similar but incomplete destruction of the BA of NSUR. However this was 
not confirmed by viable counting where the protease treatments for the most part were little 
different from simple incubation at 37 °C. Possibly proteinase K was slightly more active 
than the other three. The most significant inactivation was given by phospholipase A2 
which was much more destructive (> 94 %) than phospholipase C or any of the proteases. 
This suggested that the substance(s) responsible for the BA in NSUR might contain, or be 
associated with, phospholipid.
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Table 63v~Effect of enzyme treatments of supemate (NSN) and surfactant (NSUR) fraction 
of rat LLF* on its bactericidal activity towards B. pertussis lux and 18-323. The table 
shows the 50 % endpoints in pi (as lum-50 for luminescence experiments and VC-50 for 
viable count experiments) and the % inactivation (I). Data are the means of two 
experiments.
Treatment** Activity and effect of treatment
NSN NSUR
Lum-50 VC-50 Lum-50 VC-50
1*1 % I Hi % I pi % I 1*1 % I
Nil 135 0 215 0 20 0 10 0
Trypsin 135 0 >240 >10 50 60 30 67
Chymotrypsin 135 0 >240 >10 35 43 35 71
Subtilisin 135 0 230 7 50 60 25 60
37 °C for 30 min 155 13 >240 >10 20 0 25 60
Nil 70 0 150 0 25 0 10 0
Proteinase K 230 70 150 0 150 83 35 71
37 °C for 30 min 100 30 205 27 25 0 10 0
Nil nt nt 125 0 nt nt 15 0
Phospholipase A2 - - >240 >48 - - >240 >94
Phospholipase C - - 125 0 - - 40 63
37 °C for 30 min - - 135 7 - - 20 25
*LLF batch 44 was used by luminometry and batch 55 for viable counts.
** All proteases were used with test fluids at final concentrations of 1.9 mg/ml. 
Phospholipase A2 was at 1.1 mg/ml and Phospholipase C at 0.26 mg/ml.
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Lipid analysis and separation
Preliminary experiments on solvent extraction of NSUR to purify lipids were done 
by the method of Bligh and Dyer (1959) as modified by Coonrod et al. (1984). For this 
purpose a large batch (84 ml) of LLF from 20 rats was obtained and found to be highly 
active against B. pertussis 18-323 (Table 64). The NSN and NSUR fractions were 
prepared in the usual way and with results similar to those already reported, i.e. high 
activity in NSUR and little activity in NSN (Table 64).
Lipid extraction and chromatography : The procedure as described by Coonrod et al 
(1984) involved extraction of NSUR with a 1:2 (v/v) mixture of chloroform and methanol 
and recovery of the lipids from the lower chloroform layer. NSUR from 12 rats yielded 23 
mg lipid, or about 2 mg per animal. Aliquots of the chloroform extract were subjected to 
silicic acid chromatography as described by Daniela et al (1994) using chloroform, acetone 
and methanol for successive elutions. The results of bactericidal tests (Table 64) show that 
although only about 40 % of the initial LLF BA was recovered in the initial chloroform 
layer, the subsequent chloroform eluate from silicic acid was much more active. In fact, this 
eluate when tested at a dilution equivalent to the original LLF showed over 100 % yield. 
The procedure was repeated four times with similar results.
Subsequent batchwise elution of the silicic acid with acetone and then with methanol 
yielded very little BA.
Long-chain fa tty  acids (FA) and phosphatidylcholine (PC): Previous studies 
similar to the above by Coonrod et al (1984) led to the conclusion that the BA (towards type 
25 pneumococci) in NSUR was due to FA. These were associated with neutral lipid, and 
apparently went into the chloroform layer after chloroform/methanol extraction. In the 
present work, long-chain (14 C - 20 C) saturated and unsaturated FA and PC were 
dissolved either in NaOH, chloroform or in a mixture of chloroform and methanol and 
eventually tested as solutions in 1 % CAA. The PC was included here because of the 
inactivation reported in Table 63 after phospholipase A2 treatment.
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Table 64r Bactericidal activity of normal surfactant, its extracted lipids, and the different 
solvent eluate of extracted lipids towards B. pertussis 18-323. For completeness, the results 
with unfractionated LLF and ultracentrifuge supemate are also included.
Fraction 
(from LLF 
batch no. 55)
No. of 
observations
50 % end point*
Oil)
% recovery of activity 
from LLF
LLF 2 9.5+1.4 100
Supemate 10 138+17 7
Surfactant 12 8.0±1.4 119
Chloroform/Methanol
extract 4 24±0.9 40
Chloroform eluate 4 8.5±1.2 112
Subsequent acetone eluate 4 238±37 4
Subsequent methanol eluate 4 >240±0.0 < 4
* % end points were based on the PBS or CAA lh-counts with the fractions at 
concentrations equivalent to undiluted LLF.
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Bactericidal tests were done by viable count with 18-323 and luminometry with 
strain lux. The former method was approximately sixteen times more sensitive (Table 65), 
perhaps because the test dose of bacteria was much smaller (by a factor of 10^ CFU).
By the viable count method, the most active FA was the polyunsaturated (4 double 
bonds) arachidonic (C 20). The least active was the saturated C14 myristic. After 
arachidonic, the next most active was palmitoleic (Cl 6, one double bond). Unsaturation of 
the FA was not closely correlated with BA since the saturated C16 palmitic was quite similar 
to the unsaturated C16 palmitoleic. [Concentration (55 pM) of equal volumes of FA mixture 
was active towards B. pertussis 18-323]. Unlike the FA, phosphatidylcholine had no BA at 
the highest level tested, 1000 pM.
Morphological effects 
Transmission electron microscopic (TEM) examination
Thin sections of variously treated B. pertussis 18-323 and lux were examined by 
transmission electron microscopy to obtain morphological information about the effect of 
NSN and NSUR.
Included as negative and positive controls respectively were organisms incubated in 
PBS and CL medium, and in normal and convalescent rat serum. In addition, the 
ultrastructure of NSUR pellet was examined to see if it contained the lamellar bodies and 
tubular myelin described by Pison et al. (1994).
Surfactant Pellet (Plate 3): This shows the lamellar bodies surrounded by amorphous 
material and possibly containing the tubular myelin structures described by Pison et al. 
(1994).
Strain 18-323 in CL medium (Plate 4): The samples taken at time zero (A) and after 
lh (B) incubation show cells of mainly normal morphology initially, but in B with some 
some cells losing their internal contents and others appearing irregular in shape.
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Table 65TEffect of long-chain fatty acids (FA) and phosphatidylcholine on the viability and 
luminescence respectively of B. pertussis strains 18-323 and lux.
Fatty acid Abbreviation* 50 % end point** (fiM) Ratio of
and lipid endpoints
18-323 lux lux/18-323
Myristic 14:0 450,550 (500) >1000,>1000 (>1000) >2
Pentadecanoic 15:0 60,66 (63) nt -
Palmitic 16:0 25,95 (60) 700,700 (700) 12
Palmitoleic 16:1 (9c) 30,30 (30) 550,850 (700) 23
Elaidic 18:1 (9t) 95,105 (100) >1000,>1000 (>1000) >10
Petroselinic 18:1(6c) 60,60 (60) nt -
Oleic 18:1 (9c) 55,55 (55) >1000,>1000 (>1000) >18
Linoleic 18:2(9c,12c) 50,60 (55) 850,950 (900) 16
Arachidonic 20:4(5c,8c,l lc,14c) 15,25 (20) >1000,900 (>950) 47.5
FA mixture - 45,65 (55) 900, >1000 (>950) 17
Phosphatidylcholine - >1000,>1000 (>1000) nt -
* The number of carbon atoms is given first, then the number of double bonds. The 
positions of the lowest numbered carbon of each double bond and whether the configuration 
is cis (c) or trans (t) is indicated in parentheses.
** % end points were based on the CAA lh-counts.
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Plate 3. Transmission electron microscopy of a thin section of the 55,000 g pellet 
(surfactant) fraction of normal rat LLF. X 25,500. Arrows indicate lamellar bodies (dotted) 
and tubular myelin (plain) structures.
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Plate 4. Transmission electron microscopy of thin sections of B. pertussis 18-323 A) at
time-zero, and B) after incubation for lh at 37°C in CL medium. X 25, 500.
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Strain 18-323 in PBS (Plate 5): These micrographs were similar to those from CL
medium.
Strain 18-323 in serum (Plate 6): In normal rat serum (A) many of the cells were 
severely damaged, some having lost their internal structures. In convalescent rat serum (B) 
the damage was even more extensive, with no cells left with normal morphology.
Strain 18-323 in N SN  and NSUR (Plate 7): In NSN after 1 h incubation, some B. 
pertussis 18-323 cells (A) kept their normal morphology, a few have lost their internal 
structure while others showed some cytoplasmic membrane damage. More severe damage 
was noticed with cells incubated in NSUR (B), which caused cell membrane rupture, 
irregular cell morphology, and complete disappearance of internal structure for some cells.
Strain lux in PBS (Plate 8): B. pertussis lux showed normal intact morphological 
appearance after time zero (A) and lh (B) incubation in PBS. An interesting observation 
was that most of these bacterial cells contained cytoplasmic vacuoles or inclusion bodies 
which could represent storage granules, which are much more numerous than in strain 18- 
323. B. pertussis lux cells suspension in PBS in this experiment gave the highest value 
(4000 mv) of light output.
Strain lux in N SN  and NSUR (Plate 9): Action of NSN (A) on B. pertussis lux 
after 1 h of incubation resulted in an apparent loosening of the outer membrane and some 
loss of cell content. It was noticed that most of the cells lost their ability to produce light 
despite their normal morphology appearance. In NSUR (B), extremely severe damage of 
the cells and complete loss of internal structure, complete loss of light (cells gave only 15.5 
mv, >99 % light inactivation and rupture of cytoplasmic membrane, irregular appearance of 
the cell morphology.
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Plate 5. Transm ission electron microscopy of thin sections of B. pertussis 18-323 A) at
time-zero, and B) after incubation for lh  at 37°C in PBS. X 25, 500.
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Plate 6. Transmission electron microscopy of thin sections of B. pertussis 18-323 after lh
incubation at 37 °C in A) normal ; and B) convalescent rat serum. X 25, 500.
A
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Plate 7. Transmission electron microscopy of thin sections of B. pertussis 18-323 after 1 h
incubation at 37 °C in A) supemate; B) surfac tan t . X 25, 500.
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Plate 8. Transmission electron microscopy of thin sections of B. pertussis lux A) at time-
zero, and B) after incubation for lh at 37 °C in PBS. X 25, 500.
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Plate 9. Transmission electron microscopy of thin sections of B. pertussis lux after 1 h
incubation at 37 °C in A) supernate; B) surfactant. X 25, 500.
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Conclusions briefly, are as follows:
1) B. pertussis lux retained normal morphology in PBS during 1 h incubation better than 
18-3232 did.
2) B. pertussis 18-323 in CL medium showed the same behaviour as in PBS.
3) As judged by TEM changes, NSUR had a greater effect on both B. pertussis 18-323 and 
lux than NSN.
Tests with Phase IV B. pertussis 
A small number of experiments was done with a single batch of LLF from 
convalescent rats (exposed to euthanasia method B) batch no. 34 against B. pertussis phase 
IV (strain 30042) with strain 18-323 in parallel. The results in Table 66 show that the 
convalescent LLF was more active against the phase IV strain than against 18-323. This 
was not due to loss of viability in the PBS content of the LLF since phase IV viability was 
retained in the PBS control.
Ultrafiltration experiments (Table 66) showed that the antibacterial factor(s) in LLF 
towards both B. pertussis strains was of molecular weight greater than 10 kDa. However, 
in the 50 kDa ultrafiltration, the activity appeared in both the filtrate and the retentate.
BA towards both B. pertussis strains was destroyed by heat at 56°C and by 
treatment with trypsin or bentonite. These results are different to those previously reported 
(Tables 58, 60, 61 and 63) where the activity was partially stable to 56°C and bentonite and 
unaffected by trypsin. It was concluded that this batch of LLF containing a high molecular 
weight, heat-labile and a trypsin and bentonite sensitive protein. Further investigation of 
these interesting preliminary results is desirable.
2 3 9
Table 66HEffect of various physical and biochemical treatments of rat LLF batch no. 34 on 
its bactericidal activity towards B. pertussis 30042 IV and 18-323 I after incubation times 
of 30 and 120 min. Data from 2 observations except were stated.
Treatment 
Ultrafiltration/ 
(pore size of filter)
Mean % survival*±SEM (No. of observations) during 
incubation at 37 °C for (min)
30042IV 18-3231
30 120 30 120 .
Nil 5±1 (10) 1±0 (9) 24±5 (7) 1±1
Filtrate (10 kDa) 88±11 41±2 (1)** 66±7 39(1)
Retentate (10 kDa) 2±0 0(1) 4±1 KD
Filtrate (50 kDa) 4±1 0 17±4 3±1
Retentate (50 kDa) 2±1 0 14±5 1±1
Heat (56 °C/30 min) 97±1 93±2 117±11 120±5
Trypsin (1.9 mg/ml final) 81±3 72±4 105±5 78±6
Bentonite (11 mg/ml final) 93±1 77±3 106±15 79±1
PBS control 100.8+3 (6) 86.4+8 (5) 93.5+4 (6) 76.6+2(5
Calculation of % survival was based on PBS time-zero count data.
** data of only one observation due to lack of LLF from convalescent rats batch no. 34.
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- DEVELOPMENT OF AN EXPERIMENTAL PROTOCOL 
Rationale for the Work
The main purpose of this research was to characterise the soluble bactericidal activity 
(BA) of rat lung lavage fluid (LLF) on Bordetella pertussis. Ideally, the work would have 
been done with LLF from humans, the natural host of B. pertussis, but such material is not 
readily available from healthy subjects. The choice of the rat came from its use as a model of 
whooping cough (Wardlaw et al., 1993). Thus this rodent species appears to be the only 
non-primate laboratory animal in which pulmonary infection with B. pertussis causes a 
paroxysmal cough (Hall et a l , 1994). For this reason, the coughing rat model of pertussis 
has been extensively studied in this laboratory. The model involves the bacteria being 
administrated intrabronchially in fine agarose beads, under anaesthesia, and the coughing 
being monitored by sound-activated tape recorders. The animals also show lymphocytosis, 
another cardinal sign of pertussis in man, and they can be protected by immunization with 
whole-cell pertussis vaccine (Parton et al., 1994). The model is specific for phase-I B. 
pertussis, since phase IV bacteria, B. parapertussis and a B. pertussis transposon mutant 
lacking pertussis toxin, failed to induce coughing.
Lung Lavage Fluid
Harvesting of LLF
Since B. pertussis in the lungs of live rats must come in contact with respiratory 
tract secretions, the present work sought to explore the possible BA of these fluids. It was 
not feasible to obtain undiluted secretions from live animals and a lavage procedure on 
freshly killed rats was therefore used. The possible role of cellular defence mechanisms in 
lung lavage fluid (LLF) was not examined in this work, and only the soluble antibacterial 
activity in the cell-free supemate of centrifuged and filtered LLF was studied.
During the course of the work, four different methods of euthanasia for the rats 
were applied before collecting LLF, and some differences in antibacterial activity towards 
B. pertussis 18-323 were found. The most satisfactory method (Method D) involved 
halothane/oxygen anaesthesia, followed by heart puncture to obtain blood and cervical
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dislocation. LLF was then collected by lavage of the lungs with PBS through a tracheal
cannula. However, even with this method, one batch of LLF out of 6 collected, for no
apparent reason, had BA that was too low for intended experimental use.
By contrast, the least satisfactory method (Method B) involved suffocation in a jar 
of CO2 , followed by heart puncture and lung lavage, but without the need for cervical 
dislocation. Three out of 4 batches of LLF from normal rats were unsatisfactory when 
obtained by this method. The other two methods of euthanasia gave intermediate results. 
Thus method A, which involved halothane/oxygen anaesthesia, killing by CO2 before heart 
puncture and lung lavage, yielded two satisfactory batches out of four collected. Euthanasia 
method C used an overdose of halothane to kill the animals. Only one batch of LLF was 
collected by this method and although it was satisfactory in BA, the titre was lower than the 
most active batch of Method D. It should be noted that there no significant differences in the 
volumes of LLF collected after the different euthanasia methods and that each batch was 
generally the pooled fluid from at least 8 and, in one occasion, as many as 20 rats. Although 
not settled definitely, it appeared best to avoid CO2 during euthanasia in order to obtain LLF 
with satisfactory in vitro BA against B. pertussis strains 18-323 and lux.
Although not connected with euthanasia, mention can be made of the use of ether as 
an adjuvant to anaesthesia during the process of infection of the rats with B. pertussis. It 
was generally assumed that any effect of this treatment would be short lived. Therefore it 
was surprising to find with one batch of rats that there did appear to be a persistent effect of 
the ether 6 days later. Thus although the LLFs from normal rats showed no differences due 
to ether, the ultracentrifuge supemate (SN) fraction had higher BA if obtained from the ether 
treated rats. BA of surfactant (SUR) fraction from the same animals was not affected.
The only other authors to report on BA of rat LLF are Coonrod and Yoneda (1983), 
using pneumococci as the target organisms. These authors reported no effect on LLF BA 
that was due to the method of euthanasia. However, only intraperitoneal pentothal, or 
halothane inhalation were used before killing by exsanguination or cervical dislocation. It is 
possible that if CO2 had been used, a similar result to my observations might have been 
obtained. The method of euthanasia does not appear to have been widely studied by other
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investigators who have collected LLF from various species and for different purposes 
(Coonrod and Yoneda 1983; Coonrod etal., 1984; LaForce and Boose 1981; O'Neill et al., 
1984). The reason that CO2 euthanasia was used in my study was because Porter and 
Wardlaw (1994) from this laboratory employed it for getting LLF from mice. They found 
that mouse LLF did not support the growth of B. pertussis, but caused gradual reduction of 
bacterial viability which was complete after 2 days at 37 °C.
Composition of LLF
According to Matthews et al. (1963), the undiluted cell-free respiratory tract 
secretions from normal humans is composed of 95 % water and 5 % solids. The solids 
consisted of 2-3 % proteins and glycoproteins, 1 % lipids and 1 % minerals. The mean 
value for protein was 10 mg/ml, which was about 10 times higher than that reported by 
Boyd et al. (1944) with rabbit and cat secretions, and 30 times higher than found by 
Adamson et al. (1969) with fluid from foetal lambs. With cell-free lavage fluids from 
human and animal species and where the extent of dilution is uncertain, protein levels from 
0.07 to 2.17 mg/ml have been reported (Low et al., 1978; Porter and Wardlaw, 1994). The 
proteins include lysozyme, lactoferrin, albumin, complement and immunoglobulins 
(Masson and Heremans, 1973; Reynolds and Thompson, 1973). None of the literature on 
protein content of LLF dealt with fluids from rats, except that O'Neill et al. (1984) stated 
that protein in rat lung lavage surfactant comprised about 6 % of the material isolated.
In the present study, protein concentration in rat LLF and its fractions was 
measured with bicinchoninic acid in the presence of alkaline Cu+ (Smith et al., 1985). This 
method maintained the small protein-to-protein variation associated with the Lowry (1951) 
technique but was more sensitive and therefore suitable for the low protein levels expected 
in LLF. Analysis of 18 batches of normal rat LLF gave an average protein content (± SEM) 
of 0.4 (± 0.033) mg/ml, which is in the middle of the range (0.07 - 2.17 mg/ml) reported 
above. This concentration is equivalent in protein to about a 1:220 dilution of rat serum, i.e. 
somewhat more dilute than the mouse LLF which Wardlaw and Stevenson (1984) reported 
as being equivalent in protein to a 1: 50 dilution of serum. In rats, the method of euthanasia
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did not significantly influence the protein concentration, but LLF from convalescent rats 
tended to be higher than from normal animals. With normal LLF from 6 other animal 
species and human, the protein concentrations ranged from 0.212 to 0.630 mg/ml, i.e. 
similar to the rat fluids and similar to the results with the same batches of these other fluids 
which were previously analysed by the Lowry method by Porter and Wardlaw (1994).
It is possible that the procedure for collecting LLF could be improved by better 
standardization of technique and that the content of protein could be increased by more 
vigorous and longer washing of the respiratory tract.
In 14 batches of normal rat LLF, the mean content of lysozyme, as estimated by the 
spectrophotometric method of Wardlaw and McHenery (1982) with Micrococcus luteus, 
was 75 (ig/ml (SEM = 7 (ig/ml). LLF from convalescent rats gave somewhat higher 
values. The source of this enzyme is probably the alveolar macrophages which especially 
when activated may secrete lysozyme (Hinman et al., 1980). With alveolar macrophages 
from healthy human volunteers, Knostan et al. (1981) reported extensive release of the 
enzyme into the culture medium during 48 h in vitro. In the present work, the convalescent 
rats were at 21-42 days, well beyond the peak of infection (which was around day 10), and 
it is possible that LLF at the peak of infection might have shown greatly elevated levels of 
lysozyme.
In this study, LLF from the normal rat had the highest level of lysozyme of the 
various species tested, an observation not found in the literature and worthy of further 
study. It would be desirable in any such work to use animals of similar health status and to 
employ similar methods of euthanasia and harvesting of LLF.
Because Coonrod et al. (1984) had discovered the importance of FA in the BA of 
rat LLF towards pneumococci, analysis for these substances was done in the present study. 
Using gas-liquid chromatography of extracted lipids of the surfactant fraction, these 
previous authors estimated the total FA in three pools of normal rat LLF as 68 , 228 and 
706 (ig/ animal. In my work FA was estimated, without preliminary lipid extraction, using 
the colorimetric assay of Duncombe (1963) applied directly to LLF itself. This is based on 
the formation of the copper salts of fatty acids, which are then estimated with diethyl
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dithiocarbamate. The quantitation of the method is linear to 100 jig of FA and sensitive to 
10 jig. Twelve batches of LLF from normal rats gave a range of FA levels between 114 
and 1496 jig/ rat. The reason for the upper value being about twice of that of Coonrod et 
al. (1984) is not known but could be due to one or more of the following: my assay of FA 
on unfractionated LLF and possibly that of Coonrod et al. (1984) lost some of the FA 
during extraction processes; interference by protein or other components; the different 
method of euthanasia used by the other workers and perhaps differences in rapidity of 
harvesting the LLF. In my studies there was no evidence of systematic differences in the FA 
content of LLF associated with the different methods of euthanasia.
It was considered important to check whether the rat LLF contained antibodies to 
B. pertussis. A total of 10 batches of LLF was assayed by ELISA for antibodies of the IgG, 
IgA and IgE classes directed against the following antigens: whole-cell B. pertussis (BP) 
sonicate, pertussis toxin (PT) and filamentous haemagglutinin (FHA). For control 
purposes, serum samples from the same groups of animals were also assayed. The 10 
batches of LLF came from one normal group, one sham-operated group and 8 convalescent 
groups. These latter consisted of animals that had been vaccinated and then challenged (2 
groups), one group challenged with phase IV B. pertussis and five groups challenged with 
Phase I B. pertussis encased variously in agarose or carrageenan, with or without the use 
of ether.
In brief, no significant levels of antibodies were detected in either LLF or serum 
from the normal or sham-operated rats. However, low but detectable IgG titres were found 
in the LLF from the vaccinated and phase I-challenged convalescent rats and also from the 
animals given challenge alone with these organisms. Vaccination was associated with higher 
titres than challenge alone. Sera from phase I-challenged rats had much higher levels of 
specific IgG, although if allowance is made for the LLF being equivalent in protein to about 
a 1:220 dilution of serum, then the serum and LLF IgG titres were quite similar. These 
above results with sera are similar to those of Hall et al. (1994) and Parton et al. (1994) for 
IgG; however these authors did not study LLF. Challenge with phase IV B. pertussis 
induced serum antibodies to BP sonicate but not to FHA or PT, confirming the absence of
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these antigens in such bacteria. Variations in challenge procedure such as use of agarose or 
carrageenan, or use of ether to promote the coughing response did not influence antibody 
titres.
The IgA titres in convalescent LLF were lower than the IgG, but when multiplied 
by 220, the titres to BP sonicate in LLF were higher than those in serum. This was not the 
case with FHA or PT. No IgE antibodies were detected.
To relate these observations to other serological studies with B. pertussis is 
difficult because of the limited amount of research either with LLF or with rats. Thus 
although there are numerous papers on serological responses of infants to pertussis 
infection or vaccination (e.g. Ashworth et al., 1983; Ad Hoc Committee, 1988; and 
Marwick, 1995), ethical constraints have prevented obtaining LLF from babies.
Since complement is a well-known antibacterial factor in serum, it was necessary to 
test for it in the rat LLF in case it was present. For this purpose the highly complement- 
sensitive test organism, E. coli Lilly, was employed (Wardlaw, 1962). Moreover, 
Reynolds and Thompson (1973) reported traces of some complement components (Cl and 
C6 ) in bronchial secretions in rabbits vaccinated with Pseudomonas aeruginosa. The 
amounts were much less than in serum by 1/2550 for Cl and 1/58 for C6 . Other authors 
have detected individual components of complement in respiratory tract secretions (Boat and 
Cheng, 1980) although functional complement has not apparently been demonstrated. 
Weiss (1997) stated that "Underneath the epithelial surface (of the lungs), capillaries supply 
blood and nutrients to the mucosal layer. In response to inflammatory signals, the tight 
junctions between epithelial cells of the mucosal surface and between endothelial cells that 
line the capillaries can quickly and reversibly separate, allowing serum components 
(including immunoglobulin G [IgG] and complement to exude onto the mucosal surface". 
Weiss claimed that the intact mucosal surface has about 10 % as much complement as does 
serum.
In the present work, no functional bactericidal complement was found in LLF from 
either normal or convalescent rats. Indeed the E. coli Lilly grew in the nutrients in both 
types of bronchial secretion. Rat serum, on the other hand was rapidly bactericidal, as was
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guinea ptg serum although it was less active than that from the rat. With hindsight it would 
have been desirable to test the rat serum at a 1:220 dilution to take account of the protein 
measurements, but this was not done. Also, it would have been interesting to see if 
individual complement components could be detected as in the work of Reynolds and 
Thompson (1973). Another potential line of work would be the possible interaction of 
complement and lysozyme which may occur with other gram negative bacteria (Wardlaw, 
1962).
Antibacterial Tests with LLF 
Control fluids
At the start of the experimental work, B. pertussis suspension in PBS was prepared 
according to the procedure described by Porter et al. (1991) in their study of growth of 
Bordetella  species in LLF and other low nutrient fluids. The same workers (1993) 
observed that B. pertussis 18-334 failed to maintain viability in PBS for even 24h at 37° C. 
However, shorter times were not studied. In the present work (with strain 18-323), 37° C 
was the standard temperature, but observation times from 15 min to 24 h were explored, 
with emphasis on periods up to 120 min. Gradual loss of bacterial viability was found in 
PBS during 120 min incubation with > 98 % killing (limited by the volumes plated) after 
about 24 h. Based on a very large set of observations (N = 135) a half-life of B. pertussis 
18-323 in PBS was found to be 149 min. There appears to be no published work with 
which this value could be compared. The 24 h results was nearly the same as those of 
Porter and Wardlaw (1993), with less extensive killing.
Plastic vessels were used as test container for both studies. Although at the start of 
this work glass containers were used, but when a rapid loss of B. pertussis viability was 
observed after only 120 min of incubation, which was possibly due to the adherence of 
bacterial cells to the walls of the test vessel (Gwynn et al., 1981), after which the plastic 
containers were used throughout the study. All B. pertussis strains showed almost the 
same survival in PBS during 120 min incubation as 18-323, except both L84 and 30042 
phase IV showed better survival, which was more pronounced at 24 h.
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As a diluent used for suspending the bacterial inoculum and as a non-bactericidal 
control, 1 % CAA with salts (NaCl, CaCl2 and MgCl2 . 6H2O) showed the same behaviour 
as PBS in allowing only about 55 % survival after 120 min. Despite this similarity in loss of 
bacterial viability in both PBS and 1 % CAA, the latter was chosen for suspending the initial 
inoculum. Halperin et al. (1992) used PBS containing a casein hydrolysate for transporting 
secretions collected by nasopharyngeal aspirate. They reisolated the pertussis bacteria from 
92 % of clinical specimens held at 4°C for 1 week and from all specimens held at -20 °C 
(The use of glycerol was not mentioned). These results of Halperin and his group 
supported the choice of using 1 % CAA as diluent for storing B. pertussis at -70 °C, for 
bacterial suspension (which usually stand on the bench at room temperature for few minutes 
during experiment) and as a non-bactericidal control. Also, Hall etal. (1994) and Imaizumi 
et al. (1983a) used 1 % CAA in preparing bacterial suspensions. CAA is the standard 
diluent for B. pertussis challenge in mouse infection (Dolby and Standfast, 1961). In 
respect of half-life, B. pertussis 18-323 showed roughly a similar half-life of 155 min in 
CAA as in PBS at 37 °C.
Some difficulties were experienced in using CL-medium, described by Imaizumi et 
al. (1983a) as a growth medium for B. pertussis and for PT production. These problems 
were overcome by a minor modification of the original CL-medium, by reducing the amount 
of trace nutrients (supplement) by a factor of two ie. Ferrous sulphate from 0.36 jiM to 
0.18 JiM; L-cysteine from 3.3 pM to 1.65 JiM; niacin from 0.33 |iM to 0.16 JiM; 
glutathione from 4.9 |iM to 2.4 p,M and L-ascorbic acid from 22.70 jiM to 11.35 jiM. Also 
better survival and growth of B. pertussis 18-323 in CL-medium containing L-glutamic 
acid (Sigma, 99 % pure by TLC) than in CL-medium with L-glutamic acid sodium salt 
(BDH, containing traces amount of chloride, ammonium and lead) especially after 24 and 
48 h of incubation (see Table 22). This difference is possibly because of the state of the 
purity of these chemicals. This modified CL-medium supported the survival (during 120 
min of incubation) and growth of B. pertussis 18-323 during 24 h of incubation. The 
differences between this study and Imaizumi et al. (1983a) was that they used a 5000-times
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higher bacterial concentration at time-zero than I did; they also employed B. pertussis strain 
Tohama instead of 18-323 and an incubation temperature at 35 °C in place of 37 °C.
Porter and Wardlaw (1993) showed a linear rise in the growth of B. pertussis strain 
18-334 in CL-medium during several days of incubation at 37 °C. The different results 
obtained with CL-medium between this study (before modification) and Porter and 
Wardlaw (1993) was possibly because of one or more of: respectively use of glass Bijoux 
instead of plastic Bijoux; B. pertussis strain 18-323 instead of 18-334; lower bacterial 
inoculum (1/10) at time-zero than they used; unwashed B. pertussis suspension in place of 
washed bacterial cells; and shorter incubation time (min) instead of days. The half-life of B. 
pertussis 18-323 in CL-medium was longer (386 min) than in either CAA or PBS.
Indicators of viability
In the present studies the ability of the B. pertussis to form colonies on BG 
medium was taken as the indicator of bacteria viability. The possibility that the organisms 
may enter a viable but not-culturable state, as described with other bacteria such as 
Salmonella enteritidits (Roszak et al. 1984), Vibrio cholerae (Colwell et al. 1985) and 
Campylobacter jejuni (Jones et al. 1991) was not explored. So far, the viable but non- 
culturable state has not been reported for B. pertussis.
The possibility of using luminescence as an indicator of viability of B. pertussis 
did not exist when the present investigation was being planned. However, during the course 
of the work B. pertussis strain lux became available and was therefore used. The following 
is a brief outline of the underlying principles: Bacterial luminescence results from the 
flavin-mediated oxidation of a long chain aliphatic aldehyde catalyzed by the enzyme 
luciferase. Two of the required substrates for the bioluminescent reaction, reduced flavin 
mononucleotide (FMNH2) and molecular oxygen, are both readily available in aerobic 
bacteria ; all that is required to produce light in a recombinant bacterium is the presence of 
the lux operon and a source of long-chain aliphatic aldehyde (Hill et al., 1993)
lucifcr^sc
FMNH2 + RCHO + O2 ------------------- > FMN + RCOOH + H2O + light
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-  Luminous bacterial cells in stationary phase emit much less light per cell than 
those in log phase. Luminescence (light) can be detected by 1) vision ; 2) 35 mm 
photographic film; 3) X-ray film; and 4) photoelectrically with a luminometer or scintillation 
counter. B. pertussis lux (which was used in this study), was originally derived from B. 
pertussis 44122/7 R a streptomycin-resistant strain (Branefors, 1964). The lux (luciferase 
gene) operon from Vibrio harveyi was cloned into phase I B. pertussis 44122/7 R (made 
by McLean, H., Parton, R and Coote, J. G. [unpublished]) , E. coli WA 308 and E. coli 
DH5a. The first two of these bacteria required addition of aldehyde in order to produce 
light. E. coli lux DH5a did not require addition of aldehyde for producing light since it also 
contained the genes for aldehyde production. The detection of luminescence (light) in this 
study was done by luminometer (luminescence photometer).
B. pertussis strain lux was used in parallel with strain 18-323 for the bactericidal 
test, because results could be obtained in a few hours instead of several days. However, 
some difficulties were encountered with the luminescence experiments such as the presence 
of some compounds (Thore, 1979) such as salts (CaCl2 , NaCl and KC1) at a concentration 
range of 5 and 20 \i mol /ml and BSA (1.04 % w/v) in the test fluids which interfered with 
the measurement of luminescence. Despite this, the effect of LLF and its fractions on B. 
pertussis lux correlated quite well with the results of the viable count experiments with B. 
pertussis 18-323.
EFFECT OF LLF ON VIABILITY OF B. PERTU SSIS  
Normal ra t LLF
Sixteen batches of LLF were obtained from normal Sprague-Dawley rats of the 
highest available health status and housed in rooms with a filtered air supply. This latter 
might be important if dust and microorganisms could influence the composition and 
activities of lung fluids. As detailed above, the activity of the fluid was influenced by the 
method of euthanasia and there may also have been other significant variables, such as the 
weight of the animals although this was not explored in detail. However, there was a
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particular batch (39) of normal rats which were sacrificed by the same method (D) of 
euthanasia, and with the same volume of PBS for lavage, at average weights of 126, 253 
and 350 g. The most active LLF came from the smallest animals and the least active from 
the largest. Whether this was a simple volumetric effect of airways volume in relation to 
PBS lavage volume, or to a qualitative difference in activity related to age, would require 
further study. With another batch (40) of rats, the very large animals (455 g average) had 
more active fluid than animals of mean weight 355 g, indicating the difficulty in drawing 
conclusions about BA in relation to age separate from other factors.
The only other authors who have investigated the antibacterial activity of rat LLF are 
Coonrod and colleagues (1983, 1984) with Streptococcus pneumoniae type 25. They also 
used Sprague-Dawley rats in a 'filtered air unit' and observed a rather weak in vitro killing 
effect with LLF from animals weighing 200 g or more. Although my researches with B. 
pertussis and Coonrod's with pneumococci differ in experimental details, I observed 
significant killing with a 1/24 dilution of normal LLF with 10^ cells of strain 18-323. While 
even more highly diluted (1/30) LLF with 10^ cells of B. pertussis lux gave significant loss 
of luminescence. Coonrod and Yoneda (1983) used 10^ pneumococci and at best only got 
23 % killing with unconcentrated LLF. Even with 20-fold concentrated LLF, in the form of 
the surfactant fraction, the maximum percentage killing they reported was only 81%. This 
was accompanied by lysis.
A further possible reason for the LLF of Coonrod and Yoneda (1983) apparently 
being less active than mine is because of pentothal anaesthesia followed by exsanguination 
for euthanasia. In the second paper (Coonrod et al., 1984) euthanasia was done with an 
over dose of fluthane and the author speculated this might increase the BA of the LLF; no 
relevant data were presented. In my work it was beneficial not to use an over-dose of 
halothane for killing but to give it as the anaesthetic during exsanguination. The evidence is 
obviously incomplete but reinforces the view already expressed that the method of 
euthanasia is an important factor in the subsequent BA of rat LLF.
It would therefore appear that B. pertussis is more sensitive to the BA of rat LLF 
than are pneumococci and that either a viable count test with 18-323 or luminometry with
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strain \vtxr may be used. Indeed it may well be that B. pertussis is a specially suitable 
bacterium for research on BA of rat LLF. A total of 11 strains of phase I and 2 strains of 
phase IV B. pertussis were tested. All the phase I strains had antibacterial sensitivities 
similar to 18-323 and lux, but the two phase IV strains were resistant to the antibacterial 
activity of normal rat LLF. This observation is consistent with the possibility that LLF BA 
is due to FA since phase IV organisms are resistant to these substances while phase I B. 
pertussis is highly sensitive (Pollock, 1947; Field and Parker, 1979; Frohlich et al., 1996; 
and this study).
For phase IV strains, LLF from normal rats acted as a growth medium as it did with 
B. bronchiseptica and B. avium, when Porter and Wardlaw (1994) reported the same 
observation with other animal species and human LLF.
Normal LLF from other species
Of the eight mammalian species whose LLF was tested for BA towards B. 
pertussis, three (rat, human and calf) gave positive results. Rat was easily the most active 
but since only one sample of each human and calf LLF was tested, it would be desirable to 
examine further samples. This is especially so with LLF from humans, the natural host of 
B. pertussis, where LLF may contribute to host defence. The sample of human LLF used 
here might have had its activity reduced through having been centrifuged at a much higher 
speed (10000 rpm) than used with my rat samples (500 rpm). This factor should be 
considered in any further studies with human and animal LLF. With the latter, the method 
of euthanasia should also be researched. Thus Porter and Wardlaw (1993) used a variety of 
methods of euthanasia for collecting the LLF for studying its properties as a growth medium 
for bordetellae. The human LLF they collected and which was used in my work was 
obtained during bronchoscopy of anaesthetised adults with suspected lung disease.
In the work of Coonrod et al (1984) with pneumococci, dog, mice, rabbits and 
guinea pigs LLF were tested in addition to their main work with the rat they found LLF of 
dog to be active, mice less so, while no activity was found in LLF from rabbits and guinea 
pigs.
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Inactivation of LLF
To gain information on the nature of the antibacterial substance(s) in LLF, the effect 
of various physical and chemical treatments was studied with both 18-323 and lux. In 
general, the activity was stable to most of the treatments applied. Thus it was not affected by 
heat at 56 °C for 30 min, and there was about only 50 % inactivation during 5 min at 100 
°C. Exposure to strong acid and alkali for 18 h at 4 °C had little destructive effect. Likewise 
treatment with three different proteases caused no loss of activity. All the above 
observations suggested that the active material in unfractionated LLF did not contain 
protein. On the other hand, there was evidence of a high molecular weight, or aggregated, 
factor since the activity was not lost during dialysis; nor did the activity appear in a 30 kDa 
ultrafiltrate. Very similar observations were made by Coonrod and Yoneda (1983) with their 
anti-pneumococcal activity in rat LLF. Possibly different antibacterial substance(s) with 
different modes of action may be present in the rabbit LLF investigated by LaForce and 
Boose (1981) with E. coli as test organism. In this system the LLF was not directly 
antibacterial but had a differential effect on ability of the bacteria to grow on deoxycholate 
agar, compared with blood agar. This activity appeared to be enhanced by low-pH 
treatment.
LLF from  B. pertussis-convalescent ra ts
LLF batches from both normal and B. pertussis- convalescent rats were studied in 
this investigation and found to be different in several significant respects. The convalescent 
samples were taken at between 3 and 6 weeks after the intrabronchi al infection, a time at 
which viable B. pertussis 18-323 was no longer recoverable from the rat lungs (Hall et al., 
1994). These convalescent animals had been used for experiments by Hall et al. (1994).
To help with comparability, LLF was always obtained from normal rats at the same 
time as the sampling from the convalescents. Considered as normal animals, but kept 
separate, were those exposed to sham-operation, i.e. the anaesthesia and surgical 
procedures with administration of agarose beads but without B. pertussis. A complication 
was that the convalescent samples came from animals that had been subjected to a wide
2 5 4
variety e f  experimental treatments associated with the infection with B. pertussis. For 
example, some animals had been vaccinated before the challenge with 18-323; there was 
variation in whether or not ether was used as a promoter of subsequent coughing (Hall et 
al., 1994); there were variations in the bead material, i.e. agarose, agarose + carrageenan, 
and alginate; and finally there were alternatives to strain 18-323 used for the challenge, 
notably another phase-I (Tohama), a PT-minus (357) , an HLT-minus (1809), a phase-IV 
(L-84) and a B. parapertussis (10520).
Table 67 summarizes the information from 33 batches of LLF from normal and 
convalescent rats, together with information on the coughing recorded on between days 8 
and 14 and the antibacterial activity expressed as 30 min survival figures. These data were 
then further analysed to see if there was an association between the exposure of the rats to 
pertussis toxin (PT), their coughing response and their LLF bactericidal activity (BA). For 
comparison, PT-unexposed rats were those assumed to have had no recent and significant 
exposure to active PT if they were in any of the following categories: normal (N), sham- 
operated (SO), vaccinated and challenged (VC), or infected with B. parapertussis, or phase 
IV or PT-minus B. pertussis. On the other hand, the PT-exposed animals were those that 
were convalescent from infection with phase I B. pertussis or with the HLT-minus mutant. 
The results in bold in Table 67 show that where there was most coughing in each of the 
treatment groups, the LLF from that group of rats tended to have low BA. The coughing 
responses, which ranged from zero to 11.4 (average number of paroxysms/ animal), were 
arbitrarily divided into nil (< 0.1) and positive (>0.3) groups, and the percent survivals in 
the BA tests were divided into 2 categories of low-BA (> 50 % survival) and high-BA (< 49 
% survival).
Table 68 shows that there was a high degree of association between the exposure 
status of the rat groups to PT and the subsequent coughing and BA of the LLF. Thus in the 
PT-unexposed groups there was only 1/16 coughing-positive, whereas in the PT-exposed 
groups there were 17/17. With LLF BA in the PT-unexposed groups there were 2/16 in the 
low-BA category, compared with the PT-exposed groups where the ratio was 12/17.
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Table 67rComparison of cough induction and % survival of B. pertussis 18-323 after 30
min of incubation in the LLF from normal (N), sham-operated (SO), vaccinated and
challenged (VC) and convalescent (C) rats.
LLF Batch 
No.
Treatment Coughing*/
rat
% Survival** after 
30 min of incubation
15 N 0 26
C-Phase IV 0.1 26
C-Phase I 0.5 88
C-Phase I 3.7 84
C-Phase I 7 .1 92
16 SO 0 38
VC 0 48
VC 0.1 0
C-Phase I 1.0 65
C-Phase I 2 .1 80
17 N 0 14
VC 0 1
VC 0.1 11
C-Phase I 0.5 4
C-Phase I 1 .7 79
21 N 0 50
C-Bpp 0 0
C-PT- 0.3 0
C-HLT- 0.5 0
C-PhaseI 1.0 8
C-PhaseI 1 .3 1 0 1
34 N 0 59
C-Phase I *** 21
41 N 0 8
SO 0 0
SO 0 2
C-Phase I 2.8 79
C-PhaseI 1 1 .4 97
43 N 0 0
C-Phase I 0.4 100
C-Phase I 0.9 27
C-Phase I 3.4 0
C-Phase I 3 .9 6 6
*Coughing paroxysms/rat (days 9-14 post-infection); **% survival calculations were based
on PBS zero-time count; *** There was definite coughing on day 8 and 11 post-infection,
but not counted.
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The tentative conclusion.may therefore be drawn that rats exposed to intrabronchial 
infection with a high dose (10^) of phase I B. pertussis develop paroxysmal coughing and 
show a decline in the BA of their LLF. It should be noted that the coughing and BA 
observations were unavoidably made at different times, the former being around day 8 after 
infection, while the LLF was never obtained earlier than day 21 and sometimes as late as 
day 42. Therefore it is possible that for the observation of maximum decline in BA, the 
post-infection LLF should also be taken around day 8 when the coughing and the 
leucocytosis are at their highest levels.
B. pertussis is well known for its ability to interfere with host defence mechanisms. 
For example, adenylate cyclase toxin (ACT) of B. pertussis inhibits the killing function of 
phagocytic cells (Confer and Eaton, 1982). Tracheal cytotoxin causes ciliostasis and 
specific damage to ciliated cells and inhibition of DNA synthesis in hamster tracheal rings 
(Goldman and Baseman, 1980). Pertussis toxin (PT) inhibits (see Table 6) the functions 
(such as oxidative burst, migration, homing pattern in vivo, degranulation and target cells 
lysis) of immune effector cells such as neutrophils, monocytes, lymphocytes, mast cells and 
natural killer cells. Therefore my observation of lowered LLF BA in rats recently exposed 
to B. pertussis infection may be part of a general pattern of multiple aggressin activities.
Other B. pertussis strains
The sensitivity of other B. pertussis phase I strains to the bactericidal activity of 
convalescent rat LLF was similar to that observed with B. pertussis 18-323. LLF from 
convalescent rats exposed to euthanasia method B gave a strong BA towards B. pertussis 
30042 phase IV. This result suggested that euthanasia method B had an effect on the LLF 
by developing a new bactericidal active substance which also active towards B. pertussis 
18-323. This new substance possibly was synthesised during exposure of rats to CO2 . B. 
pertussis 30042 IV was sensitive only to this batch (34) of LLF, while all other phase I B. 
pertussis strains were insensitive to the bactericidal activity of the same batch.
The average time (half-life) required for 50 % inactivation of the B. pertussis 18- 
323 cells in LLF from normal rats was less (11 min) than that (20 min) observed with LLF
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Table 6& Correlation between rat paroxysmal cough and LLF bactericidal activity in relation 
to exposure to pertussis toxin (PT) during infection with B. pertussis (± PT) or 
parapertussis (-PT).
PT-status of Bactericidal activity: Cough:
rat group No. of batches No. of batches
Low High No. Low/Total Nil Positive No. Positive/Total
Not exposed 2 14 2/16 15 1 1/16
toPT
Exposed 12 5 12/17
toPT
0 17 17/17
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from convalescent rats (Table 46). This supported the finding above that the B. pertussis 
infection of the rats caused a reduction in BA of their LLF.
Different strains of rat
Experiments with different strain of rat showed that Sprague Dawley were not 
necessarily characteristic of rats in general in regard to response to B. pertussis. For 
example, the three other rat strain tested gave much less coughing (Wardlaw, Parton and 
Hall, [unpublished data]) than Sprague Dawley (Table 69), indeed Brown Norway did not 
appear to cough (Wardlaw, Parton and Hall, unpublished data) at a l l . Normal LLF from all 
4 rat strains had BA and without observed differences between young and old animals. 
However, remarkable differences between the strains were observed with LLF from 
convalescent rats. Thus Hooded Lister and to a less extent Lewis, resembled Sprague 
Dawley in showing much reduced BA. On the other hand, convalescent LLF from Brown 
Norway rats was just as active as from the normal animals of this strain. It is therefore clear 
that future work on the BA of rat LLF, especially in relation to B. pertussis infection 
should take account of large differences between rat strains. The possibility that Brown 
Norway rats are unresponsive to PT merits further study. Finally, Coonrod and Yoneda 
(1983) found anti-pneumococcal activity in LLF from both Sprague Dawley and Lewis rats.
Tests with phase IV
Approximately 3 batches of normal and 9 batches of convalescent LLF were tested against 
phase IV B. pertussis. Of these, only one convalescent LLF had BA against B. pertussis 
30042IV. This batch (no. 34) was exceptional in being the only batch of convalescent LLF 
obtained by euthanasia method B. might require that the batches be collected with CO2 
euthanasia. It may be noted that towards phase I B. pertussis 18-323, this batch had only 
moderate activity. There was therefore evidence that BA of LLF towards phase IV B. 
pertussis might involve different substances than towards phase I.
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Table 69r Comparison between normal and convalescent* rats of different strains and 
ages** in cough production and bactericidal activity of their LLF towards B. pertussis 18- 
323.
Strain of rats Treatment Coughing/ rat 
(8 days post infection)
% survival*** after 
30 min of incubation
Young Old Young Old
Sprague-Dawley Normal 0 0 0,0 0,0
Challenged 11.3 2 68,43 18,24
Brown Norway Normal 0 0 0,0 0 ,0
Challenged 0 ND 0,0 0,0
Lewis Normal ND 0 0,0 0,0
Challenged ND 1.3 26,21 67,66
Hooded Lister Normal 0 0 0,0 0,0
Challenged 5 1.3 113,129 90,97
*Challenged with B. pertussis 18-323 encased in agarose with dimethyl-p-cyclodextrin);
** Young rats = 4-5 weeks old (~ 110 g in weight) ; Old rats = 6-7 weeks old (~ 150 g in
weight); *** % survival based on PBS time-zero calculation.
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Inactivation studies with this particular batch showed that the BA was removed by 
ultrafiltration (10 kDa) and destroyed by heat, bentonite and trypsin. It was concluded that 
the substance(s) responsible for this BA was protein.
SUPERNATE AND SURFACTANT FRACTIONS OF LLF 
Distribution of Bactericidal Activity (BA) 
B. pertussis and other bacteria
Ultracentrifugation was applied to normal rat LLF to see whether the substance(s) of 
LLF responsible for the BA is located in supemate (SN) or pellet (SUR) fractions. This 
followed the method of other workers (Coonrod and Yoneda, 1983; Coonrod et al., 1984; 
LaForce et al., 1979; LaForce and Boose, 1981) with rat and rabbit LLF. Most of the BA 
towards B. pertussis 18-323 and lux, was found in the SUR fraction of LLF from normal 
rats. In contrast, the SN fraction showed only moderate or little activity. This is similar to 
Coonrod and Yoneda (1983) who detected BA in 20-fold concentrated rat SUR towards 
type 25 pneumococci and no activity in 20-fold concentrated SN. The opposite distribution 
was reported by LaForce and Boose (1981) who demonstrated sublethal damage of E. coli 
when incubated in the SN fraction of rabbit LLF and cultured on deoxycholate agar, and no 
effect after incubation in the SUR fraction.
In my work, B. pertussis, B. pararpertussis, S. aureus and E. coli lux DH5a were 
all sensitive to the BA of normal rat SUR, while B. bronchiseptica, E. coli Lilly, E. coli 
lux WA803, and S. pyogenes were insensitive. M. luteus was sensitive to the lysozyme in 
the rat LLF. In the work of Coonrod et al. (1984), two other strains of pneumocccus (type 
1 and 3) were similarly responsive to type 25 and were sensitive to the BA of rat SUR.
Organisms that were similar in sensitivity to pneumococci were S. viridans, S. 
pyogenes, S. bovis and 2 unidentified Bacillus species. In contrast, various other bacteria 
were insensitive, such as: S. aureus, Pseudomonas aeruginosa, Enterobacter aero genes, 
Proteus vulgaris, Serratia marcescens, Klebsiella pneumoniae, S. fecalis, S. durans and S. 
agalactiae.
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To the BA of rat SN, B. pertussis and B. parapertussis were both sensitive, while 
B. bronchiseptica, S. aureus, S. pyogenes and E. coli were insensitive and grew in SN. 
Porter and Wardlaw (1994) showed that both B. bronchiseptica and/?, avium survived 
and grew very well in all animal LLFs (which they tested) and human LLF. They also 
mentioned that both B. pertussis and B. parapertussis were not able to grow as well as the 
two animal bordetella species.
Dose-response
Quantitative titration of BA by viable counting with B. pertussis 18-323 gave 
average 50 % endpoints at about 1/24 with LLF, 1/34 with SUR, and only 1/2 with SN. 
This showed that although both SUR and SN fractions had BA, the SUR had about 17 
times as much. There was also a suggestion that the ultracentrifugation used to separate 
SUR may have removed a BA inhibitor, although this was not specifically investigated. 
Coonrod et al. (1984) also used a dilution assay with a 50 % endpoint, and found that 
concentrated rat SUR contained much more BA than concentrated SN. Note that in 
comparing the Coonrod et al. (1984) work with mine, they used a different test organism 
and also a 10^ times higher dose of bacteria.
Supernate (NSN) Fraction
Inactivation studies were done to characterize the substance(s) in normal rat 
supernate (NSN) responsible for BA. Most of the work was by viable counting with 18- 
323 which was found to be more reliable than luminometry with strain lux. Exposure of 
NSN to a variety of physical, chemical and biochemical agents lead to the conclusions that 
the BA may be due to 3 different components: protein, phospholipids, and FA. The 
evidence for protein was the loss of activity by heat, acid, alkali, and bentonite.
Contrary evidence was the fact that the activity was not significantly reduced by 
treatment with any of 4 different proteases. The evidence for phospholipids was the definite 
loss of activity by phospholipase A2 while the possibility of FA involvement was suggested 
by the ability of charcoal to remove the activity. However, other agents that might be
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expected-Io lower the activity by FA removal had relatively small effect. These included 
serum, BSA, starch, methylcellulose, and cyclodextrins. Thus the strongest evidence was 
that provided by phospholipase A2, suggesting involvement of phospholipids.
Inactivation of NSN was also studied, although less extensively, by luminometry. 
Some results so obtained were difficult to integrate with the conclusions from the viable 
counting studies with 18-323. For example, proteinase K apparently caused significant loss 
of BA of SN towards lux but not towards 18-323. However, the control test of protease 
(without NSN) + bacteria showed definitely increased luminescence, which could not be 
explained. Another discrepancy occurred with the freezing and thawing of NSN. This 
appeared to enhances the BA of SN towards 18-323 but to decrease it against lux. Further 
studies would be required to resolve these apparent inconsistencies which were observed on 
two or more occasions.
There is little published work by other investigators, with which the above may be 
compared. Coonrod et al. (1984) did not report inactivation of NSN fraction in their 
pneumococcal work because the fraction lacked activity to start with. LaForce and Boose 
(1981) stated that most of the anti-Zs. coli activity of rabbit LLF was due to high molecular 
weight heat-stable peptide which was adsorbed by bentonite and sensitive to trypsin.
Surfactant (NSUR) Fraction 
Composition
The composition of LLF NSUR has been studied by about more than 10 different 
groups of investigators such as Pruitt et al. (1971); King et al. (1974); Harwood et al. 
(1975); Shelley et al. (1984); King and Clements (1985) and others. King and Clements 
(1985) reported that dog SUR contained about 80-90 % lipids and 10 % protein by weight.
In my work, the rat SUR contained 475 pg/ml lipids, whereas protein was estimated 
to be 58 pg/ml. These figures are equivalent to 85 % lipids and 15 % protein.
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Artificial surfactant
ALEC, artificial lung expanding compound (artificial surfactant) together with rat 
lung SUR were examined for their BA towards both B. pertussis 18-323 and lux. Rat lung 
SUR showed BA towards both B. pertussis strain 18-323 and lux. whereas artificial 
surfactant exhibited no BA towards B. pertussis 18-323, although an effect on bacterial 
luminescence of B. pertussis lux was observed.
This decrease in bacterial luminescence was possibly due to the turbidity (which 
can interfere with light output measurement). The artificial surfactant was composed only of 
dipalmitoylphosphatidylcholine and phosphatidylglycerol, whereas, rat lung NSUR 
contains these phospholipids in addition to others, and also lysophospholipids, FA and 
trace amount of proteins. Coonrod et al. (1984) reported that commercially prepared 
lysophospholipids (specifically palmitoyl and myristoyl lysophosphatidylcholine) acts as a 
bactericidal agents against some bacteria such as type 25 and 3 pneumococci, S. viridans 
and S. pyogenes. Neither FA nor lysophospholipids are present in ALEC, which may 
explain why ALEC possessed no BA towards B. pertussis 18-323.
Effect of incorporation of B.pertussis lux in agarose ± DMpCD
The B. pertussis 18-323 challenge which was given intratracheally to the different 
rat strains (see footnote of table 69) was encased in agarose with dimethyl-p-cyclodextrin 
(DMpCD). An experiment was therefore done to see if DMpCD might protect the bacteria 
from the BA of the LLF of those rats. In vitro tests with B. pertussis lux encased in 
agarose ± DMPCD were incubated in normal rat SUR and in PBS. It was found that a) the 
bacterial luminescence of B. pertussis lux incorporated in agarose was decreased (50 %), 
this was possibly due to the viscosity status (which can interfere with the measurement of 
light output) of the test mixture; b) DMpCD by itself caused a 25 % reduction of bacterial 
luminescence; c) Also the BA of SUR on the bacterial luminescence was reduced by 
DMpCD, this was possibly due to the inclusion complexes formed by cyclodextrins 
(Szejtli, 1982, cited by Frohlich et al., 1996) during their binding to FA present in rat SUR.
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Inactivation
Inactivation of the BA of the normal rat surfactant (NSUR) fraction was also 
studied to characterize the substance(s) responsible for their BA towards both B. pertussis 
18-323 and lux. Exposure of the NSUR to different physical, chemical and biochemical 
agents suggested that the NSUR also contained three different active components: FA, 
phospholipids, and protein. Indication of FA was judged by charcoal adsorption, DMpCD, 
serum and BSA, pH and heat treatments. High and moderate inactivation of the NSUR BA 
respectively by phosphlipase A2 and C provided evidence for phospholipids. Evidence of 
protein was concluded from the high reduction of NSUR BA by proteinease K and also the 
moderate reduction by heat and pH treatment.
Other treatments such as freezing and thawing, dialysis, methylcellulose, starch, 
bentonite, sonication, and other cyclodextrins were not significantly destructive. On the 
other hand membrane Alteration and washing in PBS removed much activity.
Loss of activity during membrane Alteration might be due to the aggregation of the 
substance(s) responsible for BA during fractionation by ultracentriAigation and therefore the 
aggregated particles were retained by the filter. This reduction in BA was not observed in 
cell-free rat LLF before exposure to ultra centrifugation when the Auid could be filtered 
without loss of activity.
Similar results as with 18-323 inactivation experiments were observed with strain 
lux, except that no effect of pH and an enhancement (which could not be explained) of the 
NSUR BA by sonication were observed. Similarly as with NSN, the high inactivation of 
NSUR BA towards both B. pertussis 18-323 and lux by proteinease K could not be 
explained.
Coonrod and Yoneda (1983) reported that the BA of concentrated rat SUR towards 
type 25 pneumococci is not affected by heat (56°C), serum (4%), sonication or trypsin. 
They also stated that the activity was removed by heat (100°C/15min), serum (8 %), 4 times 
washing in PBS and storing at -70°C for more than 7 d. Thus my results were almost the 
same as theirs in respect of trypsin, heat, sonication and serum treatments. However, in my 
work I did not notice any reduction in the SUR BA after storage at - 70 °C.
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Pollock (1947) reported that charcoal-treated broth supported growth of B. 
pertussis by removing some inhibitors such as free fatty acids in the culture media. He also 
stated that albumin is the active fraction of blood which supports the growth of B. pertussis. 
Accordingly it is possible that the effective component in heated rat serum which inactivates 
the BA of NSUR is albumin. Charcoal and albumin supported the survival and growth of 
B. pertussis better than starch (Pollock, 1947). The same investigator stated that starch was 
not quite as efficient or reliable with small inocula as charcoal and albumin. Methylcellulose 
was mentioned by Nikolajewski et al. (1990) as one of the adsorbent agents capable of 
supporting survival and growth of B. pertussis. Imaizumi et al. (1983a) found that the 
addition of DMPCD to the medium stimulated cell growth and concluded that the effect was 
possibly due to the removal of inhibitors such as FA from the medium. Coonrod and 
Yoneda (1983) concluded that the anti-pneumococcal activity in rat SUR could be attributed 
to FA. Field and Parker, (1979) mentioned that only small concentrations (1 ppm) of FA are 
required to inhibit growth of B. pertussis strain 114.
It is possible that the BA of the test fluids is due to phospholipids since 
phospholipase A2 abolished the BA of NSUR. However, phospholipase A2 catalyses the 
hydrolysis of the ester bond at the position (2) of glycerophospholipids to form a free fatty 
acid and lysophospholipid. The excessive release of FA due to the action of phospholipase 
A2 would be expected to increase the BA of the test fluids rather than reduce it.
Coonrod and Yoneda (1983) reported that phospholipid extracts of rat surfactant 
were active against pneumococci.
Lipids and long chain fatty acids (FA)
The effect of FA acids (0.0001 - 1 mM) and phosphatidylcholine on the viability 
and luminescence respectively of B. pertussis strains 18-323 and lux was studied. It was 
found that B. pertussis 18-323 was sensitive to arachidonic, palmitoleic, oleic, linoleic, 
palmitic, petroselinic, pentadecanoic, elaidic, and myristic acid. No sensitivity was found 
with phosphatidylcholine. B. pertussis lux was not sensitive to any FA or phosphatidyl­
choline.
2 6 6
Generally, the measured FA concentration in normal rat LLF was found to be at a 
median of 46 |iM. On the other hand the concentration of FA mixture which had a BA and 
were able to kill 50 % of B. pertussis 18-323 inoculum was 55 |iM. Therefore it was 
concluded that most of the LLF FA were in the active state.
Field and Parker (1979) reported that B. pertussis strain 114 (phase not 
mentioned) showed extreme sensitivity towards unsaturated fatty acids (0.001- 0.1 mM) 
such as petroselinic, oleic, elaidic, palmitoleic, linolenic, arachidonic and linoleic. They 
also stated that the same organism was less sensitive to saturated fatty acids (0.001 - 1000 
mM) such as myristic, pentadecanoic and palmitic acids. The work of Pollok (1947), Field 
and Parker (1979) and Frohlich et al. (1996) concentrated on studying B. pertussis growth 
inhibitors whereas my study dealt with the direct BA of rat LLF towards the same bacteria.
The BA towards B. pertussis 18-323 was discovered in the chloroform fraction 
after lipid extraction of rat SUR with chloroform-methanol. Chromatography on silicic acid 
of the chloroform active fraction with chloroform, acetone and methanol, showed that the 
antibacterial activity was eluted with the neutral lipids in chloroform. Similarly Coonrod et 
al. (1984) recovered the anti-pneumococcal activity in the chloroform (neutral lipids) 
fraction after lipid extraction from rat surfactant. They also detected all of the activity with 
neutral lipids fraction after elution in chloroform after silicic acid chromatography. When 
rechromatographed on silicic acid with hexane, hexane-chloroform, and chloroform, they 
found that the BA was eluted with FA. They stated that the BA was confined to the FA 
fraction which was established by Thin-layer chromatography.
Ultrastructural changes
TEM examination of the effect of rat SUR on cells of B. pertussis 18-323 and lux 
after lh  incubation showed a severe damage to the bacterial cells, disruption of the 
cytoplasmic membrane and disappearance of internal structure. Very similar results were 
given by Coonrod and Yoneda (1983) who reported the effect of 20-fold concentrated rat 
SUR on pneumococci type 25 after 30 min incubation and they stated that the pneumococci
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showed a large cell wall defect with exudation of protoplasm. They also detected a bacterial 
"ghosts" with almost no internal structure.
Direct examination of the SUR pellet itself by transmission electron microscopy 
(TEM) showed small numbers of lamellar bodies. Jonsson et al. (1986) also detected 
lamellar bodies in human surfactant by direct examination with TEM. Coonrod and Yoneda 
(1983) reported that lamellar bodies purified by discontinuous sucrose density gradient from 
rat SUR were strongly bactericidal active against peumococci type 25. In this study, this 
batch of SUR (from rat batch no. 58) from which lamellar bodies were detected by TEM 
also showed very high BA towards B. pertussis lux. Thus further studies on the BA of rat 
SUR should pay attention to the concentration of lamellar bodies in the preparations.
CONCLUSIONS AND PERSPECTIVES
These studies have shown that normal rat LLF fractions (NSN and SUR) contained 
antibacterial active substance(s) towards B. pertussis 18-323. Preliminary evidence 
suggests that the responsible substances are protein, phospholipids and fatty acids. BA of 
LLF from convalescent rats was found to be lower than with LLF from normal animals. 
The reduction in BA was possibly due to the effect of a bacterial toxin (such as PT) on the 
antibacterial substance(s) itself or on the pneumocyte cell type II. Another substance of 
protein nature and with BA towards both phase IV B. pertussis strain 30042 and phase I B. 
pertussis strain 18-323 was found in LLF from convalescent rats exposed to euthanasia 
method B (mainly killing by CO2). It was not known whether this active substance(s) was 
originally located in the lung and which was enhanced during exposure to CO2 inhalation, 
since this active substance(s) was not discovered in other LLF from convalescent rats 
exposed to other methods of euthanasia (A, C and D).
Possible future work would be to characterize these antibacterial substance(s), to 
gain more knowledge about the behaviour of B. pertussis in the lung and how it can protect 
itself from the host defence mechanisms in LLF.
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Appendix 1. Infection of rats with B. pertussis and related bacteria
(information provided by Dr. E. Hall).
Materials for the Operation
The materials, equipment, and utensils are listed below:
12cm forceps; 12 cm curved scissors; 12 cm artery forceps; 10 cm Alms retractor 
(optional); Swann-Morton scalpel holder for no. 10 blades (All were obtained from Vet 
Drug Co); lx 22g curved bead tipped needles (IMS, Dane Mill Broadhurst Lane, Congleton 
Cheshire); dish towel to lay instruments on (several small operating towels were provided 
to place on top of the rat); several pairs of latex examination gloves for the surgeon; cotton 
wools wabs in glass petri dishes; electric warming mat; animal clippers (size 40) with blade 
in them; Dilute hibitane in sqeezy bottle or (Quik Prep) chlorohexidine / alcohol spray; 
scalpel blades (Swann Morton); 1ml syringe; 21 gauge needle; anaesthetic and bottle of 
sterile distilled water for dilutions; scissors for opening sterile packs; disinfectant wipes 
(Southern Hygiene Co Ltd); anaesthetic ether and glass beaker with cotton wool; universal 
racks (to prevent spillage of bacteria / bead mix); incubator set at 32 °C for warming the 
animals post-operatively; suturing materials (1) (Chromic cat g u t , 2 metric with 20 mm 
curved needle (Ethicon product no. W 658); suturing Materials (2) (Prolene, 3 metric, with 
60 mm straight needle (Ethicon product no. w 8623 ). Both suturing materials no.(l) and 
no.(2) were purchased from Vet Drug Co, Falkirk.
Bacterial Challenge Suspension
Bordetella pertussis strain 18-323 (NCTC 10739, Phase I) was grown on Bordet- 
Gengou (BG) Agar containing defibrinated horse blood 20 % (v/v). The growth from plates 
incubated for 24 h at 37°C was suspended in casamino acids (CAA) solution to give 2x10^ 
CFU/ml. Ten-fold serial dilutions were made in CAA and 0.1-ml volumes were plated on 
BG medium to provide viable counts.
The undiluted suspension was either used directly for infecting the rats, or more 
commonly, was first incorporated into agarose beads.
Agarose Beads
All materials and equipment were sterilised by either autoclaving or disinfected by 
immersion in ethanol followed by rinsing in sterile water.
Low-gelling-temperature agarose (Sigma) 2 % (w/v) in PBS was melted at 100°C, 
transfered to a water bath at 37°C and allowed to cool. Meanwhile, 200 ml of liquid paraffin 
(Hays Chemicals Distribution Ltd, Glasgow), previously warmed to 37°C, was transferred 
to a 600-ml beaker and mixed with a Silverson mixer-emulsifier at the lowest speed setting.
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Five ml of the bacterial suspension at 2x10^ CFU/ml were mixed with 5 ml of the 
agarose, rapidly transferred to a 10-ml syringe fitted with a 22 g x 1.5 in needle and 
expelled dropwise into the paraffin. After mixing for 5 min, the paraffin was placed on ice 
and mixing continued for a further 5 min during which time the agarose droplets solidified 
into beads of c. 100 pm diameter. This mixing procedure was done in a microbiological 
safety cabinet. The beads were deposited by centrifugation at 7000g at 4°C for 20 min, 
washed 3 times in CAA by further centrifugations under the same conditions, primarly to 
remove the paraffin oil, and resuspended to 5 ml of CAA.
The process of bead preparation, from harvesting of the challenge suspension, 
generally took c. 2-3 h and the beads containing B . pertussis were used within 2 h of 
preparation.
Alginate Beads
Alginate beads were prepared by dropping a 4 % (w/v) solution of sodium alginate 
(Sigma) in DW (8 ml) into a mixture of CAA (8 ml) and 50 mM calcium chloride (8 ml) 
with constant swirling. Large spherical beads which formed immediately sank to the bottom 
and the excess liquid was decanted off leaving 1 volume of supemate : 2 volume of beads. 
The mixture was homogenised for 30 sec followed by centrifugation at 500 g for 5 min. 
The supemate was decanted and the bead mixture resuspended with 1 volume CAA to 2 
volumes of alginate beads. This process was completed within 30 min. The alginate slurry 
was much thicker than the agarose.
For control purposes.i.e "sham" operations, agarose and alginate beads were 
prepared in the same way but without incorporation of bacteria. In several experiments, 
carrageenan (carrageenan lambda, type IV; Sigma) was incorporated into the agarose beads 
at a final concentration of 1 % (w/v). In other experiments, heat killed bacteria were used in 
place of live cells. This was done by heating the standardised bacterial suspension in a water 
bath at 56°C for 40 min after which 0.1 ml was plated out on BG medium as a check on 
sterility.
Vaccination
Each rat was given a single human dose (0.5 ml) of adsorbed diphtheria-tetanus- 
pertussis (DPT)-vaccine containing killed whole B. pertussis (Wellcome Trivax-AD) by 
intraperitoneal injection and challenged 3 weeks later with the usual infecting dose of B. 
pertussis strain 18-323.
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Anaesthesia
The anaesthetic used for surgery was an injectable combination of Hypnorm 
(midazolam hydrochloride; Janssen Pharmaceuticals Ltd, Grove, Oxford) and Hypnovel 
(fentanyl citrate and fluanisone; Roche Products Ltd, Welwyn Garden City) mixed with 
water in 1: 1:2 proportions and adminstrated intraperitoneally at a dose rate of 3.3 mg/kg, 
eg 0.3 ml per rat was sufficient. This type of anaesthetic is described as medium term and 
has the rat immobilised in 10 min and unconscious in 20 min, with the effect lasting 30-60 
min. Some variation in senstivity had been experienced and occasionally an extra 0.1ml or 
more had been given to maintain unconsciouness; the operation was started as soon as the 
rat become unconscious. For the rats of the size of 150-175 g, the administration of 
anaesthetic was considered a two-persons task (the handler and the injector), the handler 
carefully picked up the rat round the upper body between the neck and abdomen so that the 
front legs were crossed over, the back legs were secured with the other hand and by 
holding the rat in a horizontal position, the second person (injector) injected 0.3 ml of the 
anaesthetic intraperitoneally using a 1ml syringe and 21 gauge 1 inch needle.
Operative Procedure
The immune status to B. bronchiseptica was detected by ELISA, using a serum 
sample obtained from each rat tail by veni-puncture before the operation. All the autoclaved 
materials, utensils and other items required are listed above. The warming mat and the 
incubator for post-operative recovery were turned on two hours before the operation. With 
sterile gloves, the instruments were arranged on the dish towel, meanwhile the anaesthetised 
rat was placed on its back and shaved round the neck region, it was then taped to the warm 
mat and the upper chest and throat were cleaned with disinfectant, the excess fluid was 
wiped off with sterile cotton wool, and an operating towel placed over the rat with the 
opening revealing the area to be operated upon.
Using a sterile scalpel a midline incision about 3 cm long was made in the lower 
part of the neck, the subcutaneous tissue revealed was picked up with the forceps and 
divided through using the scalpel to cut only intially. Blunt dissection was continued with 
the forceps and scissors or artery forceps to expose the trachea, which looks like a clear 
tube with spiral rings round it.
At this point the retractor might prove useful in holding the tissues, meanwhile an 
assistant drew up 0.2 ml of air followed by 0.1 ml of the beadJB.pertussis mix into a 1 ml 
syringe and attached the bead-tipped needle. Using a fine 21 gauge xl inch needle, a hole 
was punctured in the trachea through which the bead-tipped needle was fed and angled 
down to the left hand side (The whole length should go in without resistance) and the
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0.1ml inoculum delivered. The wound in the skin was sutured with a single cat gut stitch 
(brown in colour) subcutaneously in the middle of the wound. Prolene (blue in colour) was 
used for 3 stitches to draw the outer skin together starting 1 mm from the edge of the wound 
to allow drainage, These stitches were tied very loosely to allow for swelling, the 
justification for using two layers of stitching was that the rats nibble the outer prolene in 1-2 
days and leave the cat gut which decomposed in about 8 days.
Ether was administered after the operation to each rat for 2 min since it was 
considerd benefical to the induction of coughing. After the operation, the rats were left to 
recuperate in an incubator at 32 °C for approximately one hour, after which they were 
transferred to cages of (two rats per cage) and kept in a room designated for them. 
Appropriate labels were attached to the cages, and entry to the room was restricted to 
authorised person only who had to wear face masks.
The rats were inspected daily for several days after the operation by the person 
legally responsible for them.
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Appendix 2. Collection of LLF from animals other than rats (based on 
information from Dr. J. Porter).
Mouse; LLF were from adult mice, and each mouse was killed in a ja r  containing CO2 
and pinned out on its back on a board. A scalpel was used for removing the fur and the skin 
from the throat, The trachea was exposed by making an incision through the tissue covering 
it, and a hole pierced in the trachea with dissection scissors. A cannula of diameter 
approximately 1 mm, with a 2 ml syringe attatched to the end was inserted into the trachea 
and tied in with fine thread and 1.5 ml of PBS passed into the lungs. After 10-15 sec the 
fluids was sucked out and transferred to a 30 ml plastic Universal. The LLF collected from 
20-30 mice on the same day was pooled, except that any with visible blood contamination 
was discarded.
The pooled collected washings were spun in a laboratory bench centrifuge (MSE 
minor ’S') at 10, 000 rpm for 15 min, afterwhich the supemate was filter-sterilized through 
a 0.45 pm filter (Gelman Science) into 1.2 ml alquots dispensed into microcentrifuge tubes. 
The tubes were stored at -20°C as were the pellets from the centrifugations.
Horse: Approximately 90 ml of LLF was obtained by Professor A.C.Wardlaw at Glasgow 
University Veterinary School from a 16-year old Arab stallion with a spinal weakness 
which had had to be put down. The fluid was centrifuged at 10, 000 rpm for 15 min. Some 
of the supemate was stored in bulk before sterilization. The remainder was filter-sterilized 
(as with mouse LLF) into 3 x 20 ml portions in 30 ml plastic Univerals, and in 1.2 ml 
aliquots in microcentrifuge tubes and stored at -20 °C.
Rabbit: LLF was similarly collected as for mouse LLF except that the rabbits were killed 
by an overdose of Sagittal (1-1.5 ml). The trachea cannulated with larger cannula (diameter 
of 2-3 mm), and 40 ml of PBS was used to wash the lungs. Centrifugation, sterilization, 
and storage of the LLF and cell pellets were as before.
Sheep: LLF was obtained from Glasgow University Veterinary School. The lungs from 
freshly slaughtered normal sheep were removed and rinsed with approximately 100 ml of 
PBS, the first rinsings being separated from the rinses 2 and 3. The PBS was poured into 
the sheep trachea and removed after 10-15 sec. Centrifugation, sterilization, and storage of 
the LLF and cell pellets were as before. Only the rinse 2 was used in this study.
Chicken: Two-year old black-spotted chickens were provided by The Royal Hospital for 
Sick Children (Glasgow), and the collection procedure was used for lung washing similar 
to that for mouse, and approximately 20-30 ml of fluid was obtained. Centrifugation, 
sterilization, and storage of the LLF and cell pellets were as before.
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Dog: A 14 kg mongrel bitch was provided by a Glasgow University Veterinary School, 
and was used for obtaining LLF. The dog was premedicated with acetylpromazine, 
anaesthetized with 5% (w/v) sodium thiopentone and maintained with halothane/nitrous 
oxide/oxygen during a 4 h operation, and killed with an injection of barbiturate. The trachea 
had previouly been incubated with a leak-proof cannula and approximately 200 ml of sterile 
PBS was poured in within 1-2 min of death. The fluid was then recoverd by tilting the 
operating table and letting the fluid run out under gravity. Centrifugation, sterilization, and 
storage of LLF and cell pellets were as before.
The pH of all animal LLF and human bronchial lavage (which were provided by 
John Porter), was measured previously by using Johnson's test paper, and found in all 
cases to be approximately 7.
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Appendix 3. ELISA of rat LLF and sera (information provided by Dr. E. Hall).
Materials
Antigens for ELISA used in this study were prepared by Hall et al. (1994) during a study 
on cough production, leucocytosis and serology of rats infected intrabronchially with B. 
pertussis. The antigen was a whole-cell sonicate from B.pertussis 18-323 grown overnight 
on BG agar plates at 37 °C, after which the bacterial culture was harvested in 1 % CAA, 
centrifuged at 7000 g for 15 min at 4 °C, suspended in ELISA coating buffer to a 
concentration equivalent of 2 x 10^ cfu / ml. Cells were disrupted by sonication (MSE 
sonicator; 4-5 pm amplitude, 20 kHz) on ice, for 30 sec with intervals of 30 sec for 
cooling, for a total of 10 min, then frozen at -20 °C ready for use when needed.
Pertussis toxin (PT) and filamentous haemagglutinin (FHA) were prepared from B. 
pertussis transposon-insertion mutants Bp 353 and Bp 357, which were respectively 
deficient in the production of FHA and PT. The bacteria were grown in CL medium; PT and 
FHA were extracted from the grown culture supemates by dye-ligand chromatography and 
the protein content of the antigens was estimated.
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Appendix 4. Code for details of experimental conditions (Excluding the test 
fluids that applies to Appendices 5, 6, 7, 9, 11, 18, 20 , 22 and 24)
Code A: See footnote on pages 312 for CL medium, 316 for PBS, 317 for CAA, 321 for 
NLLF and 326 for CLLF.
Code B: Substrain of B. pertussis 18-323 and culture conditions.
Code number Substrain Culture (d) Subculture (h)
1 A6 2 15
2 A6 2 48
3 EH1 3 0
4 EH1 3 24
5 A6 3 24
6 EH1 4 0
7 EH1 5 0
8 EH1 5 24
9 A6 5 24
10 EH1 5 48
11 EH1 6 0
12 EH1 7 0
Code C: Type of container
1- Thin walled glass bijou
2- Screw cap plastic vials (2 ml volume size)
3- U-shape microtitre plate
4- Glass conical flask (size of 100 ml volume)
Code D: Washing of vessels (both glass and plastic)
1 - Ordinary wash
2- Acid wash for glass bijou and boiling in DW for plastic ware
Code E: Preparation of the bacterial suspension (A540 = 0.45 in diluent)
Code
number
Diluent Washing
yes(Y)/No(N)
Dilution Inoculum
Oil)
Total volume
Oil)
1 PBS N 1 2000 20 500
2 PBS N 1 4000 20 500
3 PBS N 1 6000 20 500
4 CL N 1 6000 20 500
5 PBS N 1 7000 20 500
6 PBS N 1 7000 12 300
7 PBS N 1 8000 20 500
8 PBS N 1 8000 12 300
9 PBS N 1 8000 10 250
10 PBS N 1 9000 12 300
11 PBS N 1 9000 10 250
12 CAA N 1 9000 20 500
13 CAA N 1 9000 12 300
14 CAA N 1 9000 10 250
15 CAA N 1 18000 10 250
16 PBS Y 1 2000 12 300
17 PBS N 1 9000 20 500
18 DW N 1 2000 20 500
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Appendix 5. Survival (colony count) data on B. pertussis strain 18-323 in
CL medium at 37 °C. A and B are duplicates; Expt code is explained in the
Appendix 4 and footnote.
Expt Expt 
ordinal code 
no.
CFU/20|il after exposure at 37 °C for time (min)
0 15 30 60 120 1440 2880
A B A B A B A B A B A B A B
1 A 1B7C 1D 1E 1 49 9 0
2 A 1B7C 1D 1E 1 7 1 1
3 A 1B7C 1D 1E 1 170 105 6 1
4 A2B7C 1D 1E 1 137 120 175 300
5 A2B7C 1D 1E 1 60 53 54 180
6 A2B7C 1D 1E 1 47 26 57 44
7 A2B7C 1D 1E 1 14 13 11 185 228
8 A2B7C 1D 1E 1 24 26 10
9 A2B7C 1D 1E 1 240 190 185 150
10 A2B7C 1D 1E 1 230 240 230 230
11 A2B7C 1D 1E 1 50 34
12 A3B7C1D 1E2 38 41 39 34 39 34 37 27 0 2 0 0
13 A3B7C1D 1E7 16 20 13 15
14 A3B7C 1D 1E7 26 16 17 250
15 A3B 11C 1D 1E2 23 10 7
16 A3B7C 1D 1E 1 45 41
17 A3B 12C 1D 1E 18 22 13 1
18 A3B 12C 1D 1E 18 20 21 22 0
19 A3B 12C 1D 1E 18 15 28 12 0
20 A3B 12C 1D 1E 18 24 7 1 0
21 A3B 12C 1D 1E 18 27 14 110 300
22 A3B 12C 1D 1E 18 30 12 4 0
23 A3B 12C 1D 1E 18 10
24 A3B8C 1D 1E2 160 200 40 34
25 A3B8C 1D 1E2 68 88 62 70 10 11
26 A3B8C 1D 1E2 100 140 86 100 40 36 5 5
27 A3B 10C 1D2E3 52 58 68 64 24 22 5 5 5 4
28 A3B8C 1D2E2 74 80 40 42 20 24 1 3
29 A3B8C 1D2E2 50 60 32 30 22 16 4 0
30 A3B4C 1D2E2 235 245 100 80 14 31
31 A3B8C 1D2E2 200 210 80 70 20 46
32 A3B5C 1D2E2 200 210 120 124 20 26
33 A3B9C 1D2E2 140 120 120 140 22 30
34 A3B4C2D2E3 118 128 110 102 44 58 2 1
35 A3B4C4D2E3 126 112 70 76 50 50 300 300
36 A3B4C2D2E3 80 82 70 72 3 6 0 0
37 A3B4C2D2E4 98 96 96 108 8 4 0 0
38 A3B4C3D2E7 112 108 80 82 26 34 6 5
39 A3B4C2D2E7 24 30 22 30 20 20 10 10 0 0 0 0
40 A4B4C2D2E7 22 28 20 24 34 28 14 10 4 4 0 0
41 A2B4C2D2E7 20 24 18 26 24 26 16 24 8 2 0 0
42 A2B5C2D2E7 70 78 80 74 88 84 86 72 300 300 600 600
43 A2B4C2D2E5 80 70 80 66 66 64 68 58 300 300 300 300
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Expt Expt 
ordinal code 
no.
CFU/20|il after exposure at 37 °C for time (min)
0 15 30 60 120 1440 2880
A B A B A B A B A B A B A B
44 A2B5C2D2E5 70 72 70 68 72 70 62 72 300 300
45 A2B5C2D2E5 82 80 86 80 80 84 74 80 300 300 34 40
46 A2B5C2D2E5 74 84 72 68 70 68 68 70
47 A5B5C2D2E5 120 124 120128 120124 120 114 300 300 600 600
48 A5B5C2D2E5 120 112 114122 110118 100 110 300 300 600 600
49 A5B5C2D2E5 106 110 110100 106104 110 106 300 300 600 600
50 A2B5C2D2E5 90 94 100 94 98 90 102 96 250 280 340 360
51 A2B5C2D2E5 120 116 118112 116116 114 120 260 280
52 A5B5C2D2E5 106 108 110102 108106 102 110 300 300
53 A5B 1C2D2E5 172 174 170178 170174 174 168 300 300
54 A5B2C2D2E5 130 140 130136 132130 140 130 300 300 600 600
55 A5B5C2D2E5 140 130 130136 130130 130 134 300 300 600 600
56 A5B5C2D2E5 80 84 88 82 74 76 80 80 300 300 600 600
57 A5B5C2D2E5 114 116 100110 110110 98 98 300 300 600 600
58 A5B5C2D2E5 116 110 110100 110110 100 110 300 300 600 600
59 A5B5C2D2E5 140 130 141125 140130 130 130 300 300 600 600
60 A5B5C2D2E5 92 80 84 84 80 84 80 70 300 300 600 600
61 A5B5C2D2E7 124 110 300
62 A5B5C2D2E7 108 100 300 600
63 A5B5C2D2E7 116 112 102 90 300 600
64 A5B5C2D2E7 60 61 52 300 600
65 A5B5C2D2E 16 170 170 .164 160 300 600
66 A5B5C2D2E7 146 142 140 130 300 600
67 A5B5C2D2E 16 198 198 190 186 300 600
68 A5B5C2D2E7 136 132 132 130 300 600
69 A5B5C2D2E 16 158 144 142 140 300 600
70 A5B5C2D2E7 110 100 100 90 300 600
71 A5B5C2D2E 17 60 58 60 62 300
72 A5B5C2D2E 17 74 72 72 70
73 A5B5C2D2E 17 22 20 20 19 120 130
74 A5B5C2D2E7 15 14 12 8 6
75 A5B5C2D2E7 68 68 66 66 300
76 A5B5C2D2E7 32 36 34 34 300
77 A5B5C2D2E7 84 88 86 78 300 600
78 A5B5C2D2E7 88 84 82 74 300 600
79 A5B5C2D2E7 40 39 32 32 300 600
80 A5B5C2D2E7 75 66 68
81 A5B5C2D2E7 84 82 81 300
82 A5B5C2D2E7 58 62 56 300
83 A5B5C2D2E7 50 48 44 300
84 A5B5C2D2E7 74 70 60 300
85 A5B5C2D2E7 48 46 42 300
86 A5B5C2D2E7 68 58 64 55 300 600
87 A5B5C2D2E7 74 70 74 84 300 600
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Expt Expt 
ordinal code 
no.
CFU/20pl after exposure at 37 °C for time (min)
0 15 30 60 120 1440 2880
A B A B A B A B A B A B A B
88 A5B5C2D2E7 76 77 77 68 300 600
89 A5B5C2D2E7 64 49 54 60 300 600
90 A5B5C2D2E7 90 108 88 87 300 600
91 A5B5C2D2E7 48 46 56 44 300 600
92 A5B5C2D2E7 66 64 80 72 300 600
93 A5B5C2D2E7 100 108 100 98 300 600
94 A5B5C2D2E7 50 41 52 38 300 600
95 A5B5C2D2E7 95 90 110 114 300 600
96 A5B5C2D2E7 80 88 80 74 300 600
97 A5B5C2D2E7 63 56 58 50 300
98 A5B5C2D2E7 71 58 60 60 300
99 A5B5C2D2E7 78 80 54 58 58 48 48 50 300 300
100 A5B5C2D2E7 74 70 75 73 73 80 74 73 300 300
101 A5B5C2D2E7 76 78 80 84
102 A5B5C2D2E7 60 72 58 40 120
103 A5B5C2D2E7 55 79 64 51 300
104 A5B5C2D2E 11 45 33 33 35 130
105 A5B5C2D2E 11 62 64 51 57 150
106 A5B5C2D2E 14 52 40 43 43 51 300
107 A5B5C2D 1E 14 30 48 48 42 36 300
108 A5B5C2D 1E 13 75 73 60 60 66 58 44 50
109 A5B5C2D 1E 13 76 68 84 94 98 84 82 72 300 300
110 A5B5C2D 1E 13 92 100 86 90 80 86 60 70 300 300
111 A5B5C2D 1E 13 118 102 108112 98 84 98 96
112 A5B5C2D 1E 13 32 42 46 44 43 49 12 20
113 A5B5C2D 1E13 50 52 47 42 43 41 28 27 140 154
114 A5B5C2D 1E 13 32 45 34 42 40 28 47 33 130 134
115 A5B5C2D 1E 13 88 72 72 74 67 80 72 72 300 300
116 A5B5C2D 1E 13 146 136 138128 114122 90 112
117 A5B5C2D 1E 13 170 150 132142 118120 120 120
118 A5B5C2D 1E 13 136 128 110122 106126 100 130
Note: to allow entry of numbers in the data base, confluent growth is tabulated as " 600"; 
semi-confluent as "300"' while counts in the region of 200 are to be understood as only 
approximate.
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Appendix 5. continued
Code A : Variation in formulation of CL medium
Code number Glutamic Acid (a) DMpCD Vitamin supplement
or Na Glutamate (b) ( g / 1) (pi /10 ml)
Source Form
1 (BDH) (b) 0.1 100
2 (Sigma) (a) 1.0 100
3 (BDH) (b) 1.0 100
4 (BDH) (a) 1.0 100
5 (Sigma) (a) 1.0 50
For the explanation of codes B, C, D and E, see Appendix 4.
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Appendix 6. Survival (colony count) data on B. pertussis strain 18-323 in
PBS at 37 °C. A and B are duplicate; Expt code is explained in the
Appendix 4 and footnote.
Expt Expt 
ordinal code 
no.
CFU/20pl after exposure at 37 °C for time (min)
0 15 30 60 120 1440
A B A B A B A B A B A B
1 A 1B7C 1D 1E 1 26 24 0
2 A 1B7C 1D 1E 1 13 10 6 0
3 A 1B7C 1D 1E 1 230 205 180 130
4 A 1B7C 1D 1E 1 220 215 210 220
5 A1B7C 1D 1E2 46 27
6 A 1B7C1D 1E7 15 12 60 14
7 A 1B 11C 1D 1E7 11 10 7 4
8 A 1B7C 1D 1E1 41 27 62
9 A 1B 12C 1D 1E 18 22 2
10 A 1B8C 1D 1E2 68 78 52 54 24 21 2 2
11 A2B 10C 1D2E3 45 43 34 38 8 9 0 0
12 A2B8C 1D2E2 74 62 34 28 12 14 0 0 0 0
13 A2B8C1D2E2 50 48 24 28 12 12 1 0
14 A2B4C2D2E3 92 96 72 76 15 17
15 A2B4C2D2E3 70 74 80 68 8 4
16 A2B4C2D2E4 106 100 102 108 2 0
17 A2B4C3D2E3 88 108 80 84 0 0
18 A2B4C2D2E7 18 22 30 18 18 18 0 0 0 0
19 A2B5C2D2E5 70 64 76 60 70 76 56 52 8 6
20 A2B4C2D2E5 78 92 84 84 66 76 62 66 3 1
21 A2B5C2D2E5 60 64 66 64 50 68 44 48 2 0
22 A2B5C2D2E5 86 78 82 80 70 80 54 52 0 0
23 A2B5C2D2E5 80 78 52 58 60 64 40 34
24 A2B5C2D2E5 126 130 120 124 120 114 100 84 0 0
25 A2B5C2D2E5 118 110 80 74 60 68 60 54 0 0
26 A2B5C2D2E5 110 100 104 100 90 96 58 62 0 0
27 A2B5C2D2E5 84 80 88 90 80 76 68 60 0 0
28 A2B5C2D2E5 100 110 110 118 108 110 90 100 0 0
29 A2B5C2D2E5 100 98 102 98 98 98 100 94 0 0
30 A2B 1C2D2E5 130 140 140 140 130 148 140 136 6 4
31 A2B2C2D2E5 140 148 130 140 130 140 110 90 0 0
32 A2B5C2D2E5 130 136 130 130 120 130 120 130 0 0
33 A2B5C2D2E5 78 72 80 80 66 58 46 26 0 0
34 A2B5C2D2E5 110 100 100 100 98 86 86 60 0 0
35 A2B5C2D2E5 114 110 100 110 70 60 40 34 0 0
36 A2B5C2D2E5 140 136 130 134 94 90 4 4 0 0
37 A2B5C2D2E5 126 124 82 80 76 70 1 3 0 0
38 A2B6C2D2E5 68 78 68 60 62 60 50 56 2 2
39 A2B5C2D2E7 118 90 4
40 A2B5C2D2E7 110 90 3
41 A2B5C2D2E7 113 102 96 92 14
42 A2B5C2D2E7 54 50 30 0
43 A2B5C2D2E 16 160 156 156 140 1
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Appendix 6. continued
Expt Expt CFU/20fil after exposure at 37 °C for time (min)
ordinal code ________________________________________________
no. 0 15 30 60 120 1440
A B A B A B A B A B A B
44 A2B5C2D2E7 138 120 110 100 5
45 A2B5C2D2E16 190 186 184 180 12
46 A2B5C2D2E7 126 124 120 97 4
47 A2B5C2D2E16 140 120 118 110 0
48 A2B5C2D2E7 92 88 80 64 0
49 A2B5C2D2E 17 50 46 50 40 0
50 A2B5C2D2E 17 68 64 64 50
51 A2B5C2D2E 17 20 18 18 18 0
52 A2B5C2D2E7 7 5 1 1
53 A2B5C2D2E7 50 48 46 46 0
54 A2B5C2D2E7 34 30 28 24 0
55 A2B5C2D2E7 76 60 52 32 0
56 A2B5C2D2E7 70 66 52 34 0
57 A2B5C2D2E7 38 37 28 20 0
58 A2B5C2D2E7 73 40 36
59 A2B5C2D2E7 82 70 35 0
60 A2B5C2D2E7 60 44 28 0
61 A2B5C2D2E7 47 37 22 0
62 A2B5C2D2E7 52 42 34 0
63 A2B5C2D2E7 32 24 14 0
64 A2B5C2D2E7 56 54 51 52 1
65 A2B5C2D2E7 60 70 66 38 3
66 A2B5C2D2E7 74 72 70 55 9
67 A2B5C2D2E7 62 39 34 20 2
68 A2B5C2D2E7 78 100 82 61 4
69 A2B5C2D2E7 47 46 34 20 0
70 A2B5C2D2E7 59 69 73 43 2
71 A2B5C2D2E7 98 89 84 62 5
72 A2B5C2D2E7 46 34 44 33 0
73 A2B5C2D2E7 94 72 90 49 3
74 A2B5C2D2E7 97 70 60 36 1
75 A2B5C2D2E7 62 64 64 43 0
76 A2B5C2D2E7 58 42 35 14 0
77 A2B5C2D2E7 60 72 30 34 20 24 4 4 0 0
78 A2B5C2D2E7 72 80 52 52 36 36 16 16 0
79 A2B5C2D2E7 86 68 50 30 0
80 A2B5C2D2E7 65 32 36 13 0
81 A2B5C2D2E7 60 54 33 22 0
82 A2B5C2D2E 11 35 27 12 10 1
83 A2B5C2D2E 11 57 42 32 23
84 A2B5C2D2E 14 40 34 52 50 48 7
85 A2B5C2D 1E 14 42 37 41 26 39 0
86 A2B5C2D 1E 13 66 63 56 46 44 50 34 38
87 A2B5C2D 1E 13 82 84 78 80 82 80 76 78 1 0
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Appendix 6. continued
Expt Expt 
ordinal code 
no.
CFU/20pl after exposure at 37 °C for time (min)
0 15 30 60 120 1440
A B A B A B A B A B A B
88 A2B5C2D 1E 13 84 64 60 72 50 60 48 50 0 0
89 A2B5C2D 1E 13 100 110 96 84 94 87 76 70
90 A4B5C2D 1E 13 40 46 20 32 32 31 0 0
91 A4B5C2D 1E 13 55 61 58 54 38 30 0  0
92 A4B5C2D 1E 12 32 34 28 30 36 42 28 26 3 0
93 A3B5C2D 1E 12 62 70 68 62 62 58 56 76 1 0
94 A3B5C2D 1E 13 120 132 120 140 120 108 94 104
95 A3B5C2D 1E 13 150 160 140 150 130 122 110 120
96 A3B5C2D 1E 13 120 128 106 112 104 110 104 96
97 A3B5C2D 1E 13 120 136 126 132 116 126 96 110
98 A3B5C2D 1E 15 64 72 62 62
99 A3B5C2D 1E 15 58 78 70 84
100 A3B5C2D 1E 15 80 90
101 A3B5C2D 1E 15 90 96 80 82
102 A3B5C2D 1E 15 99 83 78 76 49 51 22 36
103 A3B5C2D 1E 15 76 82 80 66
104 A3B5C2D 1E 15 61 59 50 74
105 A3B5C2D 1E 15 86 76 76 72 86 62 40 52
106 A3B5C2D 1E 15 76 72 60 72
107 A3B5C2D 1E 15 70 56 48 46
108 A3B5C2D 1E 15 70 62 60 62
109 A3B5C2D 1E 15 54 50 44 38
110 A3B5C2D 1E 15 42 52 54 58
111 A3B5C2D 1E 15 34 40 20 30
112 A3B5C2D 1E 15 32 46 36 34
113 A3B5C2D 1E 15 30 24
114 A3B5C2D 1E 15 28 40 26 26
115 A3B5C2D 1E 15 36 40 34 44
116 A3B5C2D 1E 15 28 30 30 38
117 A3B5C2D 1E 15 22 22 22 24
118 A3B5C2D 1E 15 34 38 24 28
119 A3B5C2D 1E 15 11 17 13 11
120 A3B5C2D 1E 14 94 100 82 100
121 A3B5C2D 1E 14 84 90 64 74
122 A3B5C2D 1E 14 80 88 74 78 68 60
123 A3B5C2D 1E 14 70 80 86 78
124 A3B5C2D 1E 14 146 116 96 86
125 A3B5C2D 1E 14 90 90 54 62
126 A3B5C2D 1E 14 70 76 68 60 66 56 52 52
127 A3B5C2D 1E 14 108 102 108 112
128 A3B5C2D 1E 14 84 100 82 90
129 A3B5C2D 1E 14 110 96 74 80
130 A3B5C2D 1E 14 72 82 78 80
131 A3B5C2D 1E 14 86 78 60 70
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Appendix 6. continued
Expt Expt 
ordinal code
CFU/20)il after exposure at 37 °C for time (min)
no. 0 15 30 60 120 1440
A B A B A B A B A B A B
132 A3B5C2D 1E 14
133 A3B5C2D 1E 14
134 A3B5C2D 1E 14
135 A3B5C2D 1E 14
158 152 136 104 
74 68 
82 60 
112 108
105 101 
70 84 
56 72 
98 74
74 66
Note: Counts in the region of 200 are to be understood as only approximate.
Code A : Variation in formulation of PBS
Code number PBS from tablet [BDH] (a) 
or individual chemicals (b)
PH
1 a 7.2
2 b 7.2
3 b 7.3
4 b 7.4
For the explanation of codes B, C, D and E, see Appendix 4.
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Appendix 7. Survival (colony count ) data on B. pertussis strain 18-323 in
1 % (w/v) casamino acids (CAA) at 37 °C. A and B are duplicates; Expt
code is explained in the Appendix 4 and footnote.
Expt Expt CFU/20|il after exposure at 37 °C for time (min)
ordinal code
no. 0 15 30 60 120 1440
A B A B A B A B A B A B
1 AB7C1D 1E 1 17 11 7 0
2 AB7C 1D 1E 1 57 48 26 0
3 AB7C 1D 1E 1 48 33 23 0
4 AB12Q D 1E 18 8
5 AB10C1D2E3 58 72 30 26 7 7 0 0
6 AB5C2D2E 14 40 43 47 42 36
7 AB5C2D 1E 14 30 25 40 37 32 6
8 AB5C2D 1E 15 82 70 70 70
9 AB5C2D 1E 15 110 86 84 82
10 AB5C2D 1E 15 78 98 94 88
11 AB5C2D 1E 15 96 90 85 63
12 AB5C2D 1E 15 14 18
13 AB5C2D 1E 14 74 80 70 62 32 52 46 46
14 AB5C2D 1E 14 94 134 102 94
15 AB5C2D 1E 14 92 94
16 AB5C2D 1E 14 62 58
17 AB5C2D 1E 14 72 78
18 AB5C2D 1E 14 68 74
19 AB5C2D 1E 14 196 176
20 AB5C2D 1E 14 202 188
21 AB5C2D 1E 14 58 54
22 AB5C2D 1E 14 74 76
23 AB5C2D 1E 14 76 64
24 AB5C2D 1E 14 114 128
25 AB5C2D 1E14 138 112
26 AB5C2D 1E 14 100 112
27 AB5C2D 1E 14 168 120
28 AB5C2D 1E14 137 141
29 AB5C2D 1E 14 106 100
30 AB5C2D 1E 14 54 64
31 AB5C2D 1E 14 66 66
Note: Counts in the region of 200 are to be understood as only approximate.
Code A: 1% (w/v) casamino acids was prepared by dissolving lOg Casein Hydrolysate 
(Gibco), O.lg MgCl2 6H2O, 0.016g CaCl2 , and 5g NaCl in 1000 ml distilled water and
the PH of the mixture was adjusted at 7.1 with NaOH, sterilized at 121°C for 15 minutes, 
stored at 4°C ready for use, and discarded after two months if not used.
For the explanation of codes B, C, D and E, see Appendix 4.
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Appendix 8. Percent survival (based on PBS time-zero counts) of B . 
pertussis strain 18-323 in 1 % (w/v) casamino acids (CAA) after exposure 
at 37 °C for various times and in relation to Experiment Ordinal Number.
Expt
ordinal
no.
% Survival after exposure at 37 °C for time (min)
0 15 30 60 120 1440
1 100 65 42 0
2 100 80 46 0
3 98 67 47 0
4 36
5 118 51 13 0
6 77 83 90 81 69
7 100 83 133 123 107 19
8 112 103
9 100 85
10 95 98
11 118 94
12 88
13 105 90 58 63
14 109 93
15 107
16 58
17 97
18 87
19 85
20 92
21 79
22 106
23 403
24 70
25 88
26 96
27 83
28 124
29 84
30 134
31 122
Median 100 83 106 87 47 0
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Appendix 9. Survival (colony count) data on B. pertussis strain 18-323 in
normal rat LLF at 37 °C. A and B are duplicates; Expt code is explained in the
Appendix 4 and footnote.
Expt Expt 
ordinal code 
no.
CFU/20pl after exposure at 37 °C for time (min)
0 15 30 60 120 1440
A B A B A B A B A B A B
1 A 1B7C1D 1E 1 62 0 0 0
2 A 1B7C 1D 1E 1 4 5
3 A 1B7C1D 1E 1 28 0 0
4 A2B7C1D 1E 1 14 1 0
5 A2B7C 1D 1E 1 28 18 18
6 A2B7C1D 1E 1 172 155 44 0
7 A2B7C 1D 1E 1 220 165 120 71
8 A2B7C 1D 1E2 24 0
9 A2B7C 1D 1E8 21 0 0 0
10 A2B 11C 1D 1E2 17 0 0 0
11 A2B7C 1D 1E 1 40 4 0
12 A2B8C 1D 1E2 73 87 74 59 47 60 2 0
13 A2B8C 1D 1E2 110 100 110 96 66 74 0 0
14 A2B8C 1D2E2 94 94 53 65 40 30 0 0
15 A2B8C 1D2E2 44 36 40 24 14 18 0 0
16 A 1B4C2D2E8 22 32 10 14 6 8 0 0 0 0
17 A 1B5C2D2E6 82 64 54 52 62 34 0 0 0 0
18 A 1B4C2D2E6 80 90 64 66 42 42 12 10 0 0
19 A 1B5C2D2E6 80 78 80 70 40 38 18 14 0 0
20 A 1B5C2D2E6 100 80 0 0 0 0 0 0 0 0
21 A 1B5C2D2E6 54 60 0 0 0 0 0 0 0 0
22 A3B5C2D2E6 100 110 30 22 25 17 8 4 0 0
23 A3B5C2D2E6 80 74 20 18 16 16 8 4 0 0
24 A 1B5C2D2E6 100 110 4 4 0 0 0 0 0 0
25 A 1B5C2D2E6 66 70 1 0 0 0 0 0 0 0
26 A6B 1C2D2E5 180 160 170 162 120 110 90 110 2 2
27 A6B2C2D2E5 188 190 110 114 110 110 90 90 1 0
28 A6B5C2D2E6 120 130 100 110 100 90 10 4 0 0
29 A3B5C2D2E6 86 70 12 4 8 8 1 1 0 0
30 A5B5C2D2E6 114 110 32 30 7 5 0 0 0 0
31 A7B5C2D2E6 130 116 118 120 120 120 110 116 0 0
32 A5B5C2D2E6 100 110 0 0 0 0 0 0 0 0
33 A5B6C2D2E6 20 28 0 0 0 0 0 0 0 0
34 A5B5C2D2E8 80 0 0
35 A6B5C2D2E8 110 100 3
36 A5B5C2D2E8 18 0 0
37 A6B5C2D2E8 90 88 2
38 A5B5C2D2E8 56 0 0 0 0
39 A6B5C2D2E8 116 112 106 102
40 A5B5C2D2E8 20 0 0 0 0
41 A6B5C2D2E8 64 62 46 2
42 A5B5C2D2E 16 158 0 0 0 0
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Appendix 9. continued
Expt Expt 
ordinal code 
no.
CFU/20(il after exposure at 37 °C for time (min)
0 15 30 60 120 1440
A B A B A B A B A B A B
43 A5B5C2D2E8 110 0 0 0 0
44 A5B5C2D2E 16 112 0 0 0 0
45 A5B5C2D2E8 120 0 0 0 0
46 A5B5C2D2E 16 60 0 0 0 0
47 A5B5C2D2E8 40 0 0 0 0
48 A6B5C2D2E 17 58 30 10 0 0
49 A6B5C2D2E 17 60 56 34 0
50 A8B5C2D2E 17 65 62 60 26
51 A6B5C2D2E 17 22 21 13 4 0
52 A 10B5C2D2E8 97 3 0 0 0
53 A9B5C2D2E8 96 92 65 24 0
54 A 10B5C2D2E8 74 34 6 2 0
55 A9B5C2D2E8 84 98 70 42 0
56 A 10B5C2D2E8 44 26 10 3 0
57 A9B5C2D2E8 51 52 44 14 0
58 A 10B5C2D2E8 76 50 33
59 A 10B5C2D2E8 98 88 64 0
60 A 10B5C2D2E8 72 43 18 0
61 Al 1B5C2D2E8 73 0 0 0 0
62 A 12B5C2D2E8 60 29 7 1 0
63 A 13B5C2D2E8 58 1 0 0 0
64 Al 1B5C2D2E8 74 1 0 0 0
65 A 12B5C2D2E8 91 48 7 0 0
66 A 13B5C2D2E8 74 3 0 0 0
67 A 11B5C2D2E8 36 0 0 0 0
68 A 12B5C2D2E8 68 2 0 0 0
69 A 13B5C2D2E8 40 0 0 0 0
70 A 14B5C2D2E8 76 11 0 0 0
71 A 15B5C2D2E8 60 0 0 0 0
72 A 14B5C2D2E8 90 14 0 0 0
73 A 15B5C2D2E8 86 0 0 0 0
74 A 14B5C2D2E8 34 0 0 0 0
75 A 15B5C2D2E8 42 0 0 0 0
76 A I6B5C2D2E8 88 4 0 0 0
77 A I6B5C2D2E8 92 40 12 0 0
78 A 14B5C2D2E8 32 0 0 0
79 A 14B5C2D2E8 58 0 0 0
80 A 14B5C2D2E8 68 72 4 5 3 0 0 0 0 0
81 A 18B5C2D2E8 50 40 0 0 0 0 0 0 0 0
82 A I8B5C2D2E8 92 0 0 0 0
83 A 17B5C2D2E9 80 33 14 14 0
84 A 17B5C2D2E9 68 38 23 5 0
85 A20B5C2D2E 11 15 0 0 0 0
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Appendix 9. continued
Expt Expt 
ordinal code 
no.
CFU/20pl after exposure at 37 °C for time (min)
0 15 30 60 120 1440
A B A B A B A B A B A B
86 A20B5C2D2E 11 40 0 0 0 0
87 A4B5C2D2E 14 56 22 14 2 4
88 A4B5C2D 1E 14 38 22 15 6 1
89 A4B5C2D 1E 13 66 46 1 1 0 0 0
90 A4B5C2D 1E 13 90 88 42 52 32 38 24 30 0 0
91 A4B5C2D 1E 13 74 80 58 52 38 48 46 32 0 0
92 A 13B5C2D 1E 13 38 22 0 0 0 0 0 0 0 0
Note: Counts in the region of 200 are to be understood as only approximate.
*A11 normal Sprague Dawley (SD) rat lungs were washed with 5ml (except rat batch no. 37 
and 38 respectively their lungs were washed with 15 and 10 ml sterile PBS) sterile PBS 
(pH7.2 - 7.4), pooled rat LLF fluids kept in ice then centrifuged at 2000 rpm for 15 
minutes, afterwhich the pellet 1 (mainly macrophages and monocytes) was discarded, and 
the supernatant was membrane filtered (this step is stopped from batch no. 42), distributed 
in a washed sterile 2-ml volume plastic vials as about a 1ml portions, stored in -20°C for 24 
h, then transferred into -70°C for long term storage ready for use when its needed, that was 
the standard procedure for obtaining LLF, except were stated.
Code A: Different batches of normal rats from which LLF was collected
Code
number
Rat Batch* 
no.
Sex Weight (SEM) Method of ** 
euthanasia
1 15 F 230 ± 4 A
2 16 M 374 ± 6 A
3 17 M 286 A
4 21 M 190 A
5 33 M - A
6 34 M 296 ± 0 B
7 35 F - B
8 37 - 350 B
9 38.1 M 175 ± 4 B
10 38.2 M 175 ± 4 C
11 39S F 126 ± 4 D
12 39M M 253 ± 2 D
13 39L M 350 ± 6 D
14 40L M 355 ± 4 D
15 40XL M 456 ±31 D
16 41 F 170 ± 3 D
17 42 - - D
18 43 F 220 ± 3 D
19 44 - 182±9 D
20 45 F 270 ± 12 D
21 50 M 313±3 D
22 55 F 171± 3 D
23 58 F 182± 4 D
For the explanation of codes B,C,D and E see Appendix 4.
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Appendix 9. continued
* All batches of rats were normal (untreated) except rat batch no. 16, which was sham- 
operated (LGT agarose beads + carrageenan given intratracheally then rats exposed to ether. 
S= small; M = medium; L = large; XL = extra large.
**Summary of four different euthanasia methods immediately prior to collection of rat LLF
Method Procedure prior to collection of LLF
Halothane/ C02 Bleeding out Cervical Bleeding out
oxygen by heart dislocation by heart
under alone puncture before puncture after 
deathanaesthesia death
A + + +
B + +
C + +
D + + +
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Appendix 10. Batch to batch variation in bactericidal activity of normal rat
LLF towards B. pertussis 18-323.
Batch*
code
No.
of
experiments
Median % survival [Range](No. of observations) 
at incubation time (min)
0 15 30 60 120 1440
Al 11 100 23.5 26 0 0 0
[57-100] [0-95] [0-71] [0] [0-20] [0 -0]
(11) (8) (9) (1) (10) (10)
A2 12 92.5 64 37.5 0 0 0
[28-100] [0-98] [0-84] [0-62] [0-64] [0]
(12) (6) (10) (6) (9) (1)
A3 3 86 16 14 nt 5 0
[66-95] [10-21] [10-17] - [1-5] [0-0]
(3) (3) (3) - (3) (3)
A4 5 108 57.5 50 20 8 0
[76-127] [42-73] [1-65] [0-49] [0-41] [0-0]
(5) (2) (5) (5) (5) (2)
A5 13 57 0 0 nt 0 0
[17-97] [0-27] [0-5] - [0-0 ] [0-0]
(13) (11) (11) - (13) (13)
A6 10 97 87 58 nt 53 1
[81-107] [50-103] [17-70] - [0-91] [0-3]
(10) (8) (6) - (10) (9)
A l 2 109 105 106 - 100 0
[103-115][104-106] [106-106] - [97-103] [0 -0]
(2) (2) (2) - (2) (2)
A8 1 88 84 81 nt 35 nt
[88 - 88] [84 - 84] [81-81] - [35 - 35] -
(1) (1) (1) - (1) -
A9 3 109 111 80 nt 35 0
[95-128] [ 105-130] [74-110] - [27-48] [0-0 ]
(3) (3) (3) - (3) (3)
A10 3 110 39 7 nt 2 5
[84-115] [4-65] [0-25] - [0-8] [0-0]
(3) (3) (3) - (3) (3)
All-13 9 91 0 0 nt 0 0
[75-100] [0-53] [0-11] - [0-2] [0 -0]
(9) (9) (9) - (9) (9)
A14.15 10 85 0 0 0 0 0
[51-100] [0-15] [0-6] [0-0] [0-0] [0-0]
(10) (6) (10) (2) (10) (10)
A16 2 104 27 7.5 nt 0 0
[93-115] [4-50] [0-15] - [0-0 ] [0 -0]
(2) (2) (2) - (2) (2)
A17 2 129 nt 62 32.5 16 0
[124-133] - [55-69] [23-42] [9-23] [0 -0]
(2) - (2) (2) (2) (2)
A18 2 92 0 0 0 0 0
[63-121] [0-0] [0-0] [0-0] [0-0 ] [0 -0]
(2) (2) (2) (2) (2) (2)
A20 2 49 0 0 0 0 0
[33-121] [0-0] [0-0] [0-0] [0-0] [0 -0]
(2) (2) (2) (2) (2) (2)
* see Appendix 9 footnote for explanation of batch code.
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Appendix 11. Survival (colony count) data on B. pertussis strain 18-323 in
convalescent rat LLF at 37 °C. A and B are duplicates; Expt code is
explained in the Appendix 4 and footnote.
Expt Expt 
ordinal code 
no.
CFU/20jil after exposure at 37 °C for time (min)
0 15 30 60 120 1440
A B A B A B A B A B A B
1 A2B7C 1D 1E 1 4 7
2 A2B7C1D 1E 1 18 0 0
3 A5B7C 1D 1E 1 7 0 0 0
4 A5B7C 1D 1E 1 38 22 14
5 A5B7C 1D 1E 1 225 1 0 0
6 A5B7C 1D 1E 1 190 0 0 0
7 A5B7C 1D 1E2 30 0
8 A5B7C1D 1E8 24 0 0 0
9 A5B 11C 1D 1E2 21 0 0 0
10 A5B7C 1D 1E 1 44 0 0
11 A5B8C 1D 1E2 180 200 0 0
12 A5B8C 1D 1E2 110 130 44 38 0 0 0 0
13 A5B8C1D2E2 100 98 52 56 38 34 4 6
14 A 1B4C2D2E8 32 22 2 0 1 0 0 0 0 0
15 A 1B5C2D2E6 78 66 4 2 1 0 0 0 0 0
16 A 1B4C2D2E6 78 74 22 28 10 16 0 0 0 0
17 A 1B5C2D2E6 68 70 4 6 0 0 0 0 0 0
18 A 1B5C2D2E6 80 84 26 32 26 32 8 12 0 0
19 A2B5C2D2E6 82 86 80 80 70 80 48 50 1 0
20 A3B5C2D2E6 82 88 80 78 70 74 66 62 4 2
21 A4B5C2D2E6 80 86 80 78 70 78 62 50 0 0
22 A 1B5C2D2E6 80 74 36 26 38 26 7 3
23 A2B5C2D2E6 72 76 78 74 70 72 48 52
24 A3B5C2D2E6 64 60 76 70 60 70 42 48
25 A4B5C2D2E6 66 62 68 64 74 70 62 58
26 A9B5C2D2E6 100 110 10 8 0 0 0 0 0 0
27 A 10B5C2D2E6 104 108 100 98 90 98 38 38 0 0
28 A] 1B5C2D2E6 110 114 36 38 15 11 0 0 0 0
29 A 12B5C2D2E6 94 100 10 14 6 2 0 0 0 0
30 A9B5C2D2E6 98 104 24 14 4 0 0 0 0 0
31 A 10B5C2D2E6 102 96 92 90 92 94 82 84 0 0
32 Al 1B5C2D2E6 100 92 36 42 12 12 2 0 0 0
33 A 12B5C2D2E6 90 84 21 13 8 4 0 0 0 0
34 A5B5C2D2E6 94 90 88 84 60 62 20 28 0 0
35 A6B5C2D2E6 92 88 78 70 54 50 4 4 0 0
36 A7B5C2D2E6 104 92 100 98 80 87 10 8 0 0
37 A7B5C2D2E6 100 94 96 90 54 48 2 2 0 0
38 A5B5C2D2E6 92 98 70 78 80 76 20 34 0 0
39 A6B5C2D2E6 94 96 90 82 60 66 6 2 0 0
40 A7B5C2D2E6 96 90 80 76 82 78 46 52 1 1
41 A8B5C2D2E6 88 92 90 86 78 72 18 20 0 0
42 A 1B5C2D2E6 110 118 100 108 70 80 16 14 0 0
43 A2B5C2D2E6 120 112 110 112 100 118 90 180 0 0
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Expt Expt 
ordinal code 
no.
CFU/20fil after exposure at 37 °C for time (min)
0 15 30 60 120 1440
A B A B A B A B A B A B
44 A3B5C2D2E6 106 112 100 108 106 100 80 74 8 4
45 A4B5C2D2E6 114 100 110 100 100 98 98 92 2 1
46 A 1B5C2D2E6 68 74 42 40 38 36 6 6 0 0
47 A2B5C2D2E6 72 76 74 74 72 74 70 72 1 1
48 A3B5C2D2E6 74 78 70 70 70 70 70 72 6 4
49 A4B5C2D2E6 70 72 70 74 70 70 66 70 0 0
50 A 18B 1C2D2E5 170 168 70 60 70 60 3 5 0 0
51 A I8B2C2D2E5 182 170 56 40 16 14 2 2 0 0
52 A I8B5C2D2E6 124 130 50 40 34 40 6 6 0 0
53 A 18B5C2D2E8 68 2 0
54 A I8B5C2D2E8 60 0 0
55 A I8B5C2D2E8 110 32 6 0 0
56 A I8B5C2D2E8 42 31 0 0
57 A I8B5C2D2E 17 60 36 20 0
58 A I8B5C2D2E 17 62 58 28 0
59 A I8B5C2D2E 17 22 4 2 0
60 A I8B5C2D2E8 68 22 0
61 A I8B5C2D2E8 88 13 0 0
62 A 18B5C2D2E8 64 0 0 0
63 A 19B5C2D2E8 54 6 0 0 0
64 A20B5C2D2E8 89 0 0 0 0
65 A21B5C2D2E8 111 94 83 30 0
66 A22B5C2D2E8 111 112 94 58 0
67 A 19B5C2D2E8 96 0 0 0 0
68 A20B5C2D2E8 82 9 3 0 0
69 A21B5C2D2E8 100 72 56 36 0
70 A22B5C2D2E8 88 65 76 50 0
71 A23B5C2D2E8 75 54 16 0 0
72 A24B5C2D2E9 62 66 57 42 0
73 A25B5C2D2E9 66 6 0 0 0
74 A26B5C2D2E9 82 62 40 22 0
75 A23B5C2D2E9 74 55 15 0 0
76 A24B5C2D2E9 88 89 57 43 0
77 A25B5C2D2E9 90 6 0 0 0
78 A26B5C2D2E9 65 59 35 23 0
79 A 13B5C2D2E 14 47 27 32 30 27
80 A 14B5C2D2E 14 49 7 0 0 0
81 A 15B5C2D2E 14 54 22 4 0 0
82 A I6B5C2D2E 14 46 0 0 0 0
83 A 17B5C2D2E 14 58 0 0 0 0
84 A 13B5C2D 1E14 37 37 42 29 24
85 A 14B5C2D 1E 14 36 0 0 0 0
86 A 15B5C2D 1E 14 30 5 0 0 0
87 A I6B5C2D 1E 14 23 2 0 0 0
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Expt Expt 
ordinal code
no.
CFU/20pl after exposure at 37 °C for time (min)
0 15
A B A B
30 60 120
A B A B A B
1440
A B
88 A 17B5C2D 1E 14 28
89 A 15B5C2D 1E 13 62 56
90 A 15B5C2D 1E 13 79 94
91 A 15B5C2D 1E 13 94 102
0 0
1 0 
60 52 
62 56
0
0 0 
34 28 
56 48
0
0 0 
10 12 
26 30
Note: Counts in the region of 200 are to be understood as only approximate.
*A11 treated Sprague Dawley (SD) rats (exposed to the same methode of euthanasia as with 
untreated rats, see Appendix 6) lungs were washed with 5 ml sterile PBS (pH7.2-7.4), 
pooled rat LLF fluids kept in ice then centrifuged at 2000 rpm for 15 minutes, after which 
the pellet 1 (mainly macrophages and monocytes) was discarded, and the supernatant was 
membrane filtered (this step is stopped from batch no 42) distributed in a washed sterile 2- 
ml volume plastic vials as about a 1ml portions, stored in -20°C for 24 h, then transferred 
into -70°C for long term storage ready for use when its needed, that was the standard 
procedure for obtaining LLF, except were stated.
Code A: Different batches of normal rats* from which LLF was collected
Code Rat Batch/ 
no. group no.
Sex /(Weight) 
(M/F)/(SEM)
Treatment
Sham Operated Vaccination Challenge Ether
1 15/1 F/220± 4 (a) - {[a], (28)} +
2 15/2 F/227± 3 (a) - {[b], (28)} +
3 15/3 M l325±7 (a) - {[b], (28)} +
4 15/4 F/ 227± 5 (a) - {[b], (28)} -
5 16/1 M l377±6 (a) + {[b], (42)} +
6 16/2 Ml 347 ±10 (alb) + {[b], (42)} +
7 16/3 M/371±4 (a) - {[b], (42)} +
8 16/4 Ml 363±7 (a/b) - {[b], (42)} +
9 17/1 M/275 (a) + {[c], (23)} +
10 17/2 M/390 (a) - {[c], (23)} +
11 17/3 M/275 (a) + {[b], (23)} +
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Code
no.
Rat Batch/ 
group no.
Sex /(Weight) 
(M/F)/(SEM)
Treatment
Sham Operated Vaccination Challenge Ether
12 17/4 M/280 (a) - {[b], (23)} +
13 21/1 M/184 (a/c) - {[d], (28)} +
14 21/2 MI 186 (a/c) - {[e], (28)} +
15 21/3 WU 186 (a/c) - {[c], (28)} +
16 21/4 M /186 (a/c) - {[f], (28)} +
17 21/5 M/ 184 (a/c) - {[g], (28)} +
18 34/1 M/ 268±6 (a) - {[b], (28)} +
19 41/1 F / 171±3 (a) - {[nil], (23)} +
20 41/2 F / 171 ±3 (b) - {[nil], (23)} +
21 41/3 F/177±2 (a) - {[h], (23)} +
22 41/4 F/176±2 (b) - {[h], (23)} +
23 43/1 F/ 227±2 (b) - {[h], (21)} -
24 43/2 F/ 225±5 (b) - {[h], (21)} +
25 43/3 F/217±3 (a) - {[h], (21)} -
26 43/4 F/219±3 (a) - {[h], (21)} +
*Treatment:l) Sham Operated (SO) of rats consisting of: LGT-agarose (a), Alginate (b) 
and Carrageenan (c).
Appendix 8 . continued.
2) Vaccination: 0.5 ml of DPT per rat was given intraperitoneally 21 days before challenge 
(infection), + = vaccinated, - = not vaccinated.
3) Challenge: {0.1 ml of 10& cfu/ rat of B. pertussis L84 IV [a], (day of obtaining serum 
and LLF after treatment)} 18-323 EHl[b], 18-323 A6 [c], Tohama [d], BPM 1809 HLT - 
[e], B. parapertussis 10520 [f], B.pertussis BP 357 PT " [g] and 1.3 x 10^ cfu/ rati 8-323 
EH2[h]
4) Ether : Some rats exposed to ether inhalation (cotton wool saturated with ether in a small 
glass beaker which placed close to the rats nose) for 2 min after treatment operation. + = 
rats exposed to ether, - = rats not exposed to ether.
For the explanation of codes B, C, D and E, see Appendix 4.
323
Appendix 12. Comparison of batch to batch variation in bactericidal activity 
of LLF from normal (N), sham-operated (SO), vaccinated (V), and 
variously challenged (C) rats (treated with different euthanasia method) 
towards B. pertussis 18-323.
Batch*
code
Treatment 
of 
rat
No.
of
Median % Survival [range] (No. of observation) 
at incubation time (min)
0 15 30 60 120 1440
Al N 11 100 23.5 26 0 0 0
[57-100] [0-95] [0-71] [0] [0-20] [0 -0]
(11) (8) (9) (1) (10) (10)
Al C 8 97 34 26 nt 3 0
[66-100] [4-88] [0-63] - [0-13] [0 -0]
(8) (8) (8) - (8) (7)
A2 C 6 81.5 95 92 nt 63 0.5
[38-101] [69-99] [68-100] - [0-73] [0 -1]
(6) (4) (5) - (5) (4)
A3 c 4 85 90 84 nt 65.5 5
[71-105] [65-98] [65-89] - [57-79] [4-5]
(4) (4) (4) - (4) (3)
A4 c 4 86 86.5 87.5 nt 72.5 0
[66- 102] [67-98] [65-91] - [64-81] [0 - 1]
(4) (4) (4) - (4) (3)
A2** so 12 92.5 64 37.5 0 0 0
[28-100] [0-98] [0-84] [0-62] [0-64] [0]
( 12) (6) (10) (6) (9) (1)
A5 VC 17 98 34 0 0 3 0
[45-100] [0-78] [0-82] [0-0 ] [0- 100] [0 -0]
(17) (7) (10) (5) (14) (2)
A6 VC 3 83 69 48 nt 4 0
[83-103] [69-93] [48-70] - [4-4] [0 -0]
(3) (3) (3) - (3) (3)
A l c 2 96 88 80 nt 30.5 0.5
[91-101] [85-92] [73-87] - [8-53] [0 - 1]
(2) (2) (2) - (2) (2)
A8 c 2 94 91 64.5 nt 11.5 0
[90-98] [86-96] [47-82] - [2-21] [0 -0]
(2) (2) (2) - (2) (2)
A3 N 3 86 16 14 nt 5 0
[66-95] [10-21] [10-17] - [1-5] [0 -0]
(3) (3) (3) - (3) (3)
A9 VC 2 86.5 11.5 1 nt 0 0
[86-87] [7-16] [0-2] - [0-0] [0 -0]
(2) (2) (2) - (2) (2)
A10 c 2 86 79.5 78.5 nt 51.5 0
[85-87] [78-81] [77-80] - [31-72] [0 -0]
(2) (2) (2) - (2) (2)
A ll VC 2 87.5 32 10.5 nt 0.5 0
[83-92] [30-34] [10-11] - [0-1] [0 -0]
(2) (2) (2) - (2) (2)
A12 c 2 77.5 12.5 4 nt 0 0
[75-80] [10-15] [3-5] - [0-0] [0 -0]
(2) (2) (2) - (2) (2)
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Batch* Treatment No. Median % Survival [range] (No. of observation)
code of of at incubation time (min)
rat experiment
0 15 30 60 120 1440
A4 N 5 108 57.5 50 20 8 0
[76-127] [42-73] [1-65] [0-49] [0-41] [0 -0 ]
(5) (2) (5) (5) (5) (5)
A13 C 2 106.5 87.5 101 77 66 nt
[90-123] [52-123] [62-140] [58-97] [52-80] -
(2) (2) (2) (2) (2) -
A14 C 2 107 6.5 0 0 0 nt
[94-120] [0-13] [0-0] [0-0] [0-0] -
(2) (2) (2) (2) (2) -
A15 c 5 102 29.5 8 0 0 0
[80-119] [17-42] [0-78] [0-54] [0-29] [0 -0]
(5) (2) (5) (5) (5) (2)
A16 c 2 82.5 3.5 0 0 0 nt
[77-88] [0-7] [0 -0] [0-0] [0-0] -
(2) (2) (2) (2) (2) -
A17 c 2 102.5 0 0 0 0 nt
[93-112] [0-0 ] [0-0 ] [0-0] [0-0] -
(2) (2) (2) (2) (2) -
A6 N 10 97 87 58 nt 53 1
[81-107] [50-103] [17-70] - [0-91] [0-3]
(10) (8) (6) - (10) (9)
A18 c 13 94 35.5 21 nt 0 0
[55-100] [18-78] [0-38] - [0-4] [0 -0]
(13) (8) (10) - (13) (11)
A16 N 2 104 27 7.5 nt 0 0
[93-115] [4-50] [0-15] - [0-0] [0 -0]
(2) (2) (2) - (2) (2)
A19 SO 2 88.5 3 0 nt 0 0
[57-120] [0-6] [0-0] - [0-0] [0 -0]
(2) (2) (2) - (2) (2)
A20 s o 2 98.5 5.5 2 nt 0 0
[94-103] [0-11] [0-4] - [0-0] [0-0]
(2) (2) (2) - (2) (2)
A21 c 2 121 94.5 78.5 nt 38.5 0
[117-125] [90-99] [70-87] - [32-45] [0 -0]
(2) (2) (2) - (2) (2)
A22 c 2 113.5 99.5 97 nt 62 0
[110-117] [81-118] [95-99] - [61-63] [0 -0]
(2) (2) (2) - (2) (2)
A18 N 2 92 0 0 0 0 0
[63-121] [0-0 ] [0-0] [0-0] [0-0] [0 -0 ]
(2) (2) (2) (2) (2) (2)
A23 c 2 130 95 27 nt 0 0
[125-135] [90-100] [27-27] - [0-0] [0 -0]
(2) (2) (2) - (2) (2)
A24 c 2 131.5 136 99.5 nt 74 0
[103-160] [110-160] [95-104] - [70-78] [0 -0]
(2) (2) (2) - (2) (2)
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Batch* Treatment No. Median % Survival [range] (No. of observation)
code of of at incubation time (min)
rat experiment _________________________________________
0 15 30 60 120 1440
A25 C 2 137 10.5 0 nt 0 0
[110-164] [10- 11] [0-0] - [0-0] [0 -0 ]
(2) (2) (2) - (2) (2)
A26 C 2 127 105 65 nt 39 0
[118-137] [103-107] [64-67] - [37-42] [0-0]
(2) (2) (2) “ (2) (2)
* For batch code, see Appendix 9 footnote for normal rats and Appendix 11 footnote for 
treated animals.
A2** For this sham-operated rats see Appendix 9 footnote.
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Appendix 13. Influence of experimental treatment, and batch to batch 
variation, of rats on bactericidal activity of LLF obtained about 3-6 weeks 
later.
Rat batch 
No./ [Sex] 
(N or C)
B.pertussis 
(Bp)
B.parapertussis 
(B-PP)
V BM E C ME % survival* after time (min) 
incubation
30 120
15 [F](N) - - - - 0 A 26 0
15 [F] (C) L84IV - - + 0.1 A 26 0
15[M](C) 18-323 EH1 - - + 7.1 A 92 62
15[F](C) 18-323 EH1 - - + 3.7 A 84 66
15[F](C) 18-323 EH1 - - - 0.5 A 88 73
16[M](SO) - - ag+c + 0 A 38 0
16[M](C) 18-323 EH1 + ag + 0.1 A 0 3
16[M](C) 18-323 EH1 + ag+c + 0 A 48 4
16[M](C) 18-323 EH1 - ag + 2.1 A 80 31
16[M](C) 18-323 EH1 - ag+c + 1.0 A 65 12
17[M](N) - - - - 0 A 14 5
17[M](C) 18-323 A6 + ag + 0 A 1 0
17[M](C) 18-323 A6 - ag + 1.7 A 79 52
17[M](C) 18-323 EH1 + ag + 0.1 A 11 1
17[M](C) 18-323 EH1 - ag + 0.5 A 4 0
21[M](N) - - - - 0 A 50 8
21[M](C) Tohama - ag+c + 1.3 A 101 66
21[M](C) 375 H LT' - ag+c + 0.5 A 0 0
21[M](C) 18-323 A6 - ag+c + 1.0 A 8 0
21[M](C) B.pp (10520) - ag+c + 0.3 A 0 0
21[M](C) 375 P T " - ag+c + 0 A 0 0
34[M](N) - - - - ** B 58 53
34[M](C) 18-323 EH1 - ag + 0 B 21 0
41[F](N) - - - - 0 D 8 0
41[F](SO) - - ag + 0 D 0 0
41[F](SO) - - al + 0 D 2 0
41[F](C) 18-323 EH2 - ag + 2.8 D 79 39
41[F](C) 18-323 EH2 - al + 11.4 D 97 62
43[F](N) - - - - 0 D 0 0
43[F](C) 18-323 EH2 - al - 0.9 D 27 0
43[F](C) 18-323 EH2 - al + 0.4 D 100 74
43[F](C) 18-323 EH2 - ag - 3.4 D 0 0
43[F](C) 18-323 EH2 - ag + 3.9 D 65 39
Col 1: M=male; F = female; N = normal; C = challenged; SO = sham-operated 
Col 2: Substrain and transposon of B. pertussis and B. parapertussis (Bpp).
Col 3: Vaccination status (V); Column 4: Bead material (BM), ag=agarose,al=alginate, 
ag+c= agarose+carrageenan; Column 5: Ether (E); Column 6 : Coughing (C)/ per rat after 7- 
14 days after infection; Column 7: Method of euthanasia (ME).*% survival calculations 
were based on PBS time-zero count; **There was a number of coughing on day 8 and 11 
post-infection, but not counted.
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Appendix 14. Seven different dilution schemes of 10 % (v/v) decanal 
in dimethyl sulphoxide (DMSO).
Decanal in DMSO 
10 % (v/v)
1 :20
in
PBS
0.5 % 
decanal 
4.5 % 
DMSO
1 :30 
in
PBS
0.33 % 
decanal 
3 % 
DMSO
1 : 100 
in
DW
0.1 %
decanal 
0.9 % 
DMSO
1:120  
in
DW
0.08 % 
decanal 
0.75 % 
DMSO
1 : 140 
in
DW
0.07 % 
decanal 
0.64 % 
DMSO
1:180  
in
DW
0.06 % 
decanal 
0.5 % 
DMSO
1 :220 
in
DW
0.05 % 
decanal 
.41 % 
DMSO
2000 nl 2000 nl 2000 nl 2000 nl 2000 nl 2000 nl 2000 nl
100 nl 
decanal 
900 nl 
DMSO
66 nl 
decanal 
600 nl 
DMSO
20 nl 
decanal 
180 nl 
DMSO
16 nl 
decanal 
150 nl 
DMSO
14 nl 
decanal 
128 nl 
DMSO
12 nl 
decanal 
100 nl 
DMSO
10 nl 
decanal 
82 nl 
DMSO
B D E G
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Appendix 15. Three different dilution schemes of 20 % (v/v) decanal 
in dimethyl sulphoxide (DMSO).
Decanal in DMSO 
20 % (v/v)
1:140  
in
DW
1:180  
in
DW
1:220
in
DW
0.14 % 
decanal 
0.57 % 
DMSO
0.11 % 
decanal 
0.44 % 
DMSO
0.09 % 
decanal 
0.36 % 
DMSO
2000 nl 2000 nl 2000 nl
28 nl 
decanal 
114 nl 
DMSO
22 nl 
decanal 
88 nl 
DMSO
18 nl 
decanal 
72 nl 
DMSO
H I
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Appendix 16. Effect of frequent addition of decanal (at different volumes) 
on the luminescence of B. pertussis lux after incubation in PBS, CL 
medium and CAA at 37°C for various times.
Test fluid Final volume in Mean (± SEM) luminescence in mv (No. of observations)
& test mixture (nl) of B.pertussis lux after exposure at 37°C for (min)
Method* Decanal
DMSO 0 15 30 45 60
PBS 100 190±0.0 nt 100±11.5 19.3±0.7 9.3±0.67
A 900 (3) - (3) (3) (3)
CL 100 240±35.1 nt 453.3±21.9 476.7±14.5 486.3±33.7
A 900 (3) - (3) (3) (3)
PBS 6 6 206±4.0 nt 126.7±3.3 73.3±6.7 30±5.8
B 600 (3) - (3) (3) (3)
CL 6 6 230±20 nt 465±55 500±20 535±5
B 600 (2) - (2) (2) (2)
PBS 20 520±10 490±50 430±50 400±0.0 nt
C 180 (2) (2) (2) (2) -
CL 20 245±5.0 340±10 425±5.0 430+10 nt
C 180 (2) (2) (2) (2) -
CAA 20 275 210 150 150 140
C 180 (1) (1) (1) (1) (1)
PBS 17 420 340 260 240 260
D 150 (1) (1) (1) (1) (1)
CL 17 80 120 90 120 120
D 150 (1) (1) (1) (1) (1)
CAA 17 200 200 150 150 140
D 150 (1) (1) (1) (1) (1)
PBS 14 370 460 360 420 410
E 128 (1) (1) (1) (1) (1)
CL 14 80 125 120 160 165
E 128 (1) (1) (1) (1) (1)
CAA 14 210 230 165 165 150
E 128 (1) (1) (1) (1) (1)
PBS 11 164 178 140 132 110
F 100 (1) (1) (1) (1) (1)
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Test fluid Final volume in Mean (± SEM) luminescence in mv (No. of observations)
& test mixture (nl) of B.pertussis lux after exposure at 37 °C for (min)
Method* Decanal ______________________________________________
DMSO 0 15 30 45 60
CL 11 38 54 64 75 82
F 100 (1) (1) (1) 0 ) (1)
CAA 11 112 104 70 78 110
F 100 (1) (1) 0 ) (1) (1)
PBS 9 200 190 180 200 200
G 82 (1) (1) (1) (1) (1)
CL 9 45±5.0 67.5±2.5 82±4.0 87.5±2.5 99±11
G 82 (2) (2) (2) (2) (2)
CAA 9 130 140 118 110 110
G 82 (1) (1) (1) (1) (1)
PBS 29 175 170 150 130 170
H 114 (1) (1) (1) (1) (1)
CL 29 51.5±3.5 69.5±5.5 84±6.0 91±7.0 96±4.0
H 114 (2) (2) (2) (2) (2)
CAA 29 135 98 78 60 65
H 114 (1) (1) (1) ( 1) (1)
PBS 22 178 120 165 145 145
I 88 (1) (1) (1) (1) (1)
CL 22 45±5.0 47.5±0.5 58±2.0 68±0.0 79±5.0
I 88 (2) (2) (2) (2) (2)
CAA 22 120 78 76 75 70
I 88 ( 1) (1) (1) (1) (1)
PBS 18 370 420 350 360 360
J 72 (1) (1) (1) (1) (1)
CL 18 80±0.0 140±0.0 175±25 205+15 245±15
J 72 (2) (2) (2) (2) (2)
CAA 18 200 170 155 140 130
J 72 (1) • (1) (1) (1) (1)
* methods of decanal preparation A, B, C, D, E, F, and G presented in Appendix 14, and 
for methods of decanal preparation H, I and J see Appendix 15.
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Appendix 17. Comparison of batch to batch variation of LLF from normal 
(N) and convalescent (C) rats (treated with different euthanasia methods) in 
their effect on luminescence of B. pertussis lux.
Experim
particula
ent Mean % Luminescence [range] (No. of observations) 
rs after lh incubation time at different dilution / pi
Inactivation 
end point 
90 %
50%
Hi
1/1
400
1/2
200
1/4
100
1/8 
50 '
1/16
25
1/64
12.5
15 N 5 nt 9.5 nt 46 104 1 0 0
A (2) [3 -7 ] - [8 - 11] - [35 - 37] [104] 25
(2) - (2) - (2) (1)
17 N 5 nt 33 nt 49 nt 295
A (1) [5] - [33] - [49] - 30
(1) - (1) - (1) -
33 N 5 nt 10 nt 44 133 1 0 0
A (2) [3 -7 ] - [6-15] - [27-61] [133] 25
(2) - (2) - (2) (1)
34 N 108 nt 94.5 nt 129 nt > 400
B (2) [30- 186] - [54- 135] - [119-139] - >400
(2) - (2) - (2) -
35 N 169.5 nt 173 nt 158 nt > 400
B (2) [117-222] - [113 -233] - [100-217] - >400
(2) - (2) - (2) -
37 N 108 nt 106 nt 110 nt > 400
B (1) [108] - [106] - [110] - >400
(1) - (1) - (1) -
38.1 N 108.5 nt 150 nt 141 nt > 400
B (2) [56- 161] - [108 - 193] - [90- 193] - >400
(2) - (2) - (2) -
38.2 N 9.5 nt 37 nt 95 150 385
C (2) [8 - 11] - [30 - 44] - [81 - 109] [150] 75
(2) - (2) - (2) (1)
39 N 5 nt 7.5 nt 25 69 80
D (2) [5 -5 ] - [7 -8 ] - [17-33] [69] 10
(2) - (2) - (2) (1)
40 N 5 nt 11 nt 35 26 1 2 0
D(2) [5 -5 ] - [7-15] - [21-49] [26] 20
(2) - (2) - (2) (1)
41 N 23 nt 45 nt 129 105 > 400
D (2) [12-34] - [24 - 66] - [92 - 167] [105] 90
(2) - (2) - (2) (1)
42 N 159 nt 112.5 nt 110.5 nt > 400
D (2) [157-161] - [8 8 - 137] - [71 - 150] - >400
(1) - (1) - (1) -
43 N 5 nt 7 nt 33 80 80
D (2) [5 -5 ] - [5 - 10] - [17-49] [80] 20
(2) - (2) - (2) (1)
43/3 C 40 nt 84.5 nt 98 113 > 400
D(2) [26 - 54] - [67 - 102] - [81 - 115] [113] 320
(2) - (2) - (2) (1)
43/4 C 157 nt 144 nt 125 nt > 400
D(2) [140-174] - [140- 149] - [121 - 130] - >400
(2) “ (2) - (2) -
* Rat batch no; A, B, C, and D = methods of euthanasia (see Footnote of Appendix 9 ) 
; ( ) = no of experiments
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Appendix 18. Survival (colony count) data on B. pertussis 18-323 in normal
rat LLF fraction (surfactant) at 37°C. A and B are duplicates; Expt code is
explained in the Appendix 4 and footnote.
Expt Expt CFU/ 20 pi after exposure at 37°C for time (min)
ordinal code _______________________________________________
no. 0 15 30 60 120 1440
A B A B A B A B A B A B
1 A 14B5C2D2E8 70 2 0 0 0
2 A 15B5C2D2E8 74 19 0 0 0
3 A 14B5C2D2E8 110 0 0 0 0
4 A 15B5C2D2E8 98 11 0 0 0
5 A 14B5C2D2E8 42 0 0 0 0
6 A 15B5C2D2E8 30 0 0 0 0
7 A 16B5C2D2E8 8 0 0 0 0
8 A I6B5C2D2E8 28 0 0 0 0
9 A 14B5C2D2E8 46 0 0 0 0
10 A 14B5C2D2E8 56 56 0 0 0 0 0 0 0 0
11 A I8B5C2D2E8 22 33 0 0 0 0 0 0 0
12 A I8B5C2D2E8 80 0 0 0 0
13 A 17B5C2D2E9 100 22 7 0 0
14 A I8B5C2D2E9 49 0 0 0 0
15 A 17B5C2D2E9 72 20 2 0 0
16 A I8B5C2D2E9 30 0 0 0 0
17 A20B5C2D 1E 13 98 100 0 0 0 0 0 0
18 A20B5C2D 1E 13 36 32 0 0 0 0 0 0 0
19 A20B5C2D 1E 13 42 24 0 0 0 0 0 0 0 0
20 A20B5C2D 1E 13 22 16 0 0 0 0 0 0
21 A21B5C2D 1E 13 68 82 0 0 0 0 0 0
22 A22B5C2D 1E 15 0 0
23 A22B5C2D 1E 15 26 24 0 0 0 0 0 0
24 A22B5C2D 1E 15 0 0
25 A22B5C2D 1E 15 0 0
26 A22B5C2D 1E 15 0 0
27 A22B5C2D 1E 15 0 0
28 A22B5C2D 1E 15 0 0
29 A22B5C2D 1E 15 0 0
30 A22B5C2D 1E 15 0 0
31 A22B5C2D 1E 14 0 0
32 A22B5C2D 1E 14 0 0
33 A22B5C2D 1E 14 35 31 0 0 0 0 0 0
34 A21B5C2D 1E 14 0 0
35 A21B5C2D 1E 14 0 0
36 A22B5C2D 1E 14 0 0
37 A23B5C2D 1E 14 66 64 0 0 0 0 0 0
Note: All rats anaestheized with Halothane about 3-5 minutes, then killed by heart puncture 
(during taking of blood) and cervical dislocation, afterwhich LLF was collected and 
fractionated (ultracentrifugation 29000 rpm) in the same day into supemate and surfactant. 
For the explanation of code A see Appendix 9 footnote, and for codes B, C, D and E, see 
Appendix 4.
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Appendix 19 . Batch to batch variation in bactericidal activity of normal rat
LLF fraction (surfactant) towards B. pertussis 18-323.
Batch* No. Median % survival [Range](No. of observations)
code of at incubation time (min)
experiments _______________________________________________
0 15 30 60 120 1440
A14 8 91 3.5 0 nt 0 0
[60-112] [0-29] [0-0] - [0-0] [0-0]
(8) (6) (6) - (6) (6)
A16 2 21.5 0 0 nt 0 0
[8-35] [0-0] [0-0] - [0 -0 ] [0-0]
(2) (2) (2) - (2) (2)
A17 2 149 nt 36.5 8 0 0
[131-167] - [36-37] [4-12] [0 .0 ] [0 .0 ]
(2) - (2) (2) (2) (2)
A18 3 55 nt 0 0 0 0
[39-83] - [0 .0 ] [0 .0 ] [0 .0 ] [0 .0 ]
(3) - (3) (3) (3) (3)
A20 4 78.5 nt 0 0 0 0
[13-95] - [0 .0 ] [0 .0 ] [0 .0 ] [0 .0 ]
(4) - (3) (4) (4) (2)
A21 2 57 nt 0 0 0 nt
[57] - [0] [0 .0 ] [0] -
(1) - (1) (2) (1) -
A22 12 38 nt 0 0 0 nt
[31-45] - [0 .0 ] [0 .0 ] [0 .0 ] -
(2) - (2) (12) (2) -
A23 1 100 nt 0 0 0 -
[100] - [0] [0] [0] -
(1) - (1) (1) (1) -
* See Appendix 9 footnote for explanation of batch code.
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Appendix 20. Survival (colony count) data on B. pertussis 18-323 in sham-
operated and challenged (C) rats LLF fraction (surfactant) at 37 °C. Expt
Code is explained in the footnote.
Expt Expt 
ordinal code
CFU/ 20 pi after exposure at 37°C for time (min)
no. 0 15 30 60 120 1440
1 A 19B5C2D2E8 28 0 0 0 0
2 A20B5C2D2E8 4 0 0 0 0
3 A21B5C2D2E8 82 99 84 4 0
4 A22B5C2D2E8 92 98 74 9 0
5 A 19B5C2D2E8 43 0 0 0 0
6 A20B5C2D2E8 41 0 0 0 0
7 A21B5C2D2E8 101 70 58 1 0
8 A22B5C2D2E8 99 73 68 17 0
9 A23B5C2D2E9 66 22 22 0 0
10 A24B5C2D2E9 74 66 22 0 0
11 A25B5C2D2E9 70 3 0 0 0
12 A26B5C2D2E9 70 46 54 18 0
13 A23B5C2D2E9 77 32 23 0 0
14 A24B5C2D2E9 86 64 51 40 0
15 A25B5C2D2E9 57 0 0 0 0
16 A26B5C2D2E9 78 49 44 19 0
Note: All rats anaestheized with halothane for about 3-5 minutes, then killed by heart 
puncture (during taking of blood) and cervical dislocation, after which LLF was collected 
and fractionated (Ultracentrifugation 55,000 g) in the same day into supernate and 
surfactant.
For the explanation of code A see Appendix 11 footnote, and for codes B, C, D and E, see 
Appendix 4.
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Appendix 21. Comparison of batch to batch variation in bactericidal activity 
of normal (N), sham-operated (SO), and various challenges (C) rats (treated 
with euthanasia method D) LLF fraction (surfactant) towards B. pertussis 
18-323.
Batch* Treatment No. Median % Survival [range] (No. of observation) 
code of of at incubation time (min) 
rat exneriment
0 15 30 60 120 1440
A16 N 2 21.5 0 0 nt 0 0
[8-35] [0-0] [0-0 ] - [0 -0] [0-0]
(2) (2) (2) - (2) (2)
A19 SO 2 41.5 0 0 nt 0 0
[29-54] [0-0] [0-0 ] - [0-0] [0-0]
(2) (2) (2) - (2) (2)
A20 SO 2 27.5 0 0 nt 0 0
[4-51] [0-0] [0-0 ] - [0-0] [0-0]
(2) (2) (2) - (2) (2)
A21 C 2 106 96 80.5 nt 2.5 0
[86-126] [88-104] [73-88] - [1-4] [0-0]
(2) (2) (2) - (2) (2)
A22 C 2 110.5 97.0 81.5 nt 15.0 0
[97-124] [91-103] [78-85] - [9-21] [0-0]
(2) (2) (2) - (2) (2)
A18 N 3 55 nt 0 0 0 0
[39-82] - [0-0] [0-0] [0-0] [0-0 ]
(3) - (3) (3) (3) (3)
A23 C 2 125 nt 47.5 39.5 0 0
[[110-140] - [37-58] [37-42] [0 -0] [0-0]
(2) - (2) (2) (2) (2)
A24 C 2 139.5 nt 113 83 36.5 0
[123-156] - [110-116] [73-93] [0-73] [0-0]
(2) - (2) (2) (2) (2)
A25 C 2 110.5 nt 2.5 0 0 0
[104-117] - [0-5] [0-0] [0 -0] [0-0]
(2) - (2) (2) (2) (2)
A26 C 2 129.5 nt 83 85 32 0
[117-142] - [77-89] [80-90] [30-35] [0-0]
(2) - (2) (2) (2) (2)
See Appendix 11 footnote for explanation of batch code.
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Appendix 22. Survival (colony count) data on B. pertussis in normal rat
LLF fraction (supernate) at 37 °C. A and B are duplicates. Expt code is
explained in the Appendix 4 and footnote.
Expt Expt 
ordinal code 
no.
CFU/ 20 fil after exposure at 37 °C for time (min)
0 15 30 60 120 1440
A B A B A B A B A B A B
1 A 14B5C2D2E8 84 44 29 0 0
2 A 15B5C2D2E8 63 2 0 0 0
3 A 14B5C2D2E8 112 60 20 0 0
4 A15B5C2D2E8 88 5 0 0 0
5 A 14B5C2D2E8 60 2 0 0 0
6 A 15B5C2D2E8 26 0 0 0 0
7 A I6B5C2D2E8 84 66 70 0 0
8 A I6B5C2D2E8 106 91 38 0 0
9 A 14B5C2D2E8 60 22 18 2 0
10 A 14B5C2D2E8 62 72 30 28 18 18 0 0 0 0
11 A I8B5C2D2E8 60 72 11 5 3 2 0 0 0 0
12 A I8B5C2D2E8 96 36 30 8 0
13 A 17B5C2D2E9 70 37 24 3 0
14 A I8B5C2D2E9 72 26 13 0 0
15 A 17B5C2D2E9 88 50 29 10 0
16 A I8B5C2D2E9 62 5 8 4 0
17 A20B5C2D 1E 13 100 116 2 4 0 0 0 0
18 A20B5C2D 1E 13 38 32 0  0 0  0 0 0
19 A20B5C2D 1E 13 42 44 0 0 0 0 0 0 0 0
20 A20B5C2D 1E 13 110 120 50 30 16 10 4 4
21 A21B5C2D 1E 13 88 94 90 110 94 120 112 118
22 A22B5C2D 1E 15 26 24
23 A22B5C2D 1E 15 106 80 52 62 44 34 30 32
24 A22B5C2D 1E 15 16 14
25 A22B5C2D 1E 15 0 0
26 A22B5C2D 1E15 0 0
27 A22B5C2D 1E 15 0 0
28 A22B5C2D 1E 15 7 5
29 A22B5C2D 1E 15 1 1
30 A22B5C2D 1E 14 4 4
31 A22B5C2D 1E 14 10 16
32 A23B5C2D 1E 14 158 162 122 138 138 114 98 104
Note: All rats anaestheized with halothane for about 3-5 minutes , then killed by heart 
puncture (during taking of blood) and cervical dislocation, after which LLF was collected 
and fractionated (ultracentrifugation 55,000 g) in the same day into supernate and 
surfactant.
For the explanation of code A see Appendix 9 footnote, and for codes B, C, D and E, see 
Appendix 4.
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Appendix 23. Batch to batch variation in bactericidal activity of normal rat
LLF fraction (supernate) towards B. pertussis 18-323.
Batch* No. Median % survival [Range](No. of observations)
code of at incubation time (min)
experiments _______________________________________________
0 15 30 60 120 1440
A14 6 103.5 26.5 2 nt 0 0
[52-127] [0-67] [0-44] - [0-0] [0-0]
(6) (6) (6) - (6) (6)
A16 2 110.5 91.5 61 nt 0 0
[88-133] [69-114] [48-74] - [0-0] [0-0]
(2) (2) (2) - (2) (2)
A17 2 138.5 76.5 46.5 nt 11.5 0
[117-160] nt [62-91] [40-53] [5-18] [0-0]
(2) - (2) (2) (2) (2)
A18 4 116.5 nt 27 18.5 3.5 0
[92-126] - [9-47] [4-39] [0-11] [0-0]
(4) - (4) (4) (4) (4)
A20 4 89.8 nt 10.3 2.3 0.8 0
[82-98] - [0-28] [0-9] [0-3] [0-0]
(4) - (3) (4) (4) (2)
A21 1 69 nt 76 81 87 nt
[69] - [76] [81] [87] -
(1) - (1) (1) (1) -
A22 10 115 nt 70 9.5 38 nt
[115] - [70] [0-48] [38] -
(1) - (1) (10) (1) -
A23 1 100 nt 81 79 63 nt
[100] - [81] [79] [63] -
(1) - (1) (1) (1) -
For explanation of batch code see Appendix 9 footnote.
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Appendix 24. Survival (colony count) data on B. pertussis 18-323 in sham-
operated and challenged, and challenged rats LLF fraction (supernate) at
37°C. Expt code is explained in the Appendix 4 and footnote.
Expt Expt 
ordinal code 
no.
CFU/ 20 |il after exposure at 37°C for time (min)
0 15 30 60 120 1440
1 A19B5C2D2E8 90 72 52 3 0
2 A20B5C2D2E8 78 64 42 1 0
3 A21B5C2D2E8 114 110 92 62 0
4 A22B5C2D2E8 97 108 94 64 0
5 A 19B5C2D2E8 114 97 62 29 0
6 A20B5C2D2E8 84 85 52 18 0
7 A21B5C2D2E8 124 86 72 42 0
8 A22B5C2D2E8 116 89 70 44 0
9 A23B5C2D2E9 85 57 32 7 0
10 A24B5C2D2E9 78 63 52 38 1
11 A25B5C2D2E9 82 28 28 13 0
12 A26B5C2D2E9 80 64 67 40 0
13 A23B5C2D2E9 77 50 35 9 0
14 A24B5C2D2E9 85 64 77 53 3
15 A25B5C2D2E9 73 36 25 3 0
16 A26B5C2D2E9 80 68 60 59 0
Note: All rats anaestheized with halothane for 3-5 minutes, then killed by heart puncture 
(during taking of blood) and cervical dislocation, after which LLF was collected and 
fractionated (ultracentrifugation 55000 g) in the same day into supernate and surfactant.
For the explanation of code A see Appendix 11 footnote, and for codes B, C, D and E, see 
Appendix 4.
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Appendix 25. Comparison of batch to batch variation in bactericidal activity 
of normal (N), sham-operated (SO), and variously challenged (C) rats 
(treated with euthanasia method D) LLF fraction (supernate) towards B. 
pertussis 18-323. Data of two observations.
Batch*
code
Treatment
of
rat
Median % Survival [range] at incubation 
time (min)
0 15 30 60 120 1440
A16 N 110.5 91.5 61 nt 0 0
[88-133] [69-114] [48-74] - [0-0] [0-0]
A19 SO 119 98.5 66.5 nt 19.5 0
[95-143] [76-121] [55-78] - [3-36] [0-0]
A20 SO 93.5 86.5 54.5 nt 12 0
[82-105] [67-106] [44-65] - [1-23] [0-0]
A21 c 137.5 112 93.5 nt 59 0
[120-155] [108-116] [90-97] - [53-65] [0-0]
A l l c 123.5 112.5 93.5 nt 61 0
[102-145] [111-114] [88-99] - [55-67] [0.0]
A18** N 116.5 nt 27 18.5 3.5 0
[92-126] - [9-47] [4-39] [0-11] [0-0]
A23 Cl 141 nt 93 58.5 14 0
[140-142] - [91-95] [53-64] [12-16] [0-0]
A24 Cl 142.5 nt 110.5 113.5 79.5 3.5
[130-155] - [105-116] [87-140] [63-96] [2-5]
A25 Cl 135 nt 56 46 13.5 0
[133-137] - [47-65] [45-47] [5-22] [0-0]
A26 Cl 112.5 nt 115.5 110.5 87 0
[80-145] - [107-124] [109-112] [67-107] [0-0]
*See Appendix 9 footnote for normal rat LLF and Appendix 11 footnote for LLF from trea­
ted animals; **Data of four observations.
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Appendix 26. Protein concentration of membrane (0.45 pm pore size) 
filtered (F) and unfiltered (UF) LLF, supernate and surfactant collected 
from normal (N), sham-operated (SO) and convalescent rats by different 
method of euthanasia. Data are the mean of triplicates in the same 
experiment.
LLF Treatment Method Protein ug/ml (±SEM) in
batch of of
no. rats euthanasia Unfractionated Supernate Surfactant
LLF
F F F UF
15 N A 125±5 nt nt nt
Cl A 250±0 - - -
C2 A 308.±4 - - -
C3 A 250±0 - - -
C4 A 352±2 - - -
16 SO A 322±4 - - -
Cl A 323±2 - - -
C2 A 288±2 - - -
C3 A 315±5 - - -
C4 A 315+5 - - -
17 N A 477±7 - - -
Cl A 408±6 - - -
C2 A 527±7 - - -
C3 A 521 ±1 - - -
C4 A 521 ±1 - - -
33 N A 338±4 - - -
34 N B 320±3 - - -
C B 752±6 - - -
35 N B 613±6 nt nt nt
37 N B 635±10 54019 14111 -
38 N B 355±3 nt nt -
N C 140±3 - - -
39S N D 215±3 - - -
39M N D 263±2 - - -
39L N D 395±6 - - -
40L N D 338±2 223113 2910 -
40xL N D 390±3 27513 1911 -
41 N D 480±6 40714 1012 2412
SOI D 460±3 34513 1112 2912
S02 D 450±3 35212 912 2411
Cl D 755±10 67016 1411 2912
C2 D 577±9 26812 1312 2411
42 N D 40013 39212 nt 3611
43 N D 52916* nt - nt
44 N D nt 48312 - 14610
45 N D 44512 40713 - 5211
50 N D nt 35314 - 5910
55 N D - 34518 - 5810
Median 390 353 14 33
yield (%) 0 91 4 8
* Unfiltered fluids gave 550±0 pg/ml
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Appendix 27. Lysozyme concentration of filtered (F) and unfiltered (UF) 
LLF, supernate and surfactant collected from normal (N), sham-operated 
(SO) and convalescent (C) rats by different method of euthanasia. Data are 
the mean of triplicates in the same experiment.
LLF Treatment Method LZ ug/ml (±SEM) in
batch of of
no. rats euthanasia Unfractionated Supernate Surfactant
LLF
F F F UF
15 N A 16±1 nt nt nt
Cl A 53±2 - - -
C2 A 54±0 - - -
C3 A 70±3 - - -
C4 A 64±1 - - -
16 Cl A 57±1 - - -
C2 A 74±1 - - -
C3 A 73±3 - - -
C4 A 54±3 - - -
17 N A 76±3 - - -
Cl A 72±1 - - -
C2 A 90±2 - - -
C3 A 77±1 - - -
C4 A 80±1 - - -
33 N A 93±1 - - -
34 N B 84±3 - - -
C B >108±0 - - -
35 N B 92±1 - - -
37 N B 47±1 45±1 < 5±0 nt
38 N B 44±1 nt nt -
38 N C 49±0 - - -
39S N D 65±2 - - -
39M N D 95±3 - - -
39L N D 104±1 - - -
40 N D 99±1 111±5 < 5±0 -
41 N D 88±1 99+1 < 5±0 -
41 SOI D 101+4 108±5 nt -
41 S02 D 101±5 97±5 - -
41 Cl D 107±1 > 108 < 5±0 -
41 C2 D > 108±0 103±5 nt -
42 N D > 108±0 nt - 36±1
43 N D > 108±0 - - nt
44 N D nt 106±1 - 12±0
45 N D 105±1 107±7 - < 5±0
50 N D nt 110±2 - < 5±0
55 N D - 96±2 - < 5±0
Median 80 107 <5 < 5
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Appendix 28. Effect of various treatments of rat LLF on their bactericidal
activity towards B. pertussis 18-323. Data are the mean of 2 observations.
Treatment 
of LLF/ 
LLF batch 
no.
Mean % survival* [Range] at incubation time (min)
0 15 30 60 120
nil 28.50 0 0 nt 0
33 [22 - 35] [0-0] [0 -0 ] - [0 -0]
Dialysis (retentate) 81.50 12 0 nt 0
33 [80 - 83] [11-13] [0 -0 ] - [0 -0 ]
PBS 86 74.5 71.5 nt 62
[74 - 98] [74 - 75] [65 - 78] - [54 - 70]
nil 40.50 0 0 nt 0
33 [33 - 48] [0-0] [0 -0 ] - [0 -0 ]
56°C for 30 min 86.50 30.50 4.50 nt 0
33 [83 - 90] [27 - 34] [0 -9 ] - [0 -0 ]
100°C for 5 min 72 59.50 55 nt 4.50
33 [63-81] [50 - 69] [55]** - [0 -9]
PBS 93.50 85.50 83 nt 64.5
[90 - 97] [83 - 88] [83]** - [50 - 79]
nil 66.5 nt 0 0 0
40 [51 -82] - [0 -0 ] [0 -0 ] [0-0]
HC1: 0.1 M, 18 h 4°C 77.5 nt 2.50 0 0
40 [56 - 99] - [0 -5 ] [0 -0 ] [0-0]
NaOH: 0.1 M, 18h4°C 92.5 nt 25 8 1
40 [92 - 93] - [15-35] [3-13] [0-2]
At4°C 64.5 - 0 0 0
40 [44 - 85] - [0 -0 ] [0 -0 ] [0-0]
PBS 90 - 80.5 75.5 44
[82 - 98] - [59- 102] [49 - 102] [20 - 68]
nil 62.5 - 0 0 0
43 [54-71] - [0 -0 ] [0 -0 ] [0-0]
Filtrate/30 kDa 121.5 - 72.5 51.50 26
43 [114- 129] - [54-91] [43 - 60] [22 - 30]
Retentate/30 kDa 85.5 - 0 0 0
43 [77 - 94] - [0 -0 ] [0 -0 ] [0-0]
PBS 105.5 - 72 50 22.5
[103- 108] - [70 - 74] [49-51] [22 - 23]
* % survival calculations were based on CL medium time-zero count data. 
** This was a single observation
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Appendix 29. Effect of various treatment on the bactericidal activity of 
supernate (SN) and surfactant (SUR) fractions of LLF towards B. pertussis 
lux (% Luminescence calculations were based on PBS time-lh count data).
Experiment @ Mean % luminescence [range] (No. of observations) Inactivation 
particulars after lh  incubation time at different dilution / jllI end point
90 %
1/1
400
1/2
200
1/4
100
1/8
50
1/16
25
1/64
12.5
50%
SN 44 7.50 18.0 56.0 69.50 nt nt 350
A (2) [6 -9 ] [13-23] [46 - 66] [66 - 73] - - 120
SN 44 17.50 65.50 79.50 89.0 nt nt >400
B l(2 ) [13-22] [56 - 75] [71 - 88] [83 - 95] - - 255
SN 44 74.50 67.0 76.0 63.5 nt nt >400
B2 (2) [68-81] [66 - 68] [74 - 78] [51 -76] - - >400
SUR 44 1.0 nt 2.5 nt 10.50 52 40
A (2) [1 - 1] - [2 -3] - [8-13] [43-61] 20
SUR 44 2.0 nt 8.0 nt 44.5 77.0 100
B l ( 2) [2 - 2] - [5-11] - [28-61] [64 - 90] 30
SUR 44 10.50 nt 33.5 nt 73.0 86.50 >400
B2 (2) [4-17] - [11 -56] - [47 - 99] [79 - 94] 70
SN 44 15.0 34.5 77.0 80.5 nt nt >400
A (2) [1 0 - 20] [34 - 35] [76 - 78] [45-116] - - 165
SN 44 34.5 71.0 95.0 107 nt nt >400
Cl (2) [34 - 35] [57 - 85] [83 - 107] [8 8 - 126] - - 320
SN 44 43.0 88.0 111 122 nt nt >400
C2 (2) [34 - 52] [85-91] [109-113] [118-127] - - 380
SN 44 26.50 48.50 85.50 97.0 nt nt >400
D (2) [26 -27] [42 - 55] [77 - 94] [74 - 120] - - 210
Cl/PBS 1.0 * - - - - -
C2/PBS 105* - - - - -
D/PBS 94* - - - - -
SUR 44 2.50 nt 5.50 nt 19.0 60.0 75
A (2) [1 -4 ] - [2-9] - [10-28] [59-61] 20
SUR 44 1.5 nt 12.0 nt 38.50 76.50 140
Cl (2) [1 - 2] - [11-13] - [36-41] [76 - 77] 30
SUR 44 7.0 nt 14.0 nt 36.0 71.0 285
C2 (2) [4-10] - [8 - 20] - [29 - 43] [66 - 76] 30
344
Appendix 29. continued
Experiment @ Mean % luminescence [range] (No. of observations) Inactivation
particulars after lh incubation time at different dilution / (il end point
90 %
1/1
400
1/2
200
1/4
100
1/8
50
1/16
25
1/64
12.5
50%
M-l
SUR 44 2 nt 6 nt 17.50 62.50 75
D (2) [1 -3 ] - [3 -9] - [12-23] [57 - 68] 30
Cl/PBS 1.0 * - - - - -
C2/PBS 104* - - - - -
D/PBS 93* - - - - -
SN 44 2.50 13.50 76.50 89.5 nt nt 250
A (2) [2 -3 ] [10-17] [69 - 84] [79 - 100] - - 135
SN 44 4.50 20.50 68.0 94.0 nt nt 310
Ei (2) [2 -7 ] [16-25] [61 -75] [78- 110] - - 135
SN 44 6.0 18.50 74.0 100 nt nt 330
E2 (2) [4 -8 ] [11 -26] [72 - 76] [98 - 102] - - 135
SN 44 3.0 13.50 73.0 102 nt nt 255
E3 (2) [2 -4 ] [7 - 20] [66 - 80] [97 - 107] - - 135
SN 44 4.0 28.0 76.0 92.50 nt nt 320
F (2) [3 -5 ] [17-39] [75 - 77] [88 - 97] - - 155
SUR 44 1.5 nt 3.0 nt 16.0 67.0 55
A (2) [1 - 2] - [3 -3] - [15-17] [61-73] 20
SUR 44 2.0 nt 13.50 nt 67.50 94.0 160
Ei (2) [2 - 2] - [13-14] - [65 - 70] [92 - 96] 50
SUR 44 2.0 nt 7.0 nt 51.50 83.50 95
E2 (2) [2 - 2] - [6 - 8] - [47 - 56] [74 - 93] 35
SUR 44 2.0 nt 10.50 nt 71.0 83.0 125
E3 (2) [1 -3 ] - [7 - 14] - [57 - 85] [77 - 89] 50
SUR 44 1.5 nt 3.5 nt 18.0 58.0 60
F (2) [1 -3 ] - [3 -4] - [18-18] [51-65] 20
Ej/PBS 97 - - - - -
[91 - 103] - - - - -
E2/PBS 107.5 - - - - -
[103-112] - - - - -
E3/PBS 121.5 - - - - -
[105 - 138] - - - - -
F/PBS 92.0 _ _ _ _ _
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Experiment @ Mean % luminescence [range] (No. of observations) Inactivation
particulars after lh incubation time at different dilution / |il end point
90 %
1/1
400
1/2
200
1/4
100
1/8
50
1/16
25
1/64
12.5
50 %
SN 44 6.0 10.50 42.50 59.5 nt nt 250
A (2) [4 -8 ] [10-11] [37 - 48] [44 - 45] - - 90
SN 44 14.0 36.0 70.0 84.0 nt nt >400
G(2) [13-15] [33 - 39] [68 - 73] [78 - 90] - - 165
SUR 44 1.5 nt 1.5 nt 16.0 48.0 50
A (2) [1 -2 ] - [1 -2] - [8 - 24] [39 - 57] 20
SUR 44 1.5 nt 2.5 nt 11.5 49.50 40
G (2) [1 -2 ] - [2 -3] - [9 - 14] [49 - 50] 20
SN 45 4.0 7.0 15 27.5 nt nt 175
A (2) [1 -7 ] [3-11] [7 - 23] [16-39] - - 30
SN 45 5.0 9.0 14.0 27.0 nt nt 210
H (1) [5] [9] [14] [27] - - 30
SUR 45 1.5 nt 2.5 nt 9.0 35.0 30
A (2) [1 -2 ] - [1-4] - [3-15] [23 - 47] 20
SUR 45 3.0 nt 5.50 nt 9.50 31.0 30
H (2) [1 -5 ] - [1 - 10] - [2 - 17] [19-43] 20
SN 45 5.0 11.33 26.3 49.7 nt nt 265
A (3) [3 -7 ] [8 - 14] [13-49] . [34 - 77] - - 65
SN 45 1.33 1.67 2.0 7.33 nt nt 50
1(3) [1 -2 ] [1-2] [2-2] [2-11] - - <0*
SN 45 8.33 14.0 34.33 61.0** nt nt 375
F (3) [4-12] [9-19] [25 - 40] [56 - 66] - - 80
SUR 45 2.33 nt 2.33 nt 6.67 27.33 30
A (3) [2 -3 ] - [2 -3] - [6 -7 ] [21 - 38] 20
SUR 45 1.67 nt 7.67 nt 39.0 67.3 100
1(3) [1 -2 ] - [2-12] - [11-54] [45 - 79] 30
SUR 45 2.0 nt 3.0 nt 10.0 51.0* 40
F(3) [2 -2 ] - [3-3] - [9 - 12] [51] 20
I/PBS (3) 1.33 _ _ - - -
[1 -2 ] - - - - -
SN 45 9.0 14.0 25.0 54.0 nt nt 400
A (2) [7-11] [14-14] [23 - 27] [52 - 56] - - 70
SN 45 16.0 51.50 113 137 nt nt >400
J(2) [H -2 1 ] [49 - 54] [108- 118][137 - 137] - - 230
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Experiment @ Mean % luminescence [range] (No. of observations) Inactivation
particulars after lh incubation time at different dilution / pi end point
90 %
1/1 1/2 1/4 1/8 1/16 1/64 50%
400 200 100 50 25 12.5 Hi
SN 45 10.0 20.0 36.0 nt nt nt >400
F (2) [8 - 12] [20-21] [36 - 36] - - - 100
SUR 45 2.0 nt 5.50 nt 17.0 67.0 80
A (2) [2 -2 ] - [5-6] - [16-18] [63-71] 25
SUR 45 13.0 nt 56.50 nt 124 139.5 >400
J(2) [13-13] - [55 - 58] - [118 - 130][131 - 148] 150
SUR 45 2.0 nt 5.50 nt 20.0 nt 80
F(2) [2 -2 ] - [5 -6] - [19-21] - 25
J/PBS (2) 169.50 _ _ _ _ _
[169- 170] - - - - -
F/PBS (2) 96.50 _ _ _ _ _
[94 - 99] - - - - -
SUR 45 5.50 nt 19.50 nt 45.0 50.0 290
A (2) [5 -6 ] - [16-23] - [40 - 50] [50 - 50] 30
SUR 45 9.0 nt 20 nt 29.50 43.50 400
K (2) [8 - 10] - [16-24] - [21 -38] [39 - 48] 20
SUR 50 27 nt 75.75 nt 94.25 102.25 >400
A (4) [19-35] - [65 - 83] - [82 - 110][94 - 108] 260
SUR 50 62.5 nt 88.75 nt 95.25 102.25 >400
M  (4) [43 - 67] - [70 - 99] - [85- 105] [97-110] >400
SUR 50 96.5 nt 101.5 nt 97.75 99 >400
L2 (4) [81 - 103] - [95 - 105] - [71 - 112] [74- 110] >400
* This was a single observation,**Mean of 2 experiments, @ Rat batch no, ( ) = no. of 
experiments, A = untreated test fluid, B\ = heat at 56 °C for 30 min, B2 = heat at 100 °C 
for 15 min, Cl = HC1 (0.1 M final), C2 = NaOH (0.1 M final), D = test fluid at 4°C for 
overnigth, E l = trypsin (2mg/ml final), E2 = chymotrypsin (2mg/ml), E3 = subtilisin 
(2mg/ml), F = test fluid at 37°C for 30 min, G = Freezing and thawing of test fluids, H = 
dialysed test fluids, I = test fluids treated with bentonite, J = proteinase K (2mg/ml final)> K 
= sonicated surfactant, Li = surfactant washed in PBS one time, L2 = surfactant washed in
PBS four times.
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Appendix 30. Effect of various treatment on the bactericidal activity of 
supernate (SN) and surfactant (SUR) fractions of LLF from normal rats 
(batch no. 55, euthanasia method D) towards B. pertussis 18-323. Data are 
of two observations for each treatment. (% survival calculations were based 
on PBS time-lh count data).
Experiment @ Mean % survival [range] after lh incubation Inactivation
particulars time at different dilution / pi end point
90 %
1/1
240
1/2
120
1/4
60
1/8
30
1/16
15
1/64
7.5
50%
Hi
SN 16 52 52 66.5 nt nt > 240
A [11-21] [45-59] [45-59] [65-68] - - 125
SN 70.5 101.5 117.5 150.5 nt nt > 240
B1 [59-82] [91-112] [100-135] [136-165] - - >240
SN 135 123.5 130.5 101.5 nt nt > 240
B2 [105-165] [100-147] [114-147] [91-112] - - >240
PBS 104.5 _ _ _ _ _ _
B1 [91-118] - - - - - -
PBS 107.5 _ _ _ _ _ _
B2 [[88-127] - - - - - -
SUR 0 nt 0 nt 12 130.5 20
A [0-0] - [0-0] - [12-12] [123-128] 10
SUR 0 nt 0 nt 46 100 30
B1 [0-0] - [0-0] - [38-54] [85-115] 15
SUR 0 nt 15 nt 61.5 107.5 75
B2 [0-0] - [15-15] - [38-85] [100-115] 20
PBS 119 _ _ _ _ _ -
B1 [115-123] - - - - - -
PBS 134.5 _ _ _ _ _ _
B2 [127-142] - - - - - -
SN 4.5 51.5 117.5 130.5 nt nt 200
A [4-5] [45-58] [108-127] [125-136] - - 120
SN 65.5 79 131.5 122 nt nt > 240
Cl [58-73] [67-91] [108-155] [117-127] - - >240
SN 34.5 70 74.5 143.5 nt nt > 240
C2 [27-42] [67-73] [58-91] [142-145] - - 180
SN 0 17.5 22 65.5 nt nt 140
D [0-0] [17-18] [17-27] [58-73] - - 40
PBS 82.5 _ _ _ _ _ -
Cl [73-92] - - - - - -
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Experiment @ Mean % survival [range] after lh incubation Inactivation
particulars time at different dilution / pi end point
90 %
1/1
240
1/2
120
1/4
60
1/8
30
1/16
15
1/64
7.5
50%
Pi
PBS 74 - - - - - -
C2 [73-75] - - - - - -
PBS 100.5 _ _ _ _ _ _
D [83-118] - - - - - -
SUR 0 nt 0 nt 9 67 15
A [0-0] - [0-0] - [5-13] [63-71] 5
SUR 0 nt 0 nt 48 101 30
Cl [0-0] - [0-0] - [39-57] [92-110] 15
SUR 0 nt 0 nt 36.5 90 30
C2 [0-0] - [0-0] - [26-47] [83-97] 15
SUR 0 nt 0 nt 6.5 89.5 15
D [0-0] - [0-0] - [3-10] [79-100] 5
PBS nt _ _ _ _ _ -
Cl - - - - - - -
PBS 95.5 _ _ _ _ _ _
C2 [84-107] - - - - - -
PBS 89.5 _ _ _ _ _ _
D [[79-100] - - - - - -
SN 32 138 123 142 nt nt > 240
A [29-35] [122-154] [117-130] [135-150] - - 215
SN 68.5 139 154 153.5 nt nt > 240
El [67-70] [113-165] [138-170] [150-157] - - >240
SN 121 166.5 123.5 174.5 nt nt > 240
E2 [117-125] [146-187] [122-125] [174-175] - - >240
SN 40.5 126 170.5 134 nt nt > 240
E3 [33-48] [117-135] [158-183] [125-143] - - 230
SN 100 148.5 134.5 147 nt nt > 240
F [96-104] [139-158] [104-165] [133-161] - - >240
PBS 164.5 _ _ _ _ - ~
El [142-187] - - - - - -
PBS 151 _ _ _ _ _ _
E2 [135-167] - - - - - -
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Experiment @ 
particulars
Mean % survival [range] after 1 h incubation 
time at different dilution / pi
Inactivation 
end point 
90 %
1/1
240
1/2
120
1/4
60
1/8
30
1/16
15
1/64
7.5
50%
PBS 131.5 - - - - - ~
E3 [117-146] - - - - - -
PBS 127.5 _ _ _ _ _
F [125-130] - - - - - -
SUR 0 nt 0 nt 5 86.5 15
A [0-0] - [0-0] - [3-7] [83-90] 10
SUR 0 nt 6.5 nt 90.5 120.5 60
El [0-0] - [6-7] - [81-100] [108-133] 30
SUR 0 nt 11.5 nt 99 121 70
E2 [0-0] - [6-17] - [78-120] [102-140] 35
SUR 0 nt 0 nt 106 113.5 45
E3 [0-0] - [0-0] - [92-120] [94-133] 25
SUR 0 nt 0 nt 86 96 45
F [0-0] - [0-0] - [72-100] [72-120] 25
PBS 97 _ _ _ _ - -
El [94-100] - - - - - -
PBS 115.5 _ _ _ _ _ _
E2 [108-123] - - - - - -
PBS 93 _ _ _ _ _ _
E3 [86-100] - - - - - -
PBS 87.5 _ _ _ - -
F [78-97] - - - - - -
SN 16 52 52 66.5 nt nt > 240
A [11-21] [45-59] [45-59] [65-68] - - 60
SN 28 31 38.5 82.5 nt nt > 240
G [27-29] [27-35] [36-41] [59-106] - - 50
PBS 101.5 _ _ ~ - - -
G [91-112] - - - - - -
SUR 0 nt 0 nt 12 130.5 15
A [0-0] - [0-0] - [12-12] [123-128] 5
SUR 0 nt 0 nt 4 104 10
G [0-0] - [0-0] - [4-4] [100-108] 5
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Experiment @ Mean % survival [range] after lh incubation Inactivation
particulars time at different dilution / pi end point
90 %
1/1
240
1/2
120
1/4
60
1/8
30
1/16
15
1/64
7.5
50%
Ml
PBS 138 - - - - - -
G [138-138] - - - - - -
SN 0 67 I l l 83.5 nt nt 160
A [0-0] [67-67] [80-142] [67-100] - - 125
SN 22.5 40 45 86 nt nt > 240
H [20-25] [33-47] [40-50] [80-92] - - 55
PBS 86 _ _ _ _ _
H [80-92] - - - - -
SUR 0 nt 0 nt 54.5 122.5 30
A [0-0] - [0-0] - [50-59] [112-133] 15
SUR 0 nt 0 nt 106 114.5 30
H [0-0] - [0-0] -  1[94-118] [111-118] 20
PBS 49 _ _ _ - - -
H [39-59] - - - - - -
SN 4 24 I l l 123 nt nt 180
A [4-4] [22-26] [99-124] [113-133] - - 90
SN 75 97.5 105 110 nt nt > 240
11/Ben [67-83] [91-104] [95-115] [107-113] - - > 240
SN 106.5 94.5 109 87 nt nt > 240
12/Char [93-120] [85-104] [105-113] [85-89] - - >240
SN 2 69.5 107 129.5 nt nt 190
F [1-3] [63-76] [107-107] [109-150] - - 130
PBS 118 _ _ _ _ _ ~
11/Ben [99-137] - - - - - -
PBS 94.5 _ _ _ _ -
12/Char [85-104] - - - - - -
PBS 94.5 _ _ _ _ - -
F [89-100] - “ - - - -
SUR 0 nt 0 nt 0 110.5 10
A [0-0] - [0-0] - [0-0] [100-121] 5
SUR 0 nt 0 nt 43 77 30
11/Ben [0-0] - [0-0] - [36-50] [75-79] 15
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Experiment @ Mean % survival [range] after lh incubation Inactivation
particulars time at different dilution / pi end point
90 %
1/1 1/2 1/4 1/8 1/16 1/64 50%
240 120 60 30 15 7.5 Hi
SUR 134 nt 159 nt 135.5 149.5 > 240
12/Char [125-143] - [143-175] - [129-142] [142-157] >240
SUR 0 nt 0 nt 31 102 30
F [0-0] - [0-0] - [29-33] [71-133] 15
PBS 148.5 _ - _ _ _ _
11/Ben [133-164] - - - - -
PBS 131 _ _ _ _ _ _
12/Char [129-133] “ - - - - -
SN 19.5 66 121.5 139.5 nt nt =PK
A [14-25] [57-75] [121-122] [130-149] - - =Pk
SN 56 87.5 115 132.5 nt nt > 240
I3/Meth.Cell [52-60] [79-96] [111-119] [128-137] - - >240
SN 39.5 91 145 92.5 nt nt =PK
F [39-40] [83-99] [122-168] [87-98] - - =Pk
PBS 134 _ _ _ - -
I3/Meth,.Cell[125-143] - - - - - -
SUR 0 nt 0 nt 0 110.5 10
A [0-0] - [0-0] - [0-0] [100-121] 5
SUR 0 nt 0 nt 71 73.5 30
I3/Meth .Cell [0-0] - [0-0] - [46-96] [64-83] 15
SUR 0 nt 0 nt 31 102 30
F [0-0] - [0-0] - [29-33] [71-133] 15
PBS 41.5 _ _ _ _ _
I3/Meth .Cell[33-50] - - - - - -
SN 19.5 66 121.5 139.5 nt nt > 240
A [14-25] [57-75] [121-122] [130-149] - - 150
SN 4.5 105 92.5 142.5 nt nt 210
E4/Pk [3-6] [99-111] [90-95] [133-152] - - 150
SN 39.5 91 145 92.5 nt nt > 240
F [39-40] [83-99] [122-168] [87-98] - - 205
PBS 113.5 - _ _ _ -
E4/Pk [108-119] - - - - - -
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Experiment @ Mean % survival [range] after lh incubation Inactivation
particulars time at different dilution / pi end point
90 %
1/1
240
1/2
120
1/4
60
1/8
30
1/16
15
1/64
7.5
50%
SUR 0 nt 0 nt 12 98 20
A [0-0] - [0-0] - [9-15] [93-103] 10
SUR 0 nt 3 nt 100.5 125.5 50
E4/Pk [0-0] - [3-3] - 1;97-104] [124-127] 35
SUR 0 nt 0 nt 33 96.5 20
F [0-0] - [0-0] - [31-35] [96-97] 10
PBS 100.5 _ _ _ _ _ _
E4/Pk [86-115] - - - - - -
SN 0 12.5 113.5 136.5 nt nt 132
A [0-0] [9-16] [90-137] [136-137] - - 90
SN 95 151 127.5 138.5 nt nt > 240
I4/DMBCD [95-95] [147-155] 118-137] [132-145] - - >240
SN 105.5 126.5 120.5 144 nt nt > 240
I5/6CD [100-111] [95-158] [109-132] [109-179] - - >240
SN 121 123 116 133.5 nt nt > 240
16/BCD [100-142] [114-132] [95-137] [109-158] - - >240
SN 98.5 128.5 109 147.5 nt nt > 240
F [86-111] [121-136] [100-118] [127-168] - - > 240
PBS 107 _ _ _ _ _ -
I4/DMBCD[82-132] - - - - - -
PBS 84 _ _ _ _ _ _
15/BCD [68-100] - - - - - -
PBS 92.5 - - - - - -
16/ocCD [90-95] - - - - - -
PBS 105.5 _ _ _ _ _ -
F [95-116] - - - - - -
SUR 0 nt 0 nt 15 93.5 25
A [0-0] - [0-0] - [10-20] [77-110] 8
SUR 60.5 nt 92 nt 108.5 101.5 > 240
I4/DMpCD[58-63] - [84-100] - [89-128] [87-116] >240
SUR 1.5 nt 4.5 nt 76.5 87 50
15/BCD [0-3] - [3-6] - [63-90] [77-97] 16
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Experiment @ Mean % survival [range] after lh incubation Inactivation
particulars time at different dilution / pi end point
90 %
1/1
240
1/2
120
1/4
60
1/8
30
1/16
15
1/64
7.5
50%
Pi
SUR 0 nt 10 nt 72 nt 70
16/aCD [0-0] - [8-12] - [63-81] - 16
SUR 0 nt 0 nt 74 84 35
F [0-0] - [0-0] - [61-87] [68-100] 16
PBS 81.5 _ _ _ _ _ _
I4/M13CD [73-90] - - - - - -
PBS 78.5 _ _ _ _ _ _
15/BCD [74-83] - - - - - -
PBS 93.5 - - - - - -
16/aCD [93-94] - - - - - -
PBS 85 _ _ _ _ _ _
F [73-97] - - - - - -
SN 0 90 101.5 115 nt nt 165
A [0-0] [80-100] [53-150] [100-130] - - 130
SN 156.5 130 160 96.5 nt nt > 240
I7/BSA [93-220] [80-180] [140-180] [93-100] - - >240
SN 41.5 111.5 121.5 130 nt nt > 240
18/Starch [33-50] [110-113] [113-130] [120-140] - - 215
SN 93.5 131.5 133.5 148.5 nt nt > 240
19/IRS [87-100] [130-133] [87-180] [107-190] - - >240
SN 36 81.5 93.5 161.5 nt nt > 240
F [35-37] [73-90] [87-100] [153-170] - - 190
PBS 138.5 _ _ _ _ _ ~
I7/BSA [107-170] - “ - - - -
PBS 111.5 _ _ _ _ -
18/Starch [73-150] - - - - - -
PBS 143.5 _ _ _ _ - -
I9/RIS [87-200] - - - - - -
PBS 100 _ _ _ _ _
F [80-120] - - - - - -
SUR 0 nt 0 nt 27 100 30
A [0-0] - [0-0] - [24-30] [100-100] 15
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Experiment @ Mean % survival [range] after lh incubation Inactivation
particulars time at different dilution / jxl end point
_________________________________________  90 %
1/1 1/2 1/4 1/8 1/16 1/64 50%
240 120 60 30 15 7.5
SUR 0 nt 45 nt 98 94.5 120
I7/BSA [0-0] - [38-52] - 1!93-103] [89-100] 65
SUR 0 nt 0 _ 72 107 35
18/Starch [0-0] - [0-0] [66-78] [100-114] 20
SUR 0 nt 37.5 nt 89.5 92.5 115
19/IRS [0-0] - [34-41] - [89-90] [89-96] 55
SUR 0 nt 0 nt 68.5 71.5 35
F [0-0] - [0-0] - [52-85] [69-74] 20
PBS 118 _ - _ _ ~
I7/BSA [110-126] - - - - -
PBS 74 _ _ _ _ _ _
18/Starch [59-89] - “ - - - -
PBS 120 _ _ _ _ _ _
I9/RIS [110-130] - - - - - -
PBS 71.5 _ _ _ _ _ _
F [67-76] - - - - - -
SN 0 67 I l l 83.5 nt nt 160
A [0-0] [67-67] [80-142] [67-100] - - 125
SN 80.5 84 114 116 nt nt > 240
Jl/Pho(A2)[53-108] [75-93] [108-120] [100-133] - - >240
SN 0 64 62.5 122.5 nt nt 160
J2/Pho(C) [0-0] [53-75] [58-67] [120-125] - - 125
SN55 0 103 129 102 nt nt 170
F [0-0] [73-133] [125-133] [87-117] - - 135
PBS 85 _ _ _ _ _ -
J l/Pho(A2)[83-87] - - - - - -
PBS 106 _ _ _ _ _ -
J2/Pho(C) [87-125] - - - - - -
PBS 60 _ _ _ _ _ -
F [12-108] - - - - - -
SUR 0 nt 0 nt 54.5 122.5 30
A [0-0] - [0-0] - [50-59] [112-133] 75
Appendix 30. continued
Experiment @ Mean % survival [range] after lh incubation Inactivation
particulars time at different dilution / pi end point
90 %
1/1 1/2 1/4 1/8 1/16 1/64 50%
240 120 60 30 15 7.5 fd
SUR 85.5 nt 111.5 nt 139.5 185.5 > 240
J 1 /Pho( A2) [65-106] - [106-117] - [129-150] [183-188] > 240
SUR 0 nt 20 nt 144 142 90
J2/Pho(C) [0-0] - [18-22] - [117-171] [129-156] 40
SUR 0 nt 0 nt 89 111 30
F [0-0] - [0-0] - [72-106] [100-122] 20
PBS 117.5 _ _ _ _ _ -
Jl/Pho(A2)[l 11-124] - - - - -
PBS 134 _ - _ _ _ -
J2/Pho(C) [ 129-139] - - - - - -
PBS 128 _ _ _ _ -
F [1 12-144] - - - - - -
SUR 0 nt 0 nt 0 56.5 10
A [0-0] - [0-0] - [0-0] [51-62] 5
SUR 0 nt 0 nt 43 91.5 20
Kl/wash 1 [0-0] - [0-0] - [37-49] [84-99] 15
SUR 0 nt 19 nt 59 68.5 90
K2/wash 4 [0-0] - [16-22] - [54-64] [68-69] 35
SUR* 0 nt 2 nt 64.5 94 40
L 1/Sonicated [0-0] - [2-2] - [59-70] [85-103] 20
SUR* 0 nt 0 nt 55 92 30
L2/Unsonic [0-0] - [0-0] - [45-65] [79-105] 20
* Surfactant batch no. 45, @ /A = untreated test fluid, B i = heat at 56°C for 30 min, B2 = 
heat at 100°C for 15 min, Cl = HC1 (0.1 M final), C2 = NaOH (0.1 M final), D = test fluid 
at 4°C for overnigth, E l = trypsin (2mg/ml final), E2 = chymotrypsin (2mg/ml), E3 = 
subtilisin (2mg/ml), E4 = proteinase K (2mg/ml final), F = test fluid at 37°C for 30 min, G 
= freezing and thawing of test fluids, H = dialysed test fluids, Ij = test fluids treated with 
bentonite, I2 = charcoal, I3 = methyl cellulose, I4  = DMpCD, I5 = (3CD, 16 = aCD, I7 = 
bovine serum albumin (BSA) , Is = =starch, I9 = inactivated rat serum (IRS); Ji = 
Phospholipase A2, J2 = Phospholipase C, K\ = Surfactant washed in PBS one time, K2 = 
Surfactant washed in PBS four times, L] = Sonicated surfactant, L2 = Unsonicated 
surfactant.
